ID,title,actual_duration,status,study_type,fda_regulated_drug,fda_regulated_device,responsible_party,enrollment_count
BTX-BCI-016-PRT,Breast Cancer Index (BCI) Registry,7.638356164383563,Recruiting,Observational,No,No,Sponsor,3000
2018-TJ-BCD,Diagnosis Value of SEMA4C in Breast Cancer,1.0027397260273974,Not yet recruiting,Observational,No,No,Principal Investigator,2300
Breast cancer,Role of Sorcin and Annexin A3 in Breast Cancer Patients,0.6931506849315069,Unknown status,Observational,No,No,Principal Investigator,80
BC-BOMET,Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases,4.835616438356165,Recruiting,Observational,No,No,Sponsor,30
241391,A Study to Identify Breast Cancer (IDBC),3.9369863013698634,Unknown status,Observational,No,No,Sponsor,600
IL-TM-B1-01,Blood Test for Early Detection of Breast Cancer Using Todos Medical -Breast 1(TM-B1) Assay,1.4383561643835616,Unknown status,Observational,No,No,Sponsor,200
FH-Risk 2.0 Research Protocol,FH-Risk 2.0: Updating Breast Cancer Risk Estimates,2.671232876712329,Recruiting,Observational,No,No,Principal Investigator,271
ID-RPSBC-01-20201012,Genetic and Non-Genetic Breast Cancer Risk Prediction Evaluation in Indonesian Samples,2.712328767123288,Recruiting,Observational,No,No,Sponsor,316
IRST174.22,What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer?,5.991780821917808,Recruiting,Interventional,No,No,Sponsor,60000
ANILERGÄ°NN,Weight Loss and Breast Cancer,3.378082191780822,Not yet recruiting,Observational,No,No,Principal Investigator,300
32155120.7.0000.0072,Breast Cancer Survivors: Main Physical and Psychosocial Problems After Completion of Treatment,2.073972602739726,Unknown status,Observational,No,No,Principal Investigator,105
GCO 17-2188,Increasing African Immigrant Womens Participation in Breast Cancer Screening,3.3205479452054796,Recruiting,Interventional,No,No,Principal Investigator,168
233756,The HIFUB Study (HIFU in Breast Cancer),0.5041095890410959,Not yet recruiting,Interventional,No,No,Sponsor,15
D16196,A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers,2.8684931506849316,Completed,Interventional,No,Yes,Principal Investigator,18
RO1912-30902,RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients,2.0876712328767124,Unknown status,Interventional,No,No,Principal Investigator,166
UMCC 2021.087,Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid,0.9698630136986303,Recruiting,Interventional,No,No,Sponsor,40
LNs Staging of Breast cancer,Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging of Breast Cancer.,3.16986301369863,Unknown status,Interventional,No,No,Principal Investigator,50
SA18i0002,The Effect of a Patient Decision Aids for Breast Cancer Screening,1.3342465753424657,Recruiting,Interventional,No,No,Sponsor,3269
494936,Clinical Pilot Study for Personalized Risk-based Breast Cancer Screening,12.783561643835617,Recruiting,Interventional,No,No,Sponsor,80
042210,Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer,5.046575342465753,Not yet recruiting,Interventional,Yes,No,Principal Investigator,16
Yuan Shifang-1,Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device,2.9178082191780823,Unknown status,Observational,No,No,Principal Investigator,120
(818)109A-57,Mobile Application Support for Women With Breast Cancer Undergoing Chemotherapy,2.627397260273973,Recruiting,Interventional,No,No,Sponsor,70
21 SEIN 01,Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer.,1.3287671232876712,Completed,Interventional,No,No,Sponsor,61
18-181,Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening,7.3342465753424655,Recruiting,Interventional,No,No,Principal Investigator,100
catheter guided chemo-infusion,Catheter Guided Chemo-infusion in Breast Cancer,2.0849315068493155,Not yet recruiting,Interventional,No,No,Principal Investigator,50
2020/132,Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS),0.6712328767123288,Completed,Interventional,No,No,Principal Investigator,150
17-689,Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening,5.2904109589041095,"Active, not recruiting",Interventional,No,Yes,Principal Investigator,82
831804,[18F] F-GLN by PET/CT in Breast Cancer,5.663013698630137,Recruiting,Interventional,Yes,No,Sponsor,30
PI-2842,Study for the Knowledge of Risk Factors Associated With Breast Cancer in Women,1.5013698630136987,Completed,Observational,No,No,Sponsor,66
NCC2985,Characteristics and Treatment Trends of Young Breast Cancer in China,2.9178082191780823,Not yet recruiting,Observational,No,No,Principal Investigator,1000
260281,Sodium (23Na) MRI for Tumour Characterisation and Assessment of Therapy Response in Breast Cancer,5.3863013698630136,Recruiting,Observational,No,No,Principal Investigator,65
V1 11.12. 2020 (C.I.R.E.C.),Onco-liq: Kit for Breast Cancer Diagnosis.,1.9150684931506852,Recruiting,Observational,No,No,Principal Investigator,500
154/2019,Short and Long Term Effects of a Physical Therapy Program After Breast Cancer Surgery,4.235616438356165,Suspended,Interventional,No,No,Principal Investigator,36
Amr Ahmed,"The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism",1.082191780821918,Not yet recruiting,Interventional,Yes,No,Principal Investigator,200
CLM-INS-004,PERSONAL - Sleep In Breast Cancer,0.547945205479452,Completed,Observational,No,No,Sponsor,226
2022-11-076-002,Comparison of Ultrasound and Breast MRI for Breast Cancer Detection,5.005479452054795,Not yet recruiting,Interventional,No,No,Principal Investigator,1464
Health Literacy of Breast Ca,The Effect of Breast Cancer Screening Training,0.8712328767123287,Not yet recruiting,Interventional,No,No,Principal Investigator,60
miRNA in breast cancer,Aberrant Expression of Micro RNA for Diagnosis of Breast Cancer,2.0657534246575344,Not yet recruiting,Observational,No,No,Principal Investigator,50
MC1933,Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer,21.019178082191782,Recruiting,Observational,No,No,Sponsor,100
RADIOVAL,Clinical Validation of Radiomics Artificial Intelligence: Application to Breast Cancer Treatment Planning,2.504109589041096,Recruiting,Observational,No,No,Sponsor,5000
CE21096B,Factors Affecting Rehabilitation Time for Postoperative Complications Among Breast Cancer Patients,2.0000000000000004,Recruiting,Observational,No,No,Sponsor,300
ZY(2018-2020)-CCCX-2005-04,Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer,4.0191780821917815,Recruiting,Interventional,No,No,Principal Investigator,200
MicroRNA in breast cancer,Diagnostic and Prognostic Value of MicroRNA in Breast Cancer Patients,2.0027397260273974,Not yet recruiting,Observational,No,No,Principal Investigator,50
GEICAM/2016-04,Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk,6.301369863013699,"Active, not recruiting",Observational,No,No,Sponsor,777
22IC7498,Behavioural Science Messages in Breast Cancer Screening,0.5041095890410959,Completed,Interventional,No,No,Sponsor,34047
BMIBC,Impact of Body Mass Index on Outcomes of Breast Cancer Management,1.4958904109589042,Unknown status,Observational,No,No,Principal Investigator,300
3.0840453,Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53,3.2273972602739724,Completed,Observational,No,No,Sponsor,135
18 SEIN 11,"Prospective, Multicentric Study Evaluating the Surgical Treatment by Mastectomy With Immediate Prosthetic Breast Reconstruction in Patients With Breast Cancer and Receiving Adjuvant Therapy by TomoTherapy +/-Chemotherapy.",6.49041095890411,Recruiting,Interventional,No,No,Sponsor,55
HKG-KZ-BrCa-101,"Detection of Breast Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC",3.254794520547945,Terminated,Observational,No,No,Sponsor,165
Hibiscuss,"Breast Cancer Detection in Breast Surgical Specimens With the Histolog Scanner, Slide-free Confocal Microscope",2.5178082191780824,Completed,Observational,No,No,Sponsor,181
Pro00107118,A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer,2.4876712328767123,Recruiting,Observational,No,No,Sponsor,15
SNAPS Breast Cancer,SNAPS Breast Cancer Patient Study Breast Cancer Patients,2.3315068493150686,Suspended,Observational,No,No,Sponsor,500
17-447,Imaging With [11C]Martinostat in Breast Cancer,4.750684931506849,Withdrawn,Interventional,Yes,No,Sponsor-Investigator,0
22-509,Breast Cancer Survivor Educational Intervention,0.5041095890410959,Recruiting,Interventional,No,No,Principal Investigator,15
ZCHBC022,Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBC,3.2904109589041095,Recruiting,Observational,No,No,Principal Investigator,40
R.18.02.34.R1.R2,Association of Hepatitis C Virus With Breast Cancer,0.7506849315068493,Completed,Observational,No,No,Principal Investigator,650
ID-BCRPS-02-20220913,The Perspective of Healthy Individuals on Breast Cancer Risk Prediction Report In The Indonesian Population,0.2958904109589041,Recruiting,Interventional,No,No,Sponsor,20
112991,Hybrid PET/MR Imaging of Acute Cardiac Inflammation After Left-Sided Breast Cancer Radiotherapy,3.0,Unknown status,Observational,No,No,Sponsor,15
17-01549,Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer,6.50958904109589,Recruiting,Interventional,No,Yes,Sponsor,170
TET-21-001,Identification of Breast Cancer Specific Markers in Patients Compared to Healthy Participants,1.9917808219178084,Recruiting,Observational,No,No,Sponsor,60
202101073,Project Insight: Feasibility of a Breast Cancer Screening Decision Support Tool,0.3643835616438356,Completed,Interventional,No,No,Sponsor,1277
"estPerMed 1, Breast",Personalised Risk-based Breast Cancer Prevention and Screening,2.16986301369863,Unknown status,Interventional,No,No,Principal Investigator,28389
68824072019,Risk Reduction Program for Women Having High Risk of Breast Cancer,3.421917808219178,Completed,Interventional,No,No,Principal Investigator,77
3055,Correlation of Predictive Accuracy of PREDICT Version 2.2 of Indian Women With Operable Breast Cancer,4.1287671232876715,"Active, not recruiting",Observational,No,No,Principal Investigator,2780
20220303swj0211,The Psychology Intervention on Disease Acceptance and Quality of Life in Breast Cancer Patients,2.0027397260273974,Not yet recruiting,Interventional,No,No,Principal Investigator,90
RC20_0532,Breast Cancer Screening Uptake: a Randomized Controlled Trial Assessing the Effect of a Decisional Aid,2.0027397260273974,Not yet recruiting,Interventional,No,No,Sponsor,66000
Breast Cancer Risk,Breast Cancer Risk From Sonographic Glandular Tissue Component (or International GTC Study),7.167123287671233,Recruiting,Observational,No,No,Principal Investigator,16164
KMUHIRB-E(I)-20200041,"Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment",1.9068493150684933,Completed,Interventional,No,No,Principal Investigator,73
VGHKS18-CT11-17,CEDM as a Screening Tool for Breast Cancer in Higher-risk Women: A Prospective Study,3.0,Completed,Observational,No,No,Principal Investigator,351
832165,Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT,7.978082191780823,Recruiting,Observational,Yes,No,Sponsor,50
ICO-2019-08,Interest of Touch-massage in Hospital Day Care,0.5972602739726027,Completed,Observational,No,No,Sponsor,36
biomarkers in breast cancer,Circular RNA and Chemerin in Breast Cancer Patient,2.16986301369863,Not yet recruiting,Observational,No,No,Principal Investigator,80
GEICAM/2017-07,Registry Study of Pregnancy and Breast Cancer,20.134246575342466,Recruiting,Observational,No,No,Sponsor,1000
LCCC2207,"Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians",3.0027397260273974,Recruiting,Observational,No,No,Sponsor,15
4452,Development of a Horizontal Data Integration Classifier for Noninvasive Early Diagnosis of Breast Cancer,3.868493150684932,"Active, not recruiting",Interventional,No,No,Sponsor,367
MCC-21448,Study of Screening Brain MRIs in Stage IV Breast Cancer,1.6931506849315068,Recruiting,Observational,No,No,Sponsor,100
2017-0588,Implementation of a Web-based Decision Aid for Breast Cancer Surgery,1.106849315068493,Completed,Observational,No,No,Sponsor,11
SK-421-BRCA,A Digital Solution for Breast Cancer Patients,1.1315068493150684,Recruiting,Interventional,No,No,Sponsor,66
autotaxin1,Autotaxin: a Potential Biomarker for Breast Cancer.,2.202739726027397,Completed,Interventional,No,No,Principal Investigator,110
UPCC 19121,Role of the Immune Environment in Response to Therapy in Breast Cancer,10.252054794520548,Recruiting,Observational,No,No,Principal Investigator,300
DS8201-A-U302,"DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]",5.64931506849315,"Active, not recruiting",Interventional,Yes,No,Sponsor,524
CCR 5113,PIONEER Study of Lifestyle Intervention to Reduced Breast Cancer Risk,3.208219178082192,"Active, not recruiting",Interventional,No,No,Sponsor,240
2019-05-157,Genetic Characteristics of Metastatic Breast Cancer Patients,5.043835616438356,Recruiting,Interventional,No,No,Principal Investigator,300
21-480,A Formative Evaluation For Improving Breast Cancer Hormone Receptor Testing in Tanzania,0.0821917808219178,Not yet recruiting,Observational,No,No,Sponsor,70
LQ005,Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer,3.128767123287671,Unknown status,Observational,Yes,No,Principal Investigator,100
ICO-N-2017-02,Sentinel Lymph Node Procedure in Ipsilateral Invasive Breast Cancer Relapse,2.5178082191780824,Terminated,Interventional,No,No,Sponsor,50
medicin,Autotaxin (ATX) as a Marker for Breast Cancer,1.5041095890410958,Unknown status,Interventional,No,No,Principal Investigator,100
METCZ20200211,Magnetic Tracer in the Sentinel Node Procedure in Breast Cancer: the Non-radioactive Alternative for Radio-isotopes,0.526027397260274,Completed,Interventional,No,No,Principal Investigator,40
2021LC2210,Remote Breast Cancer Screening Study,3.9178082191780828,Recruiting,Observational,No,No,Principal Investigator,30000
17-581,Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds,0.4684931506849315,Completed,Observational,No,No,Principal Investigator,17
2020-A00058-31,Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening,5.920547945205479,Recruiting,Interventional,No,No,Sponsor,1100
NCC3299,Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI Technology,0.7506849315068493,Recruiting,Observational,No,No,Principal Investigator,1821
351-19,mULM to Support Breast Cancer Diagnosis and Therapy,2.6,Recruiting,Interventional,No,No,Principal Investigator,74
ESR-21-21505,The Treatment Situation of Chinese County Population With Breast Cancer,1.9260273972602742,Recruiting,Observational,No,No,Sponsor,2500
LUMHS/REC/-17,Association of Tumour Grade and Sex Steroid Receptor as a Prognostic Index in Breast Cancer,0.5424657534246575,Unknown status,Observational,No,No,Principal Investigator,382
PekingUPH10B004,Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients,5.750684931506849,Recruiting,Interventional,No,No,Sponsor,46
2014P002688a,Promoting Earlier Detection of Breast Cancer in Rwanda: Scaleup in the National Health Care System,1.7315068493150685,Completed,Observational,No,No,Principal Investigator,17379
ODELIA,A Retrospective Analysis of Magnetic Resonance Imaging Data for Breast Cancer Screening in the Open Consortium for Decentralized Medical Artificial Intelligence,5.0,"Active, not recruiting",Observational,No,No,Sponsor,25000
CD3-MUC1 in breast cancer,Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer,1.1287671232876713,Withdrawn,Interventional,No,No,Sponsor,0
LCCC 1829,Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA,12.115068493150686,Recruiting,Interventional,No,Yes,Sponsor,500
2022-080,"Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer",2.989041095890411,Recruiting,Interventional,No,No,Sponsor,30
2018-TJ-BCP,SEMA4C as a Relapse Biomarker in Breast Cancer,3.9178082191780828,Not yet recruiting,Observational,No,No,Principal Investigator,4200
20218,A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy,3.758904109589041,Completed,Interventional,Yes,No,Principal Investigator,13
2017-03-002A,PET/MR Radiomics for Breast Cancer Diagnosis,4.49041095890411,Recruiting,Observational,No,No,Sponsor,120
LA LEAST,Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer,9.610958904109589,Recruiting,Interventional,No,No,Principal Investigator,290
1905795920,Breast Cancer Self-Efficacy Scale for Partners,2.4986301369863013,Terminated,Observational,No,No,Principal Investigator,25
2015-004027-31,HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer,4.8191780821917805,Recruiting,Interventional,No,No,Sponsor,24
4-2018-0254,Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer,4.671232876712328,Recruiting,Observational,No,No,Sponsor,200
BREACE,Exercise in Older Women With Breast Cancer During Systemic Therapy,5.046575342465753,Recruiting,Interventional,No,No,Principal Investigator,100
495077,18F-FDG PET/CT Imaging for Breast Cancer,9.87945205479452,Recruiting,Interventional,No,No,Sponsor,300
CCR4684,"Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours",5.1506849315068495,Recruiting,Interventional,Yes,No,Sponsor,58
211753,BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity,2.4,Recruiting,Interventional,No,No,Principal Investigator,500
1705018188,Dedicated Breast PET/MRI in Evaluation of Extent of Disease in Women With Newly Diagnosed Breast Cancer,3.9726027397260277,Terminated,Interventional,No,Yes,Sponsor,14
22-136,"A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer",3.0027397260273974,Recruiting,Interventional,No,No,Sponsor,60
CDK-HeCOG-2019,Clinical Outcome and Toxicity Data in Patients With Advanced Breast Cancer Treated With CDK Inhibitors Combined With Endocrine Therapy,2.0054794520547947,Completed,Observational,No,No,Sponsor,340
2020-0327,Comparison of MRI With PET / CT in the Evaluation of Response to Neoadjuvant Therapy Based on the Molecular Subtypes of Breast Cancer,2.5835616438356164,Completed,Observational,No,No,Sponsor-Investigator,88
RECO_CT29B,Investigation of Urinary Biomarkers for the Detection of Breast Cancer,1.2794520547945205,Recruiting,Interventional,No,No,Sponsor,200
SH ABCD,Autoantibodies in Breast Cancer Detection,10.282191780821918,Recruiting,Observational,No,No,Sponsor,1550
D8531C00002,A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy,13.172602739726027,Recruiting,Interventional,Yes,No,Sponsor,4300
SOLTI-1910,Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.,2.1890410958904107,Recruiting,Interventional,No,No,Sponsor,63
1905202-3,ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies,4.002739726027397,Recruiting,Observational,No,No,Principal Investigator,5000
Targeted axillary dissection,Evaluation of Targeted Axillary Lymph Node Dissection in Node Positive Breast Cancer Patients Post Neo Adjuvant Therapy,1.6684931506849314,Not yet recruiting,Interventional,No,No,Principal Investigator,30
2021-0215,BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer,2.3068493150684932,Recruiting,Interventional,Yes,No,Principal Investigator,40
2022-8048-23560,Frequency of Occult Breast Cancer After Prophylactic Mastectomy Among High-Penetrance Breast Cancer Gene Positives,0.24109589041095894,Recruiting,Observational,No,No,Principal Investigator,26
GFY202001,Study of Prediction of Ovarian Reserve in Yong Breast Cancer Patients Treated With Chemotherapy,3.495890410958904,Recruiting,Observational,No,No,Principal Investigator,200
2019-A01861-56,Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients,7.830136986301371,Recruiting,Observational,No,No,Sponsor,90
18-634,Elevate! : An Elderly Breast Cancer Cohort Study,9.706849315068494,Recruiting,Observational,No,No,Principal Investigator,250
20 KHCC 202,Universal Genetic Testing Versus Guidelines-Directed Testing for Germline Pathogenic Variants Among Non-Western Patients With Breast Cancer,2.249315068493151,Recruiting,Observational,No,No,Principal Investigator,1000
IRB # 21-0026,Tear Based Sample Collection Breast Cancer Detection,4.3863013698630136,"Active, not recruiting",Observational,No,No,Sponsor,50
IRB00002991,Implementation of Online Adaptive Radiotherapy for Breast Cancer Patients on Ethos (BREAST-ART),2.2246575342465755,Recruiting,Observational,No,No,Principal Investigator,50
17-398,Feasibility of an Individualized Goals of Care Discussion Guide for Advanced Breast Cancer,1.2657534246575342,Completed,Interventional,No,No,Principal Investigator,45
ESR-17-12934,Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer,1.4958904109589042,Unknown status,Observational,No,No,Sponsor,390
LCCC 1954,Patient-centered Communication About Healthy Weight in Early Breast Cancer,0.29041095890410956,Completed,Observational,No,No,Sponsor,39
69HCL22_0613,Effect of Physical Activity in Patients With Breast Cancer.,0.4191780821917808,Withdrawn,Observational,No,No,Sponsor,0
LCCC2213,Metastatic Breast Cancer-Specific Prognostic Tool,2.0328767123287674,Recruiting,Observational,No,No,Sponsor,30
IC 2018-01,Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer,2.158904109589041,Completed,Interventional,No,No,Sponsor,15
IC 2020 08,Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer.,0.9013698630136986,Completed,Interventional,No,No,Sponsor,35
PI17/00834,Assessment of Feasibility and Acceptability of Personalized Breast Cancer Screening,2.9205479452054797,Completed,Interventional,No,No,Principal Investigator,387
PekingUMCH-FAPI-BC-1,Characterizing Breast Cancer With 68Ga-FAPI PET/CT,2.6684931506849314,Recruiting,Interventional,No,No,Sponsor,100
PekingUMCH-FAPI-BC-2,Characterizing Breast Cancer With Al18F-NOTA-FAPI-04 PET/CT,1.1397260273972603,Recruiting,Interventional,No,No,Sponsor,100
FMASUMD232/2021,Circulating microRNA 21 Expression Level Before and After Neoadjuvant Systemic Therapy in Breast Carcinoma,2.0849315068493155,Not yet recruiting,Observational,No,No,Principal Investigator,40
Breast immune checkpoint,Relationship Between Breast Cancer Subtypes and Immune Checkpoints,0.6246575342465753,Completed,Observational,No,No,Principal Investigator,60
IRB00283392,Messaging Strategies to Reduce Breast Cancer Over-screening in Older Women,0.5013698630136987,Not yet recruiting,Interventional,No,No,Sponsor,3000
IRB17-0721,Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer,4.553424657534246,"Active, not recruiting",Interventional,Yes,No,Sponsor,74
180034,ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma,3.723287671232877,Completed,Interventional,Yes,No,Principal Investigator,30
BCL IDE,Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer,2.5205479452054793,Recruiting,Interventional,No,Yes,Sponsor,448
REO 027,A Window-of-opportunity Study of Pelareorep in Early Breast Cancer,3.063013698630137,Terminated,Interventional,No,No,Sponsor,26
CentroHLO_EFBreastCancer,Evaluating and Following Breast Cancer Patients in a Better Way,1.5863013698630137,Unknown status,Observational,No,No,Principal Investigator,200
elastography in breast cancer,Shear Wave Elastography Assessment of Neoadjuvant Chemotherapy Response in Patients With Invasive Breast Cancer,1.2465753424657535,Not yet recruiting,Observational,No,No,Principal Investigator,35
2018-177-IMP-EXP-4,Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer,3.6986301369863015,Recruiting,Observational,No,No,Principal Investigator,1000
V3-MOMMO-01,Open Label Immunotherapy Trial for Breast Cancer,1.5013698630136987,Unknown status,Interventional,No,No,Sponsor,20
PROICM 2020-01 OST,Evaluation of the Prevalence of Pelvic Static Disorders in Women With Localized Breast Cancer,0.7972602739726027,Completed,Observational,No,No,Sponsor,246
077-2019,Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Chest-wall and Locally-Advanced Breast Cancer,3.9178082191780828,Recruiting,Interventional,No,No,Principal Investigator,20
18-281,Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer,4.868493150684931,Recruiting,Observational,No,No,Principal Investigator,60
2021-A02676-35,Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment,3.8958904109589048,Recruiting,Observational,No,No,Sponsor,163
84434789,Looking At Triple Negative Breast Cancer Patient Experience Patterns in Medical Trials,2.0000000000000004,Not yet recruiting,Observational,No,No,Sponsor,500
2021-004,Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study,0.8986301369863013,Recruiting,Observational,No,No,Sponsor,20
CBS-PIK3CA,Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC,3.6684931506849314,"Active, not recruiting",Observational,No,No,Sponsor,120
JuÃ§ara Phd Thesis,Emotional Evaluation and Reconstructed Breast Satisfaction,2.665753424657534,Unknown status,Interventional,No,No,Principal Investigator,110
18 SEIN 08,The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-Î± Status in Patients With Metastatic Breast Cancer HER2 + and ERÎ± Neg Treated With Trastuzumab + Pertuzumab + Taxane.,0.863013698630137,Terminated,Interventional,No,No,Sponsor,4
ARNA Breast 2021,"In Vitro Study of the Liquid Biopsy Test System of the Diagnostic Value, in Women With Various Forms of Breast Cancer",0.6136986301369863,Unknown status,Observational,No,No,Sponsor,500
SNP-17-001,Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer,2.1424657534246574,Completed,Observational,No,No,Sponsor,118
2021-012,Efficacity of Deep Inspiration Breath Hold and Intensity-modulated Radiotherapy in Preventing PErfusion Defect for Left Sided Breast Cancer (EDIPE),2.0027397260273974,Recruiting,Interventional,No,No,Sponsor,58
69HCL18_0769,Awareness About Breast Cancer Screening,0.038356164383561646,Completed,Observational,No,No,Sponsor,2264
2394,Predictive Model of Axillary Nodal Status After Neoadjuvant Chemotherapy in Breast Cancer Patients,3.991780821917809,"Active, not recruiting",Observational,No,No,Principal Investigator,1950
CASE12119,Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast Cancer,2.926027397260274,Recruiting,Interventional,No,Yes,Sponsor,100
18-124,ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer,11.03013698630137,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,82
18-461,Decisions of Young Women With Breast Cancer Regarding Fertility Preservation Before Cancer Treatment and Family Building After Treatment,4.956164383561644,"Active, not recruiting",Observational,No,No,Sponsor,209
2020-KY-064,Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer,3.0821917808219177,Recruiting,Observational,No,No,Principal Investigator,80
3049,Evaluating Breast Cancer Patients Modesty During Radiotherapy. A Multicentric Study,2.3205479452054796,Completed,Observational,No,No,Sponsor,537
EFC16133,"Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity",0.6520547945205479,Terminated,Interventional,Yes,No,Sponsor,3
CLEE011O12001,Phase IIIb Study of Ribociclib + ET in Early Breast Cancer,6.750684931506849,Not yet recruiting,Interventional,Yes,No,Sponsor,2500
82944089,Discovering Factors in Metastatic Breast Cancer Patients Clinical Trial Experiences,2.0027397260273974,Not yet recruiting,Observational,No,No,Sponsor,500
NewGiza University Protocol 1,The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study,0.3698630136986301,Not yet recruiting,Observational,Yes,No,Principal Investigator,200
s66248,Identifying Prognostic Variables for Persistent Upper Limb Dysfunctions After Breast Cancer Treatment,2.7726027397260276,Recruiting,Interventional,No,No,Principal Investigator,250
964635,The Benefit of Surgery in Stage IV of Breast Cancer,1.082191780821918,Unknown status,Interventional,No,No,Sponsor,212
3/19,Multidisciplinary Approach to Breast Cancer Through the Study of Altered Transcriptomic and Immune Accompanied by the Identification of Extractable Markers From the Radiodiagnostic Bioimaging,4.000000000000001,Recruiting,Observational,No,No,Sponsor,1000
SCCC-11118; STU-2018-0015,Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer,6.013698630136986,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,61
2019402,Supportive Effects of Craniosacral Therapy for Female Patients With Breast Cancer and Their Partners,1.5890410958904109,Not yet recruiting,Interventional,No,No,Principal Investigator,102
19-003085,"GENetic Risk Estimation of Breast Cancer Prior to Decisions on Preventive Therapy Uptake, Risk Reducing Surgery or Intensive Imaging Surveillance",5.210958904109589,Enrolling by invitation,Observational,No,No,Principal Investigator,900
RADIO-SLEEP,Sleep Disorders Prior to and During a Course of Radiotherapy for Breast Cancer,1.0794520547945206,Not yet recruiting,Interventional,No,No,Principal Investigator,51
Protocol EMIT-1,Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer,25.18904109589041,"Active, not recruiting",Observational,No,No,Principal Investigator,2298
17/09/621_Myosin VI,Nuclear Myosin VI - a Therapeutic Target in Breast Cancer,1.5780821917808219,Unknown status,Observational,No,No,Principal Investigator,120
2017/1356,Adjuvant Endocrine Therapy in Early Stage Breast Cancer: Adherence and Clinical Outcome,1.6684931506849314,Completed,Observational,No,No,Sponsor,1411
IC 2016-07,"FErtility, PrEgnancy, contRaceptIon After Breast Cancer in France",2.9835616438356163,Unknown status,Observational,No,No,Sponsor,1004
left breast cancer,Cardiac Toxicity of Hypo Fractionated Radiotherapy in Left Breast Cancer,1.5945205479452054,Not yet recruiting,Observational,No,No,Principal Investigator,45
180212-1,IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry,10.005479452054795,Recruiting,Observational,No,No,Sponsor,168
19-001,Individualizing Surveillance Mammography for Older Breast Cancer Survivors,2.128767123287671,Completed,Interventional,No,No,Principal Investigator,45
CTRP6 in Breast Cancer,The Role of C1q Tumor Necrosis Factor-related Protein 6 in Breast Cancer,1.9150684931506852,Unknown status,Observational,No,No,Principal Investigator,102
CESM in breast cancer,Accuracy Of Contrast Enhanced Mamography in Predicting Response of Breast Cancer Post Neoadjuvant Chemotherapy,2.0849315068493155,Not yet recruiting,Observational,No,No,Principal Investigator,50
UCaenNormandie,A Randomized Cluster Trial to Evaluate a Mobile Mammography Unit in Breast Cancer Screening in France (Mammobile),2.547945205479452,Enrolling by invitation,Interventional,No,No,Principal Investigator,91982
SOLTI-1903,Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer,3.778082191780822,"Active, not recruiting",Observational,No,No,Sponsor,600
Vitamin D in breast cancer,Prognostic Value of Vitamin D Levels in Egyptian Females With Breast Cancer,3.0027397260273974,Unknown status,Observational,No,No,Principal Investigator,222
17-552,Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening,5.704109589041096,"Active, not recruiting",Interventional,No,Yes,Principal Investigator,910
CCR5348,Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer,6.002739726027397,Not yet recruiting,Interventional,No,No,Sponsor,400
19HLSEIN02,Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC,0.6301369863013698,Completed,Observational,No,No,Sponsor,100
STUDY00011606,Design of Chatbot Persona for Breast Cancer Screening Outreach Among Black Women,0.2328767123287671,Recruiting,Interventional,No,No,Principal Investigator,500
03/21,A Prospective Single-center Cohort Study Preoperative Identification of Sentinel Lymph Nodes Using Contrast-enhanced CT Lymphography in Breast Cancer Patients,0.8328767123287671,Not yet recruiting,Interventional,No,No,Principal Investigator,31
AHQU-2021007,Genetic Predictors of Response to Acupuncture for Cancer-related Fatigue Among Breast Cancer Patients After Chemotherapy,1.5835616438356164,Recruiting,Interventional,No,No,Principal Investigator,60
D8530C00003,"A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer",2.6,Recruiting,Interventional,No,No,Sponsor,132
200056,"BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)",0.4684931506849315,Terminated,Interventional,Yes,No,Principal Investigator,1
182-20-CA,18F-fluoroestradiol (FES) PET/CT for Breast Cancer,2.915068493150685,Recruiting,Interventional,Yes,No,Principal Investigator,124
Shengjing-LCG008,Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy,6.002739726027397,Not yet recruiting,Interventional,No,No,Principal Investigator,450
NeoRadUKD,NeoRad Breast Cancer Study,10.506849315068493,Not yet recruiting,Interventional,No,No,Principal Investigator,1826
KY20192114-C-1,Sentinel Lymph Node Biopsy in Early Breast Cancer: a Real-world Multicenter Cross-sectional Study (CABS001 Study),2.419178082191781,Unknown status,Observational,No,No,Sponsor,21000
STUDY19060359,Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania,6.432876712328767,Recruiting,Interventional,No,Yes,Sponsor-Investigator,1650
2019.089,Using Imaging Data and Genomic Data to Predict Metastasis of Breast Cancer After Treatment,3.750684931506849,Recruiting,Observational,No,No,Principal Investigator,400
Xist,XIST Gene Deletion in Breast Cancer Therapy,2.0000000000000004,Unknown status,Observational,No,No,Principal Investigator,1
UEM0002,Synergic Effects of Physical Activity and Probiotic on Gut Immune System and Quality of Life of Breast Cancer Survivors.,1.2493150684931507,Withdrawn,Interventional,No,No,Principal Investigator,0
004181,Together After Cancer,3.164383561643836,Recruiting,Interventional,No,No,Principal Investigator,480
HERMIONE 13,Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer,2.0164383561643837,Recruiting,Observational,No,No,Sponsor,150
STANDPOINT,Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer,2.0000000000000004,Recruiting,Observational,No,No,Principal Investigator,50
NL75855.091.21,Evaluation of Contrast Enhanced Breast CT for Diagnosis and Staging of Breast Cancer,3.0027397260273974,Not yet recruiting,Observational,No,Yes,Sponsor,413
CASE5118,Assessing the Impact of the Microbiome on Breast Cancer Radiotherapy Toxicity,4.701369863013698,Recruiting,Observational,No,No,Sponsor,50
21 SEIN 09,"Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.",2.9424657534246577,Recruiting,Interventional,No,No,Sponsor,120
CINEICC-3-IAT,Mind Programme for Women With Breast Cancer,2.663013698630137,Recruiting,Interventional,No,No,Principal Investigator,154
Bakircay University,Training With Mobile Application in Breast Cancer,0.26575342465753427,Completed,Interventional,No,No,Principal Investigator,64
HR-HER2-RWS-01,The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.,4.419178082191781,Recruiting,Observational,No,No,Principal Investigator,200
01-BR-003,Guardant360Â® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer,1.7068493150684931,Completed,Observational,No,No,Sponsor,109
21149002,The Effect of Virtual Reality on Anxiety and Fatigue in Women With Breast Cancer Receiving Adjuvant Chemotherapy,0.6575342465753424,Completed,Interventional,No,No,Principal Investigator,66
21-528,Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment,2.56986301369863,"Active, not recruiting",Observational,No,No,Principal Investigator,670
DS8201-0002-EAP-MA,EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan,0.3863013698630137,Recruiting,Observational,Yes,No,Sponsor,200
AAAU1629,FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments,1.16986301369863,Not yet recruiting,Interventional,No,No,Principal Investigator,55
BC-NEO-IIT-SHR1316-SHR6390-RT,Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment,1.923287671232877,"Active, not recruiting",Interventional,No,No,Principal Investigator,24
2020-12/898,Metabolomic Profiling of Erector Spinae Plane Block* for Breast Cancer Surgery,0.663013698630137,Completed,Observational,No,No,Principal Investigator,91
CHUBX 2016/19,Adaptation of a Knowledges Exchange Portal Between (KEP) Healers and Patients : Obstacles and Sources to KEP Use for Breast Cancer Women,1.2547945205479452,Completed,Observational,No,No,Sponsor,35
IRB202100182 -N,All-extremity Exercise During Breast Cancer Chemotherapy,1.084931506849315,Recruiting,Interventional,No,No,Sponsor,68
PI-0538-2017,Breast Cancer and Its Relationship With the Microbiota,5.0,"Active, not recruiting",Observational,No,No,Principal Investigator,150
21/4657,Health Technologies Readiness in Breast Cancer Patients,0.5013698630136987,Completed,Observational,No,No,Principal Investigator,100
2019-KY-001-003,PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer,3.504109589041096,Completed,Interventional,No,No,Sponsor,15
AbantIBU,Early Detection of Lymphedema With Bio-Electrical Impedance Analysis in Patients After Breast Cancer Surgery,1.252054794520548,Withdrawn,Interventional,No,No,Sponsor,0
121K686,Online Group Therapy for Breast Cancer,0.7095890410958904,Recruiting,Interventional,No,No,Principal Investigator,51
06-2020,Prevalence of Depression and Anxiety Among Breast Cancer Patients,0.8136986301369863,Completed,Observational,No,No,Sponsor,162
NADOPTIC,Monitoring Response to NAC and Prediction of pCR in Breast Cancer Patients Using Optical Imaging,3.0027397260273974,Unknown status,Interventional,No,No,Principal Investigator,20
CHIR-07-Sentimag,Magseed and Magtrace Localization for Breast Cancer,3.66027397260274,Recruiting,Observational,No,No,Sponsor,70
Pro00020917,Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer,4.920547945205479,Recruiting,Interventional,Yes,No,Principal Investigator,39
Breast Cancer,"Effects of Continuous and Interval Physical Training Through the Intensity of the Incremental Shuttle Walk Test, on Functional Capacity and Quality of Life in Women With Malignant Breast Cancer During Chemotherapy Treatment",2.9452054794520546,Not yet recruiting,Interventional,No,No,Principal Investigator,60
BSU,The Effect of Metformin on Breast Cancer Patients,1.336986301369863,Unknown status,Interventional,No,No,Principal Investigator,80
URomLS Prot.0930/2021Rif. 6528,To Detect Cryoimmunologic Response Induced by Early Breast Cancer Ultrasound-guided Cryoablation (ICE-study),0.4054794520547945,Completed,Interventional,No,No,Principal Investigator,20
Cpetptmrbc,Correlation Between PET/CT Parameters and Tumor Markers in Recurrent Breast Cancer,1.5808219178082192,Not yet recruiting,Observational,No,No,Principal Investigator,72
SOLTI-1716,Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression,4.284931506849315,"Active, not recruiting",Interventional,No,No,Sponsor,46
2020-0724,"Droplet-BC Screening Test for the Detection of Breast Cancer, the DROPLET-BC Study",2.158904109589041,Recruiting,Observational,No,No,Sponsor,1200
LCCC 1749,Impact of Home-based Aerobic and Strength Exercises During Chemotherapy for Early Breast Cancer on Biomarkers of Aging,7.7178082191780835,Recruiting,Interventional,No,No,Sponsor,100
GIMI-IRB-20005,Multi-4SCAR-T Therapy Targeting Breast Cancer,3.5835616438356164,Recruiting,Interventional,No,No,Sponsor,100
202302017,Cryoablation vs Lumpectomy in T1 Breast Cancers,7.50958904109589,Not yet recruiting,Interventional,No,Yes,Sponsor,256
17-PP-19,Peri-gravidic Exposure to Endocrine Disrupting Persistent Organic Pollutants,2.589041095890411,Recruiting,Observational,No,No,Sponsor,320
2015-4-6-003,Prevention of Sequelae Pain After Breast Cancer Surgery by Self-massages and Self Stretching. Impact of Learning Workshops.,4.424657534246576,Recruiting,Interventional,No,No,Sponsor,144
FIRST,FreezIng bReaST Cancer in Brazil: a Before-after Study,1.832876712328767,Not yet recruiting,Interventional,No,No,Sponsor,30
PUMCH-BREAST-ctDNA screening,Clinical Application of ctDNA in Early Screening of Breast Cancer,2.0027397260273974,Unknown status,Observational,No,No,Sponsor,300
147/19,Breast Cancer: Feasibility of an Educational Intervention,0.9424657534246575,Completed,Interventional,No,No,Principal Investigator,224
STUDY00001641,Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women,2.3808219178082193,Recruiting,Interventional,No,No,Principal Investigator,320
PetrovRIO,Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB),9.180821917808219,Recruiting,Interventional,No,No,Sponsor,60
MD 177/2021,Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer,1.0000000000000002,Not yet recruiting,Observational,,,Principal Investigator,80
A5481177,A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting,1.0273972602739727,Recruiting,Observational,,,Sponsor,500
2017-KY-19,The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer,5.002739726027397,Recruiting,Observational,No,No,Sponsor-Investigator,288
Radiotherapy in breast cancer,Efficacy of Capecitabine With Adjuvant Radiotherapy in Treatment of Early Stages Breast Cancer (Retrospective Study).,0.0,Not yet recruiting,Observational,No,No,Principal Investigator,47
19-001004,Brain Health in Breast Cancer Survivors,5.013698630136986,Recruiting,Observational,No,No,Sponsor,120
19049,Specialist Recommendation on FBC (Familial Breast Cancer) Chemoprevention Prescribing,0.4438356164383562,Completed,Observational,No,No,Sponsor,50
Z211100002921033,The Detection of Cell-in-cell Structure (CICs) in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy,3.0027397260273974,Recruiting,Observational,No,No,Sponsor,175
CFDAIIUASABFDOBC,Cell Free DNA and Its Integrity Using ALU Sequences as a Biomarker for Diagnosis of Breast Cancer,2.0027397260273974,Unknown status,Observational,No,No,Principal Investigator,116
Breast cancer neoadjuvant,Evaluation of the Role of Immune Checkpoints in Response to Breast Cancer Neoadjuvant Therapy,0.8383561643835616,Recruiting,Observational,No,No,Principal Investigator,45
wanghaibo,Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer,4.47945205479452,Not yet recruiting,Interventional,No,No,Sponsor,10
2020-KY-063,Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast Cancer,2.0000000000000004,Unknown status,Observational,No,No,Principal Investigator,200
PUMCH-BC502,Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients,5.854794520547945,Recruiting,Observational,No,No,Principal Investigator,200
852-20,"Breast Cancer, Reasoning, and Activity Intervention",4.4082191780821915,Withdrawn,Interventional,No,No,Principal Investigator,0
2020[84],HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody,4.104109589041096,Recruiting,Interventional,No,No,Principal Investigator,40
SYSEC-KY-2018-018,Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients,1.9123287671232878,Unknown status,Observational,No,No,Principal Investigator,358
19-045,A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients,4.947945205479452,"Active, not recruiting",Observational,No,No,Sponsor,194
PROICM 2019-16-BCU,Evaluation of Sexual Quality of Life for Breast Cancer,0.4712328767123288,Completed,Observational,No,No,Sponsor,45
IBCSG 59-19,Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer,7.186301369863013,Recruiting,Interventional,No,No,Sponsor,400
33293720.9.0000.5505,Tele-rehabilitation in Women With Breast Cancer During COVID-19 Pandemic.,2.7534246575342465,"Active, not recruiting",Interventional,No,No,Principal Investigator,60
199080,Prospective Trial of Digital Breast Tomosynthesis (DBT) in Breast Cancer Screening.,5.542465753424658,Recruiting,Interventional,No,No,Sponsor,100000
SLN SPECT,Sentinel Lymph Node Identification in Patients With Breast Cancer Using SPECT/CT,4.1726027397260275,Unknown status,Interventional,No,No,Principal Investigator,4
SOLTI-1907,Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer,3.9506849315068497,Recruiting,Interventional,No,No,Sponsor,55
SDS-HER-01-2018,Safety and Efficacy Assessment of Diagnostic Microprobe (inPROBE) in Women at High Risk of Breast Cancer,0.5205479452054795,Completed,Interventional,No,No,Sponsor,18
APHP211502,Breast Cancer Prevention and Screening Membership,9.843835616438357,Recruiting,Interventional,No,No,Sponsor,189
ISTMET-BHWGI2022-1,Preoperative Radiotherapy and Systemic Therapy Following Surgery in de Novo Metastatic Breast Cancer,6.087671232876712,Recruiting,Observational,No,No,Sponsor,40
SCHBCC-N024,Evaluation for the Effectiveness and Safety of Cryo-ablation in the Treatment of Early Invasive Breast Cancer,5.002739726027397,Recruiting,Interventional,No,Yes,Principal Investigator,186
4817,Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation,1.252054794520548,Recruiting,Observational,No,No,Sponsor,10
EEBC,Prospective Research for Elderly (â¥65 Years Old) Early Breast Cancer Patients,3.671232876712329,Recruiting,Observational,No,No,Sponsor,1000
symptom of breast cancer,Trajectory Analysis of Symptom Distress and Cancer-related Fatigue After Adjuvant Chemotherapy in Breast Cancer Female,3.175342465753425,Not yet recruiting,Observational,No,No,Principal Investigator,120
IEO 0761/,Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer,4.586301369863014,Recruiting,Observational,No,No,Sponsor,264
CELC-G-301,Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1),4.002739726027397,Recruiting,Interventional,Yes,No,Sponsor,701
CARMA-2101,Cohort Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients Derived Organoids,2.0000000000000004,Not yet recruiting,Observational,No,No,Sponsor,100
RWD_abemaciclib,Real-world Data in Patients With Breast Cancer Treated With Abemaciclib,3.1561643835616437,Recruiting,Observational,No,No,Sponsor,108
Tiresias,To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer,5.002739726027397,Recruiting,Observational,No,No,Sponsor,150
A5481125,Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.,1.8273972602739725,Completed,Observational,,,Sponsor,847
20-1789.cc,Sexual Health in Breast Cancer Patients,4.002739726027397,Recruiting,Observational,No,No,Sponsor,100
ML40952,Tw HER2 Positive Breast Cancer Productivity & Utility Study,1.0191780821917809,Unknown status,Observational,No,No,Sponsor,300
DBCG Proton trial,The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer,17.01095890410959,Recruiting,Interventional,No,Yes,Principal Investigator,1502
OOTR-N016/KBCRN-B-003/HT-PAB,"Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer",2.441095890410959,Completed,Interventional,Yes,No,Sponsor,141
710/2021,The Effect of Arm Exercises on Arm Oedema After Breast Cancer Surgery,2.1178082191780825,Recruiting,Interventional,No,No,Sponsor-Investigator,30
19-003028,Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring,9.252054794520548,Recruiting,Observational,No,Yes,Sponsor,400
KL166-IIS-001,HER2-positive Breast Cancer Project Initiated by Investigators,2.5863013698630137,Not yet recruiting,Interventional,No,No,Principal Investigator,48
V2_16-04-2020,Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy,2.632876712328767,Recruiting,Observational,No,No,Sponsor,400
N19ASC,Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy,7.501369863013698,Not yet recruiting,Interventional,No,No,Sponsor,340
SNBvsPET/MRI 2,Axillary Staging in Early Breast Cancer: SNB vs PET/MRI,4.6219178082191785,Recruiting,Interventional,No,No,Principal Investigator,247
dingxwyh01,Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer,1.832876712328767,Unknown status,Interventional,No,No,Sponsor,50
SNUH_FMI,Molecular Profiling in Young (<50 Years of Age) Patients With Metastatic Breast Cancer,1.832876712328767,Unknown status,Interventional,No,No,Principal Investigator,200
2022/0035986,Vocational Rehabilitation for the Return to Work of Breast Cancer Patients: a Feasibility Study,1.9808219178082194,Recruiting,Interventional,No,No,Principal Investigator,25
RF-2013-02358165,Axillary Reverse Mapping (ARM) in Breast Cancer Surgery to Prevent Lymphedema. (ARMtrial),2.873972602739726,Unknown status,Interventional,No,No,Principal Investigator,300
18-516,GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases,6.8054794520547945,Recruiting,Interventional,Yes,No,Principal Investigator,47
2022106,Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer,4.101369863013699,Not yet recruiting,Observational,No,No,Principal Investigator,420
19-147,Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer,1.1123287671232878,Completed,Interventional,Yes,No,Sponsor,6
dingxwyh02,The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer,1.832876712328767,Unknown status,Interventional,No,No,Sponsor,50
19 SEIN 14,E-monitoring of Patients Under Adjuvant Hormonotherapy for Breast Cancer.,1.3945205479452054,Completed,Interventional,No,No,Sponsor,45
AURORA,New Techniques to evAlUate Response to neOadjuvant Treatments in bReast cAncer (AURORA),2.0000000000000004,Unknown status,Interventional,No,No,Sponsor,20
17/0765,Enabling the Study of Metabolism in Breast Cancer Through Collection of Fresh-tissue Biopsies,7.917808219178083,Not yet recruiting,Observational,No,No,Sponsor,240
BR02/03/21,Quadratic Phenotypic Optimisation Platform (QPOP) Utilisation to Enhance Selection of Patient Therapy Through Patient Derived Organoids in Breast Cancer,4.07123287671233,Recruiting,Interventional,No,No,Sponsor,26
2018-9529,TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer,5.473972602739726,Recruiting,Interventional,No,Yes,Sponsor,75
1186,The Role of Genetic Factors in the Development of Breast Cancer in the Kazakh Population,0.810958904109589,Completed,Observational,No,No,Principal Investigator,700
REaCT-HER TIME,Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy,1.7178082191780821,"Active, not recruiting",Interventional,No,No,Sponsor,20
01-2021,"Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.",0.915068493150685,Unknown status,Observational,No,No,Sponsor,1000
D9673R00011,Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients,1.263013698630137,Recruiting,Observational,No,No,Sponsor,3200
SOLTI-1911,Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer,8.167123287671235,Recruiting,Interventional,No,No,Sponsor,530
APHP211593,Molecular Signature for Breast Cancer,0.7534246575342466,Not yet recruiting,Observational,No,No,Sponsor,220
IC 2018-08,Breast Cancer Risk After Diagnostic Gene Sequencing,2.3643835616438356,Completed,Interventional,No,No,Sponsor,405
AHQU-2021006,Genetic Predictors to Acupuncture Response for Arthralgia Induced by Aromatase Inhibitors in Patients With Breast Cancer,2.0136986301369864,Recruiting,Interventional,No,No,Principal Investigator,59
2540,Extracellular Vesicles in Breast Cancer Patientsin Undergone Neoadjuvant Chemotherapy,6.616438356164384,Recruiting,Observational,No,No,Principal Investigator,35
FLA 18-057,Effects of Bariatric Surgery on Breast Density Improvement and Impact on Breast Cancer Risk in Severe Obese Patients,2.8547945205479452,Recruiting,Observational,No,No,Principal Investigator,35
V2011201,Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer,1.2,Withdrawn,Interventional,Yes,No,Sponsor,0
HERdi PREDICT,A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies,3.4493150684931506,Recruiting,Observational,No,No,Sponsor,40
HCB-ONC001 (ML41519),Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy,6.191780821917808,Recruiting,Interventional,No,No,Sponsor,17
IRB-300002157,RAD 1802: Pilot Trial of Dose Adapted Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI),6.287671232876712,Recruiting,Interventional,No,Yes,Principal Investigator,40
IAyas2,The Validity and Reliability of FIT-HaNSA in Breast Cancer Patients,1.5808219178082192,Unknown status,Observational,No,No,Principal Investigator,30
A5481176,A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark,0.4328767123287671,Completed,Observational,,,Sponsor,1
Shengjing-LCG009,Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients,6.041095890410959,Recruiting,Interventional,No,No,Principal Investigator,30
OTT-19-06,"A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer",1.1863013698630136,Completed,Interventional,No,No,Sponsor,40
20210312,Personalized Evidence-based Treatment in Patients With Invasive Breast Cancer,0.24657534246575347,Unknown status,Observational,No,No,Principal Investigator,3000
FAST feasibility in CU,Weekly Single Fraction Hypofractionated Adjuvant Radiotherapy for Early Stage Breast Cancer,5.394520547945206,Recruiting,Interventional,No,No,Sponsor-Investigator,20
Sentinel lymph node biopsy,Oncologic Safety of Sentinel Lymph Node Biopsy in Clinically Palpable Axillary Lymph Node in Breast Cancer Patients,2.0794520547945208,Not yet recruiting,Observational,No,No,Principal Investigator,40
BC001,Moving on After Breast Cancer Plus- for Breast Cancer Survivors,3.3232876712328765,Completed,Interventional,No,No,Sponsor,354
SOC.04/20-21,Breast Screening Atypia and Subsequent Development of Cancer in England,0.9972602739726029,Enrolling by invitation,Observational,No,No,Principal Investigator,3000
UT BCS ECS Study,Feasibility and Effectiveness of an Internet-based Intervention to Manage Fatigue in Breast Cancer Survivors,0.5972602739726027,Withdrawn,Interventional,No,No,Sponsor-Investigator,0
oddie2,Artificial Intelligence for breaST canceR scrEening in mAMmography (AI-STREAM),3.9150684931506854,Recruiting,Observational,No,No,Principal Investigator,32714
FMASU R61/2020,Knowledge and Perception of Clinical Trial Participation in Breast Cancer Patients in Egypt,0.36712328767123287,Unknown status,Observational,No,No,Principal Investigator,300
18-109,A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors,4.967123287671233,Recruiting,Observational,No,No,Sponsor,42
19-509,Genetic Testing for All Breast Cancer Patients (GET FACTS),3.7534246575342465,"Active, not recruiting",Interventional,No,No,Principal Investigator,400
19-277,Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients,3.43013698630137,"Active, not recruiting",Interventional,No,Yes,Sponsor,34
UW 20-064,Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy,8.216438356164385,Recruiting,Interventional,No,No,Principal Investigator,30
UC-0105/1701,SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer,4.682191780821918,Terminated,Interventional,No,No,Sponsor,31
20-1039,Couples QOL in Metastatic Breast Cancer,3.665753424657534,Recruiting,Interventional,No,No,Sponsor,112
BRAR1,of Androgen Receptor Expression in Breast Cancer With or Without BRCA Mutation,3.504109589041096,Recruiting,Observational,No,No,Principal Investigator,112
18-1025,Coping Together After Breast Cancer,3.9397260273972607,"Active, not recruiting",Interventional,No,No,Sponsor,240
IRB16-0396,"Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening",0.9917808219178084,Recruiting,Observational,No,No,Sponsor,200
09.2019.984,Effectiveness of Stellate Ganglion Block in Breast Cancer Related Lymphedema,0.2328767123287671,Unknown status,Interventional,No,No,Sponsor,22
O4M-B001,Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breast Cancer Patients,0.33424657534246577,Unknown status,Interventional,No,No,Sponsor,125
TaiHao TVGH2020-07-006AC#1,Evaluation of TaiHao Breast Ultrasound Diagnosis Software RN-CES Descartes,0.1643835616438356,"Active, not recruiting",Interventional,No,No,Sponsor,3
STGKS001,Artificial Intelligence in Large-scale Breast Cancer Screening,3.671232876712329,"Active, not recruiting",Interventional,No,No,Principal Investigator,55579
19-086,"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)",5.512328767123288,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,77
CNER 202107/05,eHealth Intervention for Medication Adherence in Breast Cancer Survivors,1.4027397260273973,Recruiting,Interventional,No,No,Sponsor,15
Optimune Trial,Evaluating a Novel Web-based Intervention for Breast Cancer Survivors,4.126027397260274,Terminated,Interventional,No,No,Principal Investigator,64
1808019498,Converting HR+ Breast Cancer Into an Individualized Vaccine,7.712328767123289,Recruiting,Interventional,Yes,No,Sponsor,100
Emotional security&mastectomy,Emotional Security and Quality of Life Among Breast Cancer Patient Who Have Undergo Mastectomy,0.5835616438356165,Unknown status,Observational,No,No,Principal Investigator,143
HYGEE,Evaluation of the Impact of the Use of Hypnotherapy Performed by a Virtual Reality Toolalong the Care Pathway of Patients Undergoing Breast Cancer Treatment.,2.958904109589041,"Active, not recruiting",Interventional,No,No,Sponsor,27
HNCH-BC003,Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients,2.0438356164383564,Withdrawn,Interventional,No,No,Sponsor,0
A5481115,Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan,4.252054794520548,Recruiting,Observational,,,Sponsor,1
Breast Audit,The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study,0.16986301369863013,Completed,Observational,No,No,Principal Investigator,690
STU-2018-0370,Infrared Imaging for Breast Cancer Modeling,2.96986301369863,Completed,Interventional,No,No,Principal Investigator,11
MRI in breast cancer,Breast MRI in Evaluation of Pathologic Response in Patients With Breast Cancer With Neoadjuvent Chemotherapy,2.589041095890411,Not yet recruiting,Observational,No,No,Principal Investigator,45
Prix Ruban Rose/2021/FF-01,Personalized Follow-up After Breast Cancer Surgery Via Electronic Patient Reported Outcomes,1.2465753424657535,Completed,Interventional,No,No,Sponsor,20
FUSCC-OMIT,A Trial Evaluating the Efficacy of Metastasectomy in Patients With Oligo-Metastatic Breast Cancer(OMIT),5.252054794520548,Recruiting,Interventional,No,No,Principal Investigator,172
Pyrotinib neoadjuvant,Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer,2.463013698630137,Not yet recruiting,Interventional,No,No,Sponsor,80
SMC 2021-02-102,"Selective Omission of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm studyTrial",7.265753424657534,Enrolling by invitation,Interventional,No,No,Sponsor-Investigator,178
BSMMU/2019/8874,Effect of Vitamin C and E in Breast Cancer Patients Undergoing Chemotherapy,0.9342465753424658,Unknown status,Interventional,No,No,Principal Investigator,80
20210601,Gut Microbiome Components Predict Response to Neoadjuvant Therapy in HER2-positive Breast Cancer Patients : A Prospective Study,2.9205479452054797,Recruiting,Observational,No,No,Sponsor,100
99mTc-ADAPT6 vs 99mTc-DARPinG3,Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3,0.726027397260274,Completed,Interventional,No,No,Sponsor,15
Telemonitoring BCS,"Effect of Telemonitoring on Functionality, Quality of Life and Risk of Lymphedema in Breast Cancer Survivors",0.33424657534246577,Recruiting,Interventional,No,No,Principal Investigator,30
CCTG MA.39,Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer,9.591780821917808,Recruiting,Interventional,No,Yes,Sponsor,2140
IRB-2022-166,"Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective, Multicenter, Real-world Study",4.586301369863014,Not yet recruiting,Observational,No,No,Principal Investigator,1000
2490,Characterization of Extracellular Vesicles in Breast Cancer Patients,2.750684931506849,Recruiting,Observational,No,No,Principal Investigator,105
19/317-2101,Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients,3.9835616438356167,Recruiting,Interventional,No,No,Principal Investigator,2000
2021-1116,Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks,6.720547945205479,Recruiting,Interventional,No,No,Principal Investigator,400
SPT-2021-002,Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer,3.8082191780821923,Not yet recruiting,Interventional,No,No,Principal Investigator,70
s66248-aim2,Identifying Prognostic Variables for Persistent UL Dysfunctions After Breast Cancer Treatment -Reliability and Validity,2.7726027397260276,Recruiting,Interventional,No,No,Principal Investigator,150
Cardiac safety study,Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab,2.4904109589041097,Recruiting,Observational,No,No,Sponsor,30
BGB-290-201,Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China,2.813698630136986,Completed,Interventional,No,No,Sponsor,88
10038,Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*),15.01095890410959,Recruiting,Interventional,Yes,No,Sponsor,69
Pro00085352,Examining Bioactivity of PVSRIPO in Invasive Breast Cancer,3.4246575342465753,Recruiting,Interventional,Yes,No,Sponsor,6
EORTC 1745-ETF-BCG,Adjuvant Palbociclib in Elderly Patients With Breast Cancer,13.306849315068494,"Active, not recruiting",Interventional,No,No,Sponsor,366
4523,Acupuncture Treatment of Vasomotor Symptoms in Breast Cancer Patients,3.084931506849315,Recruiting,Interventional,No,No,Sponsor,90
17-455,The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer,6.947945205479452,"Active, not recruiting",Interventional,Yes,No,Sponsor-Investigator,100
01AB21- PIK3CA,Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.,2.8493150684931505,Recruiting,Interventional,Yes,No,Sponsor,40
ICO-N-2017-12,Clinico-biological Data Collection Study of Metastatic Breast Cancer,18.03013698630137,Recruiting,Interventional,No,No,Sponsor,300
Optimune Trial Add-on,Evaluating a Novel Web-based Intervention for Breast Cancer Survivors,2.0027397260273974,Completed,Interventional,No,No,Principal Investigator,360
2018396H,TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer,3.0027397260273974,Unknown status,Interventional,No,No,Principal Investigator,200
PROICM 2020-05 SKY,Evaluation of the Efficacy of a Physical Therapy-yoga-patient Educational Program for Breast Cancer Patients With Pain Due to Hormonal Therapy Treatment.,4.471232876712329,Recruiting,Interventional,No,No,Sponsor,108
GEICAM/2019-01,Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients,12.416438356164383,"Active, not recruiting",Interventional,No,No,Sponsor,200
69HCL18_0310,Descriptive Observational Study of the Evolution of the Lifestyle Alteration in Patients With Breast Cancer,1.895890410958904,Completed,Observational,No,No,Sponsor,32
2004-261-112,Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer,0.20821917808219179,Terminated,Observational,No,No,Principal Investigator,3
MA-BC-â¡-040,Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer,1.7506849315068493,Not yet recruiting,Interventional,No,No,Sponsor,35
APHP190505,Circulating Fetal Cells and Breast Cancer,3.9671232876712335,"Active, not recruiting",Observational,No,No,Sponsor,80
2019-1183,A Phase I Dose Escalation Study of Single Fraction Ablative Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer,5.605479452054794,Recruiting,Interventional,No,Yes,Principal Investigator,70
IJB-NERABRAIN-ODN-007,Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer,0.0,Withdrawn,Interventional,No,No,Sponsor,0
19-066,Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer,5.526027397260274,Recruiting,Interventional,No,Yes,Principal Investigator,214
EH18-203,The MEDITATE-BC Study: Mindfulness-Enhanced Decision Intervention To Aid Treatment Election - Breast Cancer,1.2575342465753425,Completed,Interventional,No,No,Principal Investigator,22
22-280,Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors,2.0027397260273974,Recruiting,Observational,No,No,Sponsor,100
BakircayU,Factors Affecting Functionality in Breast Cancer Survivors,1.789041095890411,Completed,Observational,No,No,Principal Investigator,111
A211801,Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation,11.778082191780822,Recruiting,Interventional,Yes,No,Sponsor,300
SGK-SFC-001,Susan G. Komens ShareForCures,9.964383561643835,Enrolling by invitation,Observational,No,No,Sponsor,200000
CAAE: 39277420.8.0000.5313,Adaptations to Breast Cancer and Exercise Using Telehealth (ABRACE: Telehealth),2.0767123287671234,Unknown status,Interventional,No,No,Principal Investigator,36
D361DC00001,Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292),7.663013698630138,Recruiting,Interventional,Yes,No,Sponsor,700
PekingUMCH-NM25,99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer,1.0684931506849316,Completed,Interventional,No,No,Sponsor,34
5354-CL-1201,A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery,1.1397260273972603,Recruiting,Interventional,Yes,No,Sponsor,132
MO39485,"A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America",5.772602739726027,"Active, not recruiting",Observational,,,Sponsor,2907
SOC.03/20-21,"English Mammography Screening Outcomes by Age, Frequency and Test Threshold",2.9945205479452053,Enrolling by invitation,Observational,No,No,Principal Investigator,10000000
2019-228,Prophylactic Irradiation to the Contralateral Breast for BCAs Patients,6.920547945205479,Recruiting,Interventional,No,No,Sponsor,323
800646,Intervening on Womens Health for Rural Young Breast Cancer Survivors,2.5424657534246577,Recruiting,Interventional,No,No,Principal Investigator,135
NP 1521/19,Endocrinological Changes Due to Pre-medications of Chemotherapy in Patients With Breast Cancer,5.002739726027397,"Active, not recruiting",Interventional,No,No,Principal Investigator,86
DARE,"DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer",5.8493150684931505,Recruiting,Interventional,Yes,No,Sponsor,100
M2020 UK01,Breath Test to Predict Breast Cancer and Outcome of Mammography,2.0000000000000004,Unknown status,Observational,No,No,Sponsor,1000
[2019]52,HER2 Expression Detection in Breast Cancer Using 99mTc-NM-02,2.671232876712329,Completed,Interventional,No,No,Principal Investigator,10
TRA05-GEFPICS,Concordance of the IHC4 Score Performed in Local or Central Laboratory to Endopredict in ER+/HER2- Breast Cancer,3.1835616438356165,"Active, not recruiting",Observational,No,No,Sponsor,155
NOV2016PhD818,Living Better With Advanced Breast Cancer: Feasibility Evaluation of an Online Supportive Intervention.,0.8164383561643835,Completed,Interventional,No,No,Principal Investigator,41
BCP28,CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC,2.1616438356164385,Recruiting,Observational,No,No,Principal Investigator,218
GEICAM/2017-01_IBCSG 62-20_BIG,Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET),4.967123287671233,Recruiting,Interventional,No,No,Sponsor,300
GCO 17-00563,Integrated Intervention for Breast Cancer Survivors With Diabetes,1.5945205479452054,Recruiting,Interventional,No,No,Principal Investigator,60
PekingUMCH-FES-BC-1,Characterizing Breast Cancer With 18F-FES PET/CT,3.671232876712329,Recruiting,Interventional,No,No,Sponsor,50
EudraCT 2020-005200-19,Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC),1.9013698630136988,Not yet recruiting,Interventional,No,No,Sponsor,40
D9673C00007,A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer,2.6356164383561644,Recruiting,Interventional,Yes,No,Sponsor,500
LY2022-028-B,Pre-operative Therapy in Breast Cancer,8.005479452054795,Recruiting,Observational,No,No,Principal Investigator,488
ATADEK-2021/14/16,Breast Cancer and Kinesiophobia and Physical Activity,0.7863013698630137,Completed,Observational,No,No,Principal Investigator,180
J21125,Cardiometabolic Screening Program,4.997260273972603,Recruiting,Interventional,No,No,Sponsor,450
2018-9567,Pilot Study Assessing the Effect of Cyclin-dependent Kinase 4/6 Inhibitors on Body Composition in Patients With ER+/HER2- Metastatic Breast Cancer,6.901369863013699,Recruiting,Observational,No,No,Principal Investigator,20
UBRS20139,Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling,2.9424657534246577,Recruiting,Interventional,Yes,No,Principal Investigator,22
20 SEIN 13,Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer,2.96986301369863,Recruiting,Interventional,No,No,Sponsor,200
TQB3616-III-03,Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer,3.7616438356164386,Recruiting,Interventional,No,No,Sponsor,1946
MD.21.09.521.R,The Significance of Radiologically Detected Intramammary Lymph Nodes in Prediction of Axillary Lymph Nodes Status in Breast Cancer Patients,1.4684931506849315,"Active, not recruiting",Observational,No,No,Principal Investigator,30
20190283,SABER Study for Selected Early Stage Breast Cancer,4.991780821917808,Recruiting,Interventional,No,Yes,Principal Investigator,18
FISH in breast cancer,Partial PTEN Deletion in Breast Cancer,3.249315068493151,Not yet recruiting,Observational,No,No,Principal Investigator,40
NCC3075,Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer,3.0,Not yet recruiting,Interventional,No,No,Principal Investigator,60
CSPC-DMS-BC-13,Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer.,0.8191780821917808,Completed,Observational,No,No,Sponsor,1213
19900601,Effect of Lymphedema Prevention Program Based on Theory of Knowledge-attitude-practice on Postoperative Breast Cancer Patients,0.7726027397260274,Completed,Interventional,No,No,Principal Investigator,108
DBCG RT Recon,Delayed-immediate Versus Delayed Breast Reconstruction in Breast Cancer Patients With Mastectomy and Radiation Therapy,13.843835616438357,Recruiting,Interventional,No,No,Principal Investigator,590
PROICM 2019-11 PRA,A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer,12.0,Recruiting,Interventional,No,No,Sponsor,400
201819010.4,Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients,0.25205479452054796,Unknown status,Observational,Yes,No,Principal Investigator,100
2018NTLS176,Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer,5.405479452054794,Recruiting,Observational,No,No,Sponsor,40
SPHIC-TR-BCa2022-01,A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer,3.0027397260273974,Recruiting,Interventional,No,No,Principal Investigator,24
C3441020,Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer,2.0767123287671234,Terminated,Interventional,Yes,No,Sponsor,61
SRMBCNabP2022,Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer,1.1945205479452055,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,30
18ON009,Developing a Diagnostic Tool to Predict Response to Chemotherapy,1.5643835616438355,Unknown status,Observational,No,No,Sponsor,4750
FDRT-BC009,FSRT in Breast Cancer Patients With Brain Metastases,3.0027397260273974,Unknown status,Interventional,No,No,Sponsor,170
18-223,Olaparib + Sapacitabine in BRCA Mutant Breast Cancer,6.728767123287671,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,10
MCC-20897,DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer,2.6410958904109587,Recruiting,Interventional,Yes,No,Sponsor,30
21-3576.cc,Interpretations and Predictions of Patient Reported Outcomes by Breast Cancer Patients,3.9260273972602744,Recruiting,Observational,No,No,Sponsor,50
IIT2018-01-McArthur-IPI,Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer,6.556164383561644,Recruiting,Interventional,Yes,No,Sponsor-Investigator,80
BCHRD201,AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer,1.0000000000000002,Unknown status,Interventional,No,No,Principal Investigator,100
BrIMA,Specimen PET-CT Imaging for Intraoperative Margin Assessment in Breast Cancer,1.0383561643835617,Recruiting,Interventional,No,No,Sponsor,160
ChanghaiHTB,Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy,8.753424657534246,Not yet recruiting,Interventional,No,No,Principal Investigator,362
2018-00838; ch20Weber2,Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS),18.33150684931507,Recruiting,Interventional,No,No,Sponsor,1500
WSG-AM09,A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1),1.7835616438356163,Completed,Interventional,No,No,Sponsor,46
UC-0107/1903,Patients Choice in the Reduction of Their Treatment in Women Over 65 Year With Breast Cancer,3.92054794520548,Recruiting,Interventional,No,No,Sponsor,250
PANONC-1 Version: 1.1,Neoadjuvant Treatment of Breast Cancer,9.758904109589041,Not yet recruiting,Observational,Yes,No,Principal Investigator,300
AB-MR for Second Breast Cancer,Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing,4.087671232876713,Unknown status,Observational,No,No,Principal Investigator,1564
AHQU-2021005,Precision Acupuncture in the Treatment of Peripheral Neuropathy After Taxanes Chemotherapy in Breast Cancer,2.0000000000000004,Recruiting,Interventional,No,No,Principal Investigator,54
2019/FO244363,Long-term Effects of Breast Cancer Treatment,3.0,Unknown status,Observational,No,No,Sponsor,4000
BC-2019,The Influence of Treatment Position (Prone vs. Supine) on Whole Breast Target,4.835616438356165,Recruiting,Interventional,No,No,Principal Investigator,300
18-058,"Exercise, Fitness and Tumor Profiling in Breast Cancer Patients",5.920547945205479,"Active, not recruiting",Observational,No,No,Sponsor,42
KYJJ-2021-186,Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients,10.008219178082191,Recruiting,Observational,No,Yes,Sponsor,1000
19-188,"Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial",2.7013698630136984,Recruiting,Interventional,Yes,No,Principal Investigator,30
BCSCO003,Patterns of Breast Cancer Management and Prognosis of Breast Cancer in China,6.243835616438356,Not yet recruiting,Observational,No,No,Sponsor-Investigator,20000
SP00049673,Technology-Supported Physical Activity Intervention for Metastatic Breast Cancer Survivors: Fit2ThriveMB,1.4301369863013698,Completed,Interventional,No,No,Principal Investigator,49
DSCN-EHT-NIS-BC001,A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer,0.21095890410958903,Recruiting,Observational,No,No,Sponsor,1000
17-512,Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer,7.419178082191781,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,78
SCBCS025,"Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China",4.076712328767123,Recruiting,Interventional,No,No,Principal Investigator,34
19-239,Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.,5.1506849315068495,Recruiting,Interventional,Yes,No,Principal Investigator,75
LC2019L06,Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy,7.8356164383561655,Recruiting,Interventional,No,No,Principal Investigator,286
GEICAM/2016-03,Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies,29.972602739726028,Recruiting,Observational,No,No,Sponsor,8000
Breast Screening with DWI,Breast Cancer Screening With Diffusion-weighted MRI in Women at High Risk for Breast Cancer,3.665753424657534,Unknown status,Observational,No,No,Principal Investigator,890
UPCC 17120,Telehealth Weight Loss Program for Breast Cancer Survivors,2.3698630136986303,"Active, not recruiting",Interventional,No,No,Principal Investigator,22
21-183,"Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation",2.9506849315068493,Recruiting,Observational,No,No,Sponsor,78
02AB21-TucErBit,"A Phase II Study of the Safety, Tolerability and Antitumor Activity of Tucatinib in Combination With Eribulin and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer",2.5232876712328767,Recruiting,Interventional,Yes,No,Sponsor,30
IRB-48150,68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer,5.254794520547946,Suspended,Interventional,Yes,Yes,Sponsor-Investigator,20
ICO-2019-03,Bringing of PET-TDM FDG in the Determination of the Characteristics of Primary Mammary Tumors TrIple Negatives,4.967123287671233,"Active, not recruiting",Observational,No,No,Sponsor,132
Soh-Med-23-01-07,Prognostic Value of Some Biochemical Markers in Breast Cancer,0.8301369863013699,Not yet recruiting,Observational,No,No,Principal Investigator,90
IUSCC-0613,An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer,2.3534246575342466,Completed,Interventional,Yes,No,Sponsor-Investigator,18
Breast Cancer Screening,Diffusion-Weighted MRI for Breast Cancer Screening in Women With a Personal History of Breast Cancer,3.421917808219178,Not yet recruiting,Observational,No,No,Principal Investigator,1694
16-145,Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy,5.046575342465753,Recruiting,Interventional,No,Yes,Principal Investigator,98
A5481144,HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes,1.2383561643835617,Terminated,Observational,,,Sponsor,975
D133FR00138,ALEXANDRIA Study Egypt,2.241095890410959,Completed,Observational,,No,Sponsor,436
State University of SÃ£o Paulo,Aerobic Training in Treatment for Breast Cancer,2.419178082191781,Completed,Interventional,No,No,Principal Investigator,6
21-440,Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer,1.3041095890410959,Recruiting,Interventional,No,No,Sponsor,20
YM107109E,Breast Cancer Self-Management Mobile Care Application Intervention in the Quality of Life,0.4821917808219179,Completed,Interventional,No,No,Principal Investigator,112
GEICAM/2020-08,Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer,3.4027397260273973,Recruiting,Interventional,No,No,Sponsor,49
2023-09,Feasibility of Carbon-Dye Marking of Axillary Lymph Nodes Before Neoadjuvant Chemotherapy in Patients With Breast Cancer,1.063013698630137,Recruiting,Interventional,No,No,Principal Investigator,50
ARV-471-BC-201,A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery,1.2931506849315069,Recruiting,Interventional,Yes,No,Sponsor,150
grid.412416.4,The Role of Interleukin-7 Serum Level as Biological Marker in Breast Cancer,1.5424657534246575,Completed,Observational,No,No,Principal Investigator,275
18-333,A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy,5.917808219178082,"Active, not recruiting",Interventional,No,Yes,Principal Investigator,30
MA-BC-II-024,Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC),4.043835616438357,Not yet recruiting,Interventional,No,No,Principal Investigator,420
intestinal flora study,A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer,1.9479452054794524,Recruiting,Observational,No,No,Sponsor,50
ML42450,"Real-World Data on Clinical Characteristics, Demographics, and Outcomes of Patients With Metastatic Breast Cancer in Turkey",1.3808219178082193,Completed,Observational,No,No,Principal Investigator,1331
GNC-035-103,"A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer",2.0109589041095894,Recruiting,Interventional,No,No,Sponsor,29
DS8201-A-U301,DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02],6.090410958904109,"Active, not recruiting",Interventional,Yes,No,Sponsor,600
2018-09-007A,Research on the Heterogeneity of Taiwanese Breast Cancer Patients by Next Generation Sequencing (NGS) Tools,7.778082191780823,Recruiting,Observational,No,No,Sponsor-Investigator,1875
M18DMB,ModraDoc006/r in Patients With Breast Cancer,1.7780821917808218,Completed,Interventional,No,No,Sponsor,12
Microbiome_BC&PnC,Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients,3.2246575342465755,Recruiting,Observational,No,No,Sponsor,35
R148/2021,TIL Relation to pCR After Neoadjuvant Therapy in Breast Cancer Patients,1.106849315068493,Recruiting,Observational,No,No,Principal Investigator,270
ZNJC201935,Nomogram to Predict Breast Cancer Related Lymphedema,7.057534246575343,Recruiting,Interventional,No,No,Principal Investigator,600
SCHBCC0N026,A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC,1.9479452054794524,Recruiting,Interventional,No,No,Principal Investigator,20
MUKDEN-09,"Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer",4.975342465753425,Recruiting,Interventional,No,No,Principal Investigator,236
NACAGEP,"Gene Expression Profiling to Help Define the Need for Neo-Adjuvant Chemotherapy in HR+, HER- Breast Cancer Patients",2.0027397260273974,Recruiting,Observational,No,No,Sponsor,20
2017MayPR898,A Communication Skills Package to Prevent Fear of Cancer Recurrence,1.4191780821917808,Unknown status,Observational,No,No,Principal Investigator,74
RGT-419B_01-101,"First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer",2.4876712328767123,Recruiting,Interventional,Yes,No,Sponsor,48
NCC 2019-0098,Life Style Modification for Breast Canccer Survivors Using Mobile App-based Human Coaching Program,3.1315068493150684,Completed,Observational,No,No,Principal Investigator,130
21-003046,"Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer",1.9041095890410962,Recruiting,Interventional,Yes,No,Sponsor,50
SSGJ-302H-mBC-IIT-01,Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC,1.9863013698630139,Recruiting,Interventional,No,No,Principal Investigator,60
KY2019-070,Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer,8.632876712328768,Recruiting,Interventional,No,No,Principal Investigator,316
PUMA-NER-6203,A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib,1.4958904109589042,Completed,Interventional,Yes,No,Sponsor,6
A5481155,"Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy",0.5041095890410959,Completed,Observational,,,Sponsor,242
D8530C00001,Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.,5.515068493150685,Recruiting,Interventional,Yes,No,Sponsor,403
APHP191059,BIOPSY SCANNER LLTECHÂ© Technology for Diagnosis of Breast Cancer,1.3835616438356164,Unknown status,Observational,No,No,Sponsor,204
1R01CA236860-01A1,Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors,4.9150684931506845,Recruiting,Interventional,No,No,Principal Investigator,250
BT006,Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases,2.452054794520548,Recruiting,Interventional,No,No,Sponsor,10
310-17-SZMC,Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer,2.1616438356164385,Unknown status,Interventional,Yes,No,Sponsor,15
2017-01282 (BASEC),Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer,0.06301369863013699,Terminated,Interventional,No,No,Sponsor,1
CINDERELLA,Comparing Decision on Aesthetics After Breast Cancer Locoregional Treatment.,2.504109589041096,Not yet recruiting,Interventional,No,No,Sponsor,1030
CCR5214,"Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression",3.0027397260273974,Not yet recruiting,Interventional,No,No,Sponsor,324
MCC-21757,Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer,3.994520547945206,Recruiting,Interventional,No,Yes,Sponsor,86
K2022-025-01,A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer,3.0027397260273974,Not yet recruiting,Interventional,No,No,Principal Investigator,63
PUMCH-MUSD,A Comparative Study of Mammography and Ultrasound for Breast Cancer Screening and Early Diagnosis,2.96986301369863,Recruiting,Observational,No,No,Sponsor,6000
0720222005,The Postoperative Radiotherapy in N1 Breast Cancer Patients,11.424657534246576,Recruiting,Interventional,No,No,Principal Investigator,1106
D967UC00001,"Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)",8.684931506849315,Recruiting,Interventional,Yes,No,Sponsor,1134
PLEASURABLE,"Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer",6.586301369863014,"Active, not recruiting",Interventional,No,No,Principal Investigator,59
21822,"COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer",3.5342465753424657,Withdrawn,Interventional,Yes,No,Principal Investigator,0
CTNZ-2017-01,Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy,2.350684931506849,Completed,Interventional,No,No,Principal Investigator,160
20-649,"Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer",8.36986301369863,Recruiting,Interventional,Yes,No,Principal Investigator,32
2020-08-06R,Early Detection of CMP in Patients With Breast Cancer Using Cardiac Magnetic Resonance,2.8383561643835615,Recruiting,Observational,No,No,Sponsor,300
Qassim QDs-VELD,Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer,3.2465753424657535,Unknown status,Interventional,No,No,Principal Investigator,30
HR-BLTN-III-EBC,A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer,5.057534246575343,"Active, not recruiting",Interventional,No,No,Sponsor,1192
COV-19 BUMDC,COVID-19 Pandemic: Effect on Management of Patients With Breast Cancer,1.084931506849315,Completed,Observational,No,No,Sponsor-Investigator,87
14-833-02,Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study,1.5972602739726027,Completed,Interventional,No,No,Sponsor,153
17-519,Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis,7.421917808219178,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,45
Radiotherapy in Breast Cancer,Accelerated Hypofractionated 1 Week Radiotherapy in Breast Cancer Patients,1.4931506849315068,Completed,Interventional,No,No,Principal Investigator,100
2020-A01423-36,Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients,8.956164383561644,Recruiting,Observational,No,No,Sponsor,90
STML-ELA-0222,Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer,3.6027397260273974,Recruiting,Interventional,Yes,No,Sponsor,322
C3441055,Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m,0.5342465753424658,Completed,Observational,Yes,No,Sponsor,40
CRF-NHI01,Real-world Clinical Benefit Evaluation in Breast Cancer Patients With Pharmaceutical Interventions for Cancer-related Fatigue,2.3123287671232875,Recruiting,Observational,No,No,Principal Investigator,200
H-41818,Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer,10.75068493150685,Recruiting,Interventional,Yes,No,Principal Investigator,34
CLUE-BCL,Evaluation of the Treatment Response in Breast Cancer Related Lymphedema,0.4191780821917808,Completed,Interventional,No,No,Principal Investigator,30
nihan25,Women on Breast Cancer Health BelÄ±efs and ScreenÄ±ng BehavÄ±ors,0.7479452054794521,Recruiting,Interventional,No,No,Principal Investigator,200
2020-0927,Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer,3.052054794520548,Recruiting,Interventional,No,No,Sponsor,300
2020FES,16Î±-18F-fluor-17Î²-estradiol PET/CT for Visualisation of Estrogen Receptor Positive Liver Metastases From Breast Cancer,1.0000000000000002,Unknown status,Interventional,No,No,Sponsor,8
PRO00034502,Tell us Your Food Story,1.1397260273972603,Withdrawn,Observational,No,No,Principal Investigator,0
Breast cancer in females,Concurrent Paclitaxel and Radiotherapy After Adjuvant Doxorubicin and Cyclophosphamide for Stage 2 or 3 Breast Cancer,0.24931506849315072,Not yet recruiting,Observational,No,No,Principal Investigator,46
SCLND0919,Clinical Significance of Supraclavicular Lymph Node Dissection for Breast Cancer Patients With Ipsilateral Supraclavicular Lymph Node Metastasis,3.1726027397260275,Unknown status,Interventional,No,No,Sponsor-Investigator,180
KBCSG-24,Omission of Breast Surgery for Breast Cancer Patients With pCR on MRI and Vacuum-assisted Biopsy After NAC (OPTIMIST),8.443835616438356,Recruiting,Interventional,No,No,Sponsor,533
AHQU-2021001,Effect of Oxygen Inhalation on Fatigue After Chemotherapy of Breast Cancer in High Altitude Area,1.8356164383561644,Recruiting,Interventional,No,No,Sponsor-Investigator,102
Fenofibrate in Breast Cancer,Fenofibrate Role in Breast Cancer Patients,1.084931506849315,Recruiting,Interventional,No,No,Principal Investigator,50
AHQU-2021003,Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer,1.997260273972603,Recruiting,Interventional,No,No,Sponsor-Investigator,34
2018LS148,BAriaTric Surgery After Breast Cancer Treatment (BATS),1.841095890410959,Not yet recruiting,Interventional,No,No,Sponsor,40
PekingUMCH-BCa093,68Ga PET/CT Imaging in Breast Cancer Patients,2.128767123287671,Recruiting,Interventional,No,No,Sponsor,50
ADA,"An Integrative Intervention Based on Physical Activity, Nutrition and Supportive Care (the ADA Program) to Improve the Quality of Life of Breast Cancer Survivors",2.9205479452054797,Not yet recruiting,Interventional,No,No,Sponsor,160
514-0213/21-5000,Insulin Sensitivity After Breast Cancer,5.087671232876712,Recruiting,Interventional,No,No,Principal Investigator,24
CentroHLOBreastUnit,HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer,2.0027397260273974,Unknown status,Interventional,No,No,Principal Investigator,90
CCR4965,Evaluating a Digital Tool for Supporting Breast Cancer Patients,3.249315068493151,"Active, not recruiting",Interventional,No,No,Sponsor,165
GCO 21-0699,"Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer",2.926027397260274,Recruiting,Interventional,Yes,No,Principal Investigator,60
DBCG RT Natural Trial,Partial Breast Versus no Irradiation for Women With Early Breast Cancer,17.000000000000004,Recruiting,Interventional,No,No,Principal Investigator,926
IPNCb-01,Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer,2.082191780821918,Recruiting,Interventional,No,No,Sponsor,30
CSPC-KAL-BC-12,Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer,5.506849315068493,Not yet recruiting,Interventional,No,No,Principal Investigator,250
003-2017,Stereotactic Body Radiation Therapy for Breast Cancer,5.002739726027397,Recruiting,Interventional,No,No,Principal Investigator,24
Breast cancer treatment,The Anti-tumor Effect of Metformin And Atorvastatin in Breast Cancer,0.9178082191780822,Not yet recruiting,Interventional,No,No,Principal Investigator,100
18-561,NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer,4.117808219178083,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,30
E19137,Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile,1.832876712328767,Suspended,Observational,No,No,Principal Investigator,20
Vitamin D and breast cancer,Vitamin D and Calcium Supplementation in Breast Cancer,0.915068493150685,Not yet recruiting,Interventional,No,No,Principal Investigator,40
SYSEC-KY-KS-2021-182,Quantitative Assessment of Diffusion Spectrum Imaging in Breast Cancer,0.9972602739726029,Recruiting,Interventional,No,No,Sponsor-Investigator,64
CASE6119,Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer,1.9178082191780825,Recruiting,Interventional,Yes,No,Sponsor-Investigator,30
KX-ORAX-CN-007,A PK Study of Oraxol in Breast Cancer Patients,1.6356164383561644,Completed,Interventional,Yes,No,Sponsor,24
NCC2018M-042,Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant ),2.835616438356164,Unknown status,Interventional,No,No,Principal Investigator,40
CTO-IUSCCC-0803,Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis,0.5315068493150685,Recruiting,Observational,No,No,Principal Investigator,200
55791222.0.0000.5313,Water and Land-based Aerobic Training in Breast Cancer Survivors,2.9972602739726026,Not yet recruiting,Interventional,No,No,Principal Investigator,48
UF-BRE-002,Phase I/IIa Study of Pharmacokinetics and Safety of Epidiferphaneâ¢ and Taxanes in Breast Cancer Patients,3.0,Withdrawn,Interventional,Yes,No,Sponsor,0
18-010602,Screening CEDM in Intermediate and High-Risk Patient Populations,2.2904109589041095,Completed,Observational,No,No,Principal Investigator,461
GIM21 - LiqERBcept,Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial),3.1835616438356165,Completed,Interventional,No,No,Sponsor,48
BREAST-SK-001,"Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.",3.0027397260273974,Unknown status,Interventional,No,No,Sponsor,28
LR19/011/50551,Increasing Knowledge of Alcohol as a Risk Factor for Breast Cancer Among Women Attending Breast Screening Services,0.821917808219178,Completed,Interventional,No,No,Sponsor,558
STU00201961A,A Research Study for Latina Women Undergoing Breast Cancer Treatment,2.808219178082192,Completed,Interventional,No,No,Principal Investigator,51
18-641,"Young, Empowered & Strong (YES): The Young Womens Breast Cancer Study 2- Focus on Intervention Pilot",0.32602739726027397,Completed,Interventional,No,No,Principal Investigator,30
CLEE011O12301C,A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer,7.47945205479452,"Active, not recruiting",Interventional,Yes,No,Sponsor,5101
HIRSLANDEN 01 SAKK 23/18,Intelligent Vacuum Assisted Biopsy Immediately Before Surgery as an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer,4.791780821917809,Recruiting,Interventional,No,No,Principal Investigator,420
CCH-IRB-190414-P,Robotic Versus Conventional or Endoscopic Nipple Sparing Mastectomy in the Management of Breast Cancer-Prospective Study,2.4136986301369863,Recruiting,Interventional,No,Yes,Sponsor,180
348455,Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer,5.504109589041096,"Active, not recruiting",Interventional,No,No,Principal Investigator,41
SOLTI-2101,Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype,4.928767123287671,Recruiting,Interventional,Yes,No,Sponsor,456
Zz123456.,The Effect of the Mobile Application-based Support Program on the Outcomes of Breast Cancer Patients in the Pandemic,1.5890410958904109,Recruiting,Interventional,No,No,Principal Investigator,100
GBG102 - SASCIA,Sacituzumab Govitecan in Primary HER2-negative Breast Cancer,8.424657534246576,Recruiting,Interventional,No,No,Sponsor,1332
PROICM 2018-05 BCU,Sexual Quality of Life in Women During the First Year of Adjuvant Hormonal Treatment for Breast Cancer.,1.4958904109589042,Completed,Observational,No,No,Sponsor,106
CAAE: 91570318.5.0000.5149,Nutritional Status and Pharmacological Treatment: Impact on the Toxicity and Quality of Life of Patients With Colorectal and Breast Cancer,1.082191780821918,Unknown status,Observational,No,No,Principal Investigator,100
FWA00015574/6-01-2019/korany,Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment,0.6958904109589041,Completed,Interventional,No,No,Sponsor-Investigator,250
SYSKY-2022-030-01,Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer,4.879452054794521,Not yet recruiting,Observational,No,No,Principal Investigator,335
UI-ROD-OCTU02,MicroRNA Profiles in Triple Negative Breast Cancer,1.6712328767123288,Recruiting,Interventional,No,No,Principal Investigator,42
KY20182079-F-1,Breast Cancer Treatment Based on Organ-like Culture,2.9534246575342467,Unknown status,Observational,Yes,No,Sponsor,300
PN-301-21,"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer",3.758904109589041,Recruiting,Interventional,Yes,No,Sponsor,146
Radiation in breast cancer,Hypofractionated Radiotherapy Concomitantly With Weekly Boost for Breast Cancer Patients Treated With Conservative Breast Surgery,1.3315068493150686,Unknown status,Observational,No,No,Principal Investigator,50
4-2018-0160,Impact of 5-fraction Stereotactic Partial Breast Irradiation and Whole Breast Irradiation on Cosmetic Outcome and Patient-reported Outcomes in Early-stage Breast Cancer,5.002739726027397,Unknown status,Observational,No,No,Sponsor,200
ROCK,Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer,6.005479452054795,Recruiting,Interventional,No,No,Principal Investigator,25
SOLTI-1805,"A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression",2.3534246575342466,Recruiting,Interventional,No,No,Sponsor,80
KY20202075-F-2,Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer,2.665753424657534,Recruiting,Interventional,No,No,Sponsor,30
06805118.2.1001.5404,Sentinel Lymph Node Biopsy Versus no Axillary Surgery in Early Breast Cancer,11.008219178082191,Recruiting,Interventional,No,No,Principal Investigator,800
ID4060,Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer,2.580821917808219,Completed,Observational,No,No,Principal Investigator,52
AN.MCME.CR.12,Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation,3.0027397260273974,Unknown status,Interventional,Yes,No,Sponsor,25
MedOPP293,Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer,6.575342465753424,Recruiting,Interventional,No,No,Sponsor,393
iOM-110383,A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer,0.24657534246575347,Withdrawn,Interventional,No,No,Sponsor,0
IRST174.25,Partial Breast Re-irradiation in Women in Women With Locally Recurrent Breast Cancer Previously Treated With Conservative Surgery and Whole Breast Irradiation,8.926027397260274,Recruiting,Interventional,No,No,Sponsor,68
EUROPA,ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged â¥70 Years Early Stage Breast Cancer,9.005479452054795,Recruiting,Interventional,No,No,Principal Investigator,926
HM022BC3C01,A Phase â¢ Study of the Efficacy and Safety of Hemay022+Aromatase Inhibitor(AI) in Participants With ER+/HER2+ Advanced or Metastatic Breast Cancer,2.367123287671233,Recruiting,Interventional,No,No,Sponsor,339
UF-BRE-007,Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients,2.7835616438356166,Recruiting,Interventional,Yes,No,Sponsor,74
SOLTI-2103,NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial,7.684931506849316,Recruiting,Interventional,No,No,Sponsor,120
SOLTI-1503,Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer,6.383561643835616,"Active, not recruiting",Interventional,No,No,Sponsor,28
0023041/i,MONOCENTRIC PERSPECTIVE STUDY: USE OF LIQUID BIOPSY WITH DIAGNOSTIC IMAGING,3.03013698630137,Recruiting,Observational,No,No,Principal Investigator,200
LQ009,Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study,5.506849315068493,Not yet recruiting,Interventional,No,No,Principal Investigator,500
BGB-900-2001-IIT,"A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)",2.2465753424657535,Recruiting,Interventional,No,No,Principal Investigator,96
CLEE011H2301,Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer,7.638356164383563,Withdrawn,Interventional,Yes,No,Sponsor,0
2020_61,Study of the Sexual Health of Patients Treated for Breast Cancer and Followed up in the Observatory of Fertility at Jeanne de Flandre Hospital.,3.969863013698631,Recruiting,Observational,No,No,Sponsor,65
ONAWA (SOLTI-1802),Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer,0.47945205479452063,Completed,Interventional,No,No,Sponsor,10
1,Hypofractionated Radiotherapy in Breast Cancer Patients With Prosthetic Reconstruction,6.8493150684931505,Recruiting,Interventional,No,No,Sponsor,120
STUDY00010776,REJOIN Trial for Older Breast Cancer Survivors,2.463013698630137,Recruiting,Interventional,No,No,Principal Investigator,24
CASE13119,Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer,1.6712328767123288,Not yet recruiting,Interventional,No,No,Sponsor,100
ZX-2021-FES-ESTROTIMP-4,Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer,3.3123287671232875,Recruiting,Interventional,No,No,Sponsor,152
2017-0499,"Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer",3.786301369863014,Completed,Interventional,Yes,No,Sponsor,24
IIT-UM2018001,Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation,3.4136986301369863,Recruiting,Interventional,No,No,Sponsor,44
Shengjing_002,Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer,3.0821917808219177,Recruiting,Interventional,No,No,Principal Investigator,420
2022/050,Telerehabilitation in Survival Breast Cancer Patients,1.1945205479452055,Recruiting,Interventional,No,No,Principal Investigator,69
IRB-57723,Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer,4.997260273972603,Recruiting,Interventional,Yes,No,Sponsor,25
D8530C00006,"A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer",3.249315068493151,"Active, not recruiting",Interventional,No,No,Sponsor,10
3764,Stereotactic Body Radiotherapy for Patients With Breast Cancer Oligometastasis,3.249315068493151,Unknown status,Interventional,No,No,Principal Investigator,30
115858,SIGNAL During a COVID-19 Pandemic,2.504109589041096,Withdrawn,Interventional,No,No,Sponsor,0
CCH-IRB-190414-R,Robotic Versus Conventional or Endoscopic Nipple Sparing Mastectomy for Breast Cancer,2.361643835616438,Unknown status,Interventional,No,Yes,Sponsor,900
UCCS20110,Development of a Personalized Discussion Prioritization Tool for Older Adults Considering Adjuvant Chemotherapy for Breast Cancer,1.9260273972602742,"Active, not recruiting",Interventional,No,No,Principal Investigator,10
Shengjing-LJY04,Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer,10.005479452054795,Recruiting,Observational,No,No,Principal Investigator,500
2019-004559-35,Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial),7.0849315068493155,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,27
GEICAM/2017-04,Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA),4.027397260273973,Completed,Observational,No,No,Sponsor,32
KARMA Kontrast,KARMA Kontrast - a Controlled Trial Evaluating Contrast Enhanced Mammography in Early Detection of Breast Cancer,1.5561643835616439,Unknown status,Interventional,No,No,Principal Investigator,420
ACE-Breast-03,"ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)",4.66027397260274,"Active, not recruiting",Interventional,Yes,No,Sponsor,31
BREAST,BRaziLian outcomE for metAStatic breasT Cancer,3.3013698630136985,Recruiting,Observational,No,No,Sponsor,300
FMBSUREC/10102021/Rabie,Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients,3.16986301369863,Recruiting,Interventional,No,No,Principal Investigator,60
1808-42,Survey Study: Financial Impact of Breast Cancer Treatment,6.243835616438356,"Active, not recruiting",Observational,No,No,Sponsor,103
2020-535,Targeted Resection of Axillary Metastatic Lymph Nodes After Breast Cancer Neoadjuvant Chemotherapy,4.6657534246575345,Recruiting,Interventional,No,No,Sponsor,332
RP-20-013,Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer,2.750684931506849,Withdrawn,Interventional,Yes,No,Sponsor,0
EF141,Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy,1.747945205479452,Withdrawn,Interventional,No,No,Sponsor,0
STUDY00001225,The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project,4.2027397260273975,Recruiting,Interventional,No,No,Principal Investigator,452
CCR5119,KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer,6.545205479452055,Recruiting,Interventional,No,No,Sponsor,184
3475-756,"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)",12.084931506849315,"Active, not recruiting",Interventional,Yes,No,Sponsor,1240
21-271,Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity,2.0000000000000004,Recruiting,Observational,No,Yes,Sponsor,30
STUDY2019000317,Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer,10.008219178082191,Recruiting,Observational,No,No,Principal Investigator,1000
FirstHCMU_CB_001,Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast,0.5424657534246575,Unknown status,Observational,No,No,Principal Investigator,1354
2022-0055,A Study for the Neoadjuvant Treatment of Breast Cancer,5.449315068493151,Recruiting,Interventional,No,No,Sponsor,1576
WEFITTER,Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib,0.9424657534246575,Recruiting,Interventional,No,No,Principal Investigator,68
A5481178,A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer.,0.38082191780821917,Completed,Observational,,,Sponsor,48
ARO-2015-1,Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer,4.323287671232877,Recruiting,Interventional,No,No,Sponsor,564
HNCH-MBC11,Utidelone Combined With Bevacizumab in the Treatment of â¥ 2 Lines of HER-2 Negative Advanced Breast Cancer,2.5835616438356164,Not yet recruiting,Interventional,No,No,Sponsor,71
SOLTI-1507,Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients,5.501369863013698,Recruiting,Interventional,No,No,Sponsor,15
DKFZ-2019-008,Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE),6.5917808219178085,Not yet recruiting,Interventional,No,No,Sponsor,240
20170328,Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer,3.419178082191781,Completed,Interventional,No,No,Principal Investigator,31
SHPD005,Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer,4.501369863013698,Recruiting,Interventional,No,No,Sponsor,196
dAGEs,"Dietary Advanced Glycation End Products, Inflammation and Oxidative Stress in Breast Cancer Patients",3.326027397260274,Recruiting,Observational,No,No,Principal Investigator,32
20-124,YES Study - Newly Diagnosed/Metastatic Intervention,7.46027397260274,Recruiting,Interventional,No,No,Principal Investigator,400
LaPemERLA,Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole,3.8767123287671237,Recruiting,Interventional,No,No,Sponsor,40
NIR-THERMA-02,A Prospective Study to Evaluate Clinical Performance of Thermalytix in Detecting Breast Cancers,1.126027397260274,Completed,Observational,No,No,Sponsor,459
E7389-M082-602,A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants,0.4273972602739726,Completed,Observational,No,No,Sponsor,340
20-166,Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC,6.701369863013698,Recruiting,Interventional,Yes,No,Principal Investigator,110
Pro00020138,Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer,5.23013698630137,Recruiting,Interventional,Yes,No,Principal Investigator,28
18-394,DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC,11.830136986301369,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,100
2019SABE028,The Effect of Early Rehabilitation After Breast Cancer Surgery on Physical and Psychosocial Functions,1.4191780821917808,Recruiting,Interventional,No,No,Principal Investigator,42
IIBSP-PRO-2021-10,Prehabilitation for Breast Cancer Surgery,2.0000000000000004,Recruiting,Interventional,No,No,Sponsor-Investigator,64
SYSUCC-015,Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer,7.06027397260274,Recruiting,Interventional,No,No,Principal Investigator,520
REO 026-1,Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer,1.7205479452054795,"Active, not recruiting",Interventional,No,No,Sponsor,15
STUDY00001233,Novel Thermal Imaging Technique for Breast Screening,3.128767123287671,Recruiting,Observational,No,No,Sponsor,700
2019.429,Effectiveness of Character Strengths-based Intervention Among Breast Cancer Patients,0.6301369863013698,Completed,Interventional,No,No,Principal Investigator,122
CP7-005,A Study Comparing ImmunopheresisÂ® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients,4.169863013698631,Recruiting,Interventional,No,No,Sponsor,170
LY2023-054-B,RC48-ADC in HER2-low Advanced Breast Cancer,3.336986301369863,Not yet recruiting,Interventional,No,No,Principal Investigator,36
INCASE0518,Artificial Intelligence vs Physicians for Breast Cancer Patients Information,0.2191780821917808,Completed,Observational,No,No,Sponsor,150
2021/193780(REK),Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole,2.0027397260273974,Recruiting,Interventional,No,No,Principal Investigator,100
123123,Eurythmy Therapy (ERYT) as a Treatment Option for Fatigue in Metastatic Breast Cancer Patients,4.728767123287671,Recruiting,Interventional,No,No,Sponsor,196
JTU-6H-20211011001,Effect of ALND With Vein Branches Reservation on Postoperative Upper Limb Edema and Dysfunction in Breast Cancer,2.249315068493151,Recruiting,Interventional,No,No,Sponsor-Investigator,288
INST 1607,Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging,6.715068493150685,Recruiting,Observational,No,No,Sponsor,30
CIMS-4FMFES-2021-3966,4FMFES-PET Imaging of ER+ Advanced Breast Cancers,3.164383561643836,Recruiting,Interventional,No,No,Principal Investigator,150
SOLTI-1718,Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer,1.3534246575342466,Terminated,Interventional,No,No,Sponsor,12
Yunwei Wei 2019-09-13,Intestinal Microbiota of Breast Cancer Patients Undergoing Chemotherapy,1.093150684931507,Unknown status,Observational,Yes,No,Sponsor,80
HLX11-BC301,A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-PerjetaÂ® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer,3.684931506849315,Recruiting,Interventional,Yes,No,Sponsor,900
Zoledronic Acid In Breast Ca,Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole,2.0000000000000004,Recruiting,Interventional,Yes,No,Principal Investigator,50
Tacrolimus_2020,Tacrolimus as Treatment of Breast Cancer-Related Lymphedema,1.2904109589041095,Completed,Interventional,No,No,Principal Investigator,20
6788,Breast MRI for Neaodjuvant Chemotherapy Response Prediction and Evaluation in Breast Cancer,1.0000000000000002,Unknown status,Observational,No,No,Sponsor,100
KSRAD001,Using AI to Select Women for Supplemental MRI in Breast Cancer Screening,4.252054794520548,Recruiting,Interventional,No,No,Principal Investigator,2500
Stage 2 compression therapy,Adjustable Compression Wrap Versus Compression Sleeve to Control Breast Cancer-related Lymphedema,1.5835616438356164,Not yet recruiting,Interventional,No,Yes,Principal Investigator,72
CASE5120,Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer,2.926027397260274,Recruiting,Interventional,No,No,Sponsor,72
PROICM 2020-07 VIS,Professional Life After Breast Cancer: Feasibility of a Coaching Program for an Adapted Return to Work,1.63013698630137,Recruiting,Interventional,No,No,Sponsor,25
CL1-81694-003,S 81694 Plus Paclitaxel in Metastatic Breast Cancer,2.4273972602739726,Completed,Interventional,No,No,Sponsor,22
Shengjing-LCG005,Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer,5.36986301369863,Recruiting,Interventional,No,No,Principal Investigator,110
2020.KB.SAG.069,The Effect of Mobile Lymphedema Self-Care Support Program on Self-Care in Women With Breast Cancer-related Lymphedema,0.24931506849315072,Recruiting,Interventional,No,No,Principal Investigator,60
NCC1824,Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR,2.706849315068493,Unknown status,Observational,No,No,Principal Investigator,200
INNOVBC,A Guided Internet-delivered Individually-tailored ACT-influenced CBT Intervention to Improve Psychosocial Outcomes in Breast Cancer,1.83013698630137,Unknown status,Interventional,No,No,Principal Investigator,128
R20-003,Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Breast Cancer,2.0849315068493155,Recruiting,Interventional,Yes,No,Principal Investigator,20
MedOPP319,CB-103 Plus NSAI In Luminal Advanced Breast Cancer,1.9863013698630139,"Active, not recruiting",Interventional,No,No,Sponsor,80
WO39391,A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer,7.065753424657534,"Active, not recruiting",Interventional,Yes,No,Sponsor,2300
NCC1867,The Psychology of Chinese Breast Cancer Patients,2.6876712328767125,Enrolling by invitation,Observational,No,No,Sponsor-Investigator,300
20-157,Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD),2.958904109589041,Recruiting,Interventional,Yes,Yes,Sponsor-Investigator,120
2-102-21,Towards Early Detection of Breast Cancer in High Risk Population,2.16986301369863,Not yet recruiting,Observational,No,No,Sponsor,120
HunanCH-BC-001,Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer,3.0027397260273974,Not yet recruiting,Observational,No,No,Sponsor,100
2021.693,mHealth Usage Among Nigeria Women Diagnosed With Breast Cancer Receiving Chemotherapy,1.2493150684931507,Recruiting,Interventional,No,No,Principal Investigator,126
GENEXAN,GENe EXpression After Regional or General ANesthesia in Patients Undergoing Breast Cancer Surgery,1.0000000000000002,Unknown status,Interventional,No,No,Principal Investigator,100
HSC20160245H,Improving Adherence to EHT Among Breast Cancer Patients,4.082191780821918,"Active, not recruiting",Interventional,No,No,Sponsor,108
GRO-06-001,ABUS for Early-stage Breast Cancer,3.0027397260273974,Unknown status,Interventional,No,No,Principal Investigator,675
Neveen,"Demographic , Clinicopathological Characteristics and Survival of Breast Cancer",3.7534246575342465,Not yet recruiting,Observational,No,No,Principal Investigator,100
Melody_002,"MelodyÂ®, a Lab Developed Test for Breast Cancer for Women With Dense Breast Tissue",3.0027397260273974,Recruiting,Observational,No,No,Sponsor,1500
REC-H-PHBSU-21010,Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints,1.3342465753424657,Completed,Interventional,No,No,Principal Investigator,100
YOUNGBC-22,"Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer",1.3342465753424657,"Active, not recruiting",Interventional,No,No,Principal Investigator,72
16D.674,Prospective Breast Cancer Biospecimen Collection,2.706849315068493,Unknown status,Interventional,No,No,Sponsor,200
SMC- 5725-18,The Breast Cancer Personalized Nutrition Study,6.380821917808219,Recruiting,Interventional,No,No,Principal Investigator,200
2000025837,Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer,3.5232876712328767,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,6
DS8201-A-U305,A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05),10.07945205479452,Recruiting,Interventional,Yes,No,Sponsor,1600
2020/33,Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer,6.882191780821918,Recruiting,Interventional,No,No,Sponsor,40
2018.016,Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA,6.534246575342466,Recruiting,Interventional,No,No,Sponsor,164
HE071-CSP-021,A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer,2.96986301369863,Recruiting,Interventional,No,No,Sponsor,73
Shengjing_001,Study on Bisphosphonates Targeting Triple-negative Breast Cancer,3.0,Recruiting,Observational,No,No,Principal Investigator,120
PREDIX II HER2,Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer,2.1068493150684935,Terminated,Interventional,Yes,No,Sponsor-Investigator,6
ATADEK 2022-17/27,The Effect of Wearable Vibration Therapy on Shoulder Functionality in Individuals Receiving Adjuvant Radiotherapy After Breast Cancer Surgery,0.29041095890410956,Recruiting,Interventional,No,No,Principal Investigator,38
CHIR-01-sentinel,Sentinel Lymph Node Biopsy in Patients With Breast Cancer After Neoadjuvant Therapy,2.915068493150685,Completed,Interventional,No,No,Sponsor,61
R.20.05.834,Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.,2.904109589041096,Recruiting,Interventional,No,No,Principal Investigator,120
MCC-20902,Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer,4.161643835616439,"Active, not recruiting",Interventional,Yes,No,Sponsor,13
D3615C00001,Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer,4.145205479452056,"Active, not recruiting",Interventional,Yes,No,Sponsor,818
SMC-2019-05-021 (2),Real-time Interactive Digital Healthcare System in Patients With Breast Cancer; Randomized Controlled Trial,1.63013698630137,Completed,Interventional,No,No,Principal Investigator,100
PUMCH-BC501,Evaluation of Prognostic Monitoring for Breast Cancer Patients With Recurrence and Metastasis After Surgery,5.920547945205479,Recruiting,Observational,No,No,Principal Investigator,200
17/209,The Tomosynthesis Trial in Bergen - Part 2,5.416438356164384,"Active, not recruiting",Interventional,No,No,Sponsor,31082
2022-SR-494,Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer,3.219178082191781,Recruiting,Interventional,No,No,Sponsor,30
PCS-001,Breast Cancer Liquid Biopsy Trial,2.8383561643835615,Recruiting,Observational,No,No,Sponsor-Investigator,450
1563/2018,Randomized Clinical Trial Comparing Rehabilitation Robotic Versus Conventional After Breast Cancer Surgery,1.4219178082191781,Unknown status,Interventional,No,No,Sponsor,108
C3441053,Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer,0.14246575342465753,Completed,Observational,Yes,No,Sponsor,110
18-603,"Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors",2.0958904109589045,Completed,Interventional,No,No,Principal Investigator,100
2021-0170,Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer,3.4136986301369863,Recruiting,Interventional,No,No,Sponsor,190
PUMCH-SBSBC,Survival Benefits of Statins in Breast Cancer Patients,5.257534246575342,Recruiting,Interventional,No,No,Sponsor,314
B27IB3856,UCLA Breast Cancer Survivor Health Promotion Research Study,1.167123287671233,Recruiting,Interventional,No,No,Principal Investigator,30
2018.08.ST,Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma,3.0246575342465754,Terminated,Interventional,Yes,No,Principal Investigator,7
YYS-20200305,Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer,1.7780821917808218,Completed,Interventional,No,No,Sponsor,80
CAN04CLIN005,Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.,4.556164383561644,Recruiting,Interventional,No,No,Sponsor,116
YOUNGBC-7,18F-FES PET/CTs Additional Clinical Value in ER+ BC,0.3424657534246575,Completed,Observational,No,No,Principal Investigator,19
ORIN1001-001,ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer,3.849315068493151,"Active, not recruiting",Interventional,Yes,No,Sponsor,150
LUN_MMG_121,Study to Evaluate Effectiveness of Investigational Device in the Assistance of Detection and Diagnosis of Breast Cancer,0.5808219178082191,Completed,Observational,No,Yes,Sponsor,240
Breast Cancer-RISS,Ultrasound Guided Rhomboid Intercostal and Subserratus Plane Block in Breast Cancer Surgeries,0.49863013698630143,Completed,Interventional,No,No,Principal Investigator,50
TRICIA,TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence,3.4904109589041097,Recruiting,Observational,No,No,Principal Investigator,130
STML-ELA-0322,"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study",2.0027397260273974,Not yet recruiting,Interventional,Yes,No,Sponsor,80
LCCC2105,Transitioning Care: Perspectives of Older Women With Early Breast Cancer on Current Telemedicine Modalities,0.273972602739726,Completed,Observational,No,No,Sponsor,15
RJrapidplan,RapidPlan Models Establishment for Node-Positive Breast Cancer Treated With Hypofractionation Using Edge/Truebeam,3.0027397260273974,Recruiting,Observational,No,No,Principal Investigator,195
2-049-18,Randomised Controlled Study of Physical Exercise Intervention in Breast Cancer Patients at Risk of Anthracycline-induced Cardiomyopathy: The EMBRACE Study,10.583561643835617,Recruiting,Observational,No,No,Sponsor,12
MIES-BCNAT,Multimodal Imaging Evaluation System of Axillary Lymph Node Staging and Treatment Strategy for Breast Cancer Neoadjuvant Therapy,2.9972602739726026,Not yet recruiting,Observational,No,No,Principal Investigator,300
MACSSI (ET18-150),MACSSI (MAstectomie Cellules Souches Surveillance Immunitaire),3.7315068493150685,Recruiting,Observational,,,Sponsor,40
HNCH-BC010,A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer,2.3917808219178083,Recruiting,Interventional,No,No,Principal Investigator,456
22SCH740,STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER),4.002739726027397,Not yet recruiting,Interventional,Yes,No,Principal Investigator,36
eMOUVOIR-1901,Impact of Personalized and Remote Support Centered on Exercise and Physical Activity for Breast Cancer Patients,3.9561643835616445,Recruiting,Interventional,No,No,Sponsor,1133
NCC2019-0142,Prospective Cohort Study of Breast Cancer Patients Treated With Radiotherapy,15.002739726027396,Enrolling by invitation,Observational,No,No,Principal Investigator,5000
19-002792,Adipose-Induced Regeneration of Breast Skin to Treat Post-Mastectomy Radiation Injury in Breast Cancer Patients,7.213698630136986,Recruiting,Interventional,No,No,Principal Investigator,20
20G.605,Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer,3.1041095890410957,Recruiting,Interventional,Yes,No,Sponsor,25
UT BCS Sleep Study,Feasibility and Effectiveness of a Sleep Hygiene Education Program for Sleep Issues in Breast Cancer Survivors,0.4602739726027397,Withdrawn,Interventional,No,No,Principal Investigator,0
919PP17,Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin,0.6657534246575343,Completed,Interventional,No,No,Principal Investigator,100
H-50349,Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer,6.5479452054794525,Not yet recruiting,Interventional,Yes,No,Principal Investigator,185
NIS12501,"A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib",0.5698630136986301,Recruiting,Observational,No,No,Sponsor,130
B002-101,B002 in Patients With HER2-positive Breast Cancer,2.915068493150685,Completed,Interventional,No,No,Sponsor,23
MCC-21378,Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer,3.92054794520548,Recruiting,Interventional,Yes,No,Sponsor,28
"2016-051-000001, 2563",Investigating Barriers for Decision Making in a Danish Breast Cancer Screening Context,0.36164383561643837,Recruiting,Interventional,No,No,Sponsor,3000
010006,Integrin Î±6-targeted SPECT Imaging of Breast Cancer,1.3123287671232877,Completed,Interventional,No,No,Principal Investigator,9
20210504,MRI-based Approaches for Multi-parametric Model to Early Predict Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer,4.495890410958904,Recruiting,Observational,No,No,Principal Investigator,200
2021-0358,A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC),3.1205479452054794,Recruiting,Interventional,Yes,No,Sponsor,20
LACUDY,Evaluate Efficacy and Safety of LACUDY for Improving Vaginal Environment in Breast Cancer Patient,0.1917808219178082,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,60
18-2444.cc,Facial Skin Health Tracking Feasibility in Breast Cancer Patients,4.523287671232877,Recruiting,Observational,No,No,Sponsor,35
CSPC-DMS-BC-17,Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer,1.2547945205479452,Unknown status,Interventional,No,No,Principal Investigator,40
UC-0105/1815,"Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis",5.443835616438356,"Active, not recruiting",Interventional,No,No,Sponsor,186
NCC3340,A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer,2.3315068493150686,Recruiting,Interventional,No,No,Principal Investigator,26
YOMA,Effects of Yoga on the Quality of Life of Breast Cancer Patients,2.5671232876712327,Recruiting,Interventional,No,No,Principal Investigator,138
2022-7735,Life After Breast Cancer - Impact of a Life Coach,1.9616438356164385,Not yet recruiting,Interventional,No,No,Principal Investigator,120
IRB00130428,The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer,4.767123287671233,"Active, not recruiting",Interventional,Yes,Yes,Sponsor,30
HR BLTN 014,Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer,3.0821917808219177,"Active, not recruiting",Interventional,No,No,Sponsor,41
C4891023,TACTIVE-U: A Study to Learn About the Study Medicine (Called ARV-471) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B),4.602739726027397,Recruiting,Interventional,Yes,No,Sponsor,35
SYSU-2022-02,"Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.",1.4986301369863013,Recruiting,Interventional,No,No,Principal Investigator,28
GO40987,"A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer",1.832876712328767,Completed,Interventional,Yes,No,Sponsor,75
HR-BLTN-008,"Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer",3.4,Recruiting,Interventional,No,No,Sponsor,86
OkanU2,Influence of Multidisciplinary Breast Tumor Board on Physician Decision,1.252054794520548,Unknown status,Observational,No,No,Principal Investigator,120
HNCH-MBC08-BM02,Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases,2.008219178082192,Recruiting,Interventional,No,No,Sponsor,100
LET,Lymphedema Treatment Registry,1.252054794520548,Not yet recruiting,Observational,Yes,No,Principal Investigator,60
19-003532,Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers in Patients Undergoing Regional Nodal Irradiation for Breast Cancer,4.002739726027397,Recruiting,Observational,No,No,Principal Investigator,400
SNF4,Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer,4.331506849315068,Recruiting,Interventional,No,No,Principal Investigator,145
PALBOCOMP,Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use Programe,0.9534246575342467,Completed,Observational,No,No,Sponsor-Investigator,237
MA-BC-II-006,Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC),3.778082191780822,Recruiting,Interventional,No,No,Principal Investigator,20
17/013,Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer,4.835616438356165,"Active, not recruiting",Interventional,No,No,Sponsor,54
LACOG 0221,"Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil",1.4657534246575343,Recruiting,Observational,No,No,Sponsor,300
SNF3,PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer,4.331506849315068,Recruiting,Interventional,No,No,Principal Investigator,200
1780,Identifying Biomarkers for Chronic Pain After Breast Cancer Treatment.,2.750684931506849,Not yet recruiting,Observational,No,No,Principal Investigator,150
2020 - 176,Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer,0.915068493150685,Unknown status,Interventional,No,No,Principal Investigator,60
HR-TNBC-HN100,SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer,3.0027397260273974,Unknown status,Interventional,No,No,Principal Investigator,39
2018-68-1461,Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer,5.920547945205479,Recruiting,Interventional,No,No,Principal Investigator,1560
YANWQ002,the New Geneswell BCT in Vitro Diagnosis of Breast Cancer Prognosis,0.915068493150685,Unknown status,Observational,No,Yes,Sponsor,100
STU00206180,A Web-Based Tool to Improve Breast Cancer Survivorship,2.926027397260274,Completed,Interventional,No,No,Principal Investigator,84
MR-01,Monitoring Response to Neoadjuvant Chemotherapy in Breast Cancer Using Ultrafast DCE-MRI,2.493150684931507,Recruiting,Observational,No,No,Principal Investigator,80
2019-09-09,Sentinel Lymph Node Biopsy With Hybrid Technique in Breast Cancer,6.005479452054795,Recruiting,Interventional,No,No,Principal Investigator,120
UBRS20013,Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer,3.0027397260273974,Not yet recruiting,Interventional,Yes,No,Principal Investigator,20
SPI-POZ-101,A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer,0.7616438356164383,Terminated,Interventional,Yes,No,Sponsor,6
HR-BLTN-014,Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer,1.6684931506849314,Unknown status,Interventional,No,No,Principal Investigator,20
EC/TMC/108/17,Hypo-Fractionated Radiotherapy in Breast Cancer,5.005479452054795,Unknown status,Interventional,No,No,Sponsor,30
SGRT-BC,Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer,5.002739726027397,Recruiting,Interventional,No,No,Sponsor,556
CMUH108-REC3-090,A Study to Evaluate the Safety and Clinical Outcome of Using FR-Mask in Breast Cancer Patients With Radiation-irritated Skin After Radiotherapy,2.2383561643835614,Unknown status,Interventional,No,No,Principal Investigator,10
PALBOSPAIN,Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer,0.8547945205479452,Completed,Observational,No,No,Principal Investigator,815
RC48-C012,A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2,3.252054794520548,Recruiting,Interventional,No,No,Sponsor,366
261\\2021,Real-time Tele-monitoring Versus Routine Monitoring of Breast Cancer Patients Receiving Adjuvant Systemic Therapy,1.9178082191780825,Not yet recruiting,Interventional,No,No,Sponsor,150
ERIBRAIN-IPC 2017-014,Eribulin in Brain Metastases From HER2-negative Breast Cancer,1.1315068493150684,Withdrawn,Interventional,No,No,Sponsor,0
CYH33-G103,"Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer",1.6684931506849314,Unknown status,Interventional,No,No,Sponsor,228
OTT 18-02,Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT),2.5616438356164384,Completed,Interventional,No,No,Sponsor,262
SYSA1901-002,Study to Evaluate the Efficacy and Safety of SYSA1901 vs. PerjetaÂ® of HER2-Positive Breast Cancer,3.1205479452054794,Recruiting,Interventional,No,No,Sponsor,560
YBCSG-21-03,Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer,2.197260273972603,Unknown status,Interventional,No,No,Principal Investigator,92
EBaran,The Effect of Complex Decongestive Physiotherapy on Sensory Parameters in Breast Cancer Related Lymphedema.,2.0109589041095894,Unknown status,Interventional,No,No,Principal Investigator,30
99mTc-ADAPT6,99mTc-ADAPT6-based HER2 Imaging in Breast Cancer,1.2547945205479452,Completed,Observational,No,No,Sponsor,16
2019-0088,Proton Accelerated Partial Breast Irradiation,1.0191780821917809,Withdrawn,Interventional,No,No,Principal Investigator,0
R20-030,Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI,3.6684931506849314,Recruiting,Interventional,Yes,No,Principal Investigator,25
NL77000.029.21,Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients,12.526027397260274,Recruiting,Interventional,No,No,Principal Investigator,100
MUKDEN 07,A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients,5.961643835616439,Recruiting,Interventional,No,No,Principal Investigator,61
OstacoliMIND&BC,Mindful-life: Mindfulness Based Intervention vs Cognitive Behavioral Therapy in Patients With Breast Cancer,0.9972602739726029,Unknown status,Interventional,No,No,Principal Investigator,100
NCC3286,A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway,2.336986301369863,Recruiting,Interventional,No,No,Principal Investigator,64
HR-BLTN-010,A Phase â¡ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer,2.9178082191780823,Unknown status,Interventional,No,No,Sponsor-Investigator,60
KY2019,Recurrence Risk Evaluation by 21-gene Detection,0.08493150684931507,Completed,Observational,No,No,Principal Investigator,220
GS-US-595-6184,Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physicians Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy,8.06027397260274,Recruiting,Interventional,Yes,No,Sponsor,1514
CMUH106-REC3-137,Comparative Effectiveness of Acupuncture and Nonsteroidal Anti-inflammatory Drugs for the Management of Aromatase Inhibitor Induced Arthralgia Among Breast Cancer Survivors,3.7643835616438355,Completed,Interventional,No,No,Sponsor,54
2010134480,Prospective Comparison of Breast MRI vs Contrast Mammography Prior to Surgery in Breast Cancer Patients,1.9506849315068495,Unknown status,Interventional,No,Yes,Principal Investigator,100
DS8201-A-U303,Trastuzumab Deruxtecan (DS-8201a) Versus Investigators Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04],4.178082191780822,"Active, not recruiting",Interventional,Yes,No,Sponsor,557
H18-02581,"Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers",4.983561643835617,Not yet recruiting,Interventional,No,No,Principal Investigator,50
SMX 22-002,Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,3.254794520547945,Not yet recruiting,Interventional,Yes,No,Sponsor,400
18-371,"Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial",5.882191780821918,"Active, not recruiting",Interventional,No,Yes,Principal Investigator,80
K171005J,"Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility",1.5205479452054795,Completed,Interventional,No,No,Sponsor,186
9745,CESM ABMR Breast Cancer Screening Trial,4.994520547945205,Completed,Observational,No,Yes,Sponsor,256
J1836,"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer",5.134246575342465,"Active, not recruiting",Interventional,Yes,No,Sponsor,33
2019/2452,Impact of a Breast cAncer Survivorship Interprofessional Community Care Model,1.3863013698630138,Completed,Interventional,No,No,Sponsor,70
X-XJTU1AFLSY-93,"Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038",2.4164383561643836,Recruiting,Interventional,No,No,Principal Investigator,209
20-104,"Move Together Boston Feasibility Pilot (Sit Less, Move More App for Black Breast Cancer Survivors & At-Risk Relatives)",0.3643835616438356,Completed,Interventional,No,No,Principal Investigator,31
SCHBCC-N030,Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS),7.002739726027397,Not yet recruiting,Interventional,No,No,Principal Investigator,356
D967JC00001,A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer,5.008219178082192,Recruiting,Interventional,Yes,No,Sponsor,245
STUDY00022698,MammoScreen Breast Cancer Risk Assessment and Decision Aid for Breast Cancer Screening and Referrals,2.9835616438356163,Recruiting,Observational,No,,Principal Investigator,1141
CLEE011AUS64,A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors,0.16712328767123288,Completed,Observational,No,No,Sponsor,4650
NCC1888,Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib,2.0328767123287674,Not yet recruiting,Interventional,No,No,Principal Investigator,68
SCAN-B-rec,Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec),11.868493150684932,Recruiting,Observational,No,No,Sponsor,2000
LMengmeng,An Online Psychosocial Intervention for Fear of Cancer Recurrence in Breast Cancer Survivors,1.2493150684931507,Recruiting,Interventional,No,No,Principal Investigator,244
XZP-3287-3002,A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer,3.8328767123287677,Not yet recruiting,Interventional,No,No,Sponsor,372
R21-072,Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI),4.1726027397260275,Not yet recruiting,Interventional,Yes,No,Principal Investigator,20
HCI131027,Functional Precision Oncology for Metastatic Breast Cancer,4.457534246575342,Recruiting,Interventional,No,No,Sponsor,15
SCHBCC-N025,A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS),2.9205479452054797,"Active, not recruiting",Interventional,No,No,Principal Investigator,46
ERC/2020/10/11 (26/10/2020),Improving Access to Breast Cancer Screening and Treatment in Nigeria: The Triple Mobile Assessment and Patient Navigation Model,1.895890410958904,Recruiting,Interventional,No,Yes,Principal Investigator,4100
19-055,A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients,7.47945205479452,Recruiting,Interventional,Yes,No,Principal Investigator,20
SLNB-ACP,Sentinel Lymph Node Biopsy After Neoadjuvant Treatment in Breast Cancer Patents,8.613698630136986,Enrolling by invitation,Observational,,,Principal Investigator,100
AI-BMRI,Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening Breast Cancer in High-risk Women,4.082191780821918,Recruiting,Observational,No,No,Principal Investigator,5000
2019/1318,Exercise in Breast Cancer Survivors,2.4794520547945207,Completed,Interventional,No,No,Principal Investigator,210
20F.259,Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure Estimation,3.317808219178082,Recruiting,Interventional,Yes,No,Sponsor-Investigator,200
BC-P29,Selective Omission of Axillary Surgery in Triple-negative and HER2-positive Breast Cancer After NACT,8.169863013698631,Recruiting,Interventional,No,No,Principal Investigator,136
Smart,An Innovative Smartphone Application for Adverse Event Management During Breast Cancer Adjuvant Chemotherapy,0.7534246575342466,Not yet recruiting,Interventional,No,No,Sponsor,108
OMICS Mark,Metabolomics Explores Biomarkers for Metastatic Breast Cancer,3.33972602739726,Unknown status,Observational,No,No,Principal Investigator,500
RS-NAT01,Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant Therapy,3.164383561643836,Unknown status,Interventional,No,No,Sponsor,80
SMX 20-001,Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,2.367123287671233,"Active, not recruiting",Interventional,Yes,No,Sponsor,29
2021/32,The Effect of Self-compassion on Breast Cancer,0.5041095890410959,Not yet recruiting,Interventional,No,No,Principal Investigator,70
HS-10352-102,A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer,3.969863013698631,Recruiting,Interventional,No,No,Sponsor,224
BOMB,Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis,6.64931506849315,Recruiting,Interventional,No,No,Sponsor-Investigator,183
XuzhouMedSch3,Effect of Perioperative Low Dose Ketamine on Postoperative Recovery in Patients Undergoing Breast Cancer Surgery,1.367123287671233,Unknown status,Interventional,No,No,Sponsor-Investigator,100
MC220301,Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer,3.8986301369863017,Recruiting,Interventional,Yes,No,Sponsor,100
FUSCC-TNBC-BLIS,Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer,2.8328767123287673,Recruiting,Interventional,No,No,Principal Investigator,192
TeMP 2021,The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breast Cancer Surgery: a Prospective Double-Blind Randomized Clinical Trial.,6.013698630136986,Recruiting,Interventional,No,No,Principal Investigator,130
SMC 2018-07-014-011,Sleep and Activity Patterns in Pre-menopausal Breast Cancer Patients on Tamoxifen Using a Wrist-worn Internet of Things Device,2.3945205479452056,Unknown status,Observational,No,No,Principal Investigator,20
D931CC00001,Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer,4.0849315068493155,Recruiting,Interventional,Yes,No,Sponsor,80
WuhanU,Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP,5.7095890410958905,Not yet recruiting,Interventional,No,No,Principal Investigator,20
2022-017,Characterization and Kinetic of Chemotherapy-induced Cardiovascular Toxicity in Breast Cancer,0.7534246575342466,Recruiting,Observational,No,No,Sponsor,40
Stage 1 Compression Therapy,Adjustable Compression Wrap Versus Compression Bandage Reduce to Breast Cancer-related Lymphedema,1.5013698630136987,Not yet recruiting,Interventional,No,Yes,Principal Investigator,72
GEICAM/2018-03,Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer,3.1780821917808217,Recruiting,Observational,No,No,Sponsor,31
018-745,LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer,4.24109589041096,"Active, not recruiting",Interventional,Yes,No,Sponsor,10
4298,mHealth for Breast Cancer Survivors With Insomnia,0.9041095890410958,Recruiting,Interventional,No,No,Principal Investigator,76
20-371,Niraparib + Dostarlimab In BRCA Mutated Breast Cancer,8.583561643835617,Recruiting,Interventional,Yes,No,Principal Investigator,62
HBMUFH-101,A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer,2.336986301369863,Unknown status,Interventional,No,No,Principal Investigator,300
2019-KY-051,Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer,6.005479452054795,Recruiting,Interventional,No,No,Principal Investigator,185
GCX-BCT-06,Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy,9.98082191780822,Recruiting,Interventional,No,No,Sponsor,194
213355,Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer,1.9698630136986304,Completed,Interventional,Yes,No,Sponsor,21
2022-0056,A Study for the Adjuvant Treatment of Breast Cancer,5.449315068493151,Recruiting,Interventional,No,No,Sponsor,2413
20192755,Prevention of Cardiovascular Diseases Caused by Complex Treatment of Patients With Primary Operated Breast Cancer,3.6082191780821917,Completed,Interventional,No,No,Principal Investigator,100
K3_K1_2,An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain,3.4438356164383563,Recruiting,Interventional,No,No,Principal Investigator,88
MEDOPP437,PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin,4.002739726027397,Not yet recruiting,Interventional,No,No,Sponsor,28
BC-P31,Clinical Study of Glycosylated Extracellular Vesicles for Early Diagnosis of Breast Cancer,1.923287671232877,Recruiting,Observational,No,No,Principal Investigator,420
EORTC-1550-BCG,Dissecting the Pathways of Therapy Resistance in Early Breast Cancer,3.063013698630137,Recruiting,Observational,No,No,Sponsor,100
D9670C00001,"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigators Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer",5.906849315068493,Recruiting,Interventional,Yes,No,Sponsor,850
ACR A4707,Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts,3.8410958904109593,Not yet recruiting,Interventional,No,No,Sponsor,2032
42127,Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity,5.002739726027397,Not yet recruiting,Observational,No,No,Principal Investigator,120
handan1,Circulating Tumor Cells Screen for Breast Cancer,3.3315068493150686,"Active, not recruiting",Observational,No,No,Principal Investigator,200
IOM-120465,Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.,4.947945205479452,Recruiting,Observational,Yes,No,Sponsor,300
2-025-19,Is Lipid Mapping an Effective Early Detection Tool for Breast Cancer in High-risk Populations?,2.5342465753424657,Unknown status,Observational,No,No,Sponsor,40
OTT 20-11 (IT-02),INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer,1.934246575342466,Recruiting,Interventional,Yes,No,Sponsor,90
PREBCA,Progressive Relaxation Training in Breast Cancer Patients Receiving Aromatatase Inhibitor Therapy,0.9178082191780822,Completed,Interventional,No,No,Principal Investigator,44
OBU-SC-BB-BC-II-010,"Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer",3.0821917808219177,Recruiting,Interventional,No,No,Principal Investigator,216
20-09022641,Combined Immunotherapies in Metastatic ER+ Breast Cancer,4.96986301369863,Recruiting,Interventional,Yes,Yes,Sponsor,102
D9673R00025,A Study of Patients Receiving T-DXd (Trastuzumab Deruxtecan) for Treatment of HER2+ Unresectable and/or Metastatic Breast Cancer,2.8,Not yet recruiting,Observational,No,No,Sponsor,750
SaglikBilimleriU_DU,Investigation of the Effect of Education on Symptom Management on Symptom Management in Patients With Breast Cancer,0.7506849315068493,Recruiting,Interventional,No,No,Principal Investigator,52
mTPVB SPPB Ver 2,Subpectoral Plexus Block With Multi-level TPVB for Surgical Anesthesia During Primary Breast Cancer Surgery,1.6712328767123288,Not yet recruiting,Interventional,No,No,Principal Investigator,100
VersiÃ³n 4- 20/09/2020,Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors,1.2493150684931507,Completed,Interventional,No,No,Principal Investigator,10
SYSKY-2023-129-01,Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer,2.791780821917808,Recruiting,Interventional,No,No,Principal Investigator,170
R868/18-IEO 916,Predicting Effective Adaptation to Breast Cancer to Help Women to BOUNCE Back,3.0712328767123287,Recruiting,Observational,No,No,Sponsor,660
309424,Breast CANcer Risk Assessment in Younger Women: BCAN-RAY,1.9205479452054797,Not yet recruiting,Observational,No,No,Sponsor,1000
Melody_001,"Validation of MelodyÂ®, a Tear-based Screening Assay for Breast Cancer",4.504109589041096,Enrolling by invitation,Observational,No,No,Sponsor,205
19-1812.cc,"Fertility Changes Due to Cancer: an Investigation of Meaning, Psychological Distress, and Psychologi",3.89041095890411,"Active, not recruiting",Observational,No,No,Sponsor,200
UW20035,Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer,2.441095890410959,Recruiting,Interventional,Yes,No,Sponsor,15
I3Y-NS-O003,Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients With Symp-tomatic Visceral Metastases or High Tumor Burden,3.9452054794520555,Recruiting,Observational,No,No,Sponsor,120
ID-TMS-02-20201012,CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population,3.495890410958904,"Active, not recruiting",Interventional,No,No,Sponsor,150
CABC012,Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer,3.931506849315069,"Active, not recruiting",Interventional,No,No,Principal Investigator,97
ACE-Breast-07,ARX788 in Breast Cancer With Low Expression of HER2,1.6931506849315068,Recruiting,Interventional,No,No,Principal Investigator,54
2019-053,Intervention to Promote Breast Cancer Screening Among American Indian Women,4.2465753424657535,"Active, not recruiting",Interventional,No,No,Principal Investigator,142
SNB vs PET/MRI 1,Axillary Staging in Node Positive Breast Cancer Patients Receiving PST. SNB vs PET/MRI,4.410958904109589,Recruiting,Interventional,No,No,Sponsor-Investigator,110
AITIC,Artificial Intelligence in Breast Cancer Screening Programs in CÃ³rdoba (AITIC),1.9178082191780825,Recruiting,Interventional,No,No,Sponsor,27000
NIHR 128311,Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy,9.01095890410959,Recruiting,Interventional,No,No,Principal Investigator,1900
Pro00104868,Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer,4.917808219178082,Recruiting,Interventional,Yes,No,Sponsor-Investigator,18
RG_16-108,NOSTRA-Feasibility Study: A Study Looking at Ultrasound Guided Biopsies for Breast Cancer,6.616438356164384,Recruiting,Observational,No,No,Sponsor,150
STUDY00000023,TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer,4.7095890410958905,"Active, not recruiting",Interventional,Yes,No,Sponsor,24
2022/0132,The Effect of Myofascial Chain Release Techniques on Shoulder Joint Range of Motion in Breast Cancer Survivors,1.5041095890410958,Not yet recruiting,Interventional,No,No,Principal Investigator,48
2021C0128,"Brain Imaging, Nutrition, and Cognition in Breast Cancer Survivors",1.367123287671233,Recruiting,Observational,No,No,Principal Investigator,30
GMI-1359-210,A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer,1.7616438356164383,Terminated,Interventional,Yes,No,Sponsor,4
20_RIPH3_06,Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique,5.16986301369863,Recruiting,Observational,No,No,Sponsor,142
SHERO,"Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer",10.002739726027396,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,60
MA-BC-II-023,Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy,3.0684931506849313,Recruiting,Interventional,No,No,Sponsor-Investigator,100
0494-22-RMB,A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.,5.019178082191781,Recruiting,Interventional,No,No,Principal Investigator,30
ICO-A-2018-10,Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery,3.589041095890411,"Active, not recruiting",Interventional,No,No,Sponsor,140
IRB_00162526,Exercise Timing in Breast Cancer Patients,0.33424657534246577,Not yet recruiting,Interventional,No,No,Principal Investigator,40
REG-074-2020,Pre-operative Exercise During Neoadjuvant Chemotherapy in Patients With Breast Cancer,2.8547945205479452,Recruiting,Interventional,No,No,Principal Investigator,120
Woman health,Whole Body Vibration Training and Breast Cancer Risk Factors,1.0876712328767124,Completed,Interventional,No,No,Principal Investigator,40
CSIIT-C39,Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer,1.1643835616438356,Recruiting,Interventional,No,No,Sponsor,40
99mTc-ZHER2,Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2.,1.189041095890411,Completed,Interventional,No,No,Sponsor,30
HCC 22-003,Preoperative Irradiation for Stage I Breast Cancer,4.564383561643836,Recruiting,Interventional,No,Yes,Sponsor-Investigator,24
FAST-F-PG01,Ultra-hypofractionated Radiotherapy in Breast Cancer Patients,5.002739726027397,Recruiting,Observational,No,No,Principal Investigator,300
20-001670,Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring,4.000000000000001,Recruiting,Observational,No,No,Sponsor,150
CSIIT-C03,Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy,2.0876712328767124,Unknown status,Interventional,No,No,Sponsor,20
IBCSG 55-17,To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH),4.0410958904109595,"Active, not recruiting",Interventional,No,No,Sponsor,144
WO42633,A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy,13.487671232876712,Recruiting,Interventional,Yes,No,Sponsor,1700
2022-05093-02,The T-REX Trial: Tailored Regional External Beam Radiotherapy in Clinically Node-negative Breast Cancer Patients With 1-2 Sentinel Node Macrometastases.,10.8,Recruiting,Interventional,No,No,Sponsor,1350
NRG-BR007,"De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)",20.07945205479452,Recruiting,Interventional,No,No,Sponsor,1670
NCCH2113,Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study,5.3561643835616435,Recruiting,Observational,No,No,Sponsor,60
YU-FTR-ST-01,"The Effects of Upper Extremity Lymphedema on Posture, Upper Extremity Functions, and Quality of Life",0.49863013698630143,Completed,Observational,,,Principal Investigator,27
CLP0008,Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients,5.252054794520548,Recruiting,Interventional,Yes,Yes,Sponsor,323
18-040,Topical Calcipotriene Treatment for Breast Cancer Immunoprevention,6.734246575342466,Recruiting,Interventional,Yes,No,Principal Investigator,120
UPCC 01121,Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer,6.920547945205479,Recruiting,Interventional,Yes,No,Sponsor,96
Molecular imaging of HER2,Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3,1.6493150684931508,Completed,Interventional,No,No,Sponsor,30
OP-1250-002,A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients,1.9753424657534249,Recruiting,Interventional,Yes,No,Sponsor,30
GEICAM/2018-06,"Trial to Evaluate Diarrhoea Discontinuations at 3 Cycles in Patients With Early-stage HER2+, HR+ Breast Cancer Treated With Neratinib Plus Loperamide Versus Neratinib Dose Escalation Plus Loperamide Administered as Needed Versus Neratinib Plus Loperamide Plus Colesevelam (DIANER)",7.342465753424658,Recruiting,Interventional,No,No,Sponsor,315
26272819.3.0000.0068,Breast Cancer and Intrauterine Contraception,2.4027397260273973,Recruiting,Interventional,No,No,Sponsor,90
SA20I0060,Supervised Resistance TRaining amONG Women at Risk of Breast Cancer Related Lymphedema,1.4986301369863013,Recruiting,Interventional,No,No,Sponsor,106
1094/2020,Simultaneous Integrated Boost Technique in Breast Cancer Radiotherapy,5.3780821917808215,Withdrawn,Interventional,No,No,Sponsor,0
Soh-Med-23-01-34,EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast,0.16164383561643836,Not yet recruiting,Observational,No,No,Principal Investigator,40
WO42133,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)",1.2219178082191782,Completed,Interventional,Yes,No,Sponsor,221
110-163-F,A Study Evaluating Near-infrared Zone II Imaging in Sentinel Lymph Node Mapping in Breast Cancer Patients,0.9972602739726029,Recruiting,Interventional,No,No,Sponsor,30
KN035-TH-HER2,KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer,2.336986301369863,Unknown status,Interventional,No,No,Principal Investigator,59
MUKDEN 06,A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients,4.608219178082192,Recruiting,Interventional,No,No,Sponsor-Investigator,150
HNCH-MBC09-BM03,Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERMEATE),1.923287671232877,Recruiting,Observational,No,No,Sponsor,300
COSMOPOLITAN,Intraoperative Electron Radiotherapy for Low-risk Early Breast Cancer,6.586301369863014,Recruiting,Interventional,No,No,Principal Investigator,202
21-VIN-0166/SAN-0647,"A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and LynparzaÂ® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With BRCA Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer",0.536986301369863,Completed,Interventional,Yes,No,Sponsor,70
E19059,Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer,4.8273972602739725,Recruiting,Observational,No,No,Principal Investigator,120
ISB 1302-103,Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer,0.29315068493150687,Terminated,Interventional,Yes,No,Sponsor,1
0063-17,A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients,6.063013698630137,Recruiting,Interventional,Yes,No,Sponsor,657
M16-735,A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC),0.7506849315068493,Terminated,Interventional,Yes,No,Sponsor,2
NCT20210157-AI-ROL,Artificial Intelligence in Breast Cancer Screening in Region ÃstergÃ¶tland Linkoping,0.336986301369863,Completed,Observational,No,No,Principal Investigator,15500
19-524,Effects of Exercise in Patients With Metastatic Breast Cancer,7.482191780821918,Recruiting,Interventional,No,No,Principal Investigator,350
HR-BLTN-002,A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physicians Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer,2.378082191780822,Unknown status,Interventional,No,No,Principal Investigator,256
CTO-IUSCC-0684,Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer,4.252054794520548,Recruiting,Interventional,Yes,No,Sponsor-Investigator,38
Tele-Relax,Relaxation Training by Tele-Rehabilitation in Patients With Breast Cancer,1.8630136986301369,Completed,Interventional,No,No,Principal Investigator,52
NCC1865,A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer,3.5013698630136987,Unknown status,Interventional,No,No,Principal Investigator,30
KCSG BR18-16,Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer,3.336986301369863,"Active, not recruiting",Interventional,No,No,Sponsor,90
D9673R00028,PROVIDENCE - Real-world Study in Patients With HER2-positive Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan and Offered PRO-React Onco,7.1726027397260275,Not yet recruiting,Observational,,,Sponsor,390
LY01005/CT-CHN-303,Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEXÂ®,1.873972602739726,Recruiting,Interventional,No,No,Sponsor,188
IFG-08-2019,Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON),1.9726027397260277,Recruiting,Interventional,No,No,Sponsor,108
BC-Genetics,Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Doxorubicin Among Egyptian Breast Cancer Patients,2.665753424657534,Recruiting,Observational,No,No,Principal Investigator,200
XZP-3287-3001,A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer,7.964383561643837,Recruiting,Interventional,No,No,Sponsor,300
A5481126,Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy,2.0767123287671234,Completed,Interventional,No,No,Sponsor,99
GEP,Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC),2.063013698630137,Unknown status,Interventional,No,No,Principal Investigator,160
2019/2632,An Innovative Care-improvement Smartphone-based Perioperative Solution for Women Undergoing Breast Cancer Surgery,1.9506849315068495,Unknown status,Interventional,No,No,Sponsor-Investigator,112
UMMCHTNBC,Telemonitoring Hypertension and Breast Cancer,0.5780821917808219,Not yet recruiting,Interventional,No,No,Principal Investigator,40
BTCRC-BRE18-337,"Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers",4.126027397260274,Recruiting,Interventional,Yes,No,Sponsor-Investigator,37
J18138,Automated Method for Breast Cancer Detection,1.7780821917808218,Terminated,Interventional,No,Yes,Sponsor,116
19-09020752,CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer,8.832876712328767,Withdrawn,Interventional,Yes,Yes,Sponsor,0
RC31/21/0368,Impact of Adjuvant Hormone Therapy on Bone and Cardiovascular Risk,0.3232876712328767,Completed,Interventional,No,No,Sponsor,102
20-503,Feasibility of Fasting & Exercise in Pts With HR+ MBC,2.5397260273972604,"Active, not recruiting",Interventional,No,No,Principal Investigator,30
PGG-BCA2121 / MK-3475-C99,Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA),5.186301369863013,"Active, not recruiting",Interventional,Yes,No,Sponsor,50
ACTRN1261000928213,A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.,4.035616438356165,Recruiting,Interventional,No,No,Principal Investigator,200
Pro2020002182,Breast Cancer and Resistance Exercise Program,4.087671232876713,Recruiting,Interventional,No,No,Principal Investigator,50
160178,"Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer",4.416438356164384,"Active, not recruiting",Interventional,Yes,No,Sponsor-Investigator,22
MRG002-004,A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer,2.254794520547945,Recruiting,Interventional,No,No,Sponsor,350
BC-Pyrotinib-NVB,Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer,1.0986301369863014,Completed,Interventional,No,No,Sponsor,30
SYSUCC-016,GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer,2.0000000000000004,Recruiting,Interventional,No,No,Principal Investigator,306
19-396,Liquid Biopsies and Imaging in Breast Cancer,2.915068493150685,Unknown status,Interventional,No,No,Principal Investigator,100
Shengjing-LJY07,Prone Positioning CT Scan and Ultrasound Assessing Axillary Lymph Nodes in Patients With Breast Cancer Official Title: Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer,5.504109589041096,Recruiting,Interventional,No,No,Principal Investigator,500
HMPL-012-SPRING-R103,Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer,2.336986301369863,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,45
CA209-7FL,"Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer",4.156164383561644,"Active, not recruiting",Interventional,Yes,No,Sponsor,521
NCC2021291,A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN),6.032876712328767,Recruiting,Interventional,No,No,Principal Investigator,102
2022-A02271-42,Cost of Using FLUOrescence to Green of Indocyanine for the Detection of Breast Cancer.,0.9397260273972603,Recruiting,Observational,No,No,Sponsor,150
20-2338,Effects of Pinkwashed Alcohol Ads in an Online RCT,0.021917808219178082,Completed,Interventional,No,No,Sponsor,602
CNIL-2033408,Chronic Pain and Minor Breast Cancer Surgery,0.7506849315068493,Completed,Observational,No,No,Sponsor,205
22-5307,Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease,2.665753424657534,Not yet recruiting,Interventional,No,No,Sponsor,15
CEP0431/2018 arm 2,LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2),3.923287671232877,Recruiting,Interventional,No,No,Principal Investigator,195
MA-BC-II-035,Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer,4.252054794520548,Enrolling by invitation,Interventional,No,No,Principal Investigator,94
F2017000 (UAB 17112),Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer,5.32054794520548,Recruiting,Interventional,Yes,No,Principal Investigator,40
REG-028-2021,Multimodal Pain Treatment for Breast Cancer Surgery - a Prospective Cohort Study,2.0000000000000004,Recruiting,Observational,No,No,Sponsor,200
22040,Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer,5.16986301369863,Recruiting,Interventional,Yes,No,Sponsor-Investigator,83
CTMS 17-0037,Imipramine on ER+ve and Triple Negative Breast Cancer,3.6575342465753424,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,17
D0816R00025,Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer,2.336986301369863,Completed,Interventional,No,No,Sponsor,162
201801559A3,Prospective Cohort Study of Traditional Chinese Medicine for Survival of Patients With Early Breast Cancer,1.9506849315068495,Unknown status,Observational,No,No,Principal Investigator,310
MedOPP238,POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer,0.0,Withdrawn,Interventional,No,No,Sponsor,0
BTCRC-BRE19-409,"Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer",3.8876712328767127,Recruiting,Interventional,Yes,No,Sponsor-Investigator,44
2020-0342,Promoting Genetic Counseling Among African American Women With a Family History of Breast Cancer,1.673972602739726,Not yet recruiting,Interventional,No,No,Principal Investigator,106
25IB-0023,Exercise Study for Breast Cancer Survivors,1.0191780821917809,Unknown status,Interventional,No,No,Principal Investigator,30
919PP18,Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO),2.665753424657534,Completed,Interventional,No,No,Sponsor,70
18-002,A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy,5.945205479452055,"Active, not recruiting",Interventional,Yes,No,Sponsor,31
CMTNCMB,Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint Test,1.8,Unknown status,Observational,No,No,Sponsor,150
ZYYY-BC-001,Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer,2.252054794520548,Recruiting,Interventional,No,No,Sponsor,30
CAAE: 82691818.0.0000.5154,Effect of Resistance Training Variable Manipulation in Postmenopausal Breast Cancer Survivors.,1.6054794520547946,Unknown status,Interventional,No,No,Principal Investigator,80
2022/0226,Risk Factors for Shoulder Joint Motion Restriction,1.5041095890410958,Not yet recruiting,Observational,No,No,Principal Investigator,72
PMD-026-1-001,Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer,4.298630136986302,"Active, not recruiting",Interventional,Yes,No,Sponsor,50
SYSUCC-011,Relationship Between Gut Microbiome and Adjuvant Chemotherapy in Patients With Early Breast Cancer,2.057534246575343,Terminated,Observational,No,No,Principal Investigator,226
18432,Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease,4.410958904109589,"Active, not recruiting",Interventional,No,No,Sponsor,42
2020-KY-140,Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer,10.172602739726027,Recruiting,Interventional,No,No,Principal Investigator,516
2020-KY-125,Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer,4.002739726027397,Recruiting,Interventional,No,No,Principal Investigator,71
CAAE 42627521600005274,Surgical Pre-habilitation in Breast Cancer.,1.9945205479452057,Recruiting,Interventional,No,No,Sponsor,248
20-1866.cc,Promoting Informed Choice for Breast Cancer Screening,4.986301369863014,Recruiting,Observational,No,No,Sponsor,500
20201101.2,"Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer",4.002739726027397,Not yet recruiting,Interventional,No,No,Sponsor,57
SYSUCC-008,Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer,0.5753424657534246,Completed,Interventional,No,No,Principal Investigator,35
S64752,Exploring the Role of Serum Methylmalonic Acid (MMA) in Breast Cancer,1.4191780821917808,Completed,Observational,No,No,Principal Investigator,300
SURVIVE,Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer,12.991780821917809,Recruiting,Interventional,No,No,Sponsor-Investigator,3500
4352,Evaluating the Impact of Evidence-based Information About Mammography on Breast Cancer Screening Decisions,1.9178082191780825,Unknown status,Interventional,No,No,Sponsor,209
CDR0000643461,Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.,1.0000000000000002,Unknown status,Observational,No,No,Principal Investigator,300
SPHIC-TR-BCa2022-02,A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction,5.646575342465753,Recruiting,Interventional,No,No,Principal Investigator,67
KCSG BR22-20,"Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer",6.087671232876712,Not yet recruiting,Interventional,No,No,Principal Investigator,202
CRE2018013,Effects of Exercise Training at Different Timeline on Shoulder Dysfunction After Breast Cancer Modified Radical Mastectomy,1.7232876712328766,Completed,Interventional,No,No,Principal Investigator,200
IRB_00137018,A Comprehensive Oncology Rehabilitation and Exercise (CORE) Program Among Breast Cancer Survivors,2.7753424657534245,Recruiting,Interventional,No,No,Principal Investigator,72
2022-0353,Feasibility of Implementing Acupuncture Into Federally Qualified Health Center Among Breast Cancer Survivors,2.3835616438356166,Recruiting,Interventional,No,No,Principal Investigator,62
MCC-19765,Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases,4.958904109589041,"Active, not recruiting",Interventional,Yes,No,Sponsor,14
OSU-21065,Impact of Dietary Inflammatory Potential on Breast Cancer Risk,2.8383561643835615,Not yet recruiting,Observational,No,No,Principal Investigator,885
LCCC 1931,LCCC1931:Post-treatment Intervention in Women With Breast Cancer (70y/o+),5.263013698630137,"Active, not recruiting",Interventional,No,No,Sponsor,100
A5481167,Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea,1.526027397260274,"Active, not recruiting",Observational,,,Sponsor,1
4-2018-0264,Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16),1.082191780821918,Not yet recruiting,Interventional,No,No,Sponsor,30
2018/TMC/133/IRB/31,One Week Versus Three Week in Adjuvant Radiotherapy in Breast Cancer,10.008219178082191,Recruiting,Interventional,No,No,Sponsor,2100
ENDO-RESIST,Determinants of Acquired Endocrine Resistance in Metastatic Breast Cancer: A Pilot Study,3.9068493150684938,Recruiting,Observational,No,No,Sponsor,20
BRE 354,A Study of U3-1402 in Subjects With Metastatic Breast Cancer,2.578082191780822,Recruiting,Interventional,Yes,No,Sponsor,120
IR-1.1,Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway,6.002739726027397,Not yet recruiting,Interventional,No,No,Principal Investigator,270
SYSUCC-017,Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer,2.5342465753424657,Recruiting,Interventional,No,No,Principal Investigator,30
IB 2015-01,High Intensity Focused Ultrasound Treatment of Breast Tumors. BRIFU Study,2.5726027397260274,Unknown status,Interventional,No,No,Sponsor,15
20-5215.0,An Impact Assessment of a Culturally Tailored Online Psychosocial Program for Chinese Immigrant Women With Breast Cancer,2.1671232876712327,Recruiting,Interventional,No,No,Sponsor,100
MEN1611-01,MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer,4.035616438356165,"Active, not recruiting",Interventional,Yes,No,Sponsor,62
21-325,Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries),1.0000000000000002,Recruiting,Observational,No,No,Sponsor,900
SGNTUC-028,A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer,5.317808219178082,Recruiting,Interventional,Yes,No,Sponsor,650
EORTC QLQ BR45,Psychometric Properties of the Updated Module on Assessing Quality of Life of Patients With Breast Cancer,2.5123287671232877,Completed,Observational,No,No,Sponsor,576
SYSUCC-020,"Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.",2.495890410958904,Recruiting,Interventional,No,No,Sponsor-Investigator,73
BC-RWS,Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer,1.06027397260274,Not yet recruiting,Interventional,No,No,Sponsor,500
C4891001,A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.,5.205479452054795,Recruiting,Interventional,Yes,No,Sponsor,560
1234,Monitoring of Chronic Conditions in Breast Cancer,6.005479452054795,Recruiting,Observational,No,No,Sponsor,150
CCR4884,PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer,3.89041095890411,Recruiting,Interventional,Yes,No,Sponsor,45
BreastctDNA01,Breast Cancer Liquid Biopsy Stratification,5.002739726027397,"Active, not recruiting",Observational,No,No,Sponsor,59
2016-0537,Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer,7.928767123287672,"Active, not recruiting",Interventional,Yes,No,Sponsor,43
69HCL21_1085,Evaluation of the Diagnostic Performance of a Bra Prototype to Detect Breast Cancer,0.4191780821917808,Recruiting,Interventional,No,No,Sponsor,81
SGNTUC-025,A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer,4.917808219178082,Recruiting,Interventional,Yes,No,Sponsor,70
AIRC IG-23118,Single Fraction Preoperative Radiotherapy for Early Stage Breast Cancer,7.589041095890412,Recruiting,Interventional,No,No,Principal Investigator,79
3-2021-0026,"Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)",5.9150684931506845,Not yet recruiting,Interventional,No,No,Principal Investigator,59
BC-P26,Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer,0.5013698630136987,Completed,Interventional,No,No,Principal Investigator,104
STU-2022-0385,Real-time Intraoperative Breast Cancer Visualization for Margin Assessment,3.953424657534247,Recruiting,Interventional,Yes,Yes,Sponsor-Investigator,97
KOTK/2022/12550,Patient-centered Breast Cancer Teleprehabilitation,1.5863013698630137,Recruiting,Interventional,No,No,Sponsor,50
SCHBCC-N029,Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer,4.920547945205479,Recruiting,Interventional,No,No,Principal Investigator,319
PUMCH-MIRC213,99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer,1.3150684931506849,Recruiting,Interventional,No,No,Sponsor,30
A5481145,"A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer",0.7506849315068493,Completed,Observational,,,Sponsor,150
TMS01190510,Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels,1.8164383561643835,Completed,Interventional,No,No,Sponsor,151
Concordance,Concordance Between Liquid and Tissue Biopsy,2.419178082191781,Recruiting,Observational,No,No,Sponsor,120
1752/20,Local Therapy for ER/PR-positive Oligometastatic Breast Cancer,10.005479452054795,Recruiting,Interventional,No,No,Sponsor,74
IMAP-CM,Randomized and Multicenter Study to Evaluate a Customizable Support Breast Cancer Material,0.810958904109589,Completed,Interventional,No,No,Principal Investigator,125
SRB_201808_163,Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE),9.936986301369863,Recruiting,Interventional,No,No,Sponsor,565
UW16151,Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy,5.506849315068493,Recruiting,Observational,Yes,No,Sponsor,35
SMC 2020-11-051,Effect of Prophylactic Medical Compression Therapy on the Reduction of Breast Cancer-related Lymphedema in Patients With Adjuvant Docetaxel Chemotherapy: a Randomized Controlled Study,4.8054794520547945,Recruiting,Interventional,No,No,Principal Investigator,150
6037248,Using a Blood Test to Monitor Metastatic Breast Cancer Treatment,3.0027397260273974,Not yet recruiting,Observational,No,No,Sponsor-Investigator,150
2016-A01344-47,Adapted Physical Activity for Breast Cancer HER2 Positive Patient,6.35068493150685,Recruiting,Interventional,No,No,Sponsor,70
1807187-2,Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE),6.706849315068493,Recruiting,Interventional,No,No,Principal Investigator,808
Lilly-I3Y-US-I026,Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer,1.1123287671232878,Recruiting,Interventional,Yes,No,Sponsor,44
D8532C00001,A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease,8.016438356164384,Recruiting,Interventional,Yes,No,Sponsor,1342
21-159,ATEMPT 2.0: Adjuvant T-DM1 vs TH,6.879452054794521,Recruiting,Interventional,Yes,No,Principal Investigator,500
RG1121129,"Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial",0.8465753424657534,Completed,Interventional,No,No,Sponsor,27
TJ-IRB20211128,Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer,5.002739726027397,Recruiting,Observational,No,No,Sponsor,80
UC-BCG-2103,Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk,12.063013698630137,Recruiting,Interventional,No,No,Sponsor,696
21-123,Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer,3.0027397260273974,Recruiting,Interventional,Yes,No,Sponsor,106
Ketogenic Diet,Effects of Ketogenic Diet in Overweight and Obese Women With Breast Cancer,3.0027397260273974,Not yet recruiting,Interventional,No,No,Principal Investigator,56
20-172,Taking AIM at Breast Cancer,4.841095890410959,Recruiting,Interventional,No,No,Principal Investigator,300
CMUH108-REC1-113,Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients,3.202739726027397,Recruiting,Interventional,No,No,Sponsor,300
ALT-P7,"Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients",3.0136986301369864,Completed,Interventional,No,No,Sponsor,27
I236,CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer,5.208219178082191,"Active, not recruiting",Interventional,Yes,No,Sponsor,37
2019-7-Non-NSU Health,Assessing the Utility of Tissue Dielectric Constant (TDC) Measurements to Differentiate Breast Cancer From Healthy Breasts,2.8958904109589043,Completed,Interventional,No,Yes,Sponsor,60
131916,Financial Toxicity in Breast Cancer Surgery,2.5452054794520547,Recruiting,Observational,No,No,Sponsor,630
GCO 17-1585,Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer,1.3287671232876712,Terminated,Interventional,Yes,No,Principal Investigator,7
FNF201830,Health-promoting Lifestyle in a Genetic Counseling Clinic,2.3068493150684932,Completed,Observational,No,No,Principal Investigator,140
DRLCOLCT001,"Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-",1.3342465753424657,Recruiting,Observational,Yes,No,Sponsor,40
PRO00028602,Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer,3.378082191780822,Recruiting,Interventional,Yes,No,Principal Investigator,30
D0816C00018,To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.,3.7260273972602738,Completed,Interventional,Yes,No,Sponsor,256
HUB-PSI-CAMAD,Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression,0.136986301369863,Terminated,Interventional,No,No,Principal Investigator,40
REP0121,To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer,2.202739726027397,Withdrawn,Interventional,Yes,No,Sponsor,0
SBMASTER,The MASTER Study (MAmmary Cancer STatin ER Positive Study),14.0,Recruiting,Interventional,Yes,No,Principal Investigator,3360
AMCI-001,PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer,4.572602739726028,Recruiting,Interventional,Yes,No,Sponsor-Investigator,160
Fukui-2019-1,Exercise Post-Diagnosis of Breast Cancer,7.016438356164383,Recruiting,Interventional,No,No,Sponsor,165
PRO00028925,"Fulvestrant+Abemaciclib With or Without Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer",5.767123287671233,Recruiting,Interventional,Yes,No,Principal Investigator,56
K160913J,Evaluation of Individual Sensitivity to the Gonadotoxicity of Chemotherapy in Young Patients With Breast Cancer,7.758904109589042,"Active, not recruiting",Interventional,No,No,Sponsor,73
Genetic study and TDM,Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen,1.252054794520548,Unknown status,Observational,No,No,Principal Investigator,100
N-20180090,Analgesic Effect of Resistance Training for Breast Cancer Survivors,1.1205479452054794,Completed,Interventional,No,No,Principal Investigator,20
FDRT-BC016,Neoadjuvant Radiation in Locally Advanced Breast Cancer,4.756164383561644,Recruiting,Interventional,No,No,Principal Investigator,50
RF-2016-02363686,Tomosynthesis as Primary Test for Breast Cancer Screening,6.964383561643835,Recruiting,Interventional,No,No,Sponsor,8000
UPCC 10117,"Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (GLACIER)",0.7095890410958904,Withdrawn,Interventional,Yes,No,Sponsor,0
A231901CD,Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions,5.964383561643835,Recruiting,Interventional,No,No,Sponsor,700
22/409-3611,Ultra-hypofractioNated Adjuvant Radiotherapy Â± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients,8.005479452054795,Recruiting,Interventional,No,No,Principal Investigator,65
YDPLD191016-I1-SYSU-001,Biomarkers of Liposomal Doxorubicin Induced Hypersensitivity Reaction in Breast Cancer Patients,2.3917808219178083,Recruiting,Observational,No,No,Sponsor,20
BC-CIH-H-RWS,H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AIÂ±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study,2.5835616438356164,Recruiting,Interventional,No,No,Sponsor,40
4-2020-1453,"Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing (MUTATION2)",1.4191780821917808,Not yet recruiting,Interventional,No,No,Sponsor,52
IRB15-1005,Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer,0.5808219178082191,Withdrawn,Interventional,Yes,No,Sponsor,0
LCCC1820,Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer,0.2684931506849315,Withdrawn,Interventional,Yes,No,Sponsor,0
GC101-21K177,Study on TIL for the Treatment of Advanced Breast Cancer,3.0876712328767124,Recruiting,Interventional,No,No,Sponsor,50
2019.046,Lifestyles and Breast Cancer,4.512328767123288,Recruiting,Interventional,No,No,Principal Investigator,766
2020-004696-41,Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy,2.9397260273972603,Recruiting,Interventional,No,No,Sponsor,210
V3002401,Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer,1.7972602739726027,"Active, not recruiting",Interventional,Yes,No,Sponsor,210
2021-0768,A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer,4.389041095890411,Recruiting,Interventional,No,No,Sponsor,36
FDRT-BC008,Hypofractionated Vs Conventional Fractionated Postmastectomy Radiotherapy for High Risk Breast Cancer,10.169863013698631,Recruiting,Interventional,No,No,Principal Investigator,1494
A5481136,Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region,0.915068493150685,Recruiting,Observational,,,Sponsor,665
TILS001 trial,Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS,5.186301369863013,Not yet recruiting,Interventional,No,No,Sponsor,20
SYSEC-KY-KS-2022-056,Study on the Correlation Between the Quantitative Parameters of Mr Mean Cell Size Imaging and the Histopathological Characteristics of Breast Cancer,1.1397260273972603,Not yet recruiting,Interventional,No,No,Principal Investigator,200
S1709-101-888,Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer,4.506849315068493,"Active, not recruiting",Interventional,No,No,Principal Investigator,54
ARV-471-mBC-102,"ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer",1.4,Recruiting,Interventional,Yes,No,Sponsor,32
2020-07-064-002,Improvement of Range of Motion in Frozen Shoulder in Breast Cancer Survivors,1.180821917808219,Completed,Interventional,No,No,Principal Investigator,28
BR01/02/21,"Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor",3.5972602739726027,Recruiting,Interventional,No,No,Sponsor,120
MA-BC-II-020,Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer,4.589041095890411,Not yet recruiting,Interventional,Yes,No,Sponsor,490
69HCL16_0536,Facilitate and Sustain Return to Work After Breast Cancer,2.5315068493150683,Recruiting,Observational,No,No,Sponsor,420
NL68820.091.19,Minimal Invasive Breast Cancer Excision Using Vacuum Assisted Biopsy Under Ultrasound Guidance,2.3315068493150686,Recruiting,Interventional,No,No,Sponsor,170
6010121027,Protection of Cardiovascular Function With Crocin in BrEast Cancer Patients Undergoing Radiotherapy and Chemotherapy,2.493150684931507,Recruiting,Interventional,No,No,Sponsor,120
FS-1502-III1-01,FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer,2.841095890410959,Not yet recruiting,Interventional,No,No,Sponsor,314
IIT-0026,Prognostic Indicators for Radiation-induced Breast Fibrosis,3.671232876712329,Not yet recruiting,Observational,No,No,Sponsor,44
LCCC2241,Assessing Functional Status Needs Via PRO Measures for Pts With Metastatic Breast Cancer,0.7726027397260274,Not yet recruiting,Observational,No,No,Sponsor,50
2020-0708,"Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study",4.693150684931507,Recruiting,Interventional,No,No,Sponsor,240
NCC2493,Radiotherapy for Extracranial Oligometastatic Breast Cancer,5.068493150684931,Recruiting,Interventional,No,No,Principal Investigator,170
20-347,"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer",9.643835616438356,Recruiting,Interventional,Yes,No,Principal Investigator,375
2018-A01128-47,EMDR Psychotherapy for Anxious-depressive Symptoms in Breast Cancer Patient,7.257534246575342,Recruiting,Interventional,No,No,Sponsor,190
ICO 13-001,Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer,4.5917808219178085,"Active, not recruiting",Interventional,No,No,Sponsor,60
SCBCG-006,A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients,10.443835616438356,Recruiting,Interventional,No,No,Principal Investigator,794
LRP/PegGCSF/2016/004,Immunogenicity Assessment of Peg-filgrastim vs. NeulastaÂ® as Adjunct to Chemotherapy in Patients With Breast Cancer,0.8465753424657534,Completed,Interventional,Yes,No,Sponsor,138
GRACE,GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer,1.252054794520548,"Active, not recruiting",Interventional,No,No,Principal Investigator,75
21-600,Early Intervention,2.082191780821918,Not yet recruiting,Interventional,No,Yes,Principal Investigator,40
114,The Effect of Reiki on Symptom Control and Quality of Life in Breast Cancer Patients,0.5780821917808219,Not yet recruiting,Interventional,No,No,Principal Investigator,52
YLiu,Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer,1.5013698630136987,Recruiting,Observational,No,No,Principal Investigator,100
IIT2018-17-McArthur-TCDRT,"Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer",5.002739726027397,Withdrawn,Interventional,Yes,No,Sponsor,0
20 KHCC 91,SBRT for Breast Cancer Oligometastases,6.002739726027397,Recruiting,Interventional,No,No,Principal Investigator,50
SYSUCC-019,"Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial",2.336986301369863,Recruiting,Interventional,No,No,Sponsor-Investigator,126
IIT-CRM2020001,Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature,3.654794520547945,Recruiting,Interventional,No,No,Principal Investigator,55
2018-A02191-54,Needs Assessment After Cancer in Patients Treated for Breast Cancer,0.16986301369863013,Completed,Observational,No,No,Sponsor,139
2020-154,Photobiomodulation Therapy for the Management of Breast Cancer-related Lymphedema,6.945205479452055,Recruiting,Interventional,No,No,Sponsor,104
CTO-IUSCC-0715,Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs,2.4767123287671233,Completed,Interventional,No,No,Principal Investigator,62
CLEE011ABR02,Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer,0.6027397260273972,Completed,Observational,,,Sponsor,76
SP0048722,Optimizing Quality of Life in Women Living With Metastatic Breast Cancer,1.873972602739726,Completed,Interventional,No,No,Principal Investigator,31
38341220.8.0000.0072,"Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery",5.83013698630137,Recruiting,Interventional,No,No,Principal Investigator,36
Neo-ACT,Physical Exercise During Preoperative Chemotherapy for Breast Cancer,5.063013698630137,Recruiting,Interventional,No,No,Principal Investigator,712
CH-BC-059,A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations ï¼STEPï¼,5.227397260273973,Enrolling by invitation,Interventional,Yes,No,Principal Investigator,300
07102022_SR,Consciousness-based Ayurveda Lifestyle Program for Improving Quality of Life in Survivors of Breast Cancer,0.7479452054794521,"Active, not recruiting",Interventional,No,No,Sponsor-Investigator,15
GO42784,"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physicians Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)",12.243835616438357,Recruiting,Interventional,Yes,No,Sponsor,4100
145314,Safety and Efficacy of Ga68 ÎvÎ²3 IAC PET/CT for Diagnosis and Clinical Management in Angiogenic Breast Cancer Patients,2.0027397260273974,Not yet recruiting,Interventional,Yes,No,Sponsor,25
New theory(Tamoxifen&retinoic),"Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.",0.33424657534246577,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,160
20-505,A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer,3.7013698630136984,Recruiting,Interventional,Yes,No,Sponsor,34
RadiaAce001,The Effect of RadiaAce Gel in the Prevention and Treatment of Radiation Dermatitis in Breast Cancer Patients,1.2164383561643837,Recruiting,Interventional,No,No,Sponsor,120
Neo-program 2021.02.23,Resistance vs. Aerobic Training on Breast Cancer Patients Undergoing Neoadjuvant Treatment,1.3726027397260274,Recruiting,Interventional,No,No,Principal Investigator,132
ARV-471-mBC-101,A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCEÂ®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer,4.495890410958904,Recruiting,Interventional,Yes,No,Sponsor,215
275078,Digitally Distributed Yoga for Women Treated for Breast Cancer,7.005479452054795,Recruiting,Interventional,No,No,Sponsor,250
IIT-2017-NeoPACT,Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer,6.164383561643835,"Active, not recruiting",Interventional,Yes,No,Sponsor,121
2021000247,"Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.",10.96986301369863,Recruiting,Interventional,Yes,No,Sponsor,40
REaCT-70,Evaluating Harms and Benefits of Endocrine Therapy in Patients â¥70 Years of Age With Lower Risk Breast Cancer,3.0383561643835617,Recruiting,Interventional,No,No,Sponsor,100
BTCRC-BRE16-042,"Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients",6.594520547945206,Recruiting,Interventional,Yes,No,Sponsor-Investigator,47
TVD-101-002B,Study of TTI-101 in Combination for Participants With Metastatic Hormone Receptor (HR)-Positive and Human Epidermal Receptor 2 (HER2)-Negative Breast Cancer,2.0657534246575344,Recruiting,Interventional,Yes,No,Sponsor,53
20-0140-A,MonaLisa Laser Intervention for Post-Menopausal Breast Cancer Patients: A SHE CAN Study,0.8301369863013699,Withdrawn,Interventional,No,No,Principal Investigator,0
D9673R00004,"Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status",0.9123287671232877,Completed,Observational,No,No,Sponsor,798
CA209-929,"Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients",1.284931506849315,Terminated,Interventional,Yes,No,Sponsor,5
SYSEC-KY-KS-2019-099,Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy,0.4958904109589042,Completed,Observational,Yes,No,Principal Investigator,760
Glnz87?,The Effect of Guided Imagery Based on the Health Promotion Model on the Quality of Life in Breast Cancer Patients,0.7863013698630137,Completed,Interventional,No,No,Principal Investigator,68
GIM24-PALBO-BP,Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy,4.043835616438357,Recruiting,Interventional,No,No,Sponsor,168
18-115,Physiotherapy Program for Breast Cancer Women Following Surgery: A Pilot Clinical Trial,2.421917808219178,Completed,Interventional,No,No,Principal Investigator,23
IBISCO Trial,Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast Cancer,4.000000000000001,Recruiting,Interventional,No,No,Sponsor,30
NBC Che001,Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy,1.3178082191780822,Completed,Interventional,No,No,Principal Investigator,160
IC 2021-08,Digital Phenotyping in Women Over 70 Years of Age Treated for Breast Cancer With Any Type of Treatment,1.7397260273972603,Recruiting,Interventional,No,No,Sponsor,200
AI Yoga Study on Facebook - 1,Effect of Sukshma Vyayama Yoga on Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors,0.12328767123287673,Completed,Interventional,No,No,Sponsor,38
6222/22.03.2017,Intravenous Ascorbic Acid Supplementation in Neoadjuvant Chemotherapy for Breast Cancer,1.0000000000000002,Unknown status,Interventional,No,No,Principal Investigator,30
SYSEC-KY-KS-2019-055-001,MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02),6.010958904109589,Recruiting,Observational,No,No,Principal Investigator,600
EUBREAST-01,Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients With rCR and pCR in the Breast After NAST,7.887671232876714,Recruiting,Interventional,No,No,Sponsor-Investigator,350
1216-4-011,Lidocaine Versus Duloxetine for the Prevention of Taxane-Induced Peripheral Neuropathy In Breast Cancer Patients,1.4684931506849315,Completed,Interventional,No,No,Sponsor-Investigator,60
UPCC 15121,Breast Cancer Outreach Among Primary Care Patients,0.49863013698630143,Completed,Interventional,No,No,Principal Investigator,24680
OMERIC-1904,Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer,2.9808219178082194,Recruiting,Interventional,No,No,Sponsor,25
21-161,A Study of Attention and Memory Processes in Breast Cancer Survivors,2.989041095890411,Recruiting,Observational,No,No,Sponsor,48
18-217,Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job,4.986301369863014,Recruiting,Interventional,No,No,Sponsor,546
ACE-Breast-06,ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases,1.9616438356164385,Recruiting,Interventional,No,No,Principal Investigator,32
ONC-010,EndoPredictÂ® Extended Endocrine Trial (EXET),2.747945205479452,Terminated,Observational,No,No,Sponsor,855
CHLOBREASTASP,"Breast Cancer Active Surveillance, Alternative Option, Aspirin Included",5.0,Not yet recruiting,Interventional,No,No,Principal Investigator,60
CLEE011AFR01,Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France,4.542465753424658,Recruiting,Observational,,,Sponsor,482
CTO-IUSCCC-0781,Exercise in Metastatic Breast Cancer: EMBody,4.756164383561644,Not yet recruiting,Interventional,No,No,Principal Investigator,100
TT420X2101,Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer,2.978082191780822,"Active, not recruiting",Interventional,Yes,No,Sponsor,48
201808046,Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma,7.564383561643836,"Active, not recruiting",Interventional,No,Yes,Sponsor,77
178-2018,Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy,2.9205479452054797,Recruiting,Observational,No,No,Principal Investigator,100
OMC2018/01,Implementing PatientsÂ´ Competence in Oral Breast Cancer Therapy,1.7534246575342465,Unknown status,Observational,,,Sponsor,212
S61864,Magnetic Seed Localisation for Nonpalpable Breast Lesions,0.6986301369863014,Completed,Observational,No,Yes,Sponsor,192
CSPC-KAL-BC-16,Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer,2.835616438356164,Unknown status,Interventional,No,No,Principal Investigator,414
REaCT-Wellness,A Randomized Trial Evaluating Personalized vs Guideline-based Well Follow-up Strategies for Patients With Early-stage Breast Cancer,3.868493150684932,"Active, not recruiting",Interventional,No,No,Sponsor,264
NEXT-BRCA,Implementing Exercise Into Clinical Practice in Breast Cancer Care,4.2465753424657535,"Active, not recruiting",Interventional,No,No,Sponsor,85
AB PoC 2021 RUS,Retrospective Comparative in Vitro Case-controlled Study of the Liquid Biopsy Test System in Women With Breast Cancer,0.5424657534246575,Recruiting,Observational,No,No,Sponsor,150
MedOPP167,Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients,1.9205479452054797,Terminated,Interventional,No,No,Sponsor,22
LPM-008,The LightPathÂ® and 68Ga-RM2 in Breast Cancer Study,4.923287671232877,Not yet recruiting,Interventional,No,No,Sponsor,80
DATOS-20220624-ASJF-Efecto car,Cardioprotective Effect of Acute Exercise in Breast Cancer Patients,1.6904109589041096,Recruiting,Interventional,No,No,Principal Investigator,40
2019.444,Fibrotic Focus in Breast Cancer,4.000000000000001,Not yet recruiting,Observational,No,No,Principal Investigator,250
NSABP FB-13,Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer,2.276712328767123,Completed,Interventional,Yes,No,Sponsor,24
202207198RINB,Can ILR Reduce the Risk of Arm Lymphedema?,5.465753424657534,"Active, not recruiting",Interventional,No,No,Sponsor,240
FZPL-â¢-303,A Study of FluzoparibÂ±Apatinib Versus Chemotherapy Treatment of Physicians Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation,4.967123287671233,Recruiting,Interventional,No,No,Sponsor,474
SYSUCC 019,Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients,3.547945205479452,Recruiting,Interventional,No,No,Principal Investigator,47
BCSPilot01,A Combined Exercise Training Program for Women Living With Breast Cancer,0.5753424657534246,Not yet recruiting,Interventional,No,No,Principal Investigator,36
2014CB543202-03,Acupuncture for Breast Cancer Related Lymphedema,1.4164383561643836,Unknown status,Interventional,No,No,Principal Investigator,60
578-21-FB,Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy,9.506849315068493,Recruiting,Interventional,Yes,No,Sponsor-Investigator,46
1107210020,Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer,1.4136986301369863,Completed,Observational,No,No,Principal Investigator,250
107CS-6,Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer,3.6876712328767125,Unknown status,Interventional,Yes,No,Sponsor,72
BRE 381,Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer,3.336986301369863,Not yet recruiting,Interventional,Yes,No,Sponsor,36
IRB00048455,Histamine and Bone Pain Association in Participants With Breast Cancer Metastatic in the Bone,4.668493150684932,Recruiting,Observational,No,No,Sponsor,30
2022-009,Thero2-01S22 in HER2-positive Breast Cancer,4.002739726027397,Not yet recruiting,Interventional,No,No,Sponsor,320
CCR5654,"Biological Characteristics of Older Women (> 70 Years) With ER Positive, HER2 Negative Early Breast Cancer",1.1123287671232878,Enrolling by invitation,Observational,No,No,Sponsor,100
KCT 005,"A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery",0.5835616438356165,Recruiting,Interventional,No,Yes,Sponsor,20
2022-YXZX-YX-08,Ultrasound Radiomics for Predicting Breast Cancer and Axillary Lymph Node Metastasis,2.419178082191781,Not yet recruiting,Observational,No,No,Sponsor,200
G1T28-212,"Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer",1.3123287671232877,Completed,Interventional,Yes,No,Sponsor,24
SCHBCC-NO28,Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer,10.03013698630137,Recruiting,Interventional,No,No,Principal Investigator,94
PI-2021-3,Design and Evaluation of the Effects of a Physical Therapy Program With Digital Support in Patients With Breast Cancer,2.747945205479452,Recruiting,Interventional,No,No,Principal Investigator,92
ID-RCB 2022-A01488-35,Diagnostic Performance of Breast Cancer Screening Second Reading Process Assisted by AI,4.002739726027397,Not yet recruiting,Interventional,No,No,Sponsor,5000
MA-BC-â¡-021,Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer,1.7698630136986302,Recruiting,Interventional,No,No,Principal Investigator,60
2021-KY-124-001,Aesthetic Outcomes of Oncoplastic Breast Surgery for Breast Cancer in the Upper Inner Quadrant,0.7863013698630137,Recruiting,Interventional,No,No,Principal Investigator,109
NCKUH SLNB,The Validation of Sentinel Lymph Node Biopsy After Neo-adjuvant Chemotherapy in Breast Cancer Patients,1.5342465753424657,"Active, not recruiting",Observational,No,No,Sponsor,30
DFP22-0020,Resistance-type Exercise Training in Postmenopausal Women Survivors of Breast Cancer,1.4219178082191781,Not yet recruiting,Interventional,No,No,Principal Investigator,52
CCM 1505,Coronary Artery Calcium and Cardiovascular Risk Factors Analysis After RT or Breast Cancer,2.191780821917808,Recruiting,Interventional,No,No,Sponsor,100
PER.CIN.BN.95.III,Comparing Efficacy and Safety Between PertuzumabÂ® and PerjetaÂ® in Neoadjuvant Treatment of HER2+ Breast Cancer,1.7945205479452055,Completed,Interventional,No,No,Sponsor,214
21-5021,Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN),3.1945205479452055,Recruiting,Interventional,No,No,Sponsor,1150
C4891006,TACTIVE-U: A Study to Learn About the Study Medicine (Called ARV-471) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A),4.301369863013699,Recruiting,Interventional,Yes,No,Sponsor,35
2021-0840,Acupuncture for Psychoneurological Symptoms Among Breast Cancer Survivors,3.580821917808219,"Active, not recruiting",Interventional,No,No,Principal Investigator,8
OV-121,Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP,4.865753424657535,"Active, not recruiting",Interventional,No,No,Sponsor,30
042110,CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage,5.64931506849315,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,34
BC-09638,GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.,4.947945205479452,Recruiting,Interventional,No,No,Sponsor,160
LB1802,Real World Study of Biosimilar Trastuzumab in Her2 Positive Breast Cancer,4.6136986301369864,Recruiting,Observational,No,No,Sponsor,170
2018-0601,Phase III Trial Evaluating Radium Bromatum Homeopathic Treatment Efficacy on Radiodermatitis Prevention and Treatment for Breast Cancer Women,3.712328767123288,Recruiting,Interventional,No,No,Sponsor,232
D967JC00002,A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer,2.6465753424657534,"Active, not recruiting",Interventional,Yes,No,Sponsor,139
UKM14_0016,Breast Cancer Screening: Digital Breast Tomosynthesis Versus Digital 2D Mammography,6.742465753424658,"Active, not recruiting",Interventional,No,No,Sponsor,99689
RJBC-HFRNI,Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment,8.780821917808218,Recruiting,Interventional,No,No,Principal Investigator,801
m-VCAP1,Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer,1.4136986301369863,Recruiting,Interventional,No,No,Sponsor,30
19-133,An Online Research Study: BrainHealth in Breast Cancer Survivors,2.0027397260273974,Recruiting,Interventional,No,No,Sponsor,200
CLEE011A2206,"Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.",6.2904109589041095,"Active, not recruiting",Interventional,No,No,Sponsor,327
CASE3118,Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer,4.632876712328767,"Active, not recruiting",Interventional,No,Yes,Sponsor,13
2020(55),Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer,9.67123287671233,Recruiting,Interventional,No,No,Principal Investigator,214
WO40324,"A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer",5.427397260273972,"Active, not recruiting",Interventional,Yes,No,Sponsor,500
Geneplus2020BC01,ctDNA Monitoring in Early Breast Cancer,4.50958904109589,Recruiting,Observational,No,No,Sponsor,200
ML39208,A Study to Assess the Feasibility of an E-Health System (ZEMY) Designed to Manage Symptoms in Participants With Breast Cancer Under Anti-Cancer Treatment,0.852054794520548,Completed,Interventional,No,No,Sponsor,56
18/028,"Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer",5.189041095890411,Recruiting,Interventional,No,No,Sponsor,36
19-005860,Multiscale Omics for the Development of a Cohort Database and Study Platform in Breast Cancer Survivors,2.747945205479452,"Active, not recruiting",Observational,No,No,Sponsor,105
A231701CD,Increasing Patients Engagement in Breast Cancer Surgery Decision-Making,4.794520547945205,"Active, not recruiting",Interventional,No,No,Sponsor,598
FDRT-BC017,Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer,5.865753424657535,Recruiting,Interventional,No,No,Sponsor,1650
AC699-001,Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer,2.008219178082192,Recruiting,Interventional,Yes,No,Sponsor,60
2020-495,Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer,7.002739726027397,Recruiting,Interventional,No,No,Sponsor,260
CTRIAL-IE 17-13,Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer,0.9753424657534248,Terminated,Interventional,No,No,Sponsor,2
00005038,Family History and Breast Cancer Education Trial,1.4986301369863013,Completed,Interventional,No,No,Principal Investigator,196
H-43432,Sitravatinib in Metastatic Breast Cancer,1.2821917808219179,Terminated,Interventional,Yes,No,Sponsor-Investigator,3
2020-010,Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer,8.005479452054795,Recruiting,Observational,No,No,Sponsor,9000
Contralateral Screening,Screening Contralateral Breast Cancers in Patients With Newly Diagnosed Breast Cancer,3.756164383561644,Recruiting,Observational,No,No,Principal Investigator,1098
HCRN BRE18-334,"Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer",12.446575342465753,Recruiting,Interventional,Yes,No,Sponsor-Investigator,197
ACT16105,Phase 2 Study of Amcenestrant (SAR439859) Versus Physicians Choice in Locally Advanced or Metastatic ER-positive Breast Cancer,3.9397260273972607,"Active, not recruiting",Interventional,Yes,No,Sponsor,290
OSU-22013,Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer,3.3863013698630136,Recruiting,Interventional,No,No,Principal Investigator,1000
I-3364822,Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Breast Cancer,5.835616438356165,Not yet recruiting,Interventional,No,No,Sponsor,130
ICO-N-2019-04,[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers,1.1095890410958904,Completed,Interventional,No,No,Sponsor,13
2007-206-1145,"Diffusion-Weighted MRI for Diagnosis of Multifocal, Multicentric Breast Cancer",3.756164383561644,Not yet recruiting,Observational,No,No,Principal Investigator,580
20140299,Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases,3.712328767123288,Completed,Interventional,Yes,No,Sponsor,36
2019.629,Artificial Intelligence in Mammography-Based Breast Cancer Screening,4.000000000000001,Recruiting,Observational,No,No,Principal Investigator,1000
CS003-BC,Safety and Efficacy Evaluation of the P2Et Extract in Patients With Breast Cancer,1.3315068493150686,Recruiting,Interventional,No,No,Sponsor,58
2020-005722-28,Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer,5.087671232876712,Recruiting,Interventional,No,No,Sponsor,100
EORTC-1617-QLG-BCG,Follow-up in Early and Locally Advanced Breast Cancer Patients,2.463013698630137,"Active, not recruiting",Observational,No,No,Sponsor,830
MD-127-2019,Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study),2.164383561643836,Unknown status,Interventional,No,No,Principal Investigator,204
HREBA.CC-19-0354,Protein Needs Study,4.684931506849315,Recruiting,Interventional,No,No,Sponsor,30
UC-BCG-2204,Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer,3.0027397260273974,Not yet recruiting,Interventional,No,No,Sponsor,100
PYHOPE-BC-104,Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer,2.9945205479452053,Recruiting,Interventional,No,No,Sponsor,60
TMZ-TNBC,Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC),4.671232876712328,Not yet recruiting,Interventional,No,No,Sponsor,40
STUDY-20-01174,Increasing Breast Cancer Screening in Chinese Immigrants,1.452054794520548,Completed,Interventional,No,No,Principal Investigator,99
SIM-1907-02-SERD-101,"Phase I Study to Evaluate SCR-6852 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer",3.3123287671232875,Recruiting,Interventional,No,No,Sponsor,146
20-151,Refining Local-Regional Therapy for IBC,6.501369863013698,Recruiting,Interventional,No,No,Principal Investigator,50
RJBC-SHF RNI,Adjuvant Regional Nodal Radiation Therapy for One Week in Breast Cancer,6.082191780821918,Recruiting,Interventional,No,No,Principal Investigator,197
YOUNGBC-17,Real-world Study of UTD1 in Chinese Advanced Breast Cancer,1.082191780821918,Recruiting,Observational,No,No,Principal Investigator,150
HREBA.CC-21-0429,Exercise Rehabilitation Via a Mobile Application for Individuals With Breast Cancer Undergoing Chemotherapy,0.6931506849315069,Recruiting,Interventional,No,No,Sponsor,30
Metastatic Breast Cancer,"Î¤reatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer",5.002739726027397,Recruiting,Observational,No,No,Sponsor,300
UW17107,ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer,2.254794520547945,Terminated,Interventional,Yes,No,Sponsor,4
NL63209 041 18,MRI-guided Single Dose Preoperative Radiotherapy in Low-risk Breast Cancer,12.67123287671233,Withdrawn,Interventional,No,No,Principal Investigator,0
KCSG BR19-15,T-DM1 in HER2-positive Metastatic/Relapsed Breast Cancer,0.6164383561643836,Unknown status,Observational,No,No,Principal Investigator,1000
2020-AHL-001,"Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer",2.33972602739726,Not yet recruiting,Interventional,Yes,No,Sponsor,40
SAMuhammad,Outcome of Neo-adjuvant Chemotherapy Followed by Breast Conservative Surgery in Breast Cancer in Upper Egypt,2.0027397260273974,Unknown status,Interventional,No,No,Principal Investigator,45
202201100,A Low AGE (Advanced Glycation End-product) Dietary Intervention for Breast Cancer Survivors,1.1561643835616437,"Active, not recruiting",Interventional,No,No,Sponsor,14
2019-A02195-52,Immunomonitoring of Breast Cancer Patients During Systemic Treatment,4.002739726027397,Recruiting,Interventional,No,No,Sponsor,150
ShantouCH02,Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index,3.4164383561643836,Recruiting,Interventional,No,No,Principal Investigator,64
PekingUPH10B003,Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients,5.764383561643836,Recruiting,Interventional,No,No,Sponsor,46
GE-280-401,Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients,2.7424657534246575,Recruiting,Observational,Yes,No,Sponsor,206
CTMS# 19-0028,Effects of Creatine Supplementation in Breast Cancer Survivors,3.923287671232877,Recruiting,Interventional,No,No,Sponsor,30
NEO-01,OA for Breast Cancer NAC Response,1.7671232876712328,Completed,Interventional,No,Yes,Sponsor,20
NL58040.091.16,Minimal Invasive Breast Cancer Excision Using the Breast Lesion Excision System Under Ultrasound Guidance,1.4438356164383561,Terminated,Interventional,No,No,Sponsor,22
LQ006,Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer,2.7041095890410958,Unknown status,Interventional,No,No,Principal Investigator,35
MCC-19-15740,Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters),3.923287671232877,Recruiting,Interventional,No,No,Sponsor,460
K180603J,Advanced MR Techniques for Breast Cancer Detection,5.005479452054795,Withdrawn,Interventional,No,No,Sponsor,0
ABLE02,A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer,3.9397260273972607,Recruiting,Interventional,No,No,Sponsor,244
MCC-21-BRE-54,"Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer",14.627397260273973,Recruiting,Interventional,Yes,No,Sponsor-Investigator,70
CLEE011A3201C,Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer,4.219178082191782,"Active, not recruiting",Interventional,No,No,Sponsor,223
2/108/7,What Factors Affect Breast Cancer Neoadjuvant Chemotherapy Efficacy?,1.082191780821918,Unknown status,Interventional,No,No,Sponsor,25
EOC202A1101,Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer,3.1945205479452055,Completed,Interventional,No,No,Sponsor,12
HUM00140468,Acupressure for Pain and Opioid Use Among Breast Cancer Patients,1.082191780821918,Terminated,Interventional,No,No,Principal Investigator,8
18-2562.cc,Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey,4.5917808219178085,Recruiting,Interventional,No,No,Sponsor,370
19-586,Prolonged Nightly Fasting in Breast Cancer Survivors,1.9479452054794524,Completed,Interventional,No,No,Principal Investigator,40
2014CB543202-02,Warm Acupuncture for Breast Cancer Related Lymphedema,2.9397260273972603,Completed,Interventional,No,No,Principal Investigator,108
CER2021,"Prevalence of Lymphedema in Valle Del Cauca, Colombia.",3.953424657534247,"Active, not recruiting",Observational,No,No,Principal Investigator,367
IB 2017-05,Brief Intervention for Tobacco and Alcohol Risk Reduction for Couple During Breast Cancer Treatment.,3.0027397260273974,Unknown status,Interventional,No,No,Sponsor,320
On4Rehab Pilot Trial,Physical Exercise for Breast Cancer Survivors: Face-to-face Versus Home-based,0.41643835616438357,Completed,Interventional,No,No,Sponsor,12
IIT-0005,Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting,2.0136986301369864,Unknown status,Interventional,No,No,Sponsor,52
PROTECT,Prospective Surveillance for Breast Cancer-Related Lymphedema,3.9095890410958907,Recruiting,Interventional,No,No,Principal Investigator,250
MD 134/2022,Inflammatory Blood Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy,1.2493150684931507,Not yet recruiting,Observational,No,No,Principal Investigator,150
NCC2129,Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer,3.0931506849315067,Unknown status,Interventional,No,No,Principal Investigator,108
001,Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer,2.8328767123287673,Not yet recruiting,Interventional,No,No,Sponsor,60
SYSU-CSCO-2020,Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab,5.005479452054795,Not yet recruiting,Interventional,No,No,Principal Investigator,27
IRB18-0970,A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer,6.789041095890411,Recruiting,Interventional,No,No,Sponsor,400
2019-09-023,Omitting Biopsy of SEntinel Lymph Node With Radiation After Neoadjuvant Chemotherapy in Breast Cancer (OBSERB) Trial,5.0,Not yet recruiting,Interventional,No,No,Principal Investigator,1380
Shengjing-LCG004,Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT,5.36986301369863,Recruiting,Interventional,No,No,Principal Investigator,1498
A5481093,A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib),0.1643835616438356,Not yet recruiting,Observational,,,Sponsor,1300
MedOPP168,"Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer",2.841095890410959,Terminated,Interventional,No,No,Sponsor,5
LUN_DBT_121,"Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT",0.9397260273972603,Recruiting,Observational,No,Yes,Sponsor,262
I239,CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer,3.0356164383561643,"Active, not recruiting",Interventional,No,No,Sponsor,15
IRB00158622,Auricular Point Acupressure to Self-Manage Chronic Pain or Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors: Effectiveness and Scientific Underpinnings,2.136986301369863,Completed,Interventional,No,No,Sponsor,102
RFTMBCPW,Fulvestrant in Metastatic Breast Cancer,3.16986301369863,Unknown status,Interventional,No,No,Principal Investigator,30
s63338,The Added Value of a Third Supervised Training Session to a Standard 12-week Rehabilitation Program After Breast Cancer: Pilot Study,0.6575342465753424,Completed,Interventional,No,No,Sponsor,62
2017-0071,"Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer",6.36986301369863,"Active, not recruiting",Interventional,Yes,No,Sponsor,54
2019/00283,A Pilot Tele-rehabilitation Trial for Breast Cancer Survivors,2.164383561643836,Recruiting,Observational,No,No,Principal Investigator,40
20200628GD,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,2.063013698630137,Unknown status,Interventional,No,No,Principal Investigator,30
ANLO-BC,Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer,2.5315068493150683,Recruiting,Interventional,No,No,Principal Investigator,134
SHR-A1811-III-306,SHR-A1811 Versus Investigators Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial,3.0876712328767124,Not yet recruiting,Interventional,No,No,Sponsor,528
REO 028,A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study,4.06027397260274,"Active, not recruiting",Interventional,Yes,No,Sponsor,48
LQ007,Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer,2.7041095890410958,Unknown status,Interventional,No,No,Principal Investigator,32
2019-KY-049,Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positiveï¼HR-Positive Metastatic Breast Cancer,2.9726027397260273,Unknown status,Interventional,No,No,Principal Investigator,46
D9268C00001,"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigators Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)",3.827397260273973,"Active, not recruiting",Interventional,Yes,No,Sponsor,733
ET17-203 DISCO,Efficacy of Exercise Using Connected Activity Trackers and Therapeutic Education in Localized Breast Cancer,4.353424657534247,Completed,Interventional,No,No,Sponsor,436
GO 22/41,Reliability and Validity of The 6 Minute Pegboard and Ring Test in Patients With Breast Cancer,0.7506849315068493,Completed,Observational,No,No,Principal Investigator,48
YOUNGBC-16,MammaPrint Value for Pre-menopausal Breast Cancer Patients,2.0027397260273974,Recruiting,Observational,No,No,Principal Investigator,200
07068-02,Oxygen Partial Pressure After Breast Cancer Surgery,1.2712328767123289,Recruiting,Observational,No,No,Sponsor,60
EC/2017/0200,Intra-operative PET-CT: a Novel Approach to Determine Excision Margins in Lumpectomy Breast Cancer.,6.0,Recruiting,Interventional,No,No,Sponsor,100
99mTc-DARPinG3 breast cancer,99mTc-DARPinG3 SPECT/CT for Non-invasive HER2-AX in Breast Cancer With Metastatic Lymph Nodes Before Targeted Therapy,0.947945205479452,Enrolling by invitation,Observational,No,No,Sponsor,24
200277,Focused Ultrasound and Gemcitabine in Breast Cancer,2.9315068493150687,Recruiting,Interventional,Yes,Yes,Sponsor-Investigator,48
CFT / sp123,A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer,1.4986301369863013,Not yet recruiting,Interventional,No,No,Sponsor,42
2021-1201,3D Printed Breast Models in the Surgical Management of Breast Cancer,3.5835616438356164,Not yet recruiting,Interventional,No,No,Sponsor,200
FDRT-BC012,Single Arm Phase II Study of Fractionated Stereotatic Radiation Therapy (FSRT) for Bone Metastases in Breast Cancer,6.0,Recruiting,Interventional,No,No,Sponsor,120
99mTc- RM26,Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26,2.328767123287671,Enrolling by invitation,Interventional,No,No,Sponsor,10
2103254164,Pioglitazone Therapy Targeting Fatigue in Breast Cancer,1.2712328767123289,Recruiting,Interventional,Yes,No,Principal Investigator,30
MA-BC-II-026,Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC),4.47945205479452,Not yet recruiting,Interventional,No,No,Principal Investigator,35
OBU-BC-II-079,Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer,1.4986301369863013,Not yet recruiting,Interventional,No,No,Principal Investigator,65
BCD-178-2,Clinical Study of the Efficacy and Safety of BCD-178 and PerjetaÂ® as Neoadjuvant Therapy of HER2-Positive Breast Cancer,3.0054794520547947,Recruiting,Interventional,No,No,Sponsor,336
YOUNGBC-24,Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer,2.665753424657534,"Active, not recruiting",Observational,No,No,Principal Investigator,150
AAAT4412,Breast Elasticity Imaging During Neoadjuvant Chemotherapy,2.5506849315068494,Recruiting,Interventional,No,No,Principal Investigator,50
SHR6390-Ib/II-201,A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer,4.276712328767124,"Active, not recruiting",Interventional,No,No,Sponsor,146
N19MIM,Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial,9.112328767123287,"Active, not recruiting",Interventional,No,No,Sponsor,38
CA209-7A8,A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer,1.7753424657534247,Completed,Interventional,Yes,No,Sponsor,23
CFT/sp123,"A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer",1.4958904109589042,Withdrawn,Interventional,No,No,Principal Investigator,0
EVER-132-002,Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC),3.271232876712329,"Active, not recruiting",Interventional,No,No,Sponsor,331
KY20192081-F-1,Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer,3.0027397260273974,Unknown status,Interventional,No,No,Sponsor,100
AC682-001,A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer,1.8027397260273972,Recruiting,Interventional,Yes,No,Sponsor,30
ATOS-Z-201,(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer,2.378082191780822,Recruiting,Interventional,Yes,No,Sponsor,174
UC-0140/1711 - UCBG3-06,Study on Androgen Receptor and Triple Negative Breast Cancer,4.353424657534247,Completed,Interventional,No,No,Sponsor,94
2018-05-0155,Improving Brain Function After Breast Cancer Study,1.3397260273972602,Completed,Interventional,No,No,Principal Investigator,36
SBU-PCWRT-BREAST,Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer,7.052054794520548,Recruiting,Interventional,No,Yes,Principal Investigator,25
2021.240,Effectiveness of Mobile Messenger-initiated Reminder on Biannual Mammography Adherence in Breast Cancer Screening,2.0000000000000004,Not yet recruiting,Interventional,No,No,Principal Investigator,600
YOUNGBC-6,Real World Study of Lapatinib Among Metastatic Breast Cancer Patients,1.358904109589041,Completed,Observational,No,No,Principal Investigator,242
HNCH-BC008,Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer,6.931506849315069,Recruiting,Interventional,No,No,Principal Investigator,1979
PLATO study,PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate,9.153424657534247,Recruiting,Interventional,No,No,Principal Investigator,122
PI20/596,"Long-term Outcomes After Breast Cancer Liver Metastasis Surgery: an European, Retrospective, Snapshot Study",0.3780821917808219,Unknown status,Observational,No,No,Principal Investigator,300
SCBCG-022,A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Postmenopausal Breast Cancer Patients,5.002739726027397,Not yet recruiting,Observational,No,No,Principal Investigator,2000
RSRB00066846,"A Whole-food, Plant-Based Nutrition Intervention in Women With Metastatic Breast Cancer",3.991780821917809,Completed,Interventional,No,No,Principal Investigator,32
HERMIONE-10,Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer,1.9424657534246577,Recruiting,Observational,No,No,Sponsor,200
KC19EESI0325,Real-time Interactive Digital Healthcare System in Post Operation Patients With Breast Cancer; Pilot Study,0.5178082191780823,Completed,Interventional,No,No,Sponsor-Investigator,20
16-007764,Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography,0.6602739726027397,Withdrawn,Interventional,No,Yes,Principal Investigator,0
18-621,Tucatinib + Abemaciclib + Herceptin for HER2+ MBC,0.2356164383561644,Withdrawn,Interventional,Yes,No,Principal Investigator,0
STOP-BC Trial,Sulindac and Breast Density in Women at Risk of Developing Breast Cancer,6.2027397260273975,Recruiting,Interventional,Yes,No,Principal Investigator,150
IRB-59141,Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer,1.0191780821917809,Recruiting,Interventional,Yes,No,Sponsor,30
SYSU005,Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation,3.9616438356164387,Recruiting,Interventional,No,No,Principal Investigator,61
ZN-c5-002,A Study of ZN-c5 in Participants With Breast Cancer,1.3917808219178083,Completed,Interventional,Yes,No,Sponsor,35
Fudan University,NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy,3.1671232876712327,Unknown status,Interventional,No,No,Sponsor,316
18-8214-BO,Effectiveness of Ear Acupuncture to Improve Insomnia in Women With Breast Cancer,0.6904109589041096,Completed,Interventional,No,No,Principal Investigator,52
B00157,A Pilot Study of Ultrasound-guided Vacuum-assisted Excision of Breast Cancers,2.9342465753424656,Completed,Observational,No,No,Sponsor,7
1711-048-898,Unnecessary Mastectomy Due to False Size Prediction by Preoperative Imaging Studies in Breast Cancer,4.778082191780822,Recruiting,Interventional,No,No,Principal Investigator,460
2021-A03091-40,Evaluation of the Interest of a Postural and Functional Analysis for the Follow-up of the Adapted Motor Activity of Patients Treated for Breast Cancer,3.3315068493150686,Not yet recruiting,Interventional,No,No,Sponsor,60
HR-BLTN-001,Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC,1.7561643835616438,Unknown status,Interventional,No,No,Principal Investigator,79
A5481166,Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan,2.197260273972603,"Active, not recruiting",Observational,,,Sponsor,688
D081CC00012,LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS),3.7753424657534245,Recruiting,Observational,,,Sponsor,104
Luminal A sirt1,Role of SIRT1 in Regulation of Epithelial-to-mesenchymal Transition in Breast Cancer Lymph Nodes Metastasis,1.997260273972603,Unknown status,Observational,No,No,Sponsor,160
DokuzEU.Com.Garments,COMPRESSION GARMENTS in BREAST CANCER-RELATED LYMPHEDEMA,0.41643835616438357,Completed,Observational,No,No,Principal Investigator,60
P.T.REC/012/002968,RESISTANCE VERSUS AEROBIC EXERCISES ON Breast Cancer Patients,0.3013698630136986,Unknown status,Interventional,No,No,Principal Investigator,60
IIT-2021-ASSET,Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer,2.180821917808219,Recruiting,Interventional,Yes,No,Principal Investigator,18
MC200302,"Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer, the ENHANCE Study",3.934246575342466,Recruiting,Observational,No,No,Sponsor,165
4-2020-1131,Talazoparib Maintenance Therapy in Triple-negative Breast Cancer,3.0027397260273974,Not yet recruiting,Interventional,No,No,Sponsor,206
145358,"A Phase I/II Multicenter, Open-Label Study of Lu-177-Î±vÎ²3-IAC, for the Treatment of Angiogenic Breast Cancer Patients.",1.5835616438356164,Not yet recruiting,Interventional,Yes,No,Sponsor,100
UMCC 2018.016,The ConnectedCancerCare Pilot Study (CCC),1.06027397260274,Completed,Interventional,No,No,Sponsor,66
TP.102.17.22.PAR,Pilot Clinical Evaluation of a Microwave Imaging System for Breast Cancer Detection,1.7315068493150685,Recruiting,Interventional,No,No,Sponsor,103
EFC15935,Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer,3.208219178082192,"Active, not recruiting",Interventional,Yes,No,Sponsor,1068
BC-NEO-IIT-SHR6390,SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.,1.6602739726027398,Completed,Interventional,No,No,Sponsor,20
GDWCH-001,Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer,3.164383561643836,Not yet recruiting,Interventional,No,No,Principal Investigator,73
S2010,"Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study",5.095890410958904,Recruiting,Interventional,No,No,Sponsor,540
SMC-2018-10-062,Feasibility of a Modular mHealth for Tailored Rehabilitation of Breast Cancer,1.9397260273972605,Completed,Interventional,No,No,Principal Investigator,44
SMX 18001,Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation,4.36986301369863,"Active, not recruiting",Interventional,Yes,No,Sponsor,100
A5481154,Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole,4.824657534246575,"Active, not recruiting",Observational,No,No,Sponsor,42
TEBICA002,Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells,2.506849315068493,Completed,Interventional,No,No,Sponsor,5
CWCD118B12201,Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer,5.843835616438356,Not yet recruiting,Interventional,Yes,No,Sponsor,250
22-002857,"Assessment of the Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Systemic Therapy and Surgery, UTMOST Trial",1.336986301369863,Not yet recruiting,Observational,No,Yes,Sponsor,10
CALORIE,Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy,2.0027397260273974,Unknown status,Interventional,No,No,Sponsor,50
IFOM-CPO007/2019/PO006,A Master Protocol Empowering Mechanobiology Translation Research in Breast Cancer,6.380821917808219,Recruiting,Observational,No,No,Sponsor,500
S-detect 2019,Application of Deep-learning and Ultrasound Elastography in Opportunistic Screening of Breast Cancer,2.0027397260273974,Completed,Observational,No,No,Sponsor,1200
AABCSR,Stress Reactivity Among African American Breast Cancer Survivors,2.7534246575342465,Completed,Observational,No,No,Principal Investigator,110
NRG-BR008,Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer,13.901369863013699,Recruiting,Interventional,No,No,Sponsor,1300
FMSU2017-002B,Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer - A Pivotal Study,0.40273972602739727,Completed,Observational,No,Yes,Sponsor,300
2019-A01592-55,Transcutaneous Breast Cancer Diagnosis by Canine Odorology,4.156164383561644,Suspended,Interventional,No,No,Sponsor,450
ABY-025-MI301,A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer,7.2,Recruiting,Interventional,No,No,Sponsor-Investigator,160
202202045MIPA,Olaparib Maintenance Therapy in Metastatic Breast Cancer,3.0547945205479454,Recruiting,Interventional,No,No,Sponsor,300
22-07025006,Diabetes Care for Breast Cancer Patients,3.778082191780822,Recruiting,Interventional,No,No,Sponsor,76
2019/044,Evaluation of the Effect of Mediterranean Diet on Breast Cancer Patients,1.2493150684931507,Completed,Interventional,No,No,Principal Investigator,25
B2017-11,Neoadjuvant Goserelin for Triple Negative Breast Cancer,5.002739726027397,Unknown status,Interventional,No,No,Principal Investigator,180
2022-0651,The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts,5.073972602739726,Recruiting,Observational,No,No,Sponsor,1000
Pro00088926,Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer,3.8136986301369866,Completed,Interventional,No,No,Sponsor,314
Tmab-TK006-102b,Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases,1.0000000000000002,Unknown status,Interventional,No,No,Sponsor,30
YOUNGBC-10,Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients,3.0027397260273974,Completed,Observational,No,No,Principal Investigator,97
Ahead-BC-20170323,Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer,2.0027397260273974,Unknown status,Interventional,No,No,Sponsor-Investigator,30
21090645,Omega-3 and Vitamin D Supplementation in Breast Cancer Women,0.6958904109589041,Recruiting,Interventional,No,No,Principal Investigator,88
18-0234,The REACH Study: A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors,1.4191780821917808,Completed,Interventional,No,No,Principal Investigator,88
20-1434.cc,Cancer Patient Perspectives During COVID-19,2.76986301369863,"Active, not recruiting",Observational,No,No,Sponsor,89
P20CA217199-9492018,A Community Dance Intervention Engaging Breast Cancer Survivors in a Middle-income Country,1.5041095890410958,Completed,Interventional,No,No,Sponsor-Investigator,64
Pro00107216,The Effect of Intermittent Fasting on Body Composition in Women With Breast Cancer,1.663013698630137,Withdrawn,Interventional,No,No,Sponsor,0
HREBA.CC 19-0363,Rise Up After Breast Cancer,0.6657534246575343,Completed,Interventional,No,No,Sponsor,12
AHQU-2021004,Acupuncture for Stiffness of Joint Related to Aromatase Inhibitors in Patients With Early-Stage Breast Cancer,1.6136986301369862,Recruiting,Interventional,No,No,Principal Investigator,52
H20-03123,Breast Cancer Endocrine Therapy FITness (BE-FIT) Trial.,2.797260273972603,Recruiting,Interventional,No,No,Principal Investigator,132
CSPC-KAL-AE-01,Real-world Study for the Safety of Albumin-Bound Paclitaxel in Recurrent or Metastatic Breast Cancer,2.421917808219178,Unknown status,Observational,No,No,Sponsor,1000
SYS-C-201801-5010,Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer,12.008219178082191,Recruiting,Interventional,No,No,Sponsor-Investigator,210
SCBCG-021,A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Premenopausal Breast Cancer Patients,5.002739726027397,Not yet recruiting,Observational,No,No,Principal Investigator,2000
15-017,Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer,3.8082191780821923,Unknown status,Interventional,No,No,Principal Investigator,190
ZN-c5-003,A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer,1.9479452054794524,Completed,Interventional,Yes,No,Sponsor,14
114421,Understanding and Addressing Patient and Provider Preferences Around Discussions of Cost of Breast Cancer Care,2.0328767123287674,Completed,Interventional,No,No,Principal Investigator,100
M14ABC,"A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients",4.131506849315069,Terminated,Interventional,No,No,Sponsor,9
CLIN-52014-452,Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment,2.1424657534246574,Recruiting,Observational,No,No,Sponsor,419
18-004803,Evaluation of Magseed as Localization Device for Biopsy Proven Metastatic Axillary Lymph Nodes,1.0876712328767124,Terminated,Interventional,No,Yes,Principal Investigator,1
34615/4/21,The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer,1.4054794520547946,Completed,Interventional,No,No,Principal Investigator,66
CLAG525B2101,"A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer",3.4,Completed,Interventional,Yes,No,Sponsor,88
MINERVA,Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management,3.931506849315069,Recruiting,Interventional,Yes,No,Sponsor-Investigator,300
LACOG 0419,Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer,8.616438356164384,Recruiting,Interventional,No,No,Sponsor,494
CHB18.04,Quality of Life and Sexuality of Patients Over 65 Years Undergoing Adjuvant Treatment for Breast Cancer,3.249315068493151,Completed,Interventional,No,No,Sponsor,14
CSIIT-C21,A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer,2.0027397260273974,Not yet recruiting,Interventional,No,No,Principal Investigator,70
BOOG 2018-01,Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study,13.183561643835617,"Active, not recruiting",Interventional,No,No,Sponsor,462
AMC2020-17,Upper Limb Function After Breast Cancer Surgery: the Role of Post-operative Physical Therapy Intervention,1.16986301369863,Completed,Interventional,No,No,Principal Investigator,160
KY20222062-C-1,"Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer",1.1643835616438356,Not yet recruiting,Interventional,No,No,Sponsor,20
RCVDBCIIR005,Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer,1.5041095890410958,Not yet recruiting,Interventional,No,No,Principal Investigator,20
20201540,Prospective Evaluation of Targeted Axillary Dissection (TAD),3.0027397260273974,Recruiting,Interventional,No,No,Principal Investigator,45
STUDY00003282,Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer,3.6082191780821917,"Active, not recruiting",Interventional,Yes,No,Sponsor,50
IRB-2022-348,Transversus Thoracic Muscle Plane Combined With Pectoral Nerves Block for Breast Cancer Surgery,1.1561643835616437,Not yet recruiting,Interventional,No,No,Principal Investigator,116
LCCC 1639,"Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC",0.8684931506849315,Terminated,Interventional,Yes,No,Sponsor,5
SCHBCC-N034,Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D),5.0,Not yet recruiting,Interventional,No,No,Sponsor,356
2022-0431,A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC),0.7479452054794521,Not yet recruiting,Interventional,Yes,No,Sponsor,25
CBYL719C1201,Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer,6.868493150684931,Recruiting,Interventional,No,No,Sponsor,50
SYSA1802-CSP-006,A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC),2.0000000000000004,Recruiting,Interventional,No,No,Sponsor,79
201805027RSA,East Asian Breast Cancer Genome Atlas and Recurrence Risk Prediction,9.70958904109589,Recruiting,Observational,No,No,Sponsor,2000
KY2022-097-B,CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer,5.7534246575342465,Not yet recruiting,Observational,Yes,No,Principal Investigator,172
KY2019-023,Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer,7.3780821917808215,"Active, not recruiting",Interventional,No,No,Principal Investigator,53
GE-226-004,Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer,1.0027397260273974,Not yet recruiting,Interventional,Yes,No,Sponsor,12
MEDOPP447,Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer,2.3835616438356166,Withdrawn,Interventional,No,No,Sponsor,0
2021P002871,Optimizing Functional Recovery of Breast Cancer Survivors,3.591780821917808,"Active, not recruiting",Interventional,No,No,Principal Investigator,300
CABC - Kreftfor project - SEB,Coping After Breast Cancer - a Randomized Clinical Trial With Two Digital Interventions,14.967123287671233,Recruiting,Interventional,No,No,Sponsor,390
201708076,Mindful Movement in Women Receiving Adjuvant or Neoadjuvant Therapy for Breast Cancer,1.4575342465753425,Completed,Interventional,No,No,Sponsor,30
TWT-203,"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer",3.1835616438356165,Recruiting,Interventional,Yes,No,Sponsor,44
Radiodermatitistalita60,The Use of Photobiomodulation in the Management of Radiodermatitis in Breast Cancer Patients,1.7506849315068493,Not yet recruiting,Observational,No,No,Principal Investigator,60
CO41101,A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.,3.263013698630137,Completed,Interventional,Yes,No,Sponsor,242
EA1183,"Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study",7.416438356164384,Recruiting,Interventional,No,No,Sponsor,134
WO42312,"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physicians Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)",3.0,"Active, not recruiting",Interventional,Yes,No,Sponsor,303
MEDOPP367,Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status,2.0164383561643837,Recruiting,Observational,No,No,Sponsor,30000
YXH2022ZX02167,Neoadjuvant Effect of Albumin Binding Paclitaxel Compared With Common Paclitaxel in Breast Cancerï¼an Observational Single Center Study of Clinical Efficacy in Adjuvant Chemotherapy,2.6164383561643834,Recruiting,Observational,Yes,No,Sponsor-Investigator,112
NHP,Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer,1.997260273972603,Unknown status,Interventional,No,No,Sponsor,50
JU 2020/1732-51,Digi-Do - a Digital Information Tool to Help Patients Diagnosed With Breast Cancer,3.3315068493150686,"Active, not recruiting",Interventional,No,No,Principal Investigator,80
NL69081.041.19,The Effect of Hyperbaric OxygeN Therapy on brEast Cancer Patients With Late Radiation toxicitY - UMBRELLA HONEY Trial,4.013698630136987,Recruiting,Interventional,No,No,Principal Investigator,120
NCCH1607,"PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY",7.145205479452055,"Active, not recruiting",Interventional,Yes,No,Sponsor,180
AAAS2359,Family-Based Intervention Study of the Effects of Environmental Exposures on Breast Tissue Composition,1.0027397260273974,Unknown status,Interventional,No,No,Principal Investigator,90
21-06023682,"De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You",6.972602739726027,Recruiting,Observational,No,No,Sponsor,400
HSEARS20210816002,The Effects of a Nurse-led mHealth Program for Symptom Self-management of Breast Cancer Patients Undergoing Chemotherapy,0.7287671232876712,Recruiting,Interventional,No,No,Sponsor,76
GALAXY,Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancerï¼GALAXYï¼,3.578082191780822,"Active, not recruiting",Interventional,No,No,Principal Investigator,56
D926XC00001,A Study of Dato-DXd With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03),7.331506849315068,Recruiting,Interventional,Yes,No,Sponsor,1075
PUMCH-BC500,Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Breast Cancer,5.854794520547945,Recruiting,Observational,No,No,Principal Investigator,200
HRS-8080-I-101,A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults,3.452054794520548,Enrolling by invitation,Interventional,No,No,Sponsor,156
S2020-300-01,Sonazoid Contrast-enhanced Ultrasound in Assessing Effectiveness of Neoadjuvant Chemotherapy in Breast Cancer Patients.,1.3342465753424657,Unknown status,Observational,No,No,Principal Investigator,1012
99mTc-DARPinG3,99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy,0.7534246575342466,Completed,Observational,No,No,Sponsor,15
ONA-XR-103,Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer,3.410958904109589,"Active, not recruiting",Interventional,Yes,No,Sponsor,67
EMERGENCE GSO/2020/JF-001,Evaluation of Changes in the Immunological Microenvironment Surrounding Subcutaneous Breast Cancer Metastases After Liquid Nitrogen Cryotherapy,1.789041095890411,Recruiting,Interventional,No,No,Sponsor,5
Soh-Med-22-05-24,Dosimetric Comparison of Three Radiation Techniques for Hypofractionated Whole Breast Radiotherapy in Early Breast Cancer,3.0356164383561643,Not yet recruiting,Observational,No,No,Principal Investigator,30
2022-0315,Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer,9.898630136986302,Recruiting,Interventional,Yes,No,Sponsor,37
KCSG BR19-13,High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx),4.978082191780822,Recruiting,Interventional,No,No,Principal Investigator,578
STU00216520,Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia,3.8657534246575347,Recruiting,Interventional,No,No,Principal Investigator,452
SYSEC-KY-KS-2019-054-001,Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01),5.602739726027397,Recruiting,Observational,No,No,Principal Investigator,1500
ICO-2020-25,Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients,2.695890410958904,Recruiting,Interventional,No,No,Sponsor,12
20805,BATs in Patients With Breast Cancer and Leptomeningeal Metastases,2.8,Terminated,Interventional,Yes,No,Principal Investigator,3
HRS-1358-I-101,A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer,2.3945205479452056,Enrolling by invitation,Interventional,No,No,Sponsor,102
IRFMN-BRC-7103,Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer,5.391780821917808,"Active, not recruiting",Interventional,No,No,Sponsor,54
BL-M02D1-101,A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors,1.9506849315068495,Recruiting,Interventional,No,No,Sponsor,26
RJBC1901,Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer,0.6410958904109589,Terminated,Interventional,No,No,Principal Investigator,12
PELICAN-IPC 2015-016,Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer,6.772602739726027,Recruiting,Interventional,Yes,No,Sponsor,81
YO41137,"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer",5.76986301369863,"Active, not recruiting",Interventional,Yes,No,Sponsor,200
BC2,A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer,6.835616438356165,Not yet recruiting,Interventional,Yes,No,Principal Investigator,172
CO40016,"A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer",4.997260273972603,Completed,Interventional,Yes,No,Sponsor,580
ADIGYN,Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer,9.61917808219178,Recruiting,Interventional,No,No,Sponsor,1000
NICSO-GINSENG,American Ginseng for the Prevention of Moderate-severe Fatigue in Breast Cancer Patients,1.673972602739726,Unknown status,Interventional,No,No,Principal Investigator,290
ATADEK-2018 / 9,KÄ°NECTÂ® - Video Games Based Physiotherapy Programme in Patients With Breast Cancer Surgery,0.9205479452054794,Completed,Interventional,No,No,Principal Investigator,34
UW22095,Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer,2.9616438356164383,Recruiting,Interventional,No,No,Sponsor,100
HREBA.CC-18-0657,Diet Restriction and Exercise-induced Adaptations in Metastatic Breast Cancer,4.693150684931507,Enrolling by invitation,Interventional,No,No,Sponsor,50
NSABP FB-12,Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling,5.465753424657534,Recruiting,Interventional,Yes,Yes,Sponsor,64
4469,PIK3CA in HER2+ BC and pCR Trial,1.3342465753424657,"Active, not recruiting",Interventional,No,No,Sponsor,58
RTM 2015,Microwave Radiometry for the Diagnosis and Monitoring of Breast Cancer,0.4191780821917808,Withdrawn,Observational,No,No,Sponsor,0
Breast-Chi-2022,Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor,3.063013698630137,Recruiting,Observational,No,No,Sponsor,50
STUDY00018504,"Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer",8.057534246575344,Recruiting,Interventional,Yes,No,Principal Investigator,132
38RC19.362,Feasibility Study on the Characterization of the Immune Profile of Young Patients After Treatment for Breast Cancer,1.3808219178082193,Unknown status,Observational,No,No,Sponsor,26
YOUNGBC-19,Chidamide in Combination With Abemaciclib and Fulvestrant in Breast Cancer Patients Previously Treated With Palbociclib,0.8328767123287671,Recruiting,Interventional,No,No,Sponsor-Investigator,44
CTFSp161,Personalised Disease Monitoring in Metastatic Breast Cancer,10.742465753424657,Recruiting,Observational,No,No,Sponsor,100
CCR5316,A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer,8.43013698630137,Recruiting,Interventional,No,No,Sponsor,1100
STUDY00000675,Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer,3.463013698630137,Recruiting,Interventional,Yes,No,Principal Investigator,20
FILBLAU1022,Effectiveness and Safety Study of FilgrastineÂ® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy,1.5890410958904109,Not yet recruiting,Interventional,No,No,Sponsor,60
CBYL719C2303,"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.",4.8191780821917805,Recruiting,Interventional,No,No,Sponsor,234
US-MAM,The Diagnosis and Prognosis of Nonpalpable Breast Cancer Detected by the US vs Mammography: a Clinical Noninferiority Trial.,2.9972602739726026,Recruiting,Observational,No,Yes,Principal Investigator,1277
BC-IIT-SHR6390-FMTN,A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.,2.347945205479452,"Active, not recruiting",Interventional,No,No,Sponsor,35
LV,"Breast Cancer, Omics, and Precision Medicine",1.9150684931506852,Not yet recruiting,Interventional,No,No,Principal Investigator,200
CAPRICE-IPC 2020-053,A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr,4.756164383561644,Not yet recruiting,Interventional,No,No,Sponsor,72
P0268,Prospective Validation of 3D Dose Metrics as Selection Criteria for Adaptive Radiotherapy in Breast Cancer Patients,0.6328767123287671,Completed,Observational,No,No,Sponsor,46
HMPL-012-SPRING-R101,An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer,3.0027397260273974,Recruiting,Interventional,No,No,Principal Investigator,63
2107239-9,Reverse Triple Negative Immune Resistant Breast Cancer,0.6684931506849315,Recruiting,Interventional,No,No,Principal Investigator,30
Breast PTC,Postoperative Identification of Tumor Cells at the Lumpectomy Site of Patients With Early Breast Cancer,5.038356164383561,Suspended,Interventional,No,No,Sponsor,20
201900115B0,Evaluation of the Effects of the Couple-based Family Nursing for Women With Breast Cancer,0.8191780821917808,Completed,Interventional,No,No,Principal Investigator,70
2021-A02664-37,Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.,2.350684931506849,Recruiting,Interventional,No,No,Sponsor,165
EF 160,Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients With Breast Cancer,4.668493150684932,Recruiting,Interventional,No,No,Sponsor,68
D20148,Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI),3.0547945205479454,Recruiting,Interventional,Yes,No,Principal Investigator,28
CBYL719C2202,"Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant",1.093150684931507,"Active, not recruiting",Interventional,Yes,No,Sponsor,2
PUMCH-BC503,Evaluation of Prognostic Monitoring for Young Breast Cancer Patients,5.854794520547945,Recruiting,Observational,No,No,Principal Investigator,200
TRIO036,"Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer",1.8575342465753424,Completed,Interventional,Yes,No,Sponsor,19
EG017,To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer.,3.334246575342466,Not yet recruiting,Interventional,No,No,Sponsor,81
TIPN in China,Taxane Induced Peripheral Neuropathy in Chinese Patients With Breast Cancer,1.2767123287671234,Unknown status,Observational,No,No,Principal Investigator,500
2019000486,"Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer",4.421917808219178,"Active, not recruiting",Interventional,Yes,No,Sponsor,12
Alpha-Lipoic Acid,Alpha-Lipoic Acid in Breast Cancer Patients,1.6684931506849314,Completed,Interventional,No,No,Principal Investigator,64
VICC BREP 1898,Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer,4.958904109589041,"Active, not recruiting",Interventional,Yes,Yes,Sponsor-Investigator,20
MD.22.07.674,Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients,1.7917808219178082,Recruiting,Interventional,No,No,Principal Investigator,116
07-2021/EK OUSA,Impact of Novel Thoracic Wall Blocks With Dexmetomidine on Inflammatory Markers Following Breast Cancer Surgery,2.082191780821918,Not yet recruiting,Interventional,No,No,Sponsor,120
I241,Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer,5.347945205479452,Recruiting,Interventional,No,No,Sponsor,484
853.4,"Maximum Tolerated Dose, Safety and Pharmacologic Study of TRF in Women With Breast Cancer",0.8657534246575342,Unknown status,Interventional,No,No,Sponsor-Investigator,12
ShandongCHI-08,Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients,1.0000000000000002,Unknown status,Observational,No,No,Sponsor-Investigator,60
173-18-CA,Perioperative Mindfulness Proposal,4.421917808219178,Recruiting,Interventional,No,No,Sponsor,24
1400,Tahini and Dermatitis in Breast Cancer,0.1863013698630137,Not yet recruiting,Interventional,No,No,Principal Investigator,50
NCC2167,Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine,3.750684931506849,Recruiting,Interventional,No,No,Principal Investigator,138
UW 18-526,The Effect of Acupuncture for Insomnia in Breast Cancer Patients Undergoing Chemotherapy,1.6027397260273972,Completed,Interventional,No,No,Principal Investigator,30
H-1905-141-1035,Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer,5.8712328767123285,Recruiting,Interventional,No,No,Principal Investigator,180
EUBREAST-2 INDAX,Individualized Locoregional Treatment of Initially Biopsy-proven Node-positive Breast Cancer After Primary Systemic Therapy,9.002739726027396,Withdrawn,Interventional,No,No,Principal Investigator,0
HRHB-CB001,"Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer",4.002739726027397,Not yet recruiting,Interventional,No,No,Principal Investigator,280
NSABP FB-14,Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer,5.164383561643835,"Active, not recruiting",Interventional,Yes,No,Sponsor,29
ADG106-T6002,"A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer",7.712328767123289,Recruiting,Interventional,No,No,Sponsor,66
1812850942,Telephone Support for Metastatic Breast Cancer Patients,4.252054794520548,"Active, not recruiting",Interventional,No,No,Principal Investigator,250
RJBC1801,Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer,3.504109589041096,Recruiting,Interventional,No,No,Principal Investigator,100
UTAR- 8068/000,A Systemic Approach to Study the Traditional Chinese Medicine as an Adjuvant Treatment in Breast Cancer Patients,1.945205479452055,Recruiting,Interventional,No,No,Principal Investigator,30
SH APBI RISE,Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen for patIents With Favorable Risk breaSt cancEr,5.0849315068493155,Recruiting,Interventional,No,Yes,Principal Investigator,91
TOL2506A,Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer,3.8328767123287677,Recruiting,Interventional,Yes,No,Sponsor,250
852000,FES BPET-DBT in Newly Diagnosed Breast Cancer,2.756164383561644,Not yet recruiting,Interventional,Yes,Yes,Sponsor,20
2019-A02500-57,Management of Cognitive Difficulties After Cancer Treatments in Women Treated for Breast Cancer: Feasibility Study (Step 1 of the Cog-Stim Protocol),2.052054794520548,Completed,Interventional,No,No,Sponsor,20
JCOG1919E,A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer,4.441095890410959,Recruiting,Interventional,No,No,Principal Investigator,280
AI-BMRI-S,Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening and Diagnosis of Breast Cancer,3.589041095890411,Recruiting,Observational,No,No,Principal Investigator,5000
Prix Ruban Rose/2020/FF-03,Multidisciplinary Care Pathway With Electronic Patient Reported Outcomes (ePRO) Post-operative Follow-up of Breast Cancer Surgery Complications to Optimize Patient Quality of Life,1.9369863013698632,Recruiting,Interventional,No,No,Sponsor,50
SBU-SBRT-BREAST-NO-SX,Stereotactic Body Radiation Therapy (SBRT) for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery,7.035616438356165,"Active, not recruiting",Interventional,No,Yes,Principal Investigator,15
IUSCC-0680,Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors,3.9178082191780828,Recruiting,Interventional,No,Yes,Principal Investigator,72
E7389-M065-401,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",1.252054794520548,Completed,Interventional,No,No,Sponsor,200
UPCC 04119,BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy,3.652054794520548,Recruiting,Interventional,Yes,No,Principal Investigator,27
HCRN BRE20-468,"Ribociclib And Endocrine Treatment of Physicians Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer",5.219178082191781,Recruiting,Interventional,Yes,No,Sponsor-Investigator,200
2021-04,Smart Bra for Diagnosing Breast Cancer,0.5863013698630137,Not yet recruiting,Interventional,No,No,Sponsor,70
18-000718,"Team Based Psychosocial Care to Promote, Maintain and Restore Wellness of Breast Cancer Patients",5.931506849315069,"Active, not recruiting",Interventional,No,No,Principal Investigator,200
MOST Pain,Optimizing Psychological Treatment for Pain After Breast Cancer,2.0849315068493155,Recruiting,Interventional,No,No,Principal Investigator,185
AQUAFIT-2018,Water-based Versus Land-based Exercise for Breast Cancer Survivors,2.66027397260274,Recruiting,Interventional,No,No,Principal Investigator,28
Moderate Dose Omega-3,Study of Moderate Dose Omega 3 Fatty Acid Supplement in Premenopausal Women at High Risk for Breast Cancer,3.0684931506849313,Unknown status,Interventional,No,No,Sponsor-Investigator,11
Pro00104863,"Exercise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Breast Conservation Therapy for Women With Early Stage Breast Cancer",1.0000000000000002,Withdrawn,Interventional,No,No,Sponsor,0
MA40,Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor,6.0849315068493155,Recruiting,Interventional,No,No,Sponsor,250
HR-BLTN-003,Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer,4.517808219178082,"Active, not recruiting",Interventional,No,No,Principal Investigator,100
Velocity,Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer,1.4931506849315068,Recruiting,Interventional,Yes,No,Principal Investigator,20
KN026-201,Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer,6.005479452054795,"Active, not recruiting",Interventional,No,No,Sponsor,68
GBG105,"Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer",4.000000000000001,Recruiting,Interventional,No,No,Sponsor,170
KN026-208,Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer,1.5205479452054795,Recruiting,Interventional,No,No,Sponsor,30
27600,Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer,4.254794520547946,Recruiting,Interventional,No,No,Principal Investigator,176
RnaDx-BRV-BC- 01,RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy,7.506849315068493,Recruiting,Interventional,No,No,Sponsor,594
ZN-c5-001,A Study of ZN-c5 in Subjects With Breast Cancer,4.0410958904109595,Completed,Interventional,Yes,No,Sponsor,181
2020-A00398-31,Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer,4.531506849315068,Recruiting,Interventional,No,No,Sponsor,85
CSIIT-C10,Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors,0.8931506849315068,Not yet recruiting,Interventional,No,No,Principal Investigator,20
ICON CA209-9FN,Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer,9.306849315068494,"Active, not recruiting",Interventional,No,No,Principal Investigator,82
31052019,Implementation of a CDSS in Oncology Patients During COVID-19,1.095890410958904,Completed,Interventional,No,No,Principal Investigator,44
iOM-110393,Self-efficacy Coaching for Women With Breast Cancer,0.6876712328767123,Completed,Interventional,No,No,Sponsor,46
201711073,"MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer",2.4164383561643836,Withdrawn,Interventional,Yes,No,Sponsor,0
L21-076,Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers,3.4164383561643836,Not yet recruiting,Interventional,Yes,Yes,Principal Investigator,36
2020-007,Characterization of Neuromuscular Function and Fatigue After Breast Cancer Treated With Adjuvant Chemotherapy (PROTECT-04),0.936986301369863,Completed,Interventional,No,No,Sponsor,30
19-300,Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer,5.005479452054795,Recruiting,Interventional,No,Yes,Sponsor,400
RAD1901-308,Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer,5.232876712328767,"Active, not recruiting",Interventional,Yes,No,Sponsor,466
LAE205INT3101,Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer,2.8657534246575342,Recruiting,Interventional,Yes,No,Sponsor,20
201900180,89Zr-atezolizumab PET Scan and Lobular Breast Cancer,2.3698630136986303,Terminated,Interventional,No,No,Principal Investigator,1
201911047,Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer,0.4657534246575342,Terminated,Interventional,Yes,Yes,Sponsor,1
CAAP CA,Light Emitting Diode for theTreatment of Genitourinary Syndrome of Menopause Associated With Breast Cancer Treatment,2.008219178082192,Unknown status,Interventional,No,No,Sponsor,74
JTU-6H-20211230001,Effect of the Axillary Lymphatic /Vein Reflux Ratio on Postoperative Upper Limb Edema and Dysfunction in Breast Cancer,2.249315068493151,Recruiting,Observational,No,No,Sponsor-Investigator,288
BCT 2102,Tucatinib Together With Pembrolizumab and Trastuzumab,2.4904109589041097,Recruiting,Interventional,Yes,No,Sponsor,50
OCOG-2019-RHEAL,Hypofractionated LocoRegional Radiotherapy in Breast Cancer,6.890410958904109,Recruiting,Interventional,No,No,Sponsor,588
KY20223267-1,PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer,4.000000000000001,Recruiting,Interventional,No,No,Sponsor,100
SGNTUC-016,A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer,4.580821917808219,Recruiting,Interventional,Yes,No,Sponsor,565
SHEPHERD-2021-2,Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis,3.9178082191780828,Recruiting,Observational,No,No,Sponsor,600
GUMPTION,Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer,1.9150684931506852,Recruiting,Interventional,No,No,Principal Investigator,100
MA-BC-II-018,"Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial",7.704109589041097,Recruiting,Interventional,No,No,Principal Investigator,140
A5481168,Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC,0.4958904109589042,Recruiting,Observational,,,Sponsor,300
1401,Grape Juice and Dermatitis in Breast Cancer,0.1863013698630137,Not yet recruiting,Interventional,No,No,Principal Investigator,50
SCHBCC-N041,SNF Platform Study of HR+/ HER2-advanced Breast Cancer,3.923287671232877,Recruiting,Interventional,No,No,Principal Investigator,140
IBIO-301,A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer,5.517808219178082,"Active, not recruiting",Interventional,Yes,No,Sponsor,200
FUSCC-T-sunflower,Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower),3.3315068493150686,Not yet recruiting,Interventional,No,No,Principal Investigator,126
05022020,FALSE POSITIVE FINDINGS IN BREAST CANCER TOMOSYNTHESIS,1.0000000000000002,Completed,Observational,No,No,Principal Investigator,4500
BTP-66732,"A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer",3.1671232876712327,Not yet recruiting,Interventional,No,No,Sponsor,267
CSIIT-C18,Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer,2.0849315068493155,Recruiting,Interventional,No,No,Principal Investigator,82
2021C0102,"Remote Assessment of Cognition, Insulin Resistance and Omega-3 Fatty Acid Biomarkers in Breast Cancer Survivors",1.2,Recruiting,Observational,No,No,Principal Investigator,80
CTO-IUSCCC-0758,Breast Cancer BRCA1 Carriers: a Pilot Study,3.1671232876712327,Withdrawn,Observational,Yes,No,Principal Investigator,0
CLOVER,Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer,7.336986301369863,Recruiting,Interventional,No,No,Principal Investigator,2172
LOXO-PIK-21001,A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors,2.9753424657534246,Recruiting,Interventional,Yes,No,Sponsor,400
SPI-GCF-104,"Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer",5.306849315068493,Recruiting,Interventional,Yes,No,Sponsor,90
HNCH-BC006,Comparing the Efficacy of Nab-PHP and TCbHP in Neoadjuvant Therapy for HER2 Positive Operable Breast Cancer,3.2849315068493152,Recruiting,Interventional,No,No,Principal Investigator,558
2019-0550,Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer,7.13972602739726,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,13
NL74126.091.20,Adherence Improving Self-Management Strategy (AIMS) in Breast Cancer Patients Using Adjuvant Endocrine Treatment (AET),2.0493150684931507,Unknown status,Interventional,No,No,Sponsor,64
ALTERBC008,A Phase â¡ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer,1.997260273972603,Recruiting,Interventional,No,No,Principal Investigator,32
IOM-050371,Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line,4.523287671232877,Completed,Interventional,No,No,Sponsor,41
IRB-2021-04,Evaluate Impact of Exercise Program on Fatigue in Breast Cancer During Chemotherapy,3.4438356164383563,Recruiting,Interventional,No,No,Sponsor,40
DPMBC301,Compare the Efficacy and the Safety of Doxorubicin and Cyclophosphamide Followed by Taxotere Versus Doxorubicin and Cyclophosphamide Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer,2.8328767123287673,Not yet recruiting,Interventional,No,No,Sponsor,320
SYHX2011-001,A Pharmacokinetic Comparison Study of SYHX2011 and AbraxaneÂ® in Patients With Advanced Breast Cancer,0.5835616438356165,Not yet recruiting,Interventional,No,No,Sponsor,28
21-225,A Study of Multiparametric MRI and pHLIPÂ® ICG in Breast Cancer Imaging During Surgery,3.953424657534247,Recruiting,Interventional,Yes,No,Sponsor,49
KCSG-BR18-13/TR-03,Phase II Study of HerzumaÂ® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer,1.997260273972603,Unknown status,Interventional,No,No,Principal Investigator,15
SELEBREC,Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.,3.506849315068493,Recruiting,Observational,No,No,Sponsor,300
ICPS002/20,Radiofrequency Ablation (RFA) in Breast Tumors,4.627397260273972,Recruiting,Interventional,No,Yes,Principal Investigator,30
21-698,Alcohol and Breast Cancer (ABC) Trial,2.063013698630137,Recruiting,Interventional,No,No,Principal Investigator,20
RJBC2001,"Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer",7.589041095890412,"Active, not recruiting",Interventional,No,No,Principal Investigator,216
H-2009-079-1157,Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency,3.9616438356164387,Recruiting,Interventional,No,No,Principal Investigator,70
20P.020,"Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer",3.03013698630137,Withdrawn,Interventional,Yes,No,Sponsor,0
GB491-005,A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer,2.6684931506849314,Recruiting,Interventional,No,No,Sponsor,10
012342QM,Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer,5.923287671232877,Not yet recruiting,Interventional,No,No,Sponsor,87
GDWCH002(TNBC),ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer,2.5835616438356164,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,30
HR-BLTN 015,A Multi-cohort Phase II Study of HER2-positive and Triple-negative Breast Cancer Brain Metastases.,1.8383561643835618,Unknown status,Interventional,No,No,Sponsor,59
HER2BRAIN,TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN),4.000000000000001,Not yet recruiting,Interventional,No,No,Sponsor,120
HNCH-MBC10,A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast Cancer,2.0027397260273974,Not yet recruiting,Interventional,No,No,Sponsor,60
NOGGO B3,Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer,14.219178082191782,"Active, not recruiting",Observational,No,No,Sponsor,1191
IC 2020-20,Digital Phenotyping in Young Breast Cancer Patients Treated With Neoadjuvant Chemotherapy,2.9506849315068493,Recruiting,Interventional,No,No,Sponsor,300
2017-004909-41,Prevention of Cardiac Dysfunction During Breast Cancer Therapy,6.671232876712328,"Active, not recruiting",Interventional,No,No,Sponsor-Investigator,214
2022JC-55,Acupuncture for Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.,5.0,Not yet recruiting,Interventional,No,No,Principal Investigator,90
AI-Breast-US,"Using Deep Learning Methods to Analyze Automated Breast Ultrasound and Hand-held Ultrasound Images, to Establish a Diagnosis, Therapy Assessment and Prognosis Prediction Model of Breast Cancer.",4.586301369863014,Recruiting,Observational,No,Yes,Principal Investigator,10000
2021-0974,Time Restricted Eating During Chemotherapy for Breast Cancer,3.5835616438356164,Recruiting,Interventional,No,No,Principal Investigator,40
ICO-2020-28,Detection and Metabolic Characterization in DOPA PET/CT of Brain Metastases,2.164383561643836,Recruiting,Interventional,No,No,Sponsor,52
HNCH-MBC12,Study of SHR-A1811 in HER2-positive Advanced Breast Cancer With Brain Metastases,3.084931506849315,Recruiting,Interventional,No,No,Principal Investigator,75
Twisted Pink Foundation,Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer,9.832876712328767,Recruiting,Interventional,Yes,No,Principal Investigator,15
HORMONOVILLE,Evaluation of the Impact of a Pharmaceutical Interview on the Adherence to Hormonotherapy in Women With Breast Cancer,2.175342465753425,Unknown status,Interventional,No,No,Sponsor,133
ET17-093 BreastImmune03,Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease,4.419178082191781,"Active, not recruiting",Interventional,No,No,Sponsor,95
1910208-9,Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer,2.4356164383561643,Recruiting,Interventional,No,No,Principal Investigator,55
CSPC-KAL-BC-11,Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer,1.5835616438356164,Unknown status,Interventional,No,No,Principal Investigator,520
1503144-7,"Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)",2.249315068493151,Unknown status,Interventional,No,No,Principal Investigator,178
IRB00022667,Developing and Evaluating Culturally Relevant Interventions to Improve Breast Cancer Screening,2.589041095890411,Not yet recruiting,Interventional,No,No,Sponsor,350
TOL2506A-EXT,"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study",5.4301369863013695,Enrolling by invitation,Interventional,Yes,No,Sponsor,250
IKP275 / GBG91,Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients,1.6465753424657534,Completed,Interventional,No,No,Principal Investigator,356
BELIEVE@BC,Effect of the App Bone@BC Version 4.0 Under the Follow-up for Patients With Early Breast Cancer,3.421917808219178,Not yet recruiting,Interventional,No,No,Principal Investigator,120
GCC 1926,GammaPod Dose Escalation Radiation for Early Stage Breast Cancer,7.2164383561643834,Recruiting,Interventional,No,Yes,Principal Investigator,50
HIFU202207,To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer,2.3315068493150686,Not yet recruiting,Interventional,No,No,Principal Investigator,20
18-195,Screening For BCRL In Targeted Therapy For Breast Cancer,7.802739726027398,Recruiting,Observational,No,No,Principal Investigator,142
BO40747,A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer,4.619178082191781,"Active, not recruiting",Interventional,Yes,No,Sponsor,454
KA22053,The 24 Hour Effects of Remedial Exercises With and Without Compression Therapy on Breast Cancer-related Lymphedema,0.5698630136986301,Completed,Interventional,No,No,Principal Investigator,34
BOOG-2017-01,"Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.",8.134246575342466,"Active, not recruiting",Interventional,No,No,Sponsor,100
GO39869,"Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer",3.249315068493151,Completed,Interventional,Yes,No,Sponsor,14
2021-0532,Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy,3.9178082191780828,Recruiting,Observational,No,No,Sponsor,100
P2100-SUR-S11,"Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer",4.726027397260274,Recruiting,Interventional,Yes,No,Sponsor,18
BC-IIT-FMTN-SHR6390-ET,"Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer",4.147945205479452,Recruiting,Interventional,No,No,Sponsor,65
2022JC-55-1,Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.,5.002739726027397,Not yet recruiting,Interventional,No,No,Principal Investigator,90
XJTU1AF-CRF-2020-006,Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer,3.158904109589041,Recruiting,Interventional,No,No,Sponsor,120
2018-062,Reducing Metabolic Syndrome Among Breast Cancer Survivors,1.8547945205479452,Completed,Interventional,No,No,Principal Investigator,7
SPY LNM 01,A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer,1.7342465753424658,Completed,Interventional,Yes,Yes,Sponsor,151
QUILT-3.067,QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.,4.8,"Active, not recruiting",Interventional,Yes,No,Sponsor,79
1808189-7,Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer,1.1835616438356165,Unknown status,Interventional,No,No,Principal Investigator,60
Version 1.0_16.08.2021,TAD in Primary Breast Cancer With Initially â¥ 3 Suspicious Lymph Nodes,9.991780821917809,Recruiting,Observational,No,No,Sponsor,150
17041,A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer,4.813698630136987,"Active, not recruiting",Interventional,Yes,No,Sponsor,72
TSL-CM-TSL1502-â¡,A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations,3.9150684931506854,Not yet recruiting,Interventional,No,No,Sponsor,125
82071993,Assessment of Brain Cognitive Impairment in Breast Cancer,5.0,Recruiting,Observational,No,No,Sponsor,90
QL1701-002,"A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus HerceptinÂ® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer",3.4246575342465753,"Active, not recruiting",Interventional,No,No,Sponsor,474
FAVOR,"Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer",5.832876712328767,Not yet recruiting,Interventional,No,No,Principal Investigator,493
60905722.0.0000.0072,Efficacy and Safety of Ultra_HYPofractionated RadiotHerapy in Women With BrEast CaNcer Receiving Regional Nodal Radiation vs Nodal Moderate Hypofractionated Radiotherapy,8.208219178082192,Recruiting,Interventional,No,No,Principal Investigator,36
197520,Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer,7.978082191780823,Recruiting,Interventional,Yes,No,Sponsor,65
17249,A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body,0.7835616438356164,Completed,Interventional,Yes,No,Sponsor,5
Onkologikoa,PFMT Educational Intervention for Patients With Advancer Breast Cancer,1.6027397260273972,Recruiting,Interventional,No,No,Principal Investigator,42
ET17-057,Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer,5.657534246575342,Recruiting,Interventional,No,No,Sponsor,90
2019-A02397-50,Comparison of Changes in the Quality of Life of Patients Operated on Breast Cancer at the DrÃ´me ArdÃ¨che Breast Institute According to Access to Supportive Oncological Care (IDSein),2.495890410958904,Recruiting,Observational,No,No,Sponsor,310
21-018,A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer,1.9178082191780825,Recruiting,Interventional,Yes,No,Sponsor,23
ShandongCHI-20,Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer,3.0,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,100
YBCSG-22-08,Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions,1.4136986301369863,Completed,Observational,No,No,Principal Investigator,1299
AL-2001,Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.,4.673972602739726,Recruiting,Interventional,Yes,No,Sponsor,60
kazuma,"To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study",4.1726027397260275,Recruiting,Interventional,No,No,Sponsor,204
308-2017,Use of Quantitative Ultrasound to Guide Adaptive Chemotherapy Among Women With Breast Cancer,9.975342465753425,Recruiting,Interventional,No,No,Principal Investigator,120
Pro00107615,TOPS for African American Breast Cancer Survivors,1.2191780821917808,Completed,Interventional,No,No,Sponsor,26
RSINETE,RWS of Inetetamab HER2 Positive Advanced Breast Cancer,0.4191780821917808,Not yet recruiting,Observational,No,No,Sponsor-Investigator,100
AC682-002,A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer,2.16986301369863,Recruiting,Interventional,No,No,Sponsor,150
PRO00037175,Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer,4.83013698630137,Recruiting,Interventional,Yes,No,Principal Investigator,36
55516,Effectiveness of Aerobic Exercises and Laughter Yoga Compared With Yoga in Anxiety/Depression Levels in Breast Cancer,0.5616438356164384,Completed,Interventional,No,No,Principal Investigator,198
MA-BC-II-007,Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer,4.416438356164384,Not yet recruiting,Interventional,No,No,Sponsor,261
SIESTA_01,Pilot Study to Evaluate Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer,5.271232876712329,Recruiting,Observational,No,No,Sponsor,60
48347821.8.0000.5249,The Impact of Chronic Mitochondrial Antioxidant Supplementation on CardiovascularToxicity in Breast Cancer Patients,1.5013698630136987,Not yet recruiting,Interventional,No,No,Principal Investigator,44
OBU-BC-II-086,"Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy",2.589041095890411,Not yet recruiting,Interventional,No,No,Sponsor,30
200218,Mobile Apps to Reduce Distress in Breast Cancer Survivors Using an Adaptive Design,2.9315068493150687,Recruiting,Interventional,No,No,Principal Investigator,314
2017 0105,Health Benefits of HIT for Breast Cancer Patients,0.6684931506849315,Withdrawn,Interventional,No,No,Principal Investigator,0
MYBC,Multidisciplinary Shared Decision Making of Fertility Preservation in Young Women With Breast Cancer,7.005479452054795,Not yet recruiting,Interventional,No,No,Sponsor,4100
D-FR-01070-003,Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer,0.29315068493150687,Terminated,Interventional,No,No,Sponsor,4
MUKDEN01,"Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial",6.4301369863013695,"Active, not recruiting",Interventional,No,No,Principal Investigator,89
R174-A11507-17-S52,Phytoestrogens and Breast Cancer - Effects of Phytoestrogens on Markers of Disease Progression and Gene Expression,1.7534246575342465,Withdrawn,Interventional,No,No,Principal Investigator,0
000001,Reliability and Reproducibility of Bandaging in Breast Cancer,1.997260273972603,Completed,Interventional,No,No,Sponsor-Investigator,23
18-240,"Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer",4.96986301369863,Recruiting,Observational,No,No,Sponsor,300
BG01-2102,Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer,2.9616438356164383,Not yet recruiting,Interventional,No,No,Sponsor,552
19-004343,"Comprehensive Genetic Assessment, Risk and Education in a Mammography Pilot",2.780821917808219,Enrolling by invitation,Interventional,No,Yes,Principal Investigator,250
Shandong CHI-11,Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer,4.920547945205479,Not yet recruiting,Interventional,No,No,Principal Investigator,200
NCC2225,Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer,2.797260273972603,Recruiting,Interventional,No,No,Principal Investigator,100
NCC-006461,Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer,3.5835616438356164,Recruiting,Interventional,No,No,Principal Investigator,40
OZM-103,A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer,0.35342465753424657,Withdrawn,Interventional,No,No,Sponsor,0
SCHBCC-NO27,Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients,1.2273972602739727,Unknown status,Interventional,No,No,Principal Investigator,60
2022/0035983,The Unmet Needs and the Workplace Reintegration of Breast Cancer Patients: the NEW-BreCa Project,1.9808219178082194,Recruiting,Observational,No,No,Principal Investigator,115
2020/482,"Supervised Exercise, Sleep in Patients With Non Metastatic Breast Cancer",2.315068493150685,Recruiting,Interventional,No,No,Sponsor,60
TUXEDO-1,Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases,3.0,"Active, not recruiting",Interventional,No,No,Principal Investigator,15
IIT2018-25-MITA-NEOBREADS,NEOBREADS: Neoadjuvant Breast Diet Study,2.410958904109589,Terminated,Interventional,No,No,Sponsor-Investigator,2
CIBI375Y008,"A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations",3.0027397260273974,Recruiting,Interventional,No,No,Principal Investigator,20
NL76658.029.21,Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer,1.9726027397260277,Recruiting,Interventional,No,No,Principal Investigator,15
SCHBCC-N032,"Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer",3.0027397260273974,Recruiting,Interventional,No,No,Principal Investigator,37
OE861801,A Phase I Study of LX-039 Tablets,3.5315068493150683,Enrolling by invitation,Interventional,No,No,Sponsor,68
1808189-8,Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer,0.6931506849315069,Unknown status,Interventional,No,No,Principal Investigator,78
4-2018-0765,"Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients",4.391780821917808,Recruiting,Interventional,No,No,Sponsor,95
38406,Exercise and Cognitive (Brain) Function in Breast Cancer Patients Getting Chemotherapy After Breast Surgery,3.3835616438356166,Recruiting,Observational,No,No,Principal Investigator,50
2020/134,Analgesic Efficacy of Erector Spinae Plane Block After Breast Cancer Surgery,2.504109589041096,Completed,Observational,No,No,Principal Investigator,40
LB,Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer,2.789041095890411,Unknown status,Interventional,No,No,Principal Investigator,80
CSIIT-C34,Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer,2.8164383561643835,Recruiting,Interventional,No,No,Sponsor,90
19-886,RCT of CBD for Anxiety in Advanced Breast Cancer,2.082191780821918,Recruiting,Interventional,Yes,No,Principal Investigator,50
IEO 0834/,CDH1 Germline Mutations in Lobular Breast Cancer,4.580821917808219,"Active, not recruiting",Observational,No,No,Sponsor,421
FACILE,FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer,6.923287671232877,Recruiting,Interventional,No,No,Sponsor,194
RP6530-2101,"Efficacy and Safety of Tenalisib (RP6530), a PI3K Î´/Î³ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer",1.1342465753424658,"Active, not recruiting",Interventional,No,No,Sponsor,40
GEICAM/2021-08,Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab,5.671232876712328,Not yet recruiting,Interventional,No,No,Sponsor,41
SYHX2011-002,A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound),1.3397260273972602,Not yet recruiting,Interventional,No,No,Sponsor,454
ZDWY.XBZL.002,Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer,2.506849315068493,Not yet recruiting,Interventional,No,No,Principal Investigator,58
D8664R00002,ZoladexÂ® 10.8 BC RWS,2.1452054794520548,Recruiting,Observational,No,No,Sponsor,1000
BO41843,"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)",6.441095890410959,"Active, not recruiting",Interventional,Yes,No,Sponsor,992
HSEARS20180509004,Acupuncture for Joint Symptoms in Patients With Breast Cancer,2.9232876712328766,Terminated,Interventional,No,No,Principal Investigator,64
Shandong CHI-10,Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer,5.189041095890411,Not yet recruiting,Interventional,No,No,Principal Investigator,200
erector-spinae,Postoperative Analgesia in Breast Cancer Surgery: Safety and Efficiency of Ultrasound Guided Erector Spinae Plane Block,0.5342465753424658,Completed,Interventional,No,No,Sponsor-Investigator,60
CHD049-17,Pilot Study Describing the Early Evolution of the Sexual Function of Patients Receiving Adjuvant Hormone Therapy for Breast Cancer,2.232876712328767,Unknown status,Observational,No,No,Sponsor,50
OnkoFit I,Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Adjuvant Radiotherapy of Breast Cancer,5.002739726027397,Recruiting,Interventional,No,No,Principal Investigator,201
103089,A Window Trial on Curcumin for Invasive Breast Cancer Primary Tumors,3.589041095890411,"Active, not recruiting",Interventional,Yes,No,Sponsor,22
SHR6390-III-301,A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer,3.5506849315068494,Unknown status,Interventional,No,No,Sponsor,357
17575,A Study of LY3484356 in Women With Breast Cancer Before Having Surgery,1.558904109589041,Completed,Interventional,Yes,No,Sponsor,86
IMMU-132-09,Study of Sacituzumab Govitecan-hziy Versus Treatment of Physicians Choice in Participants With HR+/HER2- Metastatic Breast Cancer,5.405479452054794,"Active, not recruiting",Interventional,Yes,No,Sponsor,543
2017-IIT-HER2-Aspire,Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer,7.005479452054795,"Active, not recruiting",Interventional,Yes,No,Sponsor,3
QL1209-301,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.,2.082191780821918,Unknown status,Interventional,No,No,Sponsor,544
17395,"A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer",3.5178082191780824,Withdrawn,Interventional,Yes,No,Sponsor,0
2019-A01323-54,Health-Related Quality of Life Coupled With Therapeutic Information on Compliance to Endocrine Therapy in Breast Cancer,4.3863013698630136,Recruiting,Interventional,No,No,Sponsor,342
D967RC00001,"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer",4.671232876712328,Recruiting,Interventional,Yes,No,Sponsor,624
UPCC 10119,ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer,7.087671232876712,Recruiting,Interventional,Yes,No,Sponsor,66
WO41554,"A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer",5.6438356164383565,Recruiting,Interventional,Yes,No,Sponsor,400
2020-0198,Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test,6.375342465753425,Recruiting,Interventional,Yes,No,Sponsor,56
UC-0109/1805,My Personalized Breast Screening,6.46027397260274,Recruiting,Interventional,No,No,Sponsor,85000
SHR-1210-III-318,"A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.",3.4684931506849317,Recruiting,Interventional,No,No,Sponsor,780
H21089,Breathing Exercise for Chronic Pain Management in Breast Cancer Survivors,0.9972602739726029,Not yet recruiting,Interventional,No,No,Sponsor,72
CSPC-DMS-BC-11,Phase â¡ Study of Pegylated Liposomal Doxorubicinï¼PLDï¼Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer,3.1424657534246574,Unknown status,Interventional,No,No,Principal Investigator,30
270-2018,Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer,6.005479452054795,"Active, not recruiting",Observational,No,No,Principal Investigator,800
0379520202023,Pain Neuroscience Education and Graded Exposure to Movement in Breast Cancer Survivors,2.2465753424657535,Recruiting,Interventional,No,No,Principal Investigator,62
S63893,Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity,4.000000000000001,Withdrawn,Interventional,No,No,Sponsor,0
KM10B,Efficacy and Safety of Trastuzumab Biosimilar (HerzumaÂ®) Plus Treatment of Physicians Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer,3.5424657534246577,Unknown status,Interventional,No,No,Principal Investigator,119
TriMix-Breast,Intratumoral TriMix Injections in Early Breast Cancer Patients,6.136986301369863,Recruiting,Interventional,No,No,Sponsor,36
19-486,A Study of the Bodys Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer,3.994520547945206,Recruiting,Interventional,No,No,Sponsor,62
UC-GMP-2206,Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib,7.005479452054795,Not yet recruiting,Interventional,No,No,Sponsor,162
SYSUCC-003,Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer,3.789041095890411,Recruiting,Interventional,No,No,Principal Investigator,228
soh-Med-21-10-17,Adjuvant Whole Breast Irradiation in Five Fractions Versus Fifteen Fractions in Early Breast Cancer,2.334246575342466,Recruiting,Observational,No,No,Principal Investigator,50
2021-005,Consequences of Eccentric Cycling on Exercise-related Neuromuscular Responses and Biomarkers in Breast Cancer Patients,0.4301369863013699,Completed,Interventional,No,No,Sponsor,12
MRG002-009,A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients,1.526027397260274,Recruiting,Interventional,No,No,Sponsor,99
CBYL719G12301,Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation,3.7150684931506848,Recruiting,Interventional,Yes,No,Sponsor,511
TCF20-BRE-01,Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376,4.86027397260274,"Active, not recruiting",Interventional,No,No,Sponsor,75
GS-US-586-6144,Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer,3.052054794520548,Recruiting,Interventional,Yes,No,Sponsor,144
PMC_TTAC-0001_05,TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer,3.8136986301369866,"Active, not recruiting",Interventional,No,No,Sponsor,11
EOC103A3101,"Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer",4.7972602739726025,"Active, not recruiting",Interventional,No,No,Sponsor,375
CO41012,A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer,3.8767123287671237,"Active, not recruiting",Interventional,Yes,No,Sponsor,20
SYM013,Alopecia Prevention Scalp Cooling in Chinese Breast Cancer Patients,4.980821917808219,"Active, not recruiting",Interventional,No,No,Principal Investigator,25
SHR6390-III-302,A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer,4.4520547945205475,"Active, not recruiting",Interventional,No,No,Sponsor,426
HR-BLTN-016,Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer,3.7150684931506848,Recruiting,Observational,No,No,Principal Investigator,3000
Pro2021000838,"Aim 3, Adapting and Implementing Evidence-based Breast Cancer Follow-up in Primary Care",2.0027397260273974,Not yet recruiting,Interventional,No,No,Principal Investigator,910
CSPC-DMS-BC-K07,Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer,6.117808219178082,Recruiting,Interventional,No,No,Sponsor,372
SGNLVA-002,Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer,6.846575342465753,Recruiting,Interventional,Yes,No,Sponsor,211
WO43919,"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy",5.835616438356165,Recruiting,Interventional,Yes,No,Sponsor,400
KSVGH20-CT7-26,Influence of Co-Vid 19 Pandemic on Screening Mammography Single Institution,0.9123287671232877,Unknown status,Observational,No,No,Sponsor-Investigator,600
EMBRAVE-001,Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients,3.0027397260273974,Not yet recruiting,Interventional,Yes,No,Sponsor,100
I 72218,A Home-Based Walking Program and rTMS in Helping Breast Cancer Survivors Get More Physical Activity,2.057534246575343,Completed,Interventional,No,No,Sponsor,30
UC-0140/1812,"Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.",7.936986301369864,Recruiting,Interventional,No,No,Sponsor,158
FCN-437c-III201,"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole Â± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.",3.0027397260273974,Recruiting,Interventional,No,No,Sponsor,434
MCC-20899,Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases,3.0876712328767124,Recruiting,Interventional,Yes,No,Sponsor,31
2021-TNBC-01,Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer,3.117808219178082,Recruiting,Interventional,No,No,Sponsor-Investigator,30
FCN-437c-III202,"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant Â± Goseraline Versus Placebo Combined With Fulvestrant Â± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.",2.3315068493150686,Recruiting,Interventional,No,No,Sponsor,312
breast-202204,Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer,1.4931506849315068,Recruiting,Interventional,No,No,Sponsor,30
20150288,Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors,5.002739726027397,Withdrawn,Interventional,Yes,No,Sponsor-Investigator,0
D9673R00005,Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer,1.4657534246575343,Completed,Observational,No,No,Sponsor,763
P170927J,Evaluation of Innovative Therapeutic Approaches of Vaginal and Sexual Dysfunction After Breast Cancer Treatment,3.0,Not yet recruiting,Interventional,No,No,Sponsor,330
HBBL-01,Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study,3.0027397260273974,Unknown status,Interventional,No,No,Sponsor,80
PCZCTP-220702-001,"Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer",1.3315068493150686,Not yet recruiting,Interventional,No,No,Principal Investigator,12
FDRT-BC015,The Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer Patients,6.0,Recruiting,Observational,No,No,Sponsor,100
ERC-260,Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer,1.0794520547945206,Withdrawn,Interventional,Yes,No,Sponsor,0
POL6326-009,"Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer",2.7150684931506848,Unknown status,Interventional,Yes,No,Sponsor,384
911,"Effects of Green Coffee Extract Supplementation on Leptin, Ghrelin, Adiponectin,Anthropometric Measurements, Lipid Profile in Breast Cancer Survivors",1.4191780821917808,Unknown status,Interventional,No,No,Principal Investigator,50
EAGER-001,Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer,1.7534246575342465,Recruiting,Interventional,Yes,No,Sponsor,40
206010,Vaccination of Triple Negative Breast Cancer Patients,3.9589041095890414,Completed,Interventional,Yes,No,Sponsor,24
IRB#18853,Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening,3.7013698630136984,Recruiting,Interventional,No,Yes,Principal Investigator,210
UKFC-PU-2019-01-08,Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients,2.3123287671232875,Not yet recruiting,Interventional,No,No,Principal Investigator,324
2018-001705-91,Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer,1.7589041095890412,Completed,Interventional,No,No,Sponsor-Investigator,48
KA-20007,"The Effect of Oral Cryotherapy on Anticipatory, Acute and Late Nausea and Vomiting in Breast Cancer Patients",0.821917808219178,Completed,Interventional,No,No,Sponsor-Investigator,54
Arise-FJ-B02,Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer,2.249315068493151,Not yet recruiting,Interventional,No,No,Sponsor,20
SYSU-2021,Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer,4.0191780821917815,Recruiting,Interventional,No,No,Principal Investigator,78
SHR-A1811-II-202,A Phase Ib/II Study of SHR-A1811 Injection in HER2 Positive Breast Cancer,3.610958904109589,Recruiting,Interventional,No,No,Sponsor,402
IL-2.001,Efficacy of Interleukin-2 in Triple Negative Breast Cancer,2.0027397260273974,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,10
REaCT-Algorithm,Evaluating Whether Integration of Prognostic and Predictive Algorithms Into Routine Clinical Practice Effect Whether Oncologists Order Multigene Assays in Patients With Early Stage Breast Cancer,2.2,Completed,Observational,No,No,Sponsor,602
2019-A03112-55,Use of Cognitive Stimulation Software for Patients Over the Age of 70 Followed for Breast Cancer: COG-TAB-AGE Feasibility Study,2.4904109589041097,"Active, not recruiting",Interventional,No,No,Sponsor,55
017-396,Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer,2.8958904109589043,Completed,Interventional,No,No,Sponsor,16
G1T28-213,Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer,2.6082191780821917,"Active, not recruiting",Interventional,Yes,No,Sponsor,30
Shengjing-LCG012,A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer,1.6958904109589041,Recruiting,Interventional,No,No,Principal Investigator,100
NK/7784/Study/249,Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Breast Cancer With Brain Oligometastasis,5.002739726027397,Recruiting,Interventional,No,No,Principal Investigator,98
A5481159,Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone,0.8082191780821918,Completed,Observational,,,Sponsor,197
CL0006,Intraoperative Detection of Residual Cancer in Breast Cancer,2.175342465753425,Completed,Interventional,Yes,Yes,Sponsor,234
ZEN003694-004,A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer,4.852054794520548,Recruiting,Interventional,Yes,No,Sponsor,179
GS-US-569-6172,Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors or Triple-negative Breast Cancer,3.6164383561643834,"Active, not recruiting",Interventional,Yes,No,Sponsor,52
TED15954,Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer,4.186301369863014,"Active, not recruiting",Interventional,No,No,Sponsor,10
s2192648,Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients,1.4931506849315068,Recruiting,Interventional,No,No,Principal Investigator,60
MAMA_MOVE_Gaia After Treatment,Effects of a Physical Exercise Program in Quality of Life of Breast Cancer Survivors,3.506849315068493,Completed,Interventional,No,No,Principal Investigator,80
SunYatsenU2H-LQ5,Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer,2.336986301369863,Not yet recruiting,Observational,Yes,No,Principal Investigator,120
HNCH-BC011,Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer,7.035616438356165,Recruiting,Interventional,No,No,Sponsor-Investigator,369
NCC3397,Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer,5.002739726027397,Recruiting,Interventional,No,No,Principal Investigator,300
IC 2020-10,Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer,4.194520547945206,Recruiting,Interventional,No,No,Sponsor,214
CTMX-2009-002,Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer,2.334246575342466,"Active, not recruiting",Interventional,Yes,No,Sponsor,125
2021-SR-592,Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer,3.3835616438356166,Not yet recruiting,Observational,No,No,Sponsor,315
PR351/20,TAD After Chemotherapy in Locally Advanced Breast Cancer,3.0,Recruiting,Observational,No,No,Principal Investigator,162
2020-006106-23,Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva),3.4876712328767123,Suspended,Interventional,No,No,Sponsor,200
HR-NeoBC-HN003,Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.,1.5835616438356164,Unknown status,Interventional,No,No,Sponsor,48
IEO 1730,LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients,5.002739726027397,Recruiting,Observational,No,No,Sponsor,800
GIM23-POSTER,Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients,12.778082191780822,"Active, not recruiting",Observational,No,No,Sponsor,600
17320,"A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer",0.9945205479452056,Terminated,Interventional,Yes,No,Sponsor,4
15.03.2023,Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.,0.6684931506849315,Completed,Observational,Yes,No,Sponsor,136
PALBOBIN,Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer,2.7013698630136984,"Active, not recruiting",Interventional,No,No,Sponsor,24
2018.451,"FES (16Î±-[18F]-Fluoro-17Î²-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET",4.213698630136987,"Active, not recruiting",Interventional,No,No,Principal Investigator,40
202103030005,Evaluation and Re-evaluation of Post-mastectomy Pain Syndrome by Breast Cancer EDGE Task Force Outcomes,1.0876712328767124,Completed,Interventional,No,No,Principal Investigator,10
D8530C00002,A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer,3.106849315068493,"Active, not recruiting",Interventional,Yes,No,Sponsor,240
MA-BC-II-033,The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis,5.504109589041096,Not yet recruiting,Interventional,No,No,Sponsor,53
NL81896.078.22,Tamoxifen Prediction Study in Patients With ER+ Breast Cancer,0.8301369863013699,Not yet recruiting,Interventional,No,No,Principal Investigator,100
SDX-0103,Evexomostat Plus Alpelisib and Fulvestrant in Postmenopausal Women at Risk for Hyperglycemia With Breast Cancer,4.0191780821917815,Recruiting,Interventional,Yes,No,Sponsor,52
17-428,Olaparib In Metastatic Breast Cancer,4.750684931506849,Recruiting,Interventional,Yes,No,Principal Investigator,114
CO42177,"A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer",2.441095890410959,Completed,Interventional,Yes,No,Sponsor,83
MO39874,A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer,5.0,"Active, not recruiting",Interventional,Yes,No,Sponsor,184
202007016,Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer,5.531506849315068,"Active, not recruiting",Interventional,Yes,No,Sponsor,15
B003-101,B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer,4.3342465753424655,"Active, not recruiting",Interventional,No,No,Sponsor,45
DOUBLE,Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer,2.747945205479452,Not yet recruiting,Interventional,No,No,Principal Investigator,61
0000012,"Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient",0.16986301369863013,Unknown status,Observational,Yes,No,Sponsor,100
REaCT-5G,"A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy",2.4794520547945207,"Active, not recruiting",Interventional,No,No,Sponsor,233
STUDY00019489,177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer,1.3013698630136987,Not yet recruiting,Interventional,Yes,No,Principal Investigator,10
CO40151,A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer,4.0849315068493155,Completed,Interventional,Yes,No,Sponsor,140
TQB2450-Ib-07,A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC),1.6465753424657534,Unknown status,Interventional,No,No,Sponsor,30
R19-149,Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging,4.3342465753424655,Recruiting,Interventional,Yes,No,Principal Investigator,20
2021/609,Continuous Glucose Monitoring Profile Description Under Alpelisib treAtment in Patients With Advanced bREast Cancer,2.249315068493151,Not yet recruiting,Interventional,No,No,Sponsor,40
BOOG-2017-02,Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer,5.331506849315068,Withdrawn,Interventional,No,No,Sponsor,0
2017-A03413-50,Metastatic Breast Carcinoma and Women Sexual Quality of Life,0.06301369863013699,Completed,Observational,No,No,Sponsor,30
AK117-203,A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer,1.6054794520547946,Recruiting,Interventional,No,No,Sponsor,80
HR-NeoBC-HN002,Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.,1.9178082191780825,Completed,Interventional,No,No,Sponsor,75
2021-0491,Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen,2.082191780821918,Recruiting,Observational,No,No,Sponsor,280
2021-A02007-34,"Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients With HER2+ Breast Cancer",2.547945205479452,"Active, not recruiting",Observational,No,No,Sponsor,300
GIM26-TRASTHER,Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy,3.767123287671233,Recruiting,Observational,No,No,Sponsor,300
AND019-MN-101,A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer,2.5726027397260274,Recruiting,Interventional,Yes,No,Sponsor,61
SKB264-â¢-03,"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer",2.5616438356164384,Not yet recruiting,Interventional,No,No,Sponsor,254
NCR191600,Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer,0.915068493150685,Withdrawn,Observational,No,No,Principal Investigator,0
495573096,Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer,2.0000000000000004,Unknown status,Interventional,No,No,Principal Investigator,268
ESPB in breast cancer surgery,Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery,1.6657534246575343,"Active, not recruiting",Interventional,No,No,Principal Investigator,60
SI 475/2019,Analgesic Effect of Adding Thoracic Paravertebral Nerve Blocks to Modified PEC Block in Breast Cancer Surgery,2.5835616438356164,Recruiting,Interventional,No,No,Principal Investigator,100
JS001-026-III-TNBC,Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment,6.032876712328767,"Active, not recruiting",Interventional,No,No,Sponsor,531
CBYL719CIN01,"Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment",2.2684931506849315,Recruiting,Interventional,No,No,Sponsor,100
SPORT-DS,Single Pre-Operative Radiation Therapy - With Delayed Surgery for Low Risk Breast Cancer,4.7534246575342465,"Active, not recruiting",Interventional,No,No,Sponsor-Investigator,20
WO43571,"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)",10.24931506849315,Recruiting,Interventional,Yes,No,Sponsor,812
2020-0232,Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC),5.980821917808219,Recruiting,Interventional,Yes,No,Principal Investigator,12
TQB2450-III-06,A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC),2.082191780821918,Unknown status,Interventional,No,No,Sponsor,332
CASE5119,Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer,1.8027397260273972,Recruiting,Interventional,No,No,Sponsor,150
EVER-132-001,Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments,2.5205479452054793,"Active, not recruiting",Interventional,No,No,Sponsor,80
AH150201,"Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c",3.3753424657534246,Unknown status,Interventional,No,No,Sponsor,78
99mTc-ADAPT6 in breast cancer,99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes,0.6684931506849315,Completed,Interventional,No,No,Sponsor,30
MOST Pain Pilot,Optimizing Psychological Treatment for Pain After Breast Cancer: A Pilot Study,0.4191780821917808,Completed,Interventional,No,No,Principal Investigator,31
214-2018,Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI,2.254794520547945,Completed,Observational,No,No,Principal Investigator,100
TBDBreast50,Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer,0.0,Withdrawn,Interventional,Yes,No,Principal Investigator,0
BAC,Satisfaction Survey for the Outpatient Unit Dedicated to Post-cancer Treatment,0.6328767123287671,Completed,Observational,No,No,Sponsor,163
I237,CFI-400945 in Patients With Advanced/Metastatic Breast Cancer,4.526027397260274,"Active, not recruiting",Interventional,No,No,Sponsor,51
KarolinskaUD,"OptiBra Study, Optimal Postoperative Bra After Breastcancer Surgery",1.03013698630137,Unknown status,Interventional,No,No,Principal Investigator,200
QUILT-3.058,A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies,1.2712328767123289,Terminated,Interventional,Yes,No,Sponsor,3
20200225,Effect of Esketamine on Postoperative DepressionãGut MicrobiotaãBispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI),2.2273972602739724,Recruiting,Interventional,No,No,Principal Investigator,36
SCCC-03121; STU-2021-0657,"CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer",3.9506849315068497,Recruiting,Interventional,Yes,No,Principal Investigator,45
BC-Fluzoparib,Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer,3.8958904109589048,Recruiting,Interventional,No,No,Sponsor,40
NCC1969,Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer,3.7260273972602738,Recruiting,Interventional,No,No,Principal Investigator,35
HX008-Ib/II-TNBC-01,A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer,2.3835616438356166,Unknown status,Interventional,No,No,Sponsor,31
STUDY00004350,A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy,2.0273972602739727,Recruiting,Interventional,No,No,Principal Investigator,30
14/2021,Efficacy of Expressive Writing on Quality of Life Among Breast Cancer Survivors in Oman: A Double Blind Randomized Controlled Trial,2.9972602739726026,Not yet recruiting,Interventional,No,No,Principal Investigator,64
HNCH-MBC07,Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure,3.473972602739726,Recruiting,Interventional,No,No,Principal Investigator,87
HR-BLTN-III-NeoBC,Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer,3.857534246575343,"Active, not recruiting",Interventional,Yes,No,Sponsor,355
A5481123,RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.,0.4684931506849315,Completed,Observational,,,Sponsor,195
SYSU-2022-UCAN,Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer,4.947945205479452,Recruiting,Interventional,No,No,Principal Investigator,349
19-113,Exercise Treatment With Standard Therapy for Metastatic Breast Cancer,4.139726027397261,Recruiting,Interventional,No,No,Sponsor,53
B013-301,Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer,4.07123287671233,Recruiting,Interventional,No,No,Sponsor,450
4CAST,Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer,3.084931506849315,Not yet recruiting,Interventional,No,No,Principal Investigator,65
811,"Effects of Green Coffee Extract Supplementation on Adropin, Irisin, Vaspine,Systemic Inflammation and Oxidative Stress in Breast Cancer Survivors",1.663013698630137,Unknown status,Interventional,No,No,Principal Investigator,50
SHR1210-III-322,A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC),3.1424657534246574,Recruiting,Interventional,No,No,Sponsor,581
BC- T-DM1,Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy,2.8986301369863012,Not yet recruiting,Interventional,No,No,Sponsor,50
HERMIONE-7,"Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)",3.901369863013699,"Active, not recruiting",Interventional,No,No,Sponsor,31
RG1006427,Lifestyle Program (Scalable Nutrition and Physical Activity) for the Improvement of Nutrition and Physical Activity in Stage 0-III Breast Cancer Survivors,1.6849315068493151,Completed,Interventional,No,No,Sponsor,90
CO41863,A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer,0.36712328767123287,Terminated,Interventional,Yes,No,Sponsor,1
21030,Portable Scalp Cooling System for the Improvement of Chemotherapy-Induced Hair Loss in Patients With Metastatic Breast Cancer,0.9178082191780822,Withdrawn,Interventional,No,Yes,Sponsor,0
BAT-8001-002-CR,The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer,3.504109589041096,Unknown status,Interventional,No,No,Sponsor,410
CBYL719A0US03T,"Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer",1.8493150684931507,Recruiting,Interventional,Yes,No,Sponsor,25
EH20-251,Advanced Diffusion Tensor MRI for Breast Cancer,2.9945205479452053,Recruiting,Observational,No,Yes,Principal Investigator,120
MedOPP190,"Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)",2.5452054794520547,Terminated,Interventional,No,No,Sponsor,14
Combined CTH and HT in MBC,"Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study",2.4273972602739726,Unknown status,Interventional,Yes,No,Principal Investigator,124
KN046-203,A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer,4.298630136986302,"Active, not recruiting",Interventional,No,No,Sponsor,52
A5481095,TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.,0.33424657534246577,Completed,Observational,,,Sponsor,1
DZ2019HE001,"DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer",3.610958904109589,"Active, not recruiting",Interventional,Yes,No,Sponsor,23
S62794,"Preventing Taxane-related Peripheral Neuropathy, Pain and Nail Toxicity: A Prospective Self-controlled Trial Comparing Hilotherapy With Frozen Gloves in Early Breast Cancer",1.4219178082191781,Completed,Interventional,No,No,Sponsor,62
SHR6390-SHR1020-I-101-BC,A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer,2.0164383561643837,Recruiting,Interventional,No,No,Sponsor,76
IIT2022-07-YUAN-IB-TNBC,Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer,3.504109589041096,Not yet recruiting,Interventional,Yes,No,Sponsor-Investigator,41
MA-BC-II-047,Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase â b Study,3.0821917808219177,Not yet recruiting,Interventional,No,No,Sponsor,30
FUSCC,Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA),4.498630136986302,Not yet recruiting,Interventional,No,No,Sponsor,338
222.20,SBRT in Early Breast Cancer in Elderly Women,2.8328767123287673,Recruiting,Interventional,No,No,Principal Investigator,30
Bioscore in breast cancer,Prognostic Significance of Bioscore in Nonmetastatic Breast Cancer,2.791780821917808,Completed,Observational,No,No,Principal Investigator,317
NCC201711008,Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer,1.3424657534246576,Unknown status,Interventional,No,No,Principal Investigator,14
ShandongCHI-06,Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy,7.1726027397260275,Not yet recruiting,Interventional,No,No,Principal Investigator,200
2019-0634,Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women,1.106849315068493,Recruiting,Interventional,No,No,Sponsor,62
275142,An EORTC Study Updating the QLQ-BR23 to BR45,2.1616438356164385,Recruiting,Observational,No,No,Principal Investigator,25
NCC2474,Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer,2.249315068493151,Unknown status,Interventional,No,No,Principal Investigator,55
MK 3475-318,Effect of Pembrolizumab (KeytrudaÂ®) on Biomarkers in Early Breast Cancer.,2.2,Completed,Interventional,No,No,Sponsor,54
2019-00673; sp19Kurzeder,Digoxin Induced Dissolution of CTC Clusters,1.8986301369863017,Recruiting,Interventional,No,No,Sponsor,9
Medical Research Institute,"US Guided Erector Spinae Plane Block in Breast Cancer Surgery: Analgesia, Spread and Immunomodulation",1.1561643835616437,Completed,Interventional,No,No,Principal Investigator,60
MCLA-128-CL02,MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer,6.087671232876712,"Active, not recruiting",Interventional,Yes,No,Sponsor,101
HNCH-HER2-MBC001,Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.,1.5205479452054795,Recruiting,Interventional,No,No,Principal Investigator,46
P170929J,PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers,8.005479452054795,Not yet recruiting,Interventional,No,No,Sponsor,12
GB491-004,GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer,2.3917808219178083,Recruiting,Interventional,No,No,Sponsor,270
MORE-T trial,Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients,7.2,Recruiting,Interventional,No,No,Principal Investigator,238
2022-A01192-41,SexoMBC2 Non Interventional Study,0.4876712328767124,Recruiting,Observational,No,No,Sponsor,80
IJB-LOB-2019,Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE),3.463013698630137,Recruiting,Interventional,No,No,Sponsor,65
Cardiotoxicity study,Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients,0.9753424657534248,Unknown status,Observational,No,No,Sponsor,240
MS200647_0020,Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer,1.736986301369863,Terminated,Interventional,Yes,No,Sponsor,11
262840,CIPN in Early Stage Breast Cancer Patients,1.6027397260273972,Recruiting,Interventional,No,No,Sponsor,48
2023-YBSF-480,A Predictive Model for Breast Cancer,1.6712328767123288,Not yet recruiting,Observational,No,No,Sponsor,100
U025,Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer,3.912328767123288,Completed,Interventional,Yes,No,Sponsor,100
KN026-205,Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer,2.6027397260273974,Recruiting,Observational,Yes,No,Sponsor,36
Soh-Med-21_10_18,One Week Adjuvant Radiotherapy for Breast Cancer,2.0000000000000004,Recruiting,Interventional,No,No,Principal Investigator,100
SPH4336-301,Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer,1.632876712328767,Not yet recruiting,Interventional,No,No,Sponsor,374
HCB/2019/0786,Sexual and Vaginal Health in Breast Cancer Women Receiving Aromatase Inhibitors Before and After CO2 Laser Therapy,1.832876712328767,"Active, not recruiting",Interventional,No,No,Principal Investigator,84
2019-185-AGH,Evaluation of Mepitel FilmÂ® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer,3.879452054794521,Recruiting,Interventional,No,Yes,Principal Investigator,40
EC2019/0127,Hyperventilation and Oxygenation to Prolong Breath Hold in Breast Cancer Irradiation Treatment,1.945205479452055,Completed,Interventional,No,No,Sponsor,40
REaCT-OGF,Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy,2.4602739726027396,Recruiting,Interventional,No,No,Sponsor,240
2021P002943,Evaluating Scaleup of an Adapted Breast Cancer Early Diagnosis Program in Rwanda,1.2931506849315069,Not yet recruiting,Observational,No,No,Principal Investigator,3096
NCI-2021-08921,Metformin and Nightly Fasting in Women With Early Breast Cancer,1.8356164383561644,Not yet recruiting,Interventional,Yes,No,Sponsor,120
AIs with chemotherapy in MBC,Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer,1.7534246575342465,Not yet recruiting,Interventional,No,No,Principal Investigator,70
CTRIAL-IE 22-01,Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study),5.005479452054795,Not yet recruiting,Interventional,No,No,Sponsor,80
SIBP-01-3,A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer,2.0849315068493155,Unknown status,Interventional,No,No,Sponsor,580
20-068,MARGetuximab Or Trastuzumab (MARGOT),6.96986301369863,Recruiting,Interventional,Yes,No,Principal Investigator,171
19-002448,Interactive Care Plan for the Monitoring of Symptoms and Recovery in Patients With Stage 0-III Breast Cancer,3.265753424657534,"Active, not recruiting",Interventional,No,No,Sponsor,100
2022-09/2057,The Effect of Premedication on Postoperative Pain and Anxiety in Breast Cancer Surgery,0.29041095890410956,Recruiting,Observational,No,No,Principal Investigator,80
TEMPLATE,Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancerï¼A Prospective Multiple-center Phase II Study,2.0136986301369864,Not yet recruiting,Interventional,No,No,Sponsor,265
UC Laser,Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors,4.2027397260273975,Recruiting,Interventional,No,Yes,Principal Investigator,70
CO42867,A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer,5.367123287671233,Recruiting,Interventional,Yes,No,Sponsor,510
GBG 93,"A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).",5.0849315068493155,Recruiting,Interventional,No,No,Sponsor,150
2022-0500,Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors or Chemotherapy in Luminal B/HER2-negative Breast Cancer (DAPATH),3.084931506849315,Recruiting,Interventional,No,No,Sponsor,120
IJB-LBC-NEOCHECKRAY-2018,"Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:",6.197260273972603,Recruiting,Interventional,No,No,Sponsor,147
HR-MBC-HN001,A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer,4.112328767123288,"Active, not recruiting",Interventional,No,No,Principal Investigator,78
MCC-19803,Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer,1.7013698630136986,Terminated,Interventional,Yes,No,Sponsor,17
CAR202,A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC,2.7616438356164386,Recruiting,Interventional,No,No,Sponsor,38
20-130,Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer,4.7315068493150685,Recruiting,Interventional,No,No,Sponsor,152
BG01-2001,PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer,0.34794520547945207,Completed,Interventional,No,No,Sponsor,16
CBYL719CIN02,Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world,3.9287671232876717,Recruiting,Observational,,,Sponsor,200
ROGABREAST,"Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.",2.356164383561644,Completed,Interventional,No,No,Sponsor,9
SYSU-2021-UCAN,Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer,8.005479452054795,Not yet recruiting,Interventional,No,No,Principal Investigator,512
18040334,Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer,1.6383561643835616,Completed,Interventional,No,No,Principal Investigator,60
Labra-001,Photobiomodulation Therapy for the Prevention of Acute Radiodermatitis in Breast Cancer Patients Undergoing Radiotherapy,0.9178082191780822,Completed,Interventional,No,No,Principal Investigator,71
M19-992,"A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy",0.3835616438356164,Terminated,Interventional,Yes,No,Sponsor,4
2021-1122,"AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer",2.6684931506849314,Recruiting,Interventional,No,No,Sponsor,402
SYSKY-2022-105-01,Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer,2.336986301369863,Recruiting,Interventional,No,No,Principal Investigator,132
CS2-19004,Chemotherapy - Induced Peripheral Neuropathy,1.041095890410959,Completed,Interventional,No,No,Principal Investigator,22
CBYL719C2404,"A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting",2.6465753424657534,Recruiting,Observational,,,Sponsor,150
I2I1,Connecting Breast Cancer Survivors for Exercise,0.726027397260274,Completed,Interventional,No,No,Sponsor-Investigator,108
2019-01-064,TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery,3.4328767123287673,Unknown status,Interventional,No,No,Principal Investigator,67
ZhejiangCH-0709,RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast Cancer,4.33972602739726,Not yet recruiting,Observational,No,No,Sponsor,500
SHR-A1811-206,A Phase â b/â¡ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.,1.9123287671232878,Not yet recruiting,Interventional,No,No,Sponsor,300
FOENIX-MBC2 TAS-120-201,A Study of TAS-120 in Patients With Metastatic Breast Cancer,3.835616438356165,"Active, not recruiting",Interventional,Yes,No,Sponsor,168
IRB18-1178,Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer,4.3780821917808215,Recruiting,Interventional,Yes,No,Sponsor,60
ML43171,"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physicians Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)",3.66027397260274,Recruiting,Interventional,Yes,No,Sponsor,320
UC-BCG-2011,Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer,3.536986301369863,Recruiting,Interventional,No,No,Sponsor,55
CSIIT-C41,Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy,1.5068493150684932,Not yet recruiting,Interventional,No,No,Principal Investigator,23
MO43110,A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer,3.2273972602739724,Recruiting,Interventional,Yes,No,Sponsor,330
EUBREAST 3,AXillary Surgery After NeoAdjuvant Treatment,9.931506849315069,Recruiting,Observational,No,No,Sponsor,3000
SHR-1210-III-327,A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer,1.4136986301369863,Not yet recruiting,Interventional,No,No,Sponsor,104
EOC202A2102,"HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy",3.084931506849315,Not yet recruiting,Interventional,No,No,Sponsor,50
IEO 675,Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer,1.4191780821917808,Unknown status,Interventional,No,No,Sponsor,46
MP-05-2021-2605,Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer,1.8438356164383563,Recruiting,Interventional,No,No,Principal Investigator,98
7339-009,Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009),6.109589041095891,"Active, not recruiting",Interventional,Yes,No,Sponsor,460
MC1831,"Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer",4.676712328767123,Recruiting,Interventional,Yes,No,Sponsor,38
OSU-20380,Development of a Genetic Counseling Patient Preference Intervention for Women at Elevated Risk for Breast Cancer,1.8904109589041096,Completed,Observational,No,No,Principal Investigator,8
D933LC00001,A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer,4.526027397260274,"Active, not recruiting",Interventional,Yes,No,Sponsor,210
MA-BC-II-042,Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer,4.1068493150684935,Recruiting,Interventional,No,No,Sponsor-Investigator,80
2020-1190,Mobile-Health Delivery of Lifestyle Interventions for Women With Breast Cancer,2.5287671232876714,Recruiting,Interventional,No,No,Sponsor,30
HRS8807-I-101,"A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer",3.1835616438356165,Recruiting,Interventional,No,No,Sponsor,90
BreCLIM-2018-116-31M,BreCLIM-2 - A RCT Investigating Local Treatment for Breast Cancer Liver Metastases,10.005479452054795,Recruiting,Interventional,No,No,Sponsor,200
TQ-B3525-I-02,"A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer",1.16986301369863,Unknown status,Interventional,No,No,Sponsor,42
HKUCTR-2709,Use of Superparamagnetic Iron Oxide (SPIO) in Sentinel Lymph Node Detection for Breast Cancer,5.93972602739726,Recruiting,Interventional,No,No,Principal Investigator,300
MUKDEN5,Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer,2.9342465753424656,Not yet recruiting,Interventional,No,No,Principal Investigator,130
Prevention of neuropathy,Photobiomodulation for Prevention of Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer,1.9726027397260277,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,186
TQB3616-II-01,A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer,1.9890410958904112,Unknown status,Interventional,No,No,Sponsor,120
s61033,A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer,4.975342465753425,"Active, not recruiting",Observational,Yes,No,Principal Investigator,78
s17-00995,MBSR During AI Therapy for Breast Cancer,2.3808219178082193,Completed,Interventional,No,No,Sponsor,23
SHR9549-I-101,SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer,1.2219178082191782,Terminated,Interventional,No,No,Sponsor,4
18/0059,Health Status of Women With Breast Cancer,0.7150684931506849,Unknown status,Observational,,,Sponsor,200
3-2019-0140,Effects of Mediterranean Diet Based Intervention in Breast Cancer Patients,2.0027397260273974,Unknown status,Interventional,No,No,Principal Investigator,78
IRB00109957,THRIVE Breast Cancer App Study,3.6246575342465754,Completed,Interventional,No,No,Principal Investigator,313
IRB18-00912,Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery,4.238356164383562,Recruiting,Interventional,No,No,Principal Investigator,202
Shengjing-LJY03,CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer,4.835616438356165,Recruiting,Observational,No,No,Principal Investigator,200
0392-18-HMO,CO2 Laser Therapy for the Treatment of GSM in Patients With Breast Cancer,4.498630136986302,"Active, not recruiting",Interventional,No,No,Sponsor,60
UW19046,FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer,3.115068493150685,Recruiting,Interventional,Yes,No,Sponsor,12
I 73718,Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer,4.23013698630137,"Active, not recruiting",Interventional,Yes,No,Sponsor,9
21/079,Prediction of Individual Radiosensitivity During Radiotherapy for Breast Cancer Patients,2.649315068493151,Recruiting,Observational,No,No,Principal Investigator,550
2018-1133,Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer,4.443835616438356,"Active, not recruiting",Observational,No,No,Sponsor,24
HCB/2020/0971,Evaluation of the Impact of a Multidimensional ICT Intervention on the Quality of Life of Breast Cancer Survivors,2.578082191780822,Recruiting,Interventional,No,No,Principal Investigator,150
FJD-LCO2-19-01,A Laser and Topical Treatment Combination in the Vulvo-vaginal Atrophy Management in Breast Cancer Patients.,3.0876712328767124,Not yet recruiting,Interventional,No,No,Sponsor,98
MC01/05/20; IST-325 (KPT),Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START),4.673972602739726,Recruiting,Interventional,No,No,Sponsor,63
KROG 21-07,Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients,10.758904109589041,Not yet recruiting,Interventional,No,No,Principal Investigator,622
22012020,Bubble: A New VR-AI Way of Treatment for Hot Flashes in Women With Breast Cancer,1.073972602739726,Completed,Interventional,No,No,Principal Investigator,37
2020-1267,Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion,3.789041095890411,"Active, not recruiting",Interventional,No,Yes,Sponsor,89
HER2BAT,A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone,3.8931506849315074,Recruiting,Interventional,No,No,Sponsor-Investigator,130
18291,A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer,2.3123287671232875,Recruiting,Interventional,No,No,Sponsor,24
ARIANNA (SOLTI-1502),Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC,2.3589041095890413,Terminated,Interventional,No,No,Sponsor,34
PROICM 2019-05 MAC,Diet Modification in pAtients With Luminal Early Breast Cancer Candidate for Primary Surgery,3.1232876712328768,Recruiting,Interventional,No,No,Sponsor,75
BLI-1401-2-01,"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.",1.4958904109589042,Not yet recruiting,Interventional,Yes,No,Sponsor,44
R018-SABI-00193,Genetic Markers of Circulating Tumor DNA for Monitoring Breast Cancer Patients in Costa Rica,1.8986301369863017,Unknown status,Observational,No,No,Sponsor,25
20221120,A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause,3.0027397260273974,Not yet recruiting,Interventional,Yes,No,Principal Investigator,20
Geriatric-CDK4/6,Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?,0.2054794520547945,Not yet recruiting,Observational,Yes,No,Principal Investigator,140
CLEAR,Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer,7.002739726027397,Recruiting,Interventional,No,No,Principal Investigator,110
Regina Elena,Endometrial Changes in Breast Cancer Women.,1.0000000000000002,"Active, not recruiting",Observational,No,No,Principal Investigator,829
2.777.676,Photobiomodulation for Breast Cancer Radiodermatitis,2.8164383561643835,Completed,Interventional,No,No,Sponsor,48
IC 2017-06,Study to Assess the Impact of Personalized Coaching on the Time Period and Quality of Return to Work After Breast Cancer,3.5013698630136987,Recruiting,Interventional,No,No,Sponsor,200
Pro00087654,Family History in a Singapore Oncology Population,0.6465753424657534,Completed,Observational,No,No,Sponsor,102
IRMA,Impact of Recurrence Score on Adjuvant Treatment Decisions in Breast Cancer Patients,4.3342465753424655,Recruiting,Observational,No,No,Sponsor,250
GOG-8023,Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer,,Not yet recruiting,Observational,,,Sponsor,360
CO40115,A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer,6.090410958904109,"Active, not recruiting",Interventional,Yes,No,Sponsor,133
111-009-F,A Study for Optimization of 6% Hydroxyethyl Starch Based Indocyanine Green Near-infrared Fluorescence Navigated Sentinel Lymph Node Biopsy for Breast Cancer Patients,0.9972602739726029,Recruiting,Interventional,No,No,Sponsor,24
2020-2-4023,Deep Inspiration Breath-hold Radiotherapy for Left-sided Breast Cancer,1.8273972602739725,Recruiting,Observational,No,No,Sponsor-Investigator,166
21129002,Topical Menthol Application in Chemotherapy-Related Peripheral Neuropathy in Patients With Breast Cancer,0.7506849315068493,Completed,Interventional,No,No,Principal Investigator,60
MCC-20915,"Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab",3.9287671232876717,Recruiting,Interventional,Yes,No,Sponsor,53
PMCT-IMSLNB-MIT,Internal Mammary Sentinel Lymph Node Biopsy With Modified Injection Technique,2.504109589041096,Unknown status,Interventional,No,No,Principal Investigator,350
V2000701,Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer,1.8054794520547945,Recruiting,Interventional,Yes,No,Sponsor,186
University Brunswick,Physical Activity Levels and Functional Improvement in Breast Cancer Survivors,2.5561643835616437,Unknown status,Interventional,No,No,Sponsor,20
1605576856,Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients,1.9945205479452057,Recruiting,Interventional,Yes,No,Principal Investigator,40
3475-B49,Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49),7.095890410958904,Recruiting,Interventional,Yes,No,Sponsor,800
2018-0287,"Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study",4.909589041095891,Recruiting,Interventional,Yes,No,Sponsor,124
SABO 21-01,Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer,5.284931506849315,Recruiting,Interventional,No,No,Sponsor,345
UW20037,Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study),3.4054794520547946,Recruiting,Interventional,Yes,No,Sponsor,39
20201101,Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study),4.002739726027397,Not yet recruiting,Interventional,No,No,Sponsor,300
ZJCH-CK19B,A Prospective Validation Cohort Study of a Prediction System on nSLN Metastasis in Early Breast Cancer,1.63013698630137,Unknown status,Interventional,No,No,Principal Investigator,388
69HCL21_0145,Immediate Breast Reconstructions Increasing,0.4136986301369863,Unknown status,Observational,No,No,Sponsor,215
IPI-549-03,Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3),2.6246575342465754,"Active, not recruiting",Interventional,Yes,No,Sponsor,91
2017-0500,M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer,4.315068493150685,Terminated,Interventional,Yes,No,Sponsor,38
APG2575XU103,"A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer",2.1342465753424658,Recruiting,Interventional,Yes,No,Sponsor,65
BLTN-NeoBC1115,Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer,1.4164383561643836,Unknown status,Interventional,No,No,Principal Investigator,20
22-259,A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer,3.0027397260273974,Recruiting,Interventional,No,Yes,Sponsor,40
UW18099,Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer,8.635616438356164,Recruiting,Interventional,No,Yes,Sponsor,30
17384,A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer,2.7534246575342465,"Active, not recruiting",Interventional,Yes,No,Sponsor,2450
BL-B01D1-104,A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors,1.9753424657534249,Recruiting,Interventional,No,No,Sponsor,36
M21CSM,COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study,16.96986301369863,Recruiting,Interventional,No,No,Sponsor,118
4-2022-0600,Robot-assisted vs. Open Nipple-sparing Mastectomy With Immediate Breast Reconstruction,7.67123287671233,Not yet recruiting,Interventional,No,No,Sponsor,790
RS1637/21,Single-cell RNAseq Breast Cancer,3.0493150684931507,Recruiting,Observational,No,No,Sponsor,20
22239,Treatment of Frailty With Fisetin (TROFFi) in Breast Cancer Survivors,2.136986301369863,Recruiting,Interventional,Yes,No,Sponsor,88
202107015,"Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTumÂ® Serum Thymidine Kinase 1 (TK1) Activity Testing",5.068493150684931,Recruiting,Interventional,No,Yes,Sponsor,55
20171,Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer,2.378082191780822,Recruiting,Interventional,No,No,Sponsor,26
UPCC 17119,Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Ancillary Study,4.336986301369863,Enrolling by invitation,Observational,No,No,Sponsor,155
HS-10352-101,Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer,2.978082191780822,Recruiting,Interventional,No,No,Sponsor,54
NNG17.2,Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients,3.0493150684931507,Completed,Interventional,No,No,Sponsor,128
XJTU1AF-CRF-2018-001,Circulating Tumor DNA as Marker of Therapeutic Efficacy in Breast Cancer Patients,5.756164383561644,Recruiting,Observational,No,No,Sponsor,200
I 571719,Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors,5.002739726027397,Recruiting,Observational,No,No,Sponsor,300
2019-40016-06,Vitamin D Can Increase Pathological Response of the Breast Cancer Patients Treated With Neoadjuvant Therapy,1.5890410958904109,Unknown status,Interventional,No,No,Principal Investigator,50
2018B0521,Southeast Asian Womens Health Project,2.8767123287671232,Recruiting,Interventional,No,No,Principal Investigator,540
IRB-52869,Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer,3.7041095890410958,Recruiting,Interventional,Yes,No,Sponsor,150
D9266C00001,"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)",1.9534246575342469,Recruiting,Interventional,No,No,Sponsor,118
1B-21-6,Breast Cancer Survivorship Biorepository,6.005479452054795,Recruiting,Observational,No,No,Sponsor,1300
2017/78,"Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)",9.008219178082191,Not yet recruiting,Interventional,No,No,Sponsor,85
ICRG0201,"Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.",3.4493150684931506,Recruiting,Interventional,No,No,Sponsor,80
SHR-A1811-III-301,"A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane",2.4273972602739726,Recruiting,Interventional,No,No,Sponsor,269
IRB-63041,Study Assessing QBS72S For Treating Brain Metastases of Breast Cancer,3.9616438356164387,Recruiting,Interventional,Yes,No,Sponsor-Investigator,40
U21-02-4401,Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition,3.8986301369863017,Recruiting,Interventional,Yes,No,Sponsor,74
AssiutU AAHelmy,Multimodal Ultrasonographic Assessment of Ipsilateral Axillary Lymph Nodes in Patients With Breast Cancer: A STARD Study,1.084931506849315,Not yet recruiting,Observational,No,No,Principal Investigator,30
Pro00100408,Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer,4.53972602739726,Recruiting,Observational,No,No,Sponsor,110
Polarhis,Assessment of Lumpectomy Margins With the Histolog Scanner in Comparison With Intraoperative Imaging Techniques,1.663013698630137,Completed,Observational,No,No,Sponsor,40
GS-US-592-6173,"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physicians Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer",4.526027397260274,Recruiting,Interventional,Yes,No,Sponsor,440
SCO-120-19-22,A Study in Patients With Advanced Breast Cancer,1.6191780821917807,Recruiting,Interventional,Yes,No,Sponsor,167
GS-US-592-6238,Study of Sacituzumab Govitecan-hziy Versus Treatment of Physicians Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer,4.7835616438356166,Recruiting,Interventional,Yes,No,Sponsor,540
CBYL719C2201,Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer,4.528767123287671,Recruiting,Interventional,Yes,No,Sponsor,135
TQB3616-III-01,TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail,1.7068493150684931,Recruiting,Interventional,No,No,Sponsor,287
19/218,Increasing Access to Breast Cancer Screening Among Immigrants,9.717808219178082,"Active, not recruiting",Interventional,No,No,Principal Investigator,11355
CHANGEABLE,Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer,2.287671232876712,Recruiting,Interventional,No,No,Principal Investigator,37
19-3032.cc,Combined Modality Exercise and Appetite in Breast Cancer Survivors,1.2931506849315069,Terminated,Interventional,No,No,Sponsor,3
SCT200IITNBC,Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer,1.4493150684931506,Unknown status,Interventional,No,No,Sponsor,30
651,Breast Cancer: Axillary Conservation After Neoadjuvant Chemotherapy in Micro Metastatic Sentinel Lymph Nodes.,8.005479452054795,Recruiting,Interventional,No,No,Sponsor,850
H3B-6545-J081-103,"Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer",3.1671232876712327,"Active, not recruiting",Interventional,No,No,Sponsor,33
2019-00174 Neoadj Breast Pilot,"Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer",1.252054794520548,Withdrawn,Interventional,Yes,No,Sponsor-Investigator,0
MO40628,A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer,3.816438356164384,Completed,Interventional,Yes,No,Sponsor,160
NNG17.1,Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.,1.736986301369863,Completed,Interventional,No,No,Sponsor,50
STUDY00004618,A Patient Reminder and Self-Referral Via Online Patient Portals and Text Messaging to Improve Adherence to Breast Cancer Screening,0.5671232876712329,"Active, not recruiting",Interventional,No,No,Principal Investigator,140
19959,Effects of Computer-Assisted Cognitive Rehabilitation Programs With Breast Cancer Survivors,2.0000000000000004,Unknown status,Interventional,No,No,Sponsor,52
AIPAC-003,Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy,4.367123287671233,Recruiting,Interventional,Yes,No,Sponsor,849
18-1068,Clinician Communication About Sexual Health,0.6794520547945205,Completed,Interventional,No,No,Sponsor,32
SuleymanDU-SALMAN-F-001,The Effect of Mobile Application-based Information About Before and After Surgery,0.4136986301369863,Completed,Interventional,No,No,Principal Investigator,82
IIBSP-SIL-2017-70,Evaluation of a New Technique to Fill the Defect Generated After Conservative Surgery in Breast Cancer,2.452054794520548,Completed,Interventional,No,No,Sponsor,100
Shoulder exercise cancer,Limited Versus No-limited Shoulder Movement in Breast Cancer Surgery,0.8821917808219178,Completed,Interventional,No,No,Principal Investigator,465
NCI-2022-00004,Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body,4.2684931506849315,Recruiting,Interventional,Yes,No,Sponsor,18
GC-627-05,Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,1.8986301369863017,Completed,Interventional,Yes,No,Sponsor,393
LCCC 2104,Comparison of Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN),3.0027397260273974,Recruiting,Interventional,Yes,Yes,Principal Investigator,90
2021SQGH00743,The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer,5.0,Recruiting,Interventional,No,No,Sponsor,40
rosuva2020,Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients,3.0,Recruiting,Interventional,No,No,Principal Investigator,50
N21CPB-IRBd22-103,Communication in Breast Cancer Care,0.5726027397260274,Recruiting,Interventional,No,No,Principal Investigator,40
UPNA-CUMACA-B2022,Web-based Intervention for Long-term Breast Cancer Survivors,1.4164383561643836,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,182
213831,Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease,8.172602739726027,Recruiting,Interventional,Yes,No,Sponsor,800
Pro00109917,Noninvasive Assessment of Lymphedema Among Breast Cancer Survivors,1.1835616438356165,Recruiting,Interventional,No,Yes,Sponsor,30
GCO 17-2320,Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer,1.736986301369863,Completed,Interventional,Yes,No,Sponsor-Investigator,9
32158620.0.0000.0072,Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia,1.5671232876712329,"Active, not recruiting",Observational,No,No,Principal Investigator,38
MA-BC-II-025,Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer,6.501369863013698,Recruiting,Interventional,No,No,Sponsor,206
CPO-NBP-2002,NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy,1.5890410958904109,Not yet recruiting,Interventional,Yes,No,Sponsor,60
INT/2020/VOICE,"Implementation, Effectiveness and Impact of a Value Based Intervention for Patients With Breast or Lung Cancer",4.495890410958904,"Active, not recruiting",Interventional,No,No,Sponsor,1161
N assisted,A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment With Trastuzumab Combined With Parezumab,5.712328767123288,Recruiting,Interventional,No,No,Principal Investigator,300
PROSOM-K,Study of the Functioning of Prospective Memory in Breast Cancer and the Influence of Sleep,2.1671232876712327,Completed,Interventional,No,No,Sponsor,75
SYSKY-2022-024-01,Construction and Effect Evaluation of Malignant Fungating Wounds Care Regimen for Breast Cancer Patients,2.1013698630136988,Recruiting,Interventional,No,No,Sponsor,50
NL62441.068.17,PET-MRI for Axillary Staging in Node Negative Breast Cancer Patients,5.7753424657534245,Recruiting,Interventional,No,No,Sponsor,125
EP0062-101,Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer,2.249315068493151,Not yet recruiting,Interventional,Yes,No,Sponsor,128
LightCT-PKUPH,Light-CT in the Diagnosis of Breast Tumor and Lymph Node,5.7534246575342465,Recruiting,Observational,No,Yes,Sponsor,150
KY2022-044-B,"CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial",6.717808219178083,Recruiting,Interventional,No,No,Principal Investigator,484
SUGBG-2021001,Sentinel Node Localization and Staging With Low Dose Superparamagnetic Iron Oxide,2.495890410958904,"Active, not recruiting",Interventional,No,No,Principal Investigator,50
PI2018_843_0061,Feasibility of Total Mastectomy in Ambulatory Care,3.164383561643836,Recruiting,Interventional,No,No,Sponsor,50
2110244-11,Comparison of Dexamethasone Alone vs in Combination With Pericardium 6 (P6) Electrical Stimulation or Granisetron in the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Breast Cancer Surgery,1.4986301369863013,Recruiting,Interventional,No,No,Principal Investigator,186
2018-09-20 Version 1.2,Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer,4.586301369863014,Recruiting,Observational,Yes,No,Sponsor,40
HSM/VGH-2019-12-009CC,Web-based Oncofertility Support Tool for Reproductive-age Women With Breast Cancer,1.5945205479452054,Completed,Interventional,No,No,Principal Investigator,54
2021-A01550-41,Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast Cancer,2.9315068493150687,Recruiting,Interventional,No,No,Sponsor,354
2449PT,Effect of Exercise Mode in Breast Cancer-Related Lymphedema,1.3041095890410959,Completed,Interventional,No,No,Principal Investigator,52
20220430GD,Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation,6.66027397260274,Recruiting,Interventional,No,No,Sponsor-Investigator,66
StrataXRT,A Study of StrataXRT in the Prevention of Radiation Dermatitis in Breast Cancer Patients,0.7123287671232876,Recruiting,Interventional,No,No,Principal Investigator,50
TQB3909-Ib/II-01,A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer,0.7506849315068493,Recruiting,Interventional,No,No,Sponsor,65
events in breast cancer,Skeletal Events of Hormonal Treatment and Radiotherapy in Patient With Breast Cacer,0.0,Unknown status,Observational,No,No,Principal Investigator,100
"S-20200021, 19-16321",An Individualised Treatment vs. a Minimal Program in Women With Late-term Shoulder Impairments After Breast Cancer.,0.5178082191780823,Completed,Interventional,No,No,Sponsor,31
Exo-LCR-1807,Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.,4.254794520547946,Withdrawn,Interventional,No,No,Sponsor,0
ILLUMINE,Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer,4.249315068493151,Recruiting,Observational,Yes,No,Sponsor,100
AGO/2019/003,Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer,0.4328767123287671,Withdrawn,Interventional,No,No,Sponsor,0
C4891016,A Study to Learn About the ARV-471 (PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC),0.673972602739726,"Active, not recruiting",Interventional,No,No,Sponsor,6
MCC-19220,PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient,2.0000000000000004,Withdrawn,Interventional,Yes,No,Sponsor,0
2020-A01916-33,Adapted Fencing in Breast Cancer: a Pilot Study,0.9753424657534248,Recruiting,Interventional,No,No,Principal Investigator,24
MC220902,Evaluation of Endocrine Therapy-Induced Alopecia Among Postmenopausal and Premenopausal Female Patients With Breast Cancer,1.6383561643835616,Recruiting,Observational,No,No,Sponsor,150
BR-003,Confirmatory Clinical Evaluation of NovilaseÂ® Laser Therapy for Focal Destruction of Malignant Breast Tumors,1.9205479452054797,Not yet recruiting,Interventional,No,Yes,Sponsor,122
2021/156064(REK),Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients,12.550684931506849,Recruiting,Interventional,Yes,No,Principal Investigator,60
MedOPP199,"Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -",0.6520547945205479,Completed,Interventional,No,No,Sponsor,66
RECHMPL21_0680,Impact of Video Information Support on Preoperative Anxiety in Breast Cancer Surgery,2.778082191780822,Recruiting,Interventional,No,No,Sponsor,200
ShengjingH 3,"Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy",5.454794520547945,Recruiting,Observational,No,No,Principal Investigator,1000
18459,A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer,9.452054794520548,Recruiting,Interventional,Yes,No,Sponsor,6000
PRO00030295,Avanzando Juntas: Adapting an Evidence Based Weight Loss Program for Hispanic Breast Cancer Survivors,2.745205479452055,Completed,Interventional,No,No,Principal Investigator,40
DBCG RT SDM,Shared Decision Making With Breast Cancer Patients,3.408219178082192,"Active, not recruiting",Interventional,No,No,Sponsor,678
NBK 171/1/2021,Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a Window of Opportunity Study,4.931506849315069,Not yet recruiting,Interventional,No,No,Sponsor,126
NCC1787,Clinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast Cancer,3.084931506849315,Unknown status,Interventional,No,No,Principal Investigator,50
UCI 19-145 [HS# 1459],"Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer",6.33972602739726,Recruiting,Interventional,Yes,No,Principal Investigator,20
20923,"Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand",2.0164383561643837,Terminated,Observational,No,No,Sponsor,8
SUN-2252,Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients,2.3643835616438356,Recruiting,Observational,No,No,Principal Investigator,25
18496,"Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer",4.802739726027397,"Active, not recruiting",Interventional,Yes,No,Sponsor,28
INT214/22,Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial,2.0027397260273974,Not yet recruiting,Interventional,No,No,Sponsor,145
201906,Psychological Interventions to Prevent Late Effects in Breast Cancer,4.254794520547946,Recruiting,Interventional,No,No,Principal Investigator,200
BL-M07D1-101,A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors,1.9808219178082194,Recruiting,Interventional,No,No,Sponsor,26
22-250,TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients,3.8739726027397263,Recruiting,Interventional,No,No,Principal Investigator,270
2021-0669,Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer,1.0000000000000002,Not yet recruiting,Observational,No,No,Sponsor,12
HCI130492,Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics,4.249315068493151,Recruiting,Interventional,Yes,No,Sponsor,34
E7090-J081-102,A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer,3.558904109589041,"Active, not recruiting",Interventional,No,No,Sponsor,72
Folio No.03-2022,Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae,0.3452054794520548,Completed,Interventional,No,No,Principal Investigator,26
S63330,FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients.,4.167123287671234,Recruiting,Interventional,No,No,Sponsor,150
CA209-8H3,"Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients",6.0,Recruiting,Interventional,Yes,No,Sponsor,138
A171601,"Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer",5.967123287671233,"Active, not recruiting",Interventional,Yes,No,Sponsor,93
OP-1250-001,"A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer",3.3013698630136985,Recruiting,Interventional,Yes,No,Sponsor,94
A5481122,Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy,3.8520547945205483,"Active, not recruiting",Observational,Yes,No,Sponsor,1
21-091,A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer,2.0000000000000004,Recruiting,Interventional,Yes,No,Sponsor,50
1890-1-2019,Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy,0.5780821917808219,Completed,Observational,Yes,No,Principal Investigator,111
CARDIEJERCAN,Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients,1.0191780821917809,Not yet recruiting,Interventional,No,No,Sponsor,90
RIBBS 2019/37,Risk-Based Breast Screening in Young Women,6.035616438356165,"Active, not recruiting",Interventional,No,No,Sponsor,10270
CCR5234,Digital Delivery of Information About Genetic Testing for Breast Cancer,1.4082191780821918,"Active, not recruiting",Interventional,No,No,Sponsor,1000
2574,Prospective Thinking in Hormone-Responsive Breast Cancer,1.1369863013698631,Completed,Interventional,No,No,Principal Investigator,89
IFG-06-2019,Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer,2.515068493150685,Recruiting,Interventional,No,No,Sponsor,82
439-21,High-intensity Exercise After Treatment,1.3397260273972602,"Active, not recruiting",Interventional,No,No,Principal Investigator,7
VHIO20002,A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020,2.9205479452054797,Recruiting,Interventional,No,No,Sponsor,20
H-45698,Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ),3.756164383561644,Recruiting,Interventional,Yes,No,Sponsor-Investigator,57
FDRT-BC010,Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases,3.610958904109589,"Active, not recruiting",Interventional,No,No,Principal Investigator,39
D8666C00004,To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.,1.5972602739726027,Withdrawn,Interventional,No,No,Sponsor,0
17-0310,Narrative Visualization for Breast Cancer Survivors Physical Activity,3.580821917808219,Completed,Interventional,No,No,Sponsor,40
OTT 17-02,Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients,1.0904109589041096,Completed,Interventional,No,No,Sponsor,124
MC1835-ACCRU-BR-1701,"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery",4.906849315068493,Recruiting,Interventional,Yes,No,Sponsor,480
CCR4772,PRELUDE Study of Lymphatic Surgery to Treat Breast Cancer Related Lymphoedema,2.4684931506849317,Recruiting,Interventional,No,No,Sponsor,64
UC-BCG-2205,Treatment for Breast Cancer Patients With Meninges Invaded by Tumor Cells,3.4986301369863013,Not yet recruiting,Interventional,No,No,Sponsor,30
IEO 0837/,Patients Preferences for Adjuvant Endocrine Therapy in Early Breast Cancer,3.5753424657534247,Unknown status,Observational,No,No,Sponsor,450
PHDW-006,Psychological Factors and Oncological Outcomes of Triple-negative Breast Cancer,1.0000000000000002,Unknown status,Observational,No,No,Principal Investigator,50
AnhuiPH,A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Positive Her-2,1.5041095890410958,Unknown status,Observational,No,No,Principal Investigator,300
21094,CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer,2.12054794520548,Recruiting,Interventional,Yes,No,Sponsor,78
PECP,The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer,2.0000000000000004,Unknown status,Interventional,No,No,Sponsor,100
UPCC 11121,"Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer",17.956164383561642,Recruiting,Observational,No,No,Sponsor,200
CBYL719A03201,Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant,0.5342465753424658,Terminated,Interventional,No,No,Sponsor,2
11066,Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors,3.463013698630137,Recruiting,Interventional,No,No,Principal Investigator,375
S-64813,"Clinical, Histological and In-depth Molecular Characterization as Well as Experimental Models of Liver Metastasis From Patients With Breast Cancer in Order to Identify New Potential Treatment Avenues.",2.0027397260273974,Not yet recruiting,Observational,No,No,Principal Investigator,20
2020-0831,Comparing the Performance of Automated Breast Ultrasonography to Hand-Held Whole Breast Ultrasonography in Breast Cancer Treatment Response Assessment,0.0,Withdrawn,Observational,No,No,Sponsor,0
SDO-006-20-01,To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer,0.7561643835616438,Withdrawn,Interventional,Yes,No,Sponsor,0
ASSOCIHER,Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy,0.4191780821917808,Completed,Observational,No,No,Sponsor,518
VICC BRE 20104,Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment,3.315068493150685,Recruiting,Observational,No,No,Sponsor-Investigator,10
22-655,STOP-HER2: Stopping Trastuzumab in HER2+ MBC,12.797260273972602,Recruiting,Interventional,No,No,Principal Investigator,82
CL0007,Investigation of Novel Surgical Imaging for Tumor Excision,2.4986301369863013,Completed,Interventional,Yes,Yes,Sponsor,406
EPTTCSM (239BRC18.0129),Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer,0.4958904109589042,Unknown status,Observational,No,No,Sponsor,63
MO39193,A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer,6.057534246575343,Recruiting,Interventional,Yes,No,Sponsor,572
HSR210410,Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer,4.421917808219178,Not yet recruiting,Interventional,Yes,No,Principal Investigator,45
ALTER-BC-003,AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer,1.6684931506849314,Not yet recruiting,Interventional,No,No,Principal Investigator,42
"CD133, Breast Cancer",CD133 Expression in Mammary Invasive Ductal Carcinoma,0.5863013698630137,Recruiting,Observational,No,No,Principal Investigator,50
2021-40-2343,RWE About QOL and Compliance of Patients With OFS in China,2.4164383561643836,Not yet recruiting,Observational,Yes,No,Principal Investigator,500
NL67422.041.18,Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer,1.6712328767123288,Unknown status,Interventional,Yes,No,Principal Investigator,12
AL-TNBC-01,A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer,3.2986301369863016,"Active, not recruiting",Interventional,Yes,No,Sponsor,67
300007016,"Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations",2.249315068493151,Recruiting,Interventional,No,No,Principal Investigator,40
QUILT-3.057,QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine,3.252054794520548,Withdrawn,Interventional,Yes,No,Sponsor,0
2021-0261,Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer,1.0438356164383562,Completed,Interventional,Yes,Yes,Sponsor,167
69HCL19_0593,"PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study",2.4986301369863013,Not yet recruiting,Observational,No,No,Sponsor,200
H3B-6545-G000-102,A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer,4.000000000000001,"Active, not recruiting",Interventional,Yes,No,Sponsor,36
NCI-2018-01581,"Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer",6.052054794520548,Recruiting,Interventional,Yes,No,Sponsor,70
SIB16134,Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer,1.1945205479452055,Withdrawn,Interventional,No,No,Sponsor,0
2020-11/15,"The Effect of Art Therapy on Pain, Emesis, Anxiety and Quality of Life, Breast Cancer",1.0986301369863014,Completed,Interventional,No,No,Principal Investigator,60
20D.876,SABR-CaRe in Early Stage Breast Cancer,4.361643835616438,Recruiting,Interventional,No,No,Sponsor,80
41494,Feasibility of a Remotely-Delivered Yoga Intervention on Cognitive Function in Breast Cancer Survivors,0.6191780821917808,Completed,Interventional,No,No,Principal Investigator,18
19D.799,A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer,0.36712328767123287,Recruiting,Interventional,No,No,Sponsor,30
21-110,Anti-anxiety Biotics for Breast Cancer Survivors,0.7808219178082192,Completed,Interventional,No,No,Principal Investigator,3
GM1-CIPN-202,"A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer",2.7013698630136984,Not yet recruiting,Interventional,No,No,Sponsor,150
HSaleem,Kinesiology Taping Technique in Post-mastectomy Breast Cancer Related Lymphedema,0.9041095890410958,Recruiting,Interventional,No,No,Sponsor,50
220493,Lymphatic Function in Patients Who Have Undergone Breast Cancer Treatment,0.915068493150685,Unknown status,Interventional,No,No,Sponsor,28
2020-q12,Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer,4.109589041095891,Recruiting,Interventional,No,No,Principal Investigator,40
1280-0022,The XENERAâ¢ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread,3.452054794520548,Completed,Interventional,Yes,No,Sponsor,103
0124-18-TLV,Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor,2.4164383561643836,Unknown status,Interventional,No,No,Principal Investigator,40
112626,Three Fraction Radiation to Induce Immuno-Oncologic Response,4.663013698630137,Recruiting,Interventional,No,No,Sponsor,40
BL2014084,"This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment",1.3315068493150686,Unknown status,Interventional,Yes,No,Sponsor,60
20160504,Impact of Intensive Follow-up for Bone Metastasis on Characteristics and Prognosis of Chinese Breast Cancer Patients,1.082191780821918,Completed,Observational,No,No,Sponsor,1500
RLY-2608-101,"First-in-Human Study of Mutant-selective PI3KÎ± Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer",3.7315068493150685,Recruiting,Interventional,Yes,No,Sponsor,190
CLEE011A2207,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",6.558904109589041,"Active, not recruiting",Interventional,Yes,No,Sponsor,376
21050,An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis,2.1835616438356165,Recruiting,Interventional,Yes,Yes,Sponsor,10
55054,Inspiratory Muscle Training in Obese Breast Cancer Survivors,6.002739726027397,Not yet recruiting,Interventional,No,No,Principal Investigator,78
PILOT 171548,RISE - Reduce Sitting Time Among Breast Cancer Survivors,0.863013698630137,"Active, not recruiting",Interventional,No,No,Principal Investigator,21
Pro00109777,Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib,2.0273972602739727,Recruiting,Interventional,Yes,No,Sponsor-Investigator,48
22-225,ETHAN - ET for Male BC,13.172602739726027,Not yet recruiting,Interventional,Yes,No,Sponsor-Investigator,60
ShandongCHI-04,The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy,2.0000000000000004,Unknown status,Interventional,No,No,Sponsor-Investigator,200
1710018694,Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients,8.128767123287671,Recruiting,Interventional,Yes,No,Sponsor,41
MC1733,A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer,3.8958904109589048,Recruiting,Interventional,Yes,No,Sponsor,33
294-2018,Efficacy Study of Mepitel Film the Prophylaxis of Radiation-Induced Skin Reactions in Breast Cancer Patients,1.4904109589041097,Completed,Interventional,No,No,Principal Investigator,30
29747,T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer,4.046575342465754,Completed,Interventional,Yes,No,Sponsor,54
IFG-NIB-01,Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC,2.8383561643835615,Completed,Interventional,Yes,No,Sponsor,53
PRESSODOU-1809,Mechanical Stimulation on Pain Level and Functional Discomfort After Breast Cancer Surgery,3.4328767123287673,Recruiting,Interventional,No,No,Sponsor,120
2022/005-OST,Exploratory Evaluation of the Functional/Emotional Life Characteristics During the First Year of Ongoing Endocrine Adjuvant Treatment With Aromatase Inhibitors in Breast Cancer Patients With Reduced Bone Mineral Density,1.473972602739726,Recruiting,Observational,No,No,Principal Investigator,82
WSG-AM08,"Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC",8.084931506849315,Recruiting,Interventional,No,No,Sponsor,1670
MRG002-005,A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC),1.7232876712328766,Recruiting,Interventional,No,No,Sponsor,66
HLX10-013-TNBCneo,to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC),6.980821917808219,Not yet recruiting,Interventional,No,No,Sponsor,522
INT 192/19,Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer,3.991780821917809,"Active, not recruiting",Interventional,No,No,Sponsor,30
YWBC-001,"A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Breast Cancer",5.0,Recruiting,Observational,No,No,Sponsor,2000
IRB-53650,"Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer",1.0246575342465754,Terminated,Interventional,Yes,No,Sponsor,4
VICC BRE 17107,Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer,2.421917808219178,Terminated,Interventional,Yes,No,Principal Investigator,12
2017-004938-28,Satisfaction Assessment of Patients With Local Breast Cancer When Using Cosmetics During Chemotherapy and Post-treatment Thermal Cure,2.328767123287671,Completed,Interventional,No,No,Sponsor,30
Pro00103625,Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer,3.293150684931507,"Active, not recruiting",Interventional,Yes,No,Sponsor,18
2017/01,Study Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer Patients,4.304109589041096,Completed,Interventional,No,No,Sponsor-Investigator,62
NCI-2018-01519,Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer,8.723287671232876,Recruiting,Interventional,Yes,No,Sponsor,300
G0F9119N,CoMoon for Supporting Breast Cancer Patients on Adjuvant Endocrine Therapy,2.082191780821918,Completed,Interventional,No,No,Sponsor,77
OP_1413,Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer,3.92054794520548,Recruiting,Interventional,No,No,Principal Investigator,220
2020-001,"Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer",2.9232876712328766,Not yet recruiting,Interventional,Yes,No,Sponsor,53
NCI-2022-07265,"Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer, A ComboMATCH Treatment Trial",3.66027397260274,Recruiting,Interventional,Yes,No,Sponsor,95
AURORA US,Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer,4.167123287671234,Recruiting,Observational,No,No,Sponsor,200
G1T28-208,"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)",3.5315068493150683,"Active, not recruiting",Interventional,Yes,No,Sponsor,194
ZZBGCART-016,EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer,3.0027397260273974,Recruiting,Interventional,No,No,Sponsor,30
18HH4880,D4 Choline Breast PET/CT,2.6931506849315068,Recruiting,Observational,No,No,Sponsor,16
21-038,Fulvestrant + Neratinib In Breast Cancer,3.0027397260273974,Not yet recruiting,Interventional,Yes,No,Principal Investigator,25
STUDY00004257,"Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer",2.6191780821917807,Recruiting,Interventional,Yes,No,Principal Investigator,40
IC 2020-15,Study Evaluating Hot Flashes in Hormone Sensitive Breast Cancer,1.052054794520548,Completed,Observational,No,No,Sponsor,290
09.2019.865,Responsiveness of Outcome Scales in Breast Cancer Related Lymphedema,0.6136986301369863,Unknown status,Interventional,No,No,Sponsor,30
I-3010822,"Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer",3.92054794520548,Not yet recruiting,Interventional,Yes,No,Sponsor,12
PALBO01/2021,Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period,1.9178082191780825,Recruiting,Observational,Yes,No,Sponsor,650
UMCC 2021.056,An Attention-Restorative Therapy (ART)-Based Virtual Reality Intervention to Address Cancer-Related Cognitive Impairments Among Breast Cancer Survivors,0.5534246575342465,Completed,Interventional,No,No,Sponsor,30
BOOG 2019-01,"TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer",3.767123287671233,Recruiting,Interventional,No,No,Sponsor,50
AZV2022,The Effectiveness of Psychological Interventions in Psycho-neuroendocrine-immune Network in Breast Cancer Survivors,2.989041095890411,Recruiting,Interventional,No,No,Principal Investigator,440
RF-2016-02362383,Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer,4.208219178082192,Recruiting,Interventional,No,No,Sponsor,112
HYPART,HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART).,7.397260273972603,Recruiting,Interventional,No,No,Principal Investigator,1018
CLEE011AUS65,Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors,0.23013698630136986,Completed,Observational,No,No,Sponsor,4320
UTD-1-BM-II,"The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer.",3.0027397260273974,Recruiting,Interventional,No,No,Sponsor,43
IUSCC-0647,Effects of Aromatase Inhibitor Therapy on Muscle Function,1.536986301369863,Completed,Observational,No,No,Sponsor-Investigator,16
SL-2020076,Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude,3.16986301369863,Not yet recruiting,Observational,No,No,Principal Investigator,132
2022-A00171-42,Support and Post-therapeutic Rehabilitation for Women in Complete Remission of Breast Cancer in a Thermal Environment,4.4301369863013695,Recruiting,Observational,No,No,Sponsor,400
2018/14-01,A New Mindfulness Intervention Called Mindfulness Based Swinging Technique (MBST) for Women With Breast Cancer,3.8931506849315074,Completed,Interventional,No,No,Principal Investigator,156
UC-0140/1814,"Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients",8.005479452054795,Recruiting,Interventional,No,No,Sponsor,200
20221297,Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer,6.005479452054795,Not yet recruiting,Interventional,Yes,No,Principal Investigator,500
NBG-19-01; SWEBCG 19-01,"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC",15.536986301369865,Recruiting,Interventional,No,No,Sponsor,920
bakircaymzeren07,Does Inclusion of Diaphragmatic Breathing Exercises in Complete Decongestive Therapy Provide Further Benefits in Patients With Breast Cancer Related Lymphedema,0.4520547945205479,Recruiting,Interventional,No,No,Principal Investigator,40
2021SCR,Cone Beam Breast CT for Breast Cancer Screening,2.0000000000000004,"Active, not recruiting",Interventional,No,Yes,Sponsor,1024
Lymphedema Rehabilitation,New Therapeutic Approach in Upper Limb Lymphedema Secondary to Breast Cancer: Activity-oriented Proprioceptive Antiedema Therapy (TAPA),2.506849315068493,Unknown status,Interventional,No,No,Principal Investigator,42
VMA-253-18,Fish Oil and EPO in Breast Cancer,5.3342465753424655,Recruiting,Interventional,No,No,Principal Investigator,60
IRB-30000320,"Gut Microbe Composition, Exercise, and Breast Breast Cancer Survivors",5.624657534246575,Recruiting,Interventional,No,No,Principal Investigator,126
9764,"Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",6.536986301369863,Withdrawn,Interventional,Yes,No,Sponsor,0
EA1211,"Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial",1.8904109589041096,Not yet recruiting,Interventional,No,No,Sponsor,235
11B1920N_BCS-PAIN,The Effect of Pain Neuroscience Education and Behavioural Graded Activity on Chronic Pain in Breast Cancer Survivors,3.4712328767123286,Recruiting,Interventional,No,No,Sponsor,200
ShandongCHI-13,Comparison Study of Different Tumor Biopsy Method for Sentinel Lymph Node Biopsy in Breast Cancer,0.5808219178082191,Unknown status,Interventional,No,No,Principal Investigator,600
MIMIR-mTNBC,Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer,4.221917808219178,Not yet recruiting,Observational,No,No,Principal Investigator,64
LCCC1934,Reverse Axillary Mapping in Breast Radiation Treatment Planning,5.673972602739726,Withdrawn,Observational,No,No,Sponsor,0
3-2020-0448,Repeat Sentinel Lymph Node Biopsy in Ipsilateral Breast Tumor Recurrence,8.926027397260274,Recruiting,Interventional,No,No,Principal Investigator,532
17502,A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer,5.063013698630137,"Active, not recruiting",Interventional,Yes,No,Sponsor,500
Pro2020001306,Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer,2.706849315068493,Recruiting,Interventional,No,Yes,Principal Investigator,55
2861/20,Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer,7.16986301369863,Recruiting,Interventional,Yes,No,Principal Investigator,80
WO40181,"A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy",2.665753424657534,Terminated,Interventional,Yes,No,Sponsor,103
GY202201,Efficacy of Acupuncture Treatment for Breast Cancer-associated Insomnia,2.6164383561643834,Recruiting,Interventional,No,No,Sponsor,264
BMTN,Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer,2.6301369863013697,Completed,Interventional,No,No,Principal Investigator,54
2020-12518,Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer,6.961643835616439,Recruiting,Observational,No,No,Sponsor,549
20190304-01H,"Breaststroke Swimming After Breast Cancer Treatment/Surgery as a Means of Treatment for Seroma, Lymphedema, and Chronic Arm and Chest Pain",3.0,Recruiting,Interventional,No,No,Sponsor,128
UKT HT03_1,Prospective Assessment of Quality of Life in Patients With Locally Recurrent Breast Cancer and Hyperthermic Radiotherapy,6.419178082191781,Recruiting,Observational,No,No,Sponsor,20
30388,"Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors",5.6219178082191785,"Active, not recruiting",Interventional,Yes,No,Sponsor,20
STUDY00146320,Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens,4.134246575342466,Recruiting,Interventional,Yes,No,Principal Investigator,120
SM-88-001,Study of SM-88 in Advanced Cancers,1.0000000000000002,Withdrawn,Interventional,Yes,No,Sponsor,0
2022-A00437-36,Impact of Sleep Disturbance on Cognition and Quality of Life in Breast Cancer,4.668493150684932,Not yet recruiting,Interventional,No,No,Sponsor,75
2018-01-054,Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy,5.504109589041096,"Active, not recruiting",Observational,No,No,Principal Investigator,50
2.073.549,Pilates and Dance to Breast Cancer Patients Undergoing Treatment,2.9972602739726026,Completed,Interventional,No,No,Sponsor,74
NCI-2020-02319,Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer,3.3917808219178083,Recruiting,Interventional,Yes,No,Sponsor,106
2-114-18,Is Dietary Nitrate Effective in Reducing Aerobic Glycolysis in Breast Cancer?,1.1342465753424658,Unknown status,Interventional,No,No,Sponsor,16
P170407J,Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer,2.756164383561644,Completed,Interventional,No,No,Sponsor,8
QF-SC10914-203,A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients,2.0493150684931507,Unknown status,Interventional,No,No,Sponsor,78
BRAVE,QOL of Women With HR-Positive Metastatic BC Treated in the First-line Setting: Comparison Between Public and Private Institutions.,1.0438356164383562,Enrolling by invitation,Observational,No,No,Principal Investigator,202
D926PC00001,"A Study of Dato-DXd Versus Investigators Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)",3.5534246575342467,Recruiting,Interventional,Yes,No,Sponsor,600
NL76792.091.21,DLSCT for Breast Cancer Detection in Women With Dense Breasts,1.0000000000000002,Recruiting,Observational,No,No,Sponsor,14
IRB00376235,The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer,5.16986301369863,Not yet recruiting,Interventional,No,No,Sponsor,250
HCRN BRE18-360,Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physicians Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases,4.484931506849315,Recruiting,Interventional,Yes,No,Sponsor-Investigator,41
19-1974.cc,Appetite and Exercise in Breast Cancer Survivors,1.997260273972603,Completed,Interventional,No,No,Sponsor,21
H19-02480,BREast Cancer And Sexuality Treatment,3.9041095890410964,"Active, not recruiting",Interventional,No,No,Principal Investigator,120
190025,Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies,1.9835616438356167,Enrolling by invitation,Observational,No,No,Sponsor,500
HS-10342-201,A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer,2.252054794520548,Not yet recruiting,Interventional,No,No,Sponsor,20
2020-01-mp-BUS,Multi-parametric Breast Ultrasound Imaging as a Potential Biomarker for Breast Cancer,1.0767123287671232,Completed,Interventional,No,No,Sponsor,100
AAAS9859,Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI),3.282191780821918,Recruiting,Interventional,No,No,Principal Investigator,36
IRB202000746,"A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)",9.005479452054795,"Active, not recruiting",Interventional,Yes,No,Sponsor,65
108818,Early Detection of Cardiac Damage With CMR in Women With Breast Cancer,1.082191780821918,Unknown status,Observational,No,No,Sponsor,55
CBCSG041,Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction,5.0849315068493155,Not yet recruiting,Interventional,No,No,Principal Investigator,80
WEBAPPAC,Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer,4.498630136986302,Recruiting,Interventional,No,No,Sponsor,438
PILHLE-001,"Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial",7.005479452054795,Recruiting,Interventional,No,No,Principal Investigator,48
21-579,Low-field MRI for Breast Cancer Screening,2.0027397260273974,Not yet recruiting,Interventional,No,Yes,Principal Investigator,40
A011801,"T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial",14.323287671232876,Recruiting,Interventional,Yes,No,Sponsor,1031
Maple Tree Exercise,Individualized Exercise Oncology Program for Newly Diagnosed Breast Cancer Patients,2.276712328767123,Unknown status,Interventional,No,No,Sponsor-Investigator,70
ERC/2019/10/05,Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria,3.736986301369863,Recruiting,Interventional,No,No,Sponsor,600
A5481151,Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor,0.0,Completed,Observational,,,Sponsor,1
22145,Effects a Honey Based Syrup on Blood Parameters in Patients With Breast Cancer,0.30684931506849317,Completed,Interventional,No,No,Principal Investigator,60
ICS Maugeri - CE 2202,Standard Silicone-based vs. B-LiteÂ® Light Weight Breast Implant After Total Mastectomy and Radiotherapy for Breast Cancer,3.0821917808219177,Completed,Interventional,No,No,Sponsor,49
TCHP,Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer,2.0000000000000004,Unknown status,Interventional,No,No,Sponsor,100
19-001881,Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors,3.0931506849315067,Recruiting,Interventional,Yes,No,Sponsor,24
STU-2020-1043,Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib,3.6904109589041094,Recruiting,Interventional,Yes,No,Principal Investigator,60
D0819C00005,Lynparza Breast Cancer Clinical Experience Investigation,3.610958904109589,Completed,Observational,,,Sponsor,111
041-2018,Prehabilitation for Women Undergoing Pre-operative Chemotherapy for Breast Cancer,4.704109589041096,Completed,Interventional,No,No,Principal Investigator,63
RESCREEN,Optimized Rehabilitation Following Primary Breast Cancer Surgery,6.967123287671233,Recruiting,Interventional,No,No,Sponsor,643
NCI-2019-00048,"A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer",3.0191780821917806,Withdrawn,Interventional,Yes,No,Sponsor,0
IRB-57111,Mental Health Disparities in Spanish Speaking Latina Breast Cancer Patients,5.632876712328767,"Active, not recruiting",Interventional,No,No,Sponsor,31
2022-0959,Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery,5.33972602739726,Not yet recruiting,Interventional,No,No,Sponsor,225
I 60517,Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice,3.5643835616438357,Completed,Interventional,No,No,Sponsor,174
OSU-21185,Health Coaching-Based Navigation at the Conclusion of Treatment for the Support of Black Breast Cancer Survivors,1.1287671232876713,Recruiting,Interventional,No,No,Principal Investigator,40
A221803,Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy,3.547945205479452,Recruiting,Interventional,No,Yes,Sponsor,216
STUDY00003100,Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts,3.117808219178082,Recruiting,Interventional,Yes,No,Sponsor,36
IndonesiaU2022,The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer,2.4575342465753423,Recruiting,Interventional,No,No,Principal Investigator,26
FM-17-B01,Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer,8.775342465753425,"Active, not recruiting",Interventional,No,No,Sponsor,650
MC220303,Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women,9.849315068493151,Recruiting,Observational,No,No,Sponsor,50
STUDY00007842,Music as a Perioperative Therapy in Breast Cancer Patients,2.3013698630136985,Withdrawn,Interventional,No,No,Principal Investigator,0
STUDY00001007,Peer Support For Young Adult Women With High Breast Cancer Risk,4.882191780821918,Recruiting,Interventional,No,No,Sponsor,560
20-009279,Evaluating the Association Between Changes in the Gut Microbiome and Chemotherapy-Induced Nausea in Women Receiving Chemotherapy for Stage I-III Breast Cancer,3.0054794520547947,Recruiting,Observational,No,No,Sponsor,38
H19094,Effects of a Traditional Chinese Exercise Program on Symptom Cluster in Breast Cancer Patients,0.9232876712328767,Completed,Interventional,No,No,Principal Investigator,72
20-133,A Study of PRP Treatment for Hair Loss After Cancer Therapy in Women With Breast Cancer,3.942465753424658,"Active, not recruiting",Interventional,No,No,Sponsor,30
KKKR-Neulasta OS-01,An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (NeulastaÂ®),3.4493150684931506,Completed,Observational,No,No,Sponsor,1300
16-185671,Integrative Approaches to Cancer Survivorship: Project 3,1.789041095890411,Completed,Interventional,No,No,Sponsor,30
M18BEL,Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO,7.265753424657534,Recruiting,Interventional,No,No,Sponsor,80
"UPCC# 15122, IRB # 852205",CAR T Cells in Mesothelin-Expressing Breast Cancer,14.997260273972604,Recruiting,Interventional,Yes,Yes,Sponsor,12
HCC 20-243,Apollo Device for Metastatic Breast Cancer (MBC),5.079452054794521,Recruiting,Interventional,No,Yes,Sponsor-Investigator,30
249571,Mini-AFTERc Intervention for Fear of Cancer Recurrence,1.2219178082191782,Unknown status,Interventional,No,No,Principal Investigator,133
Alaa_Negm_MSc_2023,"Effect of Kinesiotaping Augmented By Resistive Exercise on Fatigue, Physical Strength, Quality of Life in Breast Cancer Survivors",0.3287671232876712,Not yet recruiting,Interventional,No,No,Principal Investigator,40
SunYatsenU2H-LQ3,"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC",12.002739726027396,Recruiting,Interventional,No,No,Principal Investigator,460
LCCC1745,"ARFI, VisR and DDAI Ultrasound for Improving Discrimination of Malignant and Unresponsive Breast Cancer",3.1835616438356165,Completed,Observational,No,Yes,Sponsor,45
BYEC20211201,Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC,2.3808219178082193,Recruiting,Interventional,No,No,Principal Investigator,128
18-140,Sexual Health and Rehabilitation After Ovarian Suppression Treatment,1.0000000000000002,Completed,Interventional,No,No,Principal Investigator,20
2022-0378,Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care,5.624657534246575,Recruiting,Interventional,No,No,Principal Investigator,220
20-221,Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity,4.843835616438356,Recruiting,Interventional,No,No,Principal Investigator,160
IRB-58571,Analysis of Patient Understanding of Radiation Therapy Among Patients With Breast Cancer,0.726027397260274,Completed,Interventional,No,No,Sponsor,100
BPI-1178-2019-001,A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer,3.750684931506849,Recruiting,Interventional,No,No,Sponsor,122
Organoids Breast,Developing Breast (Cancer) Organoids,5.668493150684932,Recruiting,Observational,No,No,Sponsor,60
PUMCH-2020-EBC,A Prospective Cohort Study Comparing Disparity in Surgical Procedure (Wide Local Excision Only vs Any Other Surgery Procedures) Among the Elderly Breast Cancer Patients,7.002739726027397,Not yet recruiting,Observational,No,No,Sponsor,300
E-HHC-2016-0245,Adaptive Symptom Care Using Fish-Based Nutritional Directives Post Breast Cancer,3.9561643835616445,Suspended,Interventional,No,No,Principal Investigator,150
21656,"A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer",2.1506849315068495,Recruiting,Interventional,Yes,No,Sponsor,405
UC-0140/1901,Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer,7.978082191780823,Recruiting,Interventional,No,No,Sponsor,378
HE072-CSP-002,Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance,3.0027397260273974,Not yet recruiting,Interventional,No,No,Sponsor,136
ACCRU-BR-1801,T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer,1.2657534246575342,Withdrawn,Interventional,Yes,No,Sponsor,0
17-00890,Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC),4.000000000000001,"Active, not recruiting",Interventional,Yes,No,Sponsor,8
2020-01,Exercise Therapy During Radiotherapy,0.49863013698630143,Unknown status,Interventional,No,No,Principal Investigator,40
TransRosaLEE-IPC 2021-075,"Trans-RosaLEE Study: a Biomarker-directed, Translational Study",4.750684931506849,Not yet recruiting,Interventional,No,No,Sponsor,241
UMCC 2021.109,Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer,1.5123287671232877,Recruiting,Interventional,Yes,No,Sponsor,22
TROIKA,"A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to HerceptinÂ® in HER2+ Early Breast Cancer Patients",3.901369863013699,Completed,Interventional,No,No,Sponsor,503
2000024495,Text Messaging in Patients on Adjuvant Endocrine Therapy for Breast Cancer,4.109589041095891,"Active, not recruiting",Interventional,No,No,Sponsor,400
HMCC-BR22-001,Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC),5.8931506849315065,Recruiting,Interventional,Yes,No,Sponsor,36
I 1680021,Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer,2.0027397260273974,Not yet recruiting,Interventional,Yes,No,Sponsor,19
NCC1692,Anlotinib in Metastatic HER2 Negative Breast Cancer,1.6767123287671233,Completed,Interventional,No,No,Sponsor-Investigator,26
0201263,Hypofractionation And Ultra-Hypofractionation In Adjuvant Radiotherapy For Breast Cancer,2.0027397260273974,Unknown status,Interventional,No,No,Sponsor,100
19/002,"Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer",4.586301369863014,Recruiting,Interventional,No,No,Sponsor,31
CIH-TZS-20190912,Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China,3.7150684931506848,Recruiting,Observational,Yes,No,Sponsor,612
NCI-2019-06461,"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer",3.5671232876712327,Recruiting,Interventional,Yes,No,Sponsor,12
HNCH-BC001,The TP Regimen in the Treatment of Early Triple Negative Breast Cancer,4.010958904109589,Completed,Interventional,No,No,Principal Investigator,212
S-169,Complementary and Alternative Medicine on Mental Health in Breast Cancer Patients,1.3315068493150686,Unknown status,Interventional,No,No,Principal Investigator,250
ExtremeHypofractionationBreast,Postoperative Radiation of Patients With Breast Cancer in Extreme Hypofractionation.,13.002739726027396,Not yet recruiting,Observational,No,No,Principal Investigator,100
HCI103657,Merestinib on Bone Metastases in Subjects With Breast Cancer,1.4493150684931506,Terminated,Interventional,Yes,No,Sponsor,2
HS627-III,Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel,1.3917808219178083,Unknown status,Interventional,No,No,Sponsor,408
17782,A Study of Abemaciclib in Indian Women With Advanced Breast Cancer,2.024657534246576,Recruiting,Interventional,Yes,No,Sponsor,200
LQ004,Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer,1.5835616438356164,Unknown status,Interventional,No,No,Principal Investigator,29
KutahyaMSUcancer,Clinical Classification of Pain in Breast Cancer Survivors,0.25205479452054796,Recruiting,Observational,No,No,Principal Investigator,90
2021-A03166-35,Functional Evaluation After Breast Reconstruction With a Minimally Invasive Latissimus Dorsi Flap Following Radical Surgery for Breast Cancer.,2.506849315068493,Not yet recruiting,Interventional,No,No,Sponsor,32
BR01/01/22,Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer,4.002739726027397,Not yet recruiting,Interventional,No,No,Sponsor,51
POLAR-01,Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer,2.835616438356164,"Active, not recruiting",Observational,Yes,No,Sponsor,100
UMCC 2020.122,"Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer",2.326027397260274,Recruiting,Interventional,Yes,No,Sponsor,25
CA048-001,A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread,1.895890410958904,Completed,Interventional,Yes,No,Sponsor,12
NCI-2022-10810,"Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer",3.9835616438356167,Recruiting,Interventional,Yes,No,Sponsor,24
RG1004302,Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer,4.821917808219178,Recruiting,Interventional,Yes,No,Sponsor,24
Pro00100093,A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer,5.758904109589041,Recruiting,Interventional,Yes,No,Sponsor-Investigator,39
0201-21,Implantation of CEST and CESL MRI Methods for Detection of Breast Tumors,3.084931506849315,Not yet recruiting,Interventional,No,Yes,Principal Investigator,70
CORE,Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related Cardiotoxicity,0.0821917808219178,Terminated,Interventional,No,No,Sponsor,2
ENZENO-C-101,ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study),2.5178082191780824,Recruiting,Interventional,Yes,No,Sponsor,106
19206,Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.,3.7260273972602738,Recruiting,Interventional,Yes,No,Sponsor,40
NEO-R-IPC 2019-041,Real Time Molecular Analysis of Breast Cancer Receiving Neo-adjuvant Chemotherapy,7.167123287671233,Recruiting,Observational,No,No,Sponsor,150
S00748-NIM,Ice Plant Intensive Cream for the Prevention of Hand-Foot Syndrome in Breast Cancer: Pilot Randomized Controlled Trial,0.9972602739726029,Not yet recruiting,Interventional,No,No,Sponsor,36
ATENTO19,Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO),2.0000000000000004,Recruiting,Interventional,No,No,Principal Investigator,56
STUDY00002373,Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy,2.665753424657534,Not yet recruiting,Interventional,No,Yes,Principal Investigator,50
SCHBCC-N048,Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.,3.7972602739726034,Recruiting,Interventional,No,No,Principal Investigator,223
3-2020-0343,Primary Surgical Prevention of Breast Cancer-related Lymphedema,7.0,Not yet recruiting,Interventional,No,No,Principal Investigator,72
KSF2-1707,Follow-up of Sequential Chemotherapy and Stimulation for Fertility Preservation in Young Patients With Breast Cancer,9.783561643835617,"Active, not recruiting",Interventional,No,No,Sponsor,132
UW 19-045,Acupuncture for Insomnia in Breast Cancer Patients Undergoing Chemotherapy,2.3698630136986303,Unknown status,Interventional,No,No,Principal Investigator,138
22-074,A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer,4.997260273972603,Recruiting,Interventional,Yes,No,Sponsor,55
09.2018.,Diagnostic Accuracy of Dermal Thickness in Lymphedema,0.22465753424657534,Completed,Observational,No,No,Sponsor,43
lithium and breast cancer,Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients,1.832876712328767,Completed,Interventional,No,No,Principal Investigator,50
18549,Remotivation Process for Improving Adherence to Lymphedema Treatment Programs in Patients With Breast Cancer-Related Lymphedema,4.953424657534247,"Active, not recruiting",Interventional,No,No,Sponsor,19
EGC002,Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer,3.265753424657534,Completed,Interventional,Yes,No,Sponsor,807
Multimodal Project,Multimodal Project,0.6657534246575343,Not yet recruiting,Interventional,No,No,Principal Investigator,80
201710109,Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy,4.043835616438357,"Active, not recruiting",Interventional,Yes,No,Sponsor,18
2016-003518-28,Clinical Benefit of Spa Care on Severe Radiation-induced Fibrosis After Postoperative Radiotherapy for Breast Cancer,3.0027397260273974,Unknown status,Interventional,No,No,Sponsor,142
BR01/02/19,Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA),5.136986301369863,Recruiting,Interventional,No,No,Sponsor,86
ZLiu,Radiomics of Mp-MRI Assessing NAC Outcome in Breast Cancer,3.8739726027397263,Unknown status,Observational,No,No,Principal Investigator,500
XJLL-KY20212136,RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer,3.846575342465754,Not yet recruiting,Interventional,No,No,Sponsor,20
2017-073,The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer,5.23013698630137,"Active, not recruiting",Interventional,Yes,No,Sponsor-Investigator,24
CMUH107-REC3-102,Yoga for Aromatase Inhibitor-related Knee Pain Relief in Breast Cancer Patients,0.49041095890410963,Completed,Interventional,No,No,Sponsor,60
THALIA-01,Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study,3.336986301369863,Recruiting,Observational,Yes,No,Sponsor,100
C-MOT,Copenhagen Master Observational Trial,2.4164383561643836,Recruiting,Observational,Yes,No,Principal Investigator,2400
BC-P32,Development of Multi-specific Antibodies Based on Immune Microenvironment of Breast Cancer,2.0027397260273974,Not yet recruiting,Observational,No,No,Sponsor,60
HBO001,Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy,4.838356164383562,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,60
RG1718047,"Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer",3.5835616438356164,Withdrawn,Interventional,Yes,No,Sponsor,0
19-0448,XoftÂ® Intraoperative Radiotherapy (IORT) for Patients With Early-Stage Breast Cancer,8.005479452054795,Recruiting,Observational,No,No,Principal Investigator,60
2020-006,Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients,0.673972602739726,Completed,Interventional,No,No,Sponsor,13
TX05-03,"Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With HerceptinÂ® in HER2+ Early Breast Cancer",2.6082191780821917,Completed,Interventional,Yes,No,Sponsor,809
2016/65,Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer,7.002739726027397,"Active, not recruiting",Interventional,No,No,Sponsor,47
22-490,VS-6766+Abema+Fulv in Met HR+/HER- BC,5.857534246575343,Recruiting,Interventional,Yes,No,Sponsor-Investigator,63
HCRN BRE19-433,"A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer",3.252054794520548,"Active, not recruiting",Interventional,Yes,No,Sponsor-Investigator,1
19P.117,Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences,4.36986301369863,"Active, not recruiting",Interventional,No,No,Sponsor,3
S2020-09,Comparison of Microwave Ablation With Breast Conserving Surgery for Breast Tumor,2.695890410958904,Recruiting,Interventional,No,No,Principal Investigator,300
SYSKY-2022-445-01,"Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study",0.7479452054794521,Not yet recruiting,Observational,No,No,Principal Investigator,700
CGAprediting,The Value of Geriatric Assessments in Older Patients With Breast Cancer,7.087671232876712,Recruiting,Observational,No,No,Sponsor,200
J17118,Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC,5.953424657534247,Recruiting,Interventional,Yes,No,Sponsor,100
EQ132-201,A Study of Lerociclib in Participants With Advanced Breast Cancer,4.361643835616438,Recruiting,Interventional,Yes,No,Sponsor,100
UW21062,Remote Electronic Assessment of Survivors With Feedback Communication and Directed Referrals,0.9260273972602739,Completed,Interventional,No,No,Sponsor,30
ACT16106,"Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer",1.3123287671232877,Terminated,Interventional,Yes,No,Sponsor,105
2018/8361/I,MUltimodal Targeted Axillary Surgery,3.0657534246575344,Recruiting,Interventional,No,No,Sponsor,160
427 BC SDM,Enhancing Shared Decision-Making in Breast Cancer,4.057534246575343,Completed,Interventional,No,No,Principal Investigator,140
20210901-jiangchunling,A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases,2.5863013698630137,Recruiting,Interventional,No,No,Sponsor,362
CH-BC-086,Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC,1.0000000000000002,Recruiting,Observational,No,No,Principal Investigator,600
2023-3181,Thoracic Paravertebral Block Anesthesia for Breast Cancer Surgery,1.073972602739726,Recruiting,Interventional,No,No,Principal Investigator,68
IRB00154162,Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection,1.9260273972602742,Recruiting,Observational,Yes,No,Sponsor,92
2020KT151,Trastuzumab(HenliusÂ®) Combined With Pertuzumab(PerjetaÂ®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab,2.5863013698630137,Recruiting,Observational,Yes,No,Principal Investigator,60
01,Self-applied Acupressure for Arthralgia-fatigue-sleep Disturbance in Breast Cancer,0.8136986301369863,Recruiting,Interventional,No,No,Principal Investigator,51
CHUV-DO-0009-CyberImmunoBreast,CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC),4.652054794520548,Recruiting,Interventional,No,No,Principal Investigator,40
NCC3222,Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC,2.5013698630136987,Recruiting,Observational,No,No,Principal Investigator,400
PEMBRACA,Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA),4.136986301369864,Completed,Interventional,No,No,Sponsor-Investigator,22
170115,T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery,5.2027397260273975,"Active, not recruiting",Interventional,Yes,No,Sponsor,12
IJB-EBC-Decrescendo-2020,De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade,7.123287671232877,Recruiting,Interventional,Yes,No,Sponsor,1065
ANG1005-CLN-07,ANG1005 in Leptomeningeal Disease From Breast Cancer,1.0027397260273974,Not yet recruiting,Interventional,Yes,No,Sponsor,150
FASCINATE-N,Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy,2.835616438356164,Recruiting,Interventional,No,No,Principal Investigator,716
Manual Therapy BCS,Effects of Manual Therapy on Chronic Pain and Functionality of Breast Cancer Survivors,0.3232876712328767,Terminated,Interventional,No,No,Principal Investigator,10
KUH5101090,"The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients",0.0,Withdrawn,Interventional,No,No,Principal Investigator,0
17471,Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer,5.545205479452055,"Active, not recruiting",Interventional,Yes,No,Sponsor,2
BAIBU-FTR-ED-001,Effect of Different Bandage Interface Pressures on Breast Cancer Related Lymphedema,2.9643835616438357,Completed,Interventional,No,No,Principal Investigator,21
STUDY00018239,Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer,2.547945205479452,Completed,Interventional,Yes,No,Principal Investigator,3
NCO-21001,Comparison of [68Ga]GaFAPI-46 PET/CT and [18F]FDG PET/CT Findings in Breast Carcinoma,1.821917808219178,Recruiting,Interventional,No,No,Principal Investigator,100
16-015,Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib,3.515068493150685,"Active, not recruiting",Interventional,Yes,No,Sponsor-Investigator,7
2170-29-02/1-2,The Immune Response of Breast Cancer Patients Treated With Levobupivacaine Using Paravertebral or Superficial Chest Blocks,2.671232876712329,Not yet recruiting,Interventional,No,No,Principal Investigator,100
22-10590-BO,Identification of Novel Inflammation-related Biomarkers for Early Detection of Anthracycline-induced Cardiotoxicity in Breast Cancer Patients,1.6684931506849314,Not yet recruiting,Observational,No,No,Sponsor,180
GBG 97,Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer,4.380821917808219,"Active, not recruiting",Interventional,No,No,Sponsor,150
DOT-1871-KIE-0120-I,Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW,1.747945205479452,Withdrawn,Interventional,No,No,Sponsor,0
IIT-2017-MM-BRST-Her2noRT,Omission of Radiation in Patients With Her-2 Positive Breast Cancer,8.857534246575343,Recruiting,Interventional,No,Yes,Sponsor,78
KaratayUHaticeTEZ,The Effect of Training Given by Mobile Application to Women Undergoing Breast Surgery,0.5013698630136987,Completed,Interventional,No,No,Sponsor,81
YBCSG-21-01,Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab,3.128767123287671,Recruiting,Interventional,No,No,Principal Investigator,240
4-2017-1108,"Cosmetic Outcome, Patient-reported Outcomes, and Reconstruction-related Complications in Breast Cancer Women Treated With or Without Post-mastectomy Radiation Therapy",6.002739726027397,Recruiting,Observational,No,No,Sponsor,500
UniUrb_21/10.07.2019,Movement and Health Beyond Care (MoviS),5.901369863013699,Recruiting,Interventional,No,No,Principal Investigator,172
Shengjing-LJY02,DFS and QOL After Modified Radical Mastectomy vs. Expanded Mckissock Surgery for EIC of the Breast,6.923287671232877,Recruiting,Interventional,No,No,Principal Investigator,200
2016-6346,Comparison of Healthy Diets on Breast Cancer Markers,2.1780821917808217,Completed,Interventional,No,No,Principal Investigator,11
N19TON,Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients,6.8191780821917805,Recruiting,Interventional,No,No,Sponsor,52
Soh-Med-23-02-16,Efficacy of Neoadjuvant Endocrine Therapy Compared to Chemotherapy in Breast Cancer Patients,2.336986301369863,Not yet recruiting,Interventional,No,No,Principal Investigator,100
SIMR_onc19_IIS_DAndre_Ashwaga,Ashwagandha for Cognitive Dysfunction,2.835616438356164,Unknown status,Interventional,Yes,No,Principal Investigator,80
PROICM 2018-02 SKY,Feasibility Study: Yoga Educational Project,0.9123287671232877,Completed,Interventional,No,No,Sponsor,24
GRASPA-TNBC-2018-02,Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2),2.8,Terminated,Interventional,No,No,Sponsor,27
NCI-2016-01293,Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer,5.219178082191781,"Active, not recruiting",Interventional,Yes,No,Sponsor,39
BOOG 2021-01 SEQUEL-Breast,SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast),5.750684931506849,Recruiting,Interventional,No,No,Sponsor,130
2020-1138,A Study on the Effectiveness of WeChat-based Online Education to Reduce Perioperative Anxiety in Breast Cancer Patients,1.158904109589041,Completed,Interventional,No,No,Principal Investigator,392
432-17,Facilitating Oncology Patient-Clinician Communication Via E-health Innovations,1.884931506849315,Completed,Interventional,No,No,Principal Investigator,31
20170770,"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer",6.887671232876713,Recruiting,Interventional,Yes,No,Sponsor,162
GATTUM -1,Gated Radiotherapy in Left Sided Breast Cancer Patients,1.5863013698630137,Unknown status,Observational,,,Principal Investigator,150
YX2021-070(F1),Effect of Intravenous S-ketamine on Opioid Consumption,1.747945205479452,Recruiting,Interventional,No,No,Principal Investigator,825
RI-002,Parallel Comparison of 18 Gene Classifiers and Oncotype DX (Nanostring),0.4191780821917808,Completed,Observational,No,No,Sponsor,138
LCI-BRE-MTN-NIR-001,LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer,4.756164383561644,Withdrawn,Interventional,Yes,No,Sponsor,0
7119-001,A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001),7.668493150684933,"Active, not recruiting",Interventional,Yes,No,Sponsor,56
1B-16-11,Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer,6.005479452054795,Withdrawn,Interventional,No,No,Sponsor,0
PRO2,Evaluation of the Mediduxâ¢ Digital Health Application in Patients With HER2-positive Breast Cancer During Chemotherapy in Combination With HER2-targeted Therapy or Antibody-drug Conjugate Therapy.,1.5835616438356164,Recruiting,Interventional,No,No,Sponsor,585
KTI-21-01,Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC),1.5041095890410958,Not yet recruiting,Interventional,Yes,Yes,Sponsor,15
CDX-ONC-101,"A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer",2.0438356164383564,Not yet recruiting,Interventional,Yes,No,Sponsor,24
ICL-2022-1,Personalized Preventive Support for Cognitive Impairment in Non-Metastatic Breast Cancer (EFACog),2.1726027397260275,Not yet recruiting,Interventional,No,No,Sponsor,56
1070741-1,Subclinical Lymphedema Treatment Study,7.673972602739727,"Active, not recruiting",Interventional,No,No,Principal Investigator,267
MO42319,A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC),8.572602739726028,"Active, not recruiting",Interventional,Yes,No,Sponsor,96
2021-1031,"A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer",2.180821917808219,Recruiting,Interventional,No,No,Sponsor,36
MCC-19337,HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer,6.158904109589041,"Active, not recruiting",Interventional,Yes,No,Sponsor,31
18175,"A Study of Imlunestrant, Investigators Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer",5.909589041095891,Recruiting,Interventional,Yes,No,Sponsor,860
4090,Study Evaluating Flexitouch Plus With Connectivity on Compliance in 30 Patients With Breast Cancer-Related Lymphedema.,1.2684931506849315,Completed,Interventional,No,Yes,Sponsor,29
2021332GD,Contrast-enhanced Ultrasonography Combined With Blue Dye as Dual-tracer for Sentinel Lymph Node Biopsy,2.1671232876712327,Not yet recruiting,Interventional,No,No,Principal Investigator,350
18238,Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer,3.9397260273972607,Recruiting,Interventional,Yes,No,Sponsor,350
21152,Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer,1.2136986301369863,Recruiting,Interventional,Yes,No,Sponsor,200
BLTN-Ig,Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer,3.4821917808219176,"Active, not recruiting",Interventional,No,No,Sponsor,97
I 62218,Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer,4.397260273972603,"Active, not recruiting",Interventional,Yes,No,Sponsor,8
Pro00080769,Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA),3.73972602739726,Completed,Interventional,Yes,No,Principal Investigator,45
E2019316,A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer,2.0849315068493155,Unknown status,Interventional,No,No,Sponsor,43
22-364,Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer,5.002739726027397,Recruiting,Interventional,No,No,Sponsor,140
ISK-N103,"Safety and Efficacy of IV Nerofeâ¢ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer",1.6246575342465754,Withdrawn,Interventional,No,No,Sponsor,0
NCI-2019-02752,Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer,4.032876712328767,Recruiting,Interventional,Yes,No,Sponsor,204
STao-003,Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer,4.008219178082192,Not yet recruiting,Interventional,No,No,Principal Investigator,184
RECHMPL20_0130,Contraception and Cervical and Breast Cancer Screening in Obese Versus Non-obese Women,1.252054794520548,Completed,Observational,No,No,Sponsor,439
OSU-17122,Exercise and Diet Counseling Program in Improving Quality of Life in Stage I-III Breast Cancer Survivors,4.824657534246575,Recruiting,Interventional,No,No,Principal Investigator,30
SKB264-â¡-07,SKB264 +/- KL-A167 in Recurrent or Metastatic Triple-negative Breast Cancer,2.0027397260273974,Not yet recruiting,Interventional,No,No,Sponsor,95
LonghuaH,Clinical Study on Auricular Points Sticking Plus Chinese Medication for Hot Flashes in Breast Cancer Women,0.9068493150684932,Unknown status,Interventional,No,No,Principal Investigator,92
OTT 18-01,Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL),5.087671232876712,"Active, not recruiting",Interventional,No,No,Sponsor,211
ZL-1302-002,A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC,1.6356164383561644,Unknown status,Interventional,No,No,Sponsor,120
PTC-breastNAT,PTC Guiding Neoadjuvant Treatment in Breast Cancer,2.164383561643836,Not yet recruiting,Interventional,No,No,Principal Investigator,40
MCC-21-18633,Entertainment Media to Deliver Educational Messages About Mammography in Saudi Arabia,0.08767123287671233,Completed,Interventional,No,No,Sponsor,240
Fudan-P1-201701,PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients,3.6301369863013697,"Active, not recruiting",Interventional,No,No,Principal Investigator,31
CBYL719C2005,Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib,1.3342465753424657,Recruiting,Observational,,,Sponsor,100
2018-0473,Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer,4.583561643835616,Recruiting,Interventional,No,No,Sponsor,545
BCIG,Clinical Study of Imaging Genomics Based on Machine Learning for BCIG,3.0794520547945203,Not yet recruiting,Observational,No,No,Principal Investigator,1500
2019-0638,Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer,3.0767123287671234,Recruiting,Interventional,No,No,Sponsor,30
ZG-2021-002,ZetaFuseâ¢ Bone Graft in the Repair of Bone Defects From Metastatic Breast Cancer in the Spinal Vertebral Body,1.0000000000000002,Recruiting,Interventional,No,No,Sponsor,10
NCC1786,Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer,6.167123287671233,Recruiting,Interventional,No,No,Principal Investigator,60
NU 19B07,"SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer",0.0,Withdrawn,Interventional,Yes,No,Sponsor,0
LUT-RD-02-01,LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients,1.4547945205479451,Completed,Interventional,Yes,No,Sponsor,28
Neo-RT,Neo-RT: A Study Investigating Whether Changing the Sequence of Treatments (Starting Radiotherapy Followed by Hormone Therapy Before Surgery) is Feasible,4.76986301369863,Recruiting,Observational,No,No,Sponsor-Investigator,43
MEDOPP445,Preventive stRategy for IMMU132-relatED AEs in TNBC - PRIMED,2.852054794520548,Recruiting,Interventional,No,No,Sponsor,50
OSU-18174,A QoL Intervention for Young African American Breast Cancer Survivors,1.1643835616438356,Recruiting,Interventional,No,No,Principal Investigator,30
ICR-CTSU/2017/10065,PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer,6.134246575342465,Recruiting,Interventional,No,No,Sponsor,81
VICC BRE 18108,A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer,5.8191780821917805,Recruiting,Interventional,Yes,No,Principal Investigator,36
RIGAIN,RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer,11.372602739726027,Recruiting,Interventional,No,No,Principal Investigator,540
Survey_App,Anonymous Survey of Breast Cancer Patients Concerning Their Use of Medical Apps,0.915068493150685,Recruiting,Interventional,No,No,Principal Investigator,200
DR210090_SILENCE,Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea,1.9178082191780825,Not yet recruiting,Interventional,No,No,Sponsor,338
69HCL21_0552,NEOZOL_Follow-up Study,0.6684931506849315,Not yet recruiting,Observational,No,No,Sponsor,50
OSU-21035,Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors,4.178082191780822,Recruiting,Interventional,No,No,Principal Investigator,360
19-031,ADVANCE (A Pilot Trial),4.002739726027397,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,41
INCMNSZ REF 1239,Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients,3.750684931506849,Unknown status,Interventional,No,No,Sponsor,20
OSU-20101,A Quality of Life Intervention (Y-AMBIENT) for Young African American With Stage I-III Breast Cancer,2.5863013698630137,Recruiting,Interventional,No,No,Principal Investigator,40
UW18063,Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS,5.997260273972603,Recruiting,Interventional,Yes,No,Sponsor,12
N201912134,A Patient-centered Continuous and Interdisciplinary Shared Decision Making Approach for Breast Cancer Rehabilitation,1.0000000000000002,Unknown status,Interventional,No,No,Sponsor,264
SAHZhejiangU---Breast,Application of Radiomics in Breast Cancer,10.923287671232877,Recruiting,Observational,No,No,Sponsor,2000
IRST174.21,"Yoga on QOL Physiological Distress&Fatigue, on Patients Affected by Breast Cancer in Adjuvant Radiotherapy",2.673972602739726,Unknown status,Interventional,No,No,Sponsor,120
PEAR-TNBC_ Protocol_v2.0,Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment,2.5726027397260274,Recruiting,Observational,No,No,Sponsor,60
ML42876,The Efficacy and Safety of Neoadjuvant Trastuzumab Plus Taxane With and Without Pertuzumab Therapy,0.547945205479452,Recruiting,Observational,No,No,Sponsor-Investigator,1500
OSU-18201,Intensity Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Treating Patients With Lymph-Node Positive Breast Cancer,4.978082191780822,"Active, not recruiting",Interventional,No,Yes,Principal Investigator,61
H-1912-010-086,To Assess the Efficacy of the LYMPHA in the Prevention of Lymphedema Following Axillary Dissection for Breast Cancer,1.9863013698630139,Unknown status,Interventional,No,No,Sponsor,34
MHICC-2018-003,"Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia",4.0849315068493155,Recruiting,Observational,No,No,Sponsor,300
DAN-22220205,A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer,2.241095890410959,Recruiting,Interventional,Yes,No,Sponsor,30
UPCC 21118,"HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer",3.463013698630137,Recruiting,Interventional,Yes,No,Sponsor,54
IRB00049171,Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer,1.7068493150684931,Completed,Observational,No,No,Sponsor,25
MA-BC-II-002,Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer,3.5287671232876714,Recruiting,Interventional,No,No,Principal Investigator,208
I 2612022,Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer,4.002739726027397,Not yet recruiting,Interventional,Yes,No,Sponsor,25
M21CAR,DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy,14.843835616438357,Not yet recruiting,Interventional,No,No,Sponsor,595
IFOM-CPT008/2022/PO007,Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel,2.882191780821918,Recruiting,Interventional,No,No,Sponsor,37
RG1122380,STEMVAC in Patients With Early Stage Triple Negative Breast Cancer,1.452054794520548,Recruiting,Interventional,Yes,No,Sponsor,33
4070,A Study Evaluating FT-SW in Unilateral Breast Cancer-Related Lymphedema Patients,0.043835616438356165,Terminated,Interventional,No,Yes,Sponsor,2
RG1003977,Acute Exercise Intervention in Reducing Breast Cancer Risk in Healthy Participants,3.2684931506849315,Completed,Interventional,No,No,Sponsor,102
2022-0239,Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen,10.427397260273972,Recruiting,Observational,Yes,No,Sponsor,150
20190812,Succinylated Gelatin for Prevention of Fluid Retention in Patients With Breast Cancer Receiving Docetaxel Chemotherapy,1.082191780821918,Completed,Interventional,No,No,Principal Investigator,216
BabesBolyaiOncovox,A Guided Online Intervention to Improve Quality of Life in Breast Cancer Patients - a Randomised Clinical Trial,0.4575342465753425,Recruiting,Interventional,No,No,Principal Investigator,140
CADPT01A12101C,Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).,4.0191780821917815,Terminated,Interventional,Yes,No,Sponsor,64
V2011801,P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .,1.4986301369863013,Withdrawn,Interventional,Yes,No,Sponsor,0
R.18.02.33,Wide Margin vs. Narrow Margin in Postneoadjuvant Lumpectomy,7.005479452054795,Recruiting,Interventional,No,No,Principal Investigator,370
Exactis-05,RWD Study in HER2+ mBC Patients in Third-Line Therapy,0.6602739726027397,Completed,Observational,No,No,Sponsor,63
R21052,Factors Influencing Breast Cancer Resection Volumes And Their Impact on Treatment Outcome (FIBRATIO),2.8465753424657536,Recruiting,Observational,No,No,Sponsor,250
MCC-19-14621,Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx,2.9424657534246577,Completed,Interventional,No,No,Sponsor,12
I-19-04120,Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer,3.0246575342465754,Recruiting,Interventional,Yes,No,Sponsor,23
042001,"INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study",3.2164383561643834,Recruiting,Interventional,Yes,No,Principal Investigator,25
767/29-09-2017,Vaginal Laser Therapy in Breast Cancer Survivors,1.6684931506849314,Unknown status,Interventional,No,No,Principal Investigator,50
WSG-AM12,NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer,4.838356164383562,Not yet recruiting,Interventional,No,No,Sponsor,402
CSIIT-C37,Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer,1.3397260273972602,Not yet recruiting,Interventional,No,No,Sponsor,60
STUDY00002985,Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer,3.1945205479452055,Recruiting,Interventional,No,No,Principal Investigator,40
i 67518,Exercise and Nutrition Education in Improving Physical Function and Quality of Life in Older Breast Cancer Survivors,2.158904109589041,Terminated,Interventional,No,No,Sponsor,10
HCI153239,"Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC",4.734246575342466,Suspended,Interventional,No,No,Sponsor,80
268-2017,Assessment of Left-sided Cardiac Sparing Through the Use of 3-dimensional Surface Matching-based Deep Inspiration Breath Hold and Active Breathing Control,3.7041095890410958,Completed,Interventional,No,No,Principal Investigator,40
16-304,Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma,12.008219178082191,"Active, not recruiting",Interventional,No,Yes,Principal Investigator,400
2019-A02374-53,"Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast Cancer",2.7041095890410958,Unknown status,Interventional,No,No,Sponsor,220
2022-191,Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients,4.252054794520548,Not yet recruiting,Interventional,No,No,Principal Investigator,1206
NCI-2017-02320,"Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer",0.0,Withdrawn,Interventional,Yes,No,Sponsor,0
GIM25-CAPT,Atezolizumab Plus CArboplatin Plus Nab-paclitaxel,4.002739726027397,Recruiting,Interventional,No,No,Sponsor,104
ERC/2018/06/01,Case Control Study to Identify Modifiable Risk Factors for Colorectal and Breast Cancer in Nigeria,2.9726027397260273,Recruiting,Observational,No,No,Principal Investigator,800
ELA-0121,Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer,3.254794520547945,Recruiting,Interventional,Yes,No,Sponsor,106
844978,Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts,3.805479452054795,Recruiting,Observational,No,No,Principal Investigator,500
APPI2-PT-2020-AIMSS,Targeted Physiotherapeutic Treatment for Aromatase Inhibitor-associated Musculoskeletal Pain in Breast Cancer Survivors,3.128767123287671,Recruiting,Interventional,No,No,Principal Investigator,120
EDP1503-101,"A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors",2.8684931506849316,Completed,Interventional,Yes,No,Sponsor,69
S2020-300,Prospective Multicenter Study on Clinical Application of Sonazoid in Breast Tumor,1.1287671232876713,Recruiting,Observational,No,No,Principal Investigator,181
187519,"Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer",4.0630136986301375,Recruiting,Interventional,Yes,No,Sponsor-Investigator,150
OnerCengiz,The Effect of Mindfulness Program on Spiritual Well-BeingBreast Cancer Patients,0.7506849315068493,Completed,Interventional,No,No,Principal Investigator,70
PH-CP026,PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy,3.493150684931507,Completed,Interventional,No,No,Sponsor,67
B1432020000025,"Pain, Nutrition and Glycemic Response in Chronic Low Back Pain and Breast Cancer Survivors",2.243835616438356,Completed,Interventional,No,No,Principal Investigator,121
IFG-05-2019,Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO,3.5123287671232877,Recruiting,Interventional,Yes,No,Sponsor,89
CTP-BRST-01,Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases,7.846575342465754,Recruiting,Interventional,No,No,Sponsor,30
A221801,"Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial",4.6657534246575345,Not yet recruiting,Interventional,No,Yes,Sponsor,250
50619,Patient Outcomes From Second Film-readers and Test Threshold Relaxation in Breast Screening,5.249315068493151,Enrolling by invitation,Observational,No,No,Principal Investigator,10000000
2016-0538,Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer,4.5698630136986305,Recruiting,Interventional,Yes,No,Sponsor,28
2018/455,Stochastic Modulated Vibrations on Autonomic Nervous System of Breast Cancer Patients During Radiotherapy,1.3287671232876712,Unknown status,Interventional,No,No,Principal Investigator,130
MC2031,"Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer",1.819178082191781,Withdrawn,Interventional,Yes,No,Sponsor,0
2019-1237,Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy,4.380821917808219,Recruiting,Observational,No,No,Sponsor,110
9988,Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors,1.2410958904109588,Completed,Interventional,No,No,Sponsor,20
TN.32.1.17.SATF,Pilot Clinical Study on a Low-power Electromagnetic Wave Breast Imaging Device for Cancer Screening Purposes.,1.5753424657534247,Completed,Interventional,No,No,Sponsor,25
ACT-MBC,ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC),2.0547945205479454,Recruiting,Observational,No,Yes,Sponsor,65
KN026-US-I-001,KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer,3.5397260273972604,"Active, not recruiting",Interventional,Yes,No,Sponsor,22
MC1931,Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer,4.095890410958905,Recruiting,Interventional,Yes,No,Sponsor,29
CBTMMUH,Effect of Perioperative CBT on Chronic Persistent Postsurgical Pain Among Breast Cancer Patients,1.7534246575342465,Completed,Interventional,No,No,Principal Investigator,48
20180259-01H,Mid-point Transverse Process to Pleura Block for Breast Cancer Surgery: A Randomized Controlled Trial,4.000000000000001,Recruiting,Interventional,No,No,Sponsor,150
2017-0502,M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer,6.416438356164384,"Active, not recruiting",Interventional,Yes,No,Sponsor,20
PHRI.SCHOLAR-2,Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction,4.421917808219178,Recruiting,Interventional,No,No,Sponsor,130
OSU-18317,Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer,3.0602739726027397,Recruiting,Interventional,Yes,No,Principal Investigator,20
e-OTCAT20,Telehealth Program to Prevent Cancer and Chemotherapy-related Cognitive Impairment.,2.9972602739726026,Enrolling by invitation,Interventional,No,No,Principal Investigator,98
23-050,A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction,5.005479452054795,Not yet recruiting,Interventional,Yes,No,Sponsor,50
287482,ARTISS a Single-centre Randomised Control Study,1.4958904109589042,Recruiting,Interventional,No,No,Sponsor,138
19447,Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors,1.0000000000000002,Withdrawn,Interventional,No,No,Sponsor,0
20G.093,"Tai Chi for Relieving Aromatase Inhibitor-Induced Arthralgia in Patients With Stage I-III Breast Cancer, the TaiChi4Joint Trial",1.7863013698630137,Completed,Interventional,No,No,Sponsor,39
ANI251_BCS-PI,PI-targeted PNE+MI Compared to BIOMEDICAL Education in BCS,3.0027397260273974,Recruiting,Interventional,No,No,Sponsor,156
NCI-2019-05187,"Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer",4.002739726027397,Recruiting,Interventional,Yes,No,Sponsor,42
OUMK59829,Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer,5.0,Not yet recruiting,Interventional,No,No,Principal Investigator,23
STUDY00000057,"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor",4.671232876712328,"Active, not recruiting",Interventional,Yes,No,Sponsor,19
LACOG 0122,Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study,1.16986301369863,Not yet recruiting,Observational,No,No,Sponsor,400
239531,Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors,2.9863013698630136,Recruiting,Interventional,Yes,No,Sponsor,60
Castle06(BC),Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy,1.9205479452054797,Recruiting,Interventional,No,No,Principal Investigator,15
STUDY02000934_1,A Single Arm Pilot Study to Refine a Novel Approach to Exercise Promotion Based on Affect-regulation,0.8410958904109589,Completed,Interventional,No,No,Principal Investigator,37
IFG-01-2022,"Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients",3.9726027397260277,Recruiting,Interventional,No,No,Sponsor,1000
PI-0171-2020,Pain Treatment in a Breast Cancer Population. PaiNEd Study.,1.4109589041095891,Recruiting,Interventional,No,No,Principal Investigator,72
STU-2019-0529,Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM),2.3972602739726026,Terminated,Interventional,Yes,No,Principal Investigator,6
NBC Sur001,Targeted Biopsy of Carbon Nanoparticles Labelled Axillary Node for cN+ Breast Cancer,3.6,Recruiting,Interventional,No,No,Principal Investigator,100
RG1718049,Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy,1.9123287671232878,Terminated,Interventional,No,No,Sponsor,15
55457122.3.0000.5330,Onco-Genomas Brasil: Mapping Breast and Prostate Cancer in the Brazilian Public Health System,1.1424657534246576,Recruiting,Observational,No,No,Sponsor,550
2020-A02045-34,The E-consult Application for Patients With Breast Cancer: Interest in Empathy and Empowerment of Patients.,1.895890410958904,Completed,Observational,No,No,Sponsor,206
ESPvsPECS/AOP,Comparison of Erector Spinae Plane Block With PECS II Block in Patients Undergoing Breast Cancer Surgery,1.0000000000000002,Withdrawn,Interventional,No,No,Principal Investigator,0
MP-12-2021-2565,Single Pre-Operative Radiation Therapy - With Delayed or No Surgery (SPORT-DNS),7.235616438356164,Recruiting,Interventional,No,No,Principal Investigator,80
S1703,S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer,19.476712328767125,Recruiting,Interventional,No,No,Sponsor,1320
OSU-19152,EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer,1.2328767123287672,Recruiting,Interventional,No,Yes,Principal Investigator,30
2018-11-128,Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer,4.000000000000001,Recruiting,Interventional,No,No,Principal Investigator,136
OSU-20340,Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer,1.8383561643835618,Recruiting,Interventional,Yes,No,Principal Investigator,50
PAXMAN,Cooling Cap Trial to Prevent Permanent Chemotherapy-induced Alopecia in Breast Cancer Patients,1.6849315068493151,Completed,Interventional,No,Yes,Principal Investigator,170
MC210303,Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast Cancer,3.901369863013699,Recruiting,Interventional,No,Yes,Principal Investigator,5
2020-01097,Effect of Heavy-load Resistance Training During Chemotherapy on Muscle Cellular Outcomes,4.076712328767123,"Active, not recruiting",Interventional,No,No,Principal Investigator,40
NL80749.058.22 DIRECT 2,"Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer",9.008219178082191,Recruiting,Interventional,No,No,Principal Investigator,240
NCI-2022-04956,"Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer",3.0027397260273974,Recruiting,Interventional,Yes,No,Sponsor,57
IRB-2022-329,Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency,2.83013698630137,Not yet recruiting,Interventional,No,No,Principal Investigator,50
N20ESP,Ultrasound-guided Erector Spinae Plane Block Versus Paravertebral Block in Breast Cancer Patients Undergoing Mastectomy With Immediate Reconstruction - a Non-inferiority Trial,1.5835616438356164,Recruiting,Interventional,No,No,Sponsor,100
SMC2018-09-029-003,The Effects of Anesthetics on Persistent Pain Following Breast Cancer Surgery,0.9972602739726029,Completed,Observational,No,No,Sponsor,89
UZBRU_VHH1_3,Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients,5.673972602739726,Recruiting,Interventional,No,No,Sponsor,55
17753,T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer,4.235616438356165,Recruiting,Interventional,Yes,No,Principal Investigator,25
35945/10/22,Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients,2.0027397260273974,Enrolling by invitation,Interventional,Yes,No,Principal Investigator,56
2019-5382,Fruit and Vegetable Intervention in Lactating Women to Reduce Breast Cancer Risk,4.441095890410959,Recruiting,Interventional,No,No,Sponsor,400
IRB00105944,"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis",4.504109589041096,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,38
IRB202201483,Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors,0.5589041095890411,Recruiting,Interventional,No,No,Sponsor,28
MC18C3,Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer,4.205479452054795,Recruiting,Interventional,Yes,No,Sponsor,18
2022-376,Digital Cognitive Behavioral Therapy for Insomnia for Chronic Insomnia in Breast Cancer Survivors,2.336986301369863,Not yet recruiting,Interventional,No,No,Principal Investigator,264
2019-1042,Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer,8.608219178082193,Recruiting,Observational,No,No,Sponsor,62
20-002712,Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer,4.273972602739726,Recruiting,Interventional,Yes,No,Sponsor,20
Gabapentin RCT,Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy,1.997260273972603,Unknown status,Interventional,Yes,No,Sponsor,46
FS-CY1502-Ph1-01,Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.,5.6438356164383565,Recruiting,Interventional,No,No,Sponsor,297
167514,Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib,4.0630136986301375,Completed,Interventional,Yes,No,Principal Investigator,11
G1T48-01,"G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer",4.394520547945206,Completed,Interventional,Yes,No,Sponsor,107
PH-CP032,PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients,0.46301369863013697,Recruiting,Interventional,No,No,Sponsor,36
2018-0062,Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer,4.676712328767123,Recruiting,Interventional,Yes,No,Sponsor,60
URomLS-2019a,The Recovery of Reaching Movement in Breast Cancer Survivors: Two Different Rehabilitative Protocols in Comparison,1.526027397260274,Completed,Interventional,No,No,Principal Investigator,66
ODO-TE-B201,"Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC",2.347945205479452,Terminated,Interventional,Yes,No,Sponsor,152
ReMig,Rehabilitation on Equal Terms - The ReMig Study,2.345205479452055,Recruiting,Observational,No,No,Sponsor,140
MAMMoutreach,Opt-in vs. Opt-out for Breast Cancer Screening,0.3698630136986301,Not yet recruiting,Interventional,No,No,Principal Investigator,871
EVE-CWM-01,Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study,0.3315068493150685,Completed,Observational,,,Principal Investigator,14
SAFE-FORWARD,Safety of Ultra-hypofractionated Whole Breast Irradiation After Breast-conserving Surgery,1.0027397260273974,Recruiting,Observational,No,No,Principal Investigator,60
20-222,Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy,1.9205479452054797,Recruiting,Interventional,No,No,Principal Investigator,30
20-001275,"Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer",4.978082191780822,Recruiting,Interventional,Yes,No,Sponsor,88
2018-8984,Low Energy Dissection Vs. Electrocautery in Lumpectomy Shaved Surgical Margins,1.2547945205479452,Unknown status,Observational,No,Yes,Sponsor,20
OSU-22083,Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer,2.0493150684931507,Recruiting,Interventional,No,No,Principal Investigator,40
CF22200A,Effects of an Exercise Intervention on Taxane-induced Peripheral Neuropathy in Breast Cancer Survivors,1.082191780821918,Not yet recruiting,Interventional,No,No,Sponsor,88
2018-0550,Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy,4.964383561643835,"Active, not recruiting",Interventional,Yes,No,Sponsor,6
3543,Effectiveness of Ultrasound Guided PECS Block on Opioid Consumption and Patient Satisfaction Through Adequate Pain Control Following Breast Cancer Surgery.,1.6602739726027398,Recruiting,Interventional,No,No,Principal Investigator,70
EstroTEP COMPARE,Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES,1.0876712328767124,Unknown status,Interventional,No,No,Sponsor,25
230/HÄÄÄ-ÄHYD,2D Speckle-tracking Echocardiography in Chemotherapy-induced Cardiomyopathy With Cardiovascular Risk Factors,2.789041095890411,Recruiting,Observational,No,No,Sponsor,300
2020-0715,Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer,6.813698630136987,Recruiting,Interventional,Yes,No,Sponsor,30
NCI-2019-06088,Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones,3.5095890410958903,Recruiting,Interventional,Yes,No,Sponsor,70
MA-BC-II-037,Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02),3.621917808219178,Recruiting,Interventional,No,No,Principal Investigator,120
A5481152,First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.,7.476712328767123,Recruiting,Observational,,,Sponsor,1900
S2007,Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases,5.964383561643835,Recruiting,Interventional,Yes,No,Sponsor,44
LCZ696ABM001.001,Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM),5.002739726027397,Not yet recruiting,Interventional,No,No,Sponsor,600
2018-0127,Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer,2.3835616438356166,Unknown status,Interventional,Yes,No,Sponsor,50
19-004024,RBX7455 Before Surgery for the Treatment of Operable Breast Cancer,5.298630136986302,"Active, not recruiting",Interventional,Yes,No,Sponsor,30
ANG-002,Harvest of CTCs From MBC Patients Using the Parsortixâ¢ PC1 System,1.7589041095890412,Completed,Observational,No,Yes,Sponsor,421
115300-20-52703,Early Rehabilitation for Breast Cancer - A Randomized Control Trial,1.7506849315068493,Unknown status,Interventional,No,No,Principal Investigator,32
MC1635,Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery,5.394520547945206,"Active, not recruiting",Interventional,Yes,No,Sponsor,82
IIT2019-21-Basho-TOPAZ,TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases,2.0027397260273974,Withdrawn,Interventional,Yes,No,Sponsor-Investigator,0
81603703,Effects of Infrared Laser Moxibustion on Cancer-related Fatigue in Breast Cancer Patients,3.1041095890410957,Completed,Interventional,No,No,Sponsor,140
38RC20.120,"Complications After Lumpectomy, Sentinel Node and Radiotherapy in Breast Cancer Patients and Physiotherapy Care",0.6602739726027397,Completed,Observational,No,No,Sponsor,71
BTCRC BRE15-024,Ribociclib and Bicalutamide in AR+ TNBC,6.326027397260274,Recruiting,Interventional,Yes,No,Sponsor-Investigator,37
2021-375,Efficacy of Metformin as Preventive Treatment in Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients,0.5506849315068493,Completed,Interventional,No,No,Principal Investigator,76
3474028/2019,Effects of the Anchor System in the Postural Stability,4.002739726027397,Recruiting,Interventional,No,No,Sponsor-Investigator,80
2020-0245,"Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial",0.947945205479452,Withdrawn,Interventional,Yes,No,Sponsor,0
18-000427,"Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted",4.980821917808219,"Active, not recruiting",Interventional,Yes,No,Sponsor,6
CASE11119,Evaluating the Effectiveness of an Individualized Nutrition and Physical Activity Counseling Program,2.9013698630136986,Recruiting,Interventional,No,No,Sponsor,60
ZLYNXM202014,Identification and Preservation of Arm Lymphatics,5.282191780821917,Recruiting,Interventional,No,No,Principal Investigator,1200
19.07,ImmunoBreast - A Phase Ib Study,3.0821917808219177,Recruiting,Interventional,No,No,Sponsor-Investigator,20
REaCT-Low Risk HER-2,A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer,3.03013698630137,Completed,Interventional,No,No,Sponsor,51
D19160,Lumpectomy Specimen Margin Evaluation With Tomography and Structured Light Imaging,2.1068493150684935,Completed,Observational,No,No,Principal Investigator,100
PRO00035701,"Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer",6.2,Withdrawn,Interventional,Yes,No,Principal Investigator,0
REaCT-CHRONO,Evaluating the Dose Timing (Morning vs Evening) of Endocrine Therapy and Its Effects on Tolerability and Compliance,2.0876712328767124,"Active, not recruiting",Interventional,No,No,Sponsor,247
Acu-CIPN,Acupuncture in Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer,3.249315068493151,Recruiting,Interventional,No,No,Principal Investigator,102
202104085,Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma,7.887671232876714,Recruiting,Interventional,No,Yes,Sponsor,130
ZL-MG-BC-001,A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC,0.6712328767123288,Completed,Interventional,No,No,Sponsor,16
P170104J,"A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer",3.931506849315069,Unknown status,Interventional,No,No,Sponsor,54
Pro00104214,Well-Being After Breast Cancer Surgery,3.8958904109589048,Recruiting,Interventional,No,No,Sponsor,564
CLEE011AIT01,"Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant",6.413698630136986,"Active, not recruiting",Interventional,No,No,Sponsor,287
MedOPP150,"First Line Atezolizumab, Paclitaxel, and Bevacizumab (AvastinÂ®) in mTNBC",3.1561643835616437,Recruiting,Interventional,No,No,Sponsor,100
ODO-TE-B202,Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC,1.9589041095890414,Terminated,Interventional,Yes,No,Sponsor,294
IO Panel,Tumor Immune Mechanism of Axillary Lymph Node Metastasis in Early Luminal Type A Breast Cancer,1.6684931506849314,Unknown status,Observational,No,No,Sponsor,120
Study00146761,Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers,2.0794520547945208,Recruiting,Interventional,Yes,No,Sponsor-Investigator,20
17-546,Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC,7.536986301369863,"Active, not recruiting",Interventional,Yes,No,Sponsor-Investigator,33
DRACARYS,Dragonboat Activity for Breast Cancer,0.3780821917808219,Completed,Interventional,No,No,Sponsor,32
PA18-1077,"Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery",3.8630136986301373,Recruiting,Observational,No,No,Sponsor,600
RIPH2_BREYSSE_ETAPH,"Therapeutic Education and Nursing Support Program for Supportive Care, in Patients Treated With Hormone Therapy for Non-metastatic Breast Cancer",2.9808219178082194,Recruiting,Interventional,No,No,Sponsor,300
I 60217,Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects,4.668493150684932,Recruiting,Interventional,No,No,Sponsor,200
21-001819,"Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer",2.9863013698630136,Recruiting,Interventional,Yes,No,Sponsor,18
ARC-2 (AB928CSP0002),A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies,2.7150684931506848,Completed,Interventional,Yes,No,Sponsor,35
IRB00076577,Oral Aromatase Inhibitors Modify the Gut Microbiome,1.4273972602739726,Recruiting,Observational,No,No,Sponsor,25
RJ-101-RCT-001,Study to Investigate the Effect of AB-101 in Breast Cancer Survivors,1.2602739726027397,Completed,Interventional,Yes,No,Sponsor,3
KEK 2021-D0051,HER2-directed Biosimilar in Breast Cancer: Real World ePRO,1.5424657534246575,Recruiting,Observational,No,No,Sponsor,60
SCHBCC-N046,FUSCC Refractory TNBC Platform Study (FUTURE2.0),3.254794520547945,Not yet recruiting,Interventional,No,No,Principal Investigator,120
2021-1151-002,OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk,9.90958904109589,Recruiting,Interventional,No,No,Principal Investigator,418
Aqua POLO-IPC 2019-028,Feasibility Study of an Adapted and Supported Water Polo Program to Reduce Fatigue Related to Cancer and Improve Psychological and Social Recovery in Patients With Breast Cancer Remission,0.7972602739726027,Unknown status,Interventional,No,No,Sponsor,24
OSU-20408,An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors,3.1671232876712327,Recruiting,Interventional,No,No,Principal Investigator,40
21D.625,Intermittent Fasting for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery,1.7616438356164383,Suspended,Interventional,No,No,Sponsor,55
TNBC-NEO,Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC,6.980821917808219,Withdrawn,Interventional,No,No,Principal Investigator,0
RD19/125787,Guide for Prioritisation of Patients for Referral to Breast Clinics,3.0,Suspended,Observational,No,No,Sponsor,4000
13/21,Continuous Pectoral Nerve Block in Breast Cancer Surgery,0.2958904109589041,Completed,Interventional,No,No,Principal Investigator,48
NCI-2017-01960,Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer,3.778082191780822,Completed,Interventional,Yes,No,Sponsor,24
USB_22 Trial,Serratus Anterior Plane Block to Prevent Chronic Postoperative Pain in Breast Cancer,0.9972602739726029,Recruiting,Interventional,No,No,Sponsor,94
YOUNGBC-12,Eribulin in mTNBC Patients,1.0164383561643837,Completed,Observational,No,No,Principal Investigator,208
CSIIT-C25,Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC,2.0027397260273974,Recruiting,Interventional,No,No,Principal Investigator,59
SAKK 95/17,Activity Program During Aromatase Inhibitor Therapy,6.684931506849315,"Active, not recruiting",Interventional,No,No,Sponsor,375
2018-A01019-46,Evaluation of the Efficacy of a Homeopathic Protocol in Patients With Non-metastatic Breast Cancer,3.526027397260274,Completed,Interventional,No,No,Sponsor,140
Fisioterapia en Linfedema,Effects of Physiotherapy in the Treatment of Lymphedema After Breast Cancer,0.6575342465753424,Completed,Interventional,No,No,Principal Investigator,28
2019-0752,Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations,3.9041095890410964,"Active, not recruiting",Interventional,Yes,No,Sponsor,8
STUDY00003705,Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer,0.4465753424657534,Recruiting,Interventional,No,No,Principal Investigator,27
CL 2775,Use of Topical Olive Oil Cream for Prophylaxis Against Acute Radiodermatitis in Breast Cancer Patients,1.5726027397260274,Recruiting,Interventional,No,No,Principal Investigator,132
STUDY00003782,RAGE Inhibition to Decrease Therapy Cardiotoxicity in Women With Early Breast Cancer,1.5068493150684932,Recruiting,Interventional,Yes,No,Sponsor,48
X9001194,UK Ibrance Patient Program (IPP) Study,2.0109589041095894,Completed,Observational,,,Sponsor,191
MUST-02-001,Safety and Performance of the Multi-Modal UltraSound Tomography (MUST) Device in Breast Cancer Screening,1.8,Unknown status,Interventional,No,Yes,Sponsor,1333
UEM QuirÃ³n,Effects of a Physical Exercise Intervention During Neoadjuvant Chemotherapy in Women With Breast Cancer,2.16986301369863,Unknown status,Interventional,No,No,Principal Investigator,80
IB2022-04,Evaluation of Cognitive Management for Chemobrain in Patients Treated for Breast Cancer.,1.832876712328767,Recruiting,Interventional,No,No,Sponsor,164
D5336C00001,To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.,5.567123287671233,"Active, not recruiting",Interventional,Yes,No,Sponsor,273
CE 193/17,"Oxidative Stress, Anxiety and Depression in Breast Cancer Patients: Impact of Music Therapy",1.9123287671232878,Completed,Interventional,No,No,Principal Investigator,60
IRAS 314460,CLI and FAR for Intraoperative Margin Assessment,2.1726027397260275,Not yet recruiting,Interventional,No,No,Sponsor,60
UPCC12118,Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab,5.4,"Active, not recruiting",Interventional,Yes,No,Sponsor,69
LCCC 1716,PET/MR in Surgical Planning for Breast CA Treated With Neoadj Chemo,1.2027397260273973,Terminated,Interventional,No,Yes,Sponsor,1
YL202-INT-101-01,A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer,2.9506849315068493,Recruiting,Interventional,Yes,No,Sponsor,80
227/KEPK/IX/2022,The Effectiveness of Lymphatic Bypass Supermicrosurgery,1.736986301369863,Recruiting,Interventional,No,No,Principal Investigator,140
OFA,Opioid Free Anesthesia in Breast Cancer Surgery,1.704109589041096,Completed,Interventional,No,No,Principal Investigator,80
STUDY00021243,Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer,3.0657534246575344,Recruiting,Interventional,Yes,No,Principal Investigator,25
HNCH-2022KY59,UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases,2.9178082191780823,Recruiting,Interventional,No,No,Sponsor,30
Prevention of radiodermatitis,Photobiomodulation for Prevention of Radiodermatitis in Women With Breast Cancer Undergoing Adjuvant Radiotherapy,2.0027397260273974,Not yet recruiting,Interventional,No,No,Principal Investigator,148
EXERT-BC,"EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Breast CA",0.8328767123287671,Recruiting,Observational,No,No,Sponsor-Investigator,40
D3614C00001,Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC,4.284931506849315,Recruiting,Interventional,Yes,No,Sponsor,924
AH150202-1,"Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin",3.0,Recruiting,Interventional,No,No,Sponsor,70
yifeng,Prevalence and Risk Factors for Pain and Related Adverse Reactions Among Breast Cancer Survivors on Aromatase Inhibitors,0.3041095890410959,Recruiting,Observational,No,No,Principal Investigator,1200
MEC-2021-0829,An Integrated Optimization of Surgery and Radiotherapy Techniques to Improve Cosmetic Outcome and Quality of Life in Breast Conserving Therapy for Breast Cancer Patients (STARLINGS Study),3.3945205479452056,Recruiting,Observational,No,No,Principal Investigator,750
YOUNGBC-23,The Rechallenge of ADCs in MBC Patients,2.0027397260273974,"Active, not recruiting",Observational,No,No,Principal Investigator,100
D8530C00007,AZD9833 China PK Study,2.0027397260273974,Recruiting,Interventional,No,No,Sponsor,30
NEODOC-2021668610-165,Evaluation of NeoNaviaÂ® Biopsy System in Axillary Lymph Nodes,2.3753424657534246,Unknown status,Observational,No,No,Sponsor,140
21-194,"A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer",2.0000000000000004,Recruiting,Interventional,Yes,No,Sponsor,28
Exactis-03,Combination of Olaparib and Navitoclax in Women With HGSC and TNBC,2.4684931506849317,Recruiting,Interventional,No,No,Sponsor,36
MedOPP100,A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent,3.7095890410958905,Terminated,Interventional,No,No,Sponsor,7
SYSU003-2020,Nail Changes Associated With Chemotherapy and Prevention of Nail Pigmentation by Ice Water Immersion,2.8328767123287673,Unknown status,Interventional,No,No,Principal Investigator,120
MS201922_0010,Study of M4344 in Combination With Niraparib,2.750684931506849,Withdrawn,Interventional,Yes,No,Sponsor,0
HR-BLTN-III-MBC-C,A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer,5.276712328767124,"Active, not recruiting",Interventional,Yes,No,Sponsor,590
ZWI-ZW25-202,A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer,3.0547945205479454,"Active, not recruiting",Interventional,Yes,No,Sponsor,86
MC1892,Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy,3.0027397260273974,Withdrawn,Interventional,Yes,Yes,Sponsor,0
MC1734,"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer",3.5561643835616437,Recruiting,Interventional,Yes,No,Sponsor,200
UW20058,Intraoperative Evaluation of Axillary Lymphatics,1.073972602739726,Recruiting,Interventional,No,Yes,Sponsor,25
DokuzEUBanuNihan,Diagnostic Contribution of Ultrasonography in Breast Cancer-Related Lymphedema,0.07945205479452055,Completed,Interventional,No,No,Principal Investigator,34
202207200MIPB,"A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC",4.0410958904109595,Recruiting,Interventional,No,No,Sponsor,60
2019COIMBRA001,Combining Interventions of Fertility Preservation to Mitigate Fertility Loss After Breast Cancer,1.1643835616438356,Unknown status,Interventional,No,No,Sponsor,41
TADANAC,Targeted Axillary Dissection After Neo-adjuvant Chemotherapy,3.115068493150685,Recruiting,Observational,No,No,Sponsor,100
00055029,Investigation of a Digital Healthy Habits Program for Individuals With Breast Cancer,0.10410958904109589,Completed,Observational,No,No,Sponsor,30
C4391002,A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors,5.8,Recruiting,Interventional,Yes,No,Sponsor,144
CPH-2022-10-MHS-2,Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine,0.8986301369863013,Recruiting,Interventional,No,No,Sponsor,66
HCRN BRE17-141,Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in Triple Positive Breast Cancers,1.5342465753424657,Recruiting,Interventional,Yes,No,Sponsor-Investigator,48
YOUNGBC-11,First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients,3.1397260273972605,Recruiting,Interventional,No,No,Principal Investigator,90
C4891018,A Study to Learn About the Study Medicine (Called ARV-471) in People With ER+/HER2- Advanced BC in China,1.7863013698630137,Recruiting,Interventional,No,No,Sponsor,9
P-2020-246,Stick Together - Pilot Intervention Study,1.3287671232876712,Enrolling by invitation,Interventional,No,No,Principal Investigator,50
YOUNGBC-18,Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC,2.750684931506849,Recruiting,Interventional,No,No,Principal Investigator,41
SHR-1210-APTN-IIT-TNBC,A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC,2.723287671232877,Completed,Interventional,No,No,Principal Investigator,40
PF008,Treatment Patterns of Neratinib in HER2+ EBC in China,3.750684931506849,Not yet recruiting,Observational,No,No,Sponsor,500
FMUUH-BC-2201,PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients,1.3424657534246576,Not yet recruiting,Interventional,No,No,Principal Investigator,214
20-153,Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC,6.69041095890411,Recruiting,Interventional,Yes,No,Sponsor-Investigator,110
OBU-BC-II-024,Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer,6.421917808219178,Recruiting,Interventional,No,No,Principal Investigator,104
328717,Effects of a Physical Exercise and Health Education Program for Women With Breast Cancer Undergoing Chemotherapy,3.923287671232877,Unknown status,Interventional,No,No,Sponsor,136
2066383,Metacognitive Strategy Training in Cancer-related Cognitive Impairment,1.8136986301369864,Recruiting,Interventional,No,No,Principal Investigator,44
2021-5644,App for Adverse Events to Oral Chemotherapy - Pilot Study,0.9561643835616439,Recruiting,Interventional,No,No,Sponsor-Investigator,30
MC1935,Assessing the Rate of Complications in X-Ray Therapy Versus Proton Beam Radiation Therapy After Breast Conserving Surgery or Mastectomy in Treating Patients With Breast Cancer,4.002739726027397,Recruiting,Interventional,No,No,Sponsor,98
19F.265,A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer,5.567123287671233,Recruiting,Interventional,No,No,Sponsor,340
201901698B0,Music Therapy in Patients With Breast Cancer- a Randomized Controlled Trial,0.3315068493150685,Unknown status,Interventional,No,No,Sponsor,130
2,A Feasibility Study of the Bone@BC App Version 3.0,1.9150684931506852,Not yet recruiting,Interventional,No,No,Principal Investigator,50
2018-0477,Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer,4.336986301369863,Recruiting,Observational,No,No,Sponsor,1410
MedOPP253,Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer,3.315068493150685,"Active, not recruiting",Interventional,No,No,Sponsor,54
S-20180117,Treatment of Breast Cancer-related Lymphedema With Stem Cells and Fat Grafting,2.4547945205479453,Completed,Interventional,No,No,Principal Investigator,80
BZ01/17,Effect of Quilting Sutures on Post-operative Drainage After Mastectomy and/or Axillary Lymph Node Dissection,1.6164383561643836,Terminated,Interventional,No,No,Sponsor,10
712,Effects of Interpectoral-Pectoserratus Plane Block After Breast Cancer Surgery,0.49863013698630143,Not yet recruiting,Observational,No,No,Principal Investigator,60
RC48-C006,A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases,5.69041095890411,Recruiting,Interventional,No,No,Sponsor,301
KGYY-001,Plasmodium Immunotherapy for Breast and Liver Cancers,3.3945205479452056,Unknown status,Interventional,No,No,Sponsor,60
1808852902,"Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets",2.3534246575342466,Completed,Interventional,Yes,No,Sponsor,14
UHaiArtBC,The Role of Emotional Processing in Improving the Quality of Life of Breast Cancer Patients,3.0,Completed,Interventional,No,No,Principal Investigator,343
16381,Responsiveness to Acute Changes in Exercise and Relaxation (RACER) Trial,0.3726027397260274,Completed,Interventional,No,No,Principal Investigator,40
NL67059.068.18,Microsurgical Treatment of Breast Cancer-related Lymphedema by Lymphaticovenous Anastomosis,3.5835616438356164,Recruiting,Interventional,No,No,Sponsor,120
WHUH-BC-001,Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received â¦ 1 Line of Chemotherapy,3.0027397260273974,Not yet recruiting,Interventional,No,No,Principal Investigator,52
ALRN-6924-1-05,A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer,0.12054794520547947,Terminated,Interventional,Yes,No,Sponsor,6
202301160RINA,Novel MRI Techniques on Evaluation of Lymphedema,3.6465753424657534,Recruiting,Observational,No,No,Sponsor,210
IRB00223131,Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study,2.893150684931507,"Active, not recruiting",Interventional,No,No,Sponsor,55
202111198,Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM),6.50958904109589,Not yet recruiting,Interventional,Yes,No,Sponsor,42
Shengjing-LCG003,Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy,4.868493150684931,Not yet recruiting,Interventional,No,No,Principal Investigator,152
AHQU-2022002,Personalized Electroacupuncture Treatment for Chemotherapy-induced Nausea and Vomiting in Breast Cancer (PET),2.8,Recruiting,Interventional,No,No,Principal Investigator,234
IC 2019-04,MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery,1.484931506849315,Completed,Interventional,No,No,Sponsor,182
STU00201961B,A Research Study for Latina Women With Breast Cancer,2.0657534246575344,"Active, not recruiting",Interventional,No,No,Principal Investigator,58
2-107-05-079,Use of a Remifentanil-propofol Mixture in Patients Undergoing Breast Cancer Surgery,0.4,Completed,Interventional,No,No,Principal Investigator,84
2001272738,Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women,3.0027397260273974,Withdrawn,Observational,No,No,Sponsor,0
2018/781,Pre-operative Hypnosis to Prevent Side Effects After Surgery,2.671232876712329,Completed,Interventional,No,No,Principal Investigator,14
2012-090-1182,Shared Decision Making in Surveillance for Distant Metastasis in Breast Cancer,2.5726027397260274,Enrolling by invitation,Interventional,No,No,Principal Investigator,368
IRB00054587,Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases,4.389041095890411,Recruiting,Interventional,Yes,No,Sponsor,19
VSN-18-199,The Effects of Light Therapy to Treat Cancer-related Side Effects,4.065753424657535,Recruiting,Interventional,No,No,Principal Investigator,240
2022YF035-01,Dalpiciclib Plus Letrozole and Capecitabine,1.9780821917808222,Not yet recruiting,Interventional,No,No,Sponsor,48
22-544,TRUDI: TDXD+Durva in HER2+/Low IBC,9.509589041095891,Not yet recruiting,Interventional,Yes,No,Sponsor-Investigator,63
2019-06-027,Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation,2.208219178082192,Unknown status,Observational,No,No,Principal Investigator,583
MRI in response assesment,Functional MRI in Predicting Response to Chemotherapy,4.545205479452055,Recruiting,Observational,No,No,Principal Investigator,50
021-013772,Marker Technique Comparison in Targeted Axillary Dissection,1.5068493150684932,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,40
GCO 15-1783,Systematic Light Exposure for Fatigue in Breast Cancer Patients,4.263013698630137,Recruiting,Interventional,No,No,Principal Investigator,248
1191/2018,"Exercise, Cancer and Cognition: The ECCO-Study",6.005479452054795,Recruiting,Interventional,No,No,Principal Investigator,126
NCI-2017-01119,Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer,5.13972602739726,"Active, not recruiting",Interventional,Yes,No,Sponsor,600
UAB 1794,"Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD",5.421917808219178,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,17
19-5080,Cardio-Oncology Rehabilitation Exercise,1.7178082191780821,Recruiting,Observational,No,No,Principal Investigator,100
METIS,ACH-TH vs EC-TH as Neoadjuvant Therapy for HER2-positive EBC,2.978082191780822,Unknown status,Interventional,No,No,Principal Investigator,180
IUSCC-0616 (1709077419),Investigating the Preventative Ability of Massage Therapy on Paclitaxel Induced Peripheral Neuropathy,0.6821917808219178,Terminated,Interventional,No,No,Sponsor-Investigator,5
IRB00092014,IORT-Breast at Medical Center Navicent Health,10.794520547945206,Recruiting,Observational,No,Yes,Sponsor,300
APA-PG1,Adapted Physical Activity (APA) in a Breast Cancer Population.,4.000000000000001,"Active, not recruiting",Interventional,No,No,Principal Investigator,100
26778919.3.0000.0072,Acupuncture for Peripheral Neuropathy Induced by Paclitaxel in Early Stage Breast Cancer,2.082191780821918,Unknown status,Interventional,No,No,Sponsor,60
HSM/VGH-2017-01-011AC,Effects of Naturalistic Decision-Making Model-based Oncofertility Care Education,2.334246575342466,Completed,Interventional,No,No,Principal Investigator,140
H2207-207-1346,Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor,3.0027397260273974,Not yet recruiting,Interventional,No,No,Principal Investigator,64
CRM-BRE-002,The Malaysian Soy and Mammographic Density Study,1.5342465753424657,Unknown status,Interventional,No,No,Sponsor,282
BC-TATOO-2020,Application of Preoperative Axillary Lymph Node Marking With Nano-Carbon in Breast Cancer Patients Before Neoadjuvant Chemotherapy,3.0821917808219177,Recruiting,Interventional,No,No,Sponsor,200
ICO-N-2018-03,Sentinel Lymph Node After Neoadjuvant Chemotherapy in Breast Carcinoma,4.7315068493150685,Recruiting,Interventional,No,No,Sponsor,385
20190511,Ultrasound-assisted CNSs Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy,1.5013698630136987,Completed,Interventional,No,No,Principal Investigator,330
RG1121659,Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer,1.6849315068493151,Recruiting,Interventional,Yes,No,Sponsor,60
17-AKD-186,Erector Spinae Block in Segmental Mastectomy.,1.0767123287671232,Unknown status,Interventional,No,No,Principal Investigator,30
Immuno2020-01,A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC,3.4356164383561643,"Active, not recruiting",Interventional,No,No,Principal Investigator,46
BGB-A317-ZW25-101,Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab,6.76986301369863,"Active, not recruiting",Interventional,Yes,No,Sponsor,71
STUDY00011444,Nurse AMIE: Addressing Metastatic Individuals Everyday,1.5068493150684932,Completed,Interventional,No,No,Principal Investigator,21
TQB3616-â¢-02,"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Flulvesant Versus Placebo in Combination With Flulvesant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer",4.002739726027397,Not yet recruiting,Interventional,No,No,Sponsor,428
ATOX-2018,Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer,8.049315068493152,Recruiting,Interventional,No,No,Principal Investigator,284
A5481150,Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC,3.794520547945206,Recruiting,Observational,No,No,Sponsor,350
SHAW001,Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients,4.000000000000001,Not yet recruiting,Interventional,Yes,No,Principal Investigator,40
71306642-5/24,Serratus Plane Plus Pectoral I Block Versus Serratus Plane Block for Perioperative Analgesia in Breast Cancer Surgery,0.4575342465753425,Completed,Interventional,No,No,Principal Investigator,60
CETC 002,Association of Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With Immunomodulation and Circulating Tumor Cell Phenotype in Relation to Patient Age.,5.504109589041096,Recruiting,Observational,No,No,Principal Investigator,200
2021-0077,Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer,4.1589041095890416,Recruiting,Interventional,Yes,No,Sponsor,25
SYSA1501-CSP-005,"DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer",1.6684931506849314,Not yet recruiting,Interventional,No,No,Sponsor,191
00031569,Photoacoustic Lymph Node Imaging,6.16986301369863,Suspended,Observational,No,No,Sponsor-Investigator,20
1028595,Chemotherapy-Induced Peripheral Neuropathy-Essential Oil Intervention,1.515068493150685,Completed,Interventional,No,No,Sponsor,26
QoLMa,Quality of Life Improvement During Chemotherapy,3.419178082191781,Recruiting,Interventional,No,No,Sponsor-Investigator,62
CTPR-0015,An Efficacy Study of the XoftÂ® AxxentÂ® eBxÂ® IORT SystemÂ® Lite,12.008219178082191,Withdrawn,Interventional,No,Yes,Sponsor,0
FZPL-Ib-105,A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC,1.6876712328767123,Completed,Interventional,No,No,Sponsor,32
TDM of TAM,Therapeutic Dose Monitoring (TDM) of Tamoxifen,0.9068493150684932,"Active, not recruiting",Interventional,No,No,Principal Investigator,40
STUDY20110029,Screening Contrast-Enhanced Mammography as an Alternative to MRI,2.958904109589041,"Active, not recruiting",Interventional,Yes,Yes,Sponsor-Investigator,600
ECP 250 - 15/16,Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer,2.0000000000000004,Unknown status,Interventional,No,No,Sponsor,104
CTR20220630,Mindfulness Yoga and Sexual Functioning,2.0027397260273974,Not yet recruiting,Interventional,No,No,Principal Investigator,78
2022-001,Deformable Image Registration for Breast Adaptive Tomotherapy,0.7698630136986301,Completed,Observational,,,Sponsor,40
REC 22/WA/0164,Acceptance and Usability of an App Promoting Healthy Behaviours Amongst Young Women at Increased Risk of Breast Cancer,0.34794520547945207,Completed,Interventional,No,No,Principal Investigator,35
2019DEPO-TRIGGER001,DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation,1.1643835616438356,Unknown status,Interventional,No,No,Sponsor,30
OSU-16288,Nipple Aspirate Fluid in Detecting Breast Cancer,4.438356164383562,Recruiting,Interventional,No,No,Principal Investigator,100
20.478.486,Is Breast Massage Necessary to Find Sentinel Lymph Node?,1.652054794520548,Recruiting,Interventional,No,No,Principal Investigator,72
829400,Abbreviated Breast MRI After Cancer Treatment,6.068493150684931,"Active, not recruiting",Observational,No,No,Sponsor,500
J16146,Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins,5.4301369863013695,Recruiting,Interventional,No,No,Sponsor,200
2022-A02337-36,4D CT Scan With Respiratory Gating Versus 3D CT Scan Concerning Cardiac Dosimetry Assesment for Left Sided Breast Cancers Radiotherapy.,0.3287671232876712,Not yet recruiting,Interventional,No,No,Sponsor,13
STUDY00001721,Evaluation of Hydroxychloroquine to Prevent CIPN,1.5041095890410958,Not yet recruiting,Interventional,Yes,No,Sponsor,24
H19017,Somatic Acupressure for Symptom Cluster Management in Breast Cancer Patients,1.347945205479452,Completed,Interventional,No,No,Sponsor,51
1100903,Effect of Acupuncture vs Chinese Medicine vs Combined Therapy on Aromatase Inhibitor-related Arthralgia Among Women With Early-Stage Breast Cancer,0.8273972602739726,Recruiting,Interventional,No,No,Principal Investigator,72
LAAVA2,Laser Therapy for Vulvovaginal Symptoms in Breast Cancer Patients,3.191780821917808,Unknown status,Interventional,No,No,Sponsor,70
BXu-1839,The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency,5.778082191780822,Recruiting,Interventional,No,No,Principal Investigator,200
NABP201801,A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC,1.6082191780821917,Suspended,Interventional,No,No,Sponsor,375
RG1121642,Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer,2.4,Recruiting,Interventional,Yes,No,Sponsor,20
C-plus-Pairs,"A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.",0.5041095890410959,Recruiting,Interventional,No,No,Principal Investigator,46
46.20 PAR ComEt CBM,Breast Stereotactic Radiotherapy to Primary Tumors in Metastatic Patients,2.750684931506849,Recruiting,Interventional,No,No,Sponsor,30
URomLS_4,Metabolomic Evaluation of Psycho-surgical Synergy on Body Image Restoration After Breast Cancer,1.263013698630137,Recruiting,Interventional,No,No,Principal Investigator,80
012418QM,Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC,7.120547945205479,"Active, not recruiting",Interventional,No,No,Sponsor,146
R_ReLoCC,Registry of Local Recurrences After Breast-conserving Surgery,3.4164383561643836,Not yet recruiting,Observational,No,No,Sponsor,3000
2020466,PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC,3.0027397260273974,Not yet recruiting,Interventional,No,No,Principal Investigator,49
SYM011,AKY15-HK-301_NEPA Study,7.846575342465754,Recruiting,Interventional,No,No,Principal Investigator,60
2021-0031,"An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer",2.8986301369863012,Recruiting,Interventional,No,Yes,Sponsor,100
16-0040-02,Pink Warrior 2: Teleconference-based Gaming Support,1.8821917808219177,Completed,Interventional,No,No,Sponsor,20
X4P-001-201,"A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC",1.832876712328767,Enrolling by invitation,Interventional,No,No,Sponsor,24
2022-008,Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C),8.005479452054795,Not yet recruiting,Interventional,No,No,Sponsor,800
2017-0479,Comprehensive Lifestyle Change To Prevent Breast Cancer,3.4136986301369863,Recruiting,Interventional,No,No,Sponsor,60
SYSU-2022-01,Mechanism Exploration of Anti-HER-2 Small-molecule Tyrosine Kinase Inhibitor-related Diarrhea and Establishment of Prevention and Treatment Model(Measure),1.3068493150684932,Recruiting,Interventional,No,No,Principal Investigator,100
SAKK 21/18,Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC,1.8082191780821917,Terminated,Interventional,No,No,Sponsor,25
HelouEl,Factor Influencing Breast Surgery Type Decision-Making,0.1780821917808219,Completed,Observational,No,No,Sponsor-Investigator,380
2018/827,Aspects of Breast-conserving Surgery,3.495890410958904,Completed,Observational,No,No,Sponsor,351
RWS-PEGCSF,Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer,2.947945205479452,Unknown status,Observational,No,No,Sponsor,2000
736-19,The Patterns of Activity and Cognition During Treatment (PACT) Study,1.7917808219178082,"Active, not recruiting",Interventional,No,No,Principal Investigator,40
198411013011,The Effect of Walking Exercise Based on TOUS on Peripheral Neuropathy and Arthralgia-Myalgia in Women With Breast Cancer,1.2136986301369863,Recruiting,Interventional,No,No,Principal Investigator,68
AP1907-50101,Perioperative Analgesic Modalities for Breast Cancer Surgeries,0.4246575342465753,Completed,Interventional,No,No,Principal Investigator,75
YOUNGBC-13,18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response,1.895890410958904,Completed,Observational,No,No,Sponsor-Investigator,30
2021-19,The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC,4.295890410958904,Recruiting,Interventional,No,No,Principal Investigator,46
A5481170,European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies,1.1369863013698631,Recruiting,Observational,Yes,No,Sponsor,2400
RLY-5836-101,First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors,2.797260273972603,Recruiting,Interventional,Yes,No,Sponsor,220
BRI-ROL-001,Combination Study of SV-BR-1-GM With Retifanlimab,5.293150684931507,Recruiting,Interventional,Yes,No,Sponsor,36
RP-PG-1214-20016,What Are the Benefits and Harms of Risk Stratified Screening in the NHS Breast Screening Programme: Study Protocol,2.915068493150685,Completed,Interventional,No,No,Principal Investigator,32298
220287,The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies,1.956164383561644,Not yet recruiting,Interventional,No,No,Principal Investigator,25
PI17/01687,Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity,3.5835616438356164,"Active, not recruiting",Interventional,No,No,Principal Investigator,122
BCP-25,Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study),4.821917808219178,Recruiting,Interventional,No,No,Sponsor-Investigator,256
20210312/2,Neoadjuvant Chemotherapy in Breast Cancer,3.052054794520548,Recruiting,Interventional,No,No,Principal Investigator,1200
2018-1518,"Pain, Psychological, and Endocannabinoid Responses to Yoga in Breast Cancer Survivors With Chemotherapy-induced Neuropathic Pain",0.5123287671232877,Completed,Interventional,No,No,Sponsor,6
EUBREAST-4,MEthods for LOcalization of Different Types of Breast Lesions,3.9178082191780828,Recruiting,Observational,No,No,Sponsor,7416
UCI 18-79 [HS# 2020-5660],Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer,1.5698630136986302,Terminated,Interventional,Yes,No,Principal Investigator,1
ePOST,Efficacy of Point Of Service Testing in MBC,5.145205479452055,Recruiting,Interventional,No,No,Sponsor,100
URCC16070,Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer,7.2027397260273975,Recruiting,Interventional,Yes,No,Principal Investigator,1600
Shengjing-LJY06,Axillary Lymph Node Treatment Guided by Naocarbon Tracing After Neoadjuvant Chemotherapy,7.002739726027397,Recruiting,Interventional,No,No,Principal Investigator,100
Pro00105104,Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477),0.473972602739726,Terminated,Interventional,Yes,No,Principal Investigator,1
202210064DIPD,"LLLT for BCRL: a Randomized, Placebo-controlled Study",1.7095890410958905,Not yet recruiting,Interventional,No,No,Sponsor,54
PERT.21.001,"A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)",2.2904109589041095,Not yet recruiting,Interventional,No,No,Sponsor,268
HCI140278,[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial,4.0849315068493155,Recruiting,Interventional,Yes,No,Sponsor,6
MedOPP068,PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA),3.6575342465753424,Completed,Interventional,No,No,Sponsor,198
69HCL17_0480,Collaborative Self-Management Support in Chronic Conditions - Qualitative Study,1.2027397260273973,Completed,Observational,No,No,Sponsor,109
KCT003,A Multi-center Randomized Control Cross-over Study to Evaluate the Safety and Effectiveness of the Dayspring Active Wearable Compression Device vs. an Advanced Pneumatic Compression Device for Treating Breast Cancer Related Lymphedema,0.5835616438356165,Recruiting,Interventional,No,Yes,Sponsor,50
SILMET_0107665,SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET),4.000000000000001,Recruiting,Interventional,No,No,Sponsor-Investigator,70
S-20180134,Prevention of Breast Cancer-related Lymphedma With Tacrolimus,2.515068493150685,"Active, not recruiting",Interventional,No,No,Principal Investigator,60
241379,Carbon Dye Tattooing of Biopsied Axillary Node in Breast Cancer,1.2602739726027397,Completed,Interventional,No,No,Principal Investigator,100
A5481158,Swedish Ibrance Registries Insights (SIRI),2.0438356164383564,Recruiting,Observational,,,Sponsor,1500
2021/270,Effect of Nurse-led Supportive Care on Quality of Life,0.4328767123287671,Completed,Interventional,No,No,Principal Investigator,42
EUBREAST-11R,International Prospective REgistry on Pre-pectorAl Breast REconstruction,4.002739726027397,Not yet recruiting,Observational,No,No,Sponsor-Investigator,1236
202109031MIPD,"Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC",2.956164383561644,Recruiting,Interventional,No,No,Sponsor,56
00048814,Mobile Behavior Change Program for Weight Loss in Breast Cancer Survivors,0.5232876712328768,Completed,Interventional,No,No,Sponsor,30
JD-LK-2022-136-01,"Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)",1.967123287671233,Not yet recruiting,Interventional,No,No,Sponsor,45
2017/12-SBO-GHMG,Autohypnosis and Cancerology,4.109589041095891,Completed,Interventional,No,No,Sponsor,120
WSG-NIS04 / PROOFS,PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS,12.490410958904109,Recruiting,Observational,No,No,Sponsor,1470
LYT-100-2020-01,LYT-100 in Healthy Volunteers and BCRL,2.526027397260274,Completed,Interventional,Yes,No,Sponsor,50
SCHBCC-N023,Patient Report Outcome-Reconstruction and Oncoplastic Cohort,5.504109589041096,Recruiting,Observational,No,No,Principal Investigator,10000
2017-0328,Development of Exercise Promotion Program Using a Mobile Community,0.9178082191780822,Completed,Interventional,No,No,Principal Investigator,64
2179 CE,Music Listening in Radiotherapy Treatment,2.5753424657534247,Completed,Interventional,No,No,Sponsor,60
Pro00117242,Moving Forward Together 4,2.16986301369863,Recruiting,Interventional,No,No,Principal Investigator,68
MC1937,Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer,8.005479452054795,Recruiting,Observational,No,No,Sponsor,500
2018-A03054-51,Loreline Study: Characterization of Long Responders Under Eribuline,1.5205479452054795,Completed,Observational,No,No,Sponsor,97
US-003,Magseed Enabled Long-Term Localization of Axillary Lymph Nodes,4.8054794520547945,Recruiting,Interventional,No,Yes,Sponsor,65
7119-002,Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002),3.504109589041096,"Active, not recruiting",Interventional,Yes,No,Sponsor,25
21-169,Scalp Cooling in MBC,4.652054794520548,Recruiting,Interventional,No,Yes,Principal Investigator,120
2018-002,Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast,3.8191780821917813,Unknown status,Interventional,Yes,No,Sponsor,27
12345,The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer,3.0,"Active, not recruiting",Interventional,No,No,Sponsor,120
GLSI-21-01,Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects,4.30958904109589,Recruiting,Interventional,Yes,No,Sponsor,598
A221702,Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection,4.5917808219178085,Recruiting,Interventional,No,No,Sponsor,516
22-006606,3D Ultrasound for the Imaging of Axillary Lymph Nodes in Patients With Breast Cancer,2.128767123287671,Recruiting,Interventional,No,Yes,Principal Investigator,60
CAPRICE,Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study,3.756164383561644,Terminated,Interventional,No,No,Sponsor,57
CT/2019/CANFLAX,Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study?,2.1945205479452055,Unknown status,Interventional,No,No,Principal Investigator,60
20-754,Axillary Lymph Node Tattoo Marking Study,3.504109589041096,Recruiting,Interventional,No,No,Principal Investigator,80
URomLS-2019,The Sequelae of Mastectomy and Quadrantectomy Respect to the Reaching Movement in Breast Cancer Survivors,0.978082191780822,Completed,Interventional,No,No,Principal Investigator,65
2021-01-075,PALbociclib Endocrine Therapy Followed by Talazo vs. Talazoz-Atezo Study,6.3342465753424655,Not yet recruiting,Interventional,No,No,Principal Investigator,178
mavis20023,Application-Enabled Shared Decision-Making,1.0000000000000002,Completed,Interventional,No,No,Principal Investigator,31
HiFi-APBI,High Five (HiFi) Accelerated Partial Breast Irradiation Study,4.252054794520548,Recruiting,Interventional,No,No,Sponsor,60
Self-compassion FCR,Fear-focused Self-Compassion Therapy for Young Breast Cancer Patients Fear of Cancer Recurrence,2.210958904109589,Recruiting,Interventional,No,No,Principal Investigator,160
20-010751,3D Ultrasound Breast Imaging,4.117808219178083,Recruiting,Interventional,No,Yes,Principal Investigator,125
IJB-BC-TDM1BM-2016,Kadcyla In pAtients With bRAin Metastasis,0.5068493150684932,Withdrawn,Interventional,No,No,Sponsor,0
1B-15-6,Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors,0.3972602739726027,Withdrawn,Interventional,No,Yes,Sponsor,0
P018,"A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel",2.673972602739726,Withdrawn,Interventional,Yes,No,Sponsor,0
QUILT 2021-1,The QUILT Study: Quilting Sutures in Patients Undergoing Breast Cancer Surgery,0.915068493150685,Not yet recruiting,Interventional,No,No,Principal Investigator,113
2020-10/850,Correlation of Preoperative Anxiety With Early Postoperative Cognitive Dysfunction in Breast Cancer Patients,0.726027397260274,Completed,Observational,No,No,Principal Investigator,200
IEO 0758/,Histology VABB-Histology Post Surgery Pilot Project (BETTY Trial),3.5863013698630137,"Active, not recruiting",Observational,No,No,Sponsor,22
MC18C1,Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer,4.024657534246576,"Active, not recruiting",Interventional,Yes,No,Sponsor,2
GN19ON381,Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy,1.6986301369863013,Recruiting,Observational,No,No,Principal Investigator,60
CBYL719H12301,Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss,4.032876712328767,"Active, not recruiting",Interventional,Yes,No,Sponsor,137
2021/03,A Deep Learning Method to Evaluate QT on Ribociclib,2.0027397260273974,Not yet recruiting,Observational,No,No,Sponsor,60
WSG-AM11,"Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC",7.249315068493151,Recruiting,Interventional,No,No,Sponsor,1250
2018-0528,An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction,4.93972602739726,Recruiting,Interventional,No,No,Sponsor,25
1024489,Exercise to Prevent AnthraCycline-based Cardio-Toxicity Study 2.0 (EXACT2),4.676712328767123,Recruiting,Interventional,No,No,Principal Investigator,100
OBI-822-011,Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC,9.073972602739726,Recruiting,Interventional,Yes,Yes,Sponsor,668
CCR 5006,Exploring the Link Between Cancer Genetics and PPSP,0.4191780821917808,Unknown status,Observational,No,No,Sponsor,104
ICO-N-2018-12,Intravenous Chemotherapy and Plant-based Dietary Supplements,1.115068493150685,Completed,Observational,No,No,Sponsor,200
20180349,Health Economy Register,1.4931506849315068,Completed,Observational,,,Sponsor,219
MSCW2019,Mindfulness and Self-compassion Focussed Walking,3.4,Recruiting,Interventional,No,No,Principal Investigator,135
H-18016600,Metabolic and Bone Changes After Adjuvant Cancer Treatments in Early Non-metastatic Breast Cancer,7.8794520547945215,Recruiting,Observational,No,No,Principal Investigator,120
2020-12-044-012,Pilot Study to Evaluate the Prevention and Safety of Doxorubicin-induced Cardiomyopathy Using Extracorporeal Shock Waves,2.665753424657534,Recruiting,Interventional,No,No,Principal Investigator,72
IJB-PRINTEMPS-2022,Multidisciplinary Approach to Fatigue,5.038356164383561,Recruiting,Interventional,No,No,Sponsor,50
NIS07075,Real-life Pan-HER-blockade With Neratinib,4.504109589041096,Recruiting,Observational,No,No,Sponsor,300
HNCH-BC009,"Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer",2.4164383561643836,Recruiting,Interventional,No,No,Principal Investigator,403
c5ZTCN100,A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS,1.063013698630137,Completed,Interventional,Yes,No,Sponsor,12
CRO-2019-26,Does Type of Anesthesia Influence Inflammation Change After Breast Surgery?,2.0054794520547947,Unknown status,Interventional,No,No,Sponsor,68
YM111146EF,Effects of Kombucha Intervention on Emotional Distress and Sleep Quality in Breast Cancer Survivors,3.0027397260273974,Recruiting,Interventional,No,No,Principal Investigator,60
AP2205-5015,Erector Spinae Plane Block Versus General Anesthesia in Breast Cancer Surgeries,0.7863013698630137,Recruiting,Interventional,No,No,Principal Investigator,120
LCCC1921,Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer,2.526027397260274,Completed,Interventional,Yes,No,Sponsor,55
182113,Improving Cognition After Cancer,4.4,Recruiting,Interventional,No,No,Principal Investigator,250
EC /2018/0996,Pre- or Postoperative Accelerated Radiotherapy,3.175342465753425,Completed,Interventional,No,No,Sponsor,20
ICO_UCC_202001,SMS Messaging as a Tool to Improve Cancer Screening Programs,2.293150684931507,Unknown status,Interventional,No,No,Sponsor,20000
19-008929,Cryotherapy for the Prevention of Taxane-Induced Sensory Neuropathy of the Hands and Feet in Breast Cancer Patients,4.942465753424657,"Active, not recruiting",Interventional,No,Yes,Sponsor,80
2018-172,The Effects of Wheat Sprouts Supplements on the Key Health Indicators of the Patients With Breast Cancer After Chemotherapy,1.4465753424657535,Completed,Observational,No,No,Sponsor,60
19-578,Sacituzumab Govitecan In TNBC,6.238356164383561,"Active, not recruiting",Interventional,Yes,No,Sponsor-Investigator,51
Ref. 070/2018,Comparative Analysis of Three Locoregional Anesthesia Methods in Breast Tumour Pathology Surgery,2.082191780821918,Completed,Interventional,No,No,Sponsor,103
2021-04031,Supporting Women With Breast Cancer to Practice DIBH at Home Before Radiation Therapy,5.580821917808219,Not yet recruiting,Interventional,No,No,Principal Investigator,160
A211601,Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502,3.964383561643836,Terminated,Observational,No,No,Sponsor,18
PSCI 21-045,Trial Assessing Light Intensity Exercise on the Health of Older Breast Cancer Survivors,1.9424657534246577,Recruiting,Interventional,No,No,Principal Investigator,56
22-4004,African Cancer Genome: GMD,1.5917808219178082,Recruiting,Observational,No,No,Principal Investigator,1500
AC-TMSQ-2018,Effect of Therapeutic Massage on Sleep Quality and Stress Levels in Women With Breast Cancer,0.7753424657534247,Completed,Interventional,No,No,Principal Investigator,40
STU-2019-0769,PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer,1.8986301369863017,Completed,Interventional,Yes,No,Principal Investigator,14
R-2021-3203-005,Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.,5.1808219178082195,Recruiting,Interventional,No,No,Principal Investigator,72
CD07_TNBC,Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC,3.4054794520547946,"Active, not recruiting",Interventional,Yes,No,Sponsor,48
F16J16000620002,Innovation in Mammography: Tomosynthesis Pathways,2.9972602739726026,Unknown status,Interventional,No,No,Sponsor,6000
NUR20-0124CRYO,The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer,0.5013698630136987,Terminated,Interventional,No,No,Principal Investigator,14
32551/09/2018,Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy,1.2493150684931507,Completed,Interventional,No,No,Principal Investigator,83
AAAS3402,Glucose Monitoring During Chemotherapy,4.087671232876713,"Active, not recruiting",Observational,No,No,Principal Investigator,22
2017-1535,OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease,4.534246575342466,"Active, not recruiting",Interventional,Yes,No,Sponsor,45
HUM00208684,Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging,3.9369863013698634,Recruiting,Observational,No,No,Principal Investigator,100
12341234,Brass Mesh Bolus in Rotational Post-Mastectomy Radiation Therapy,1.0000000000000002,Not yet recruiting,Interventional,No,No,Principal Investigator,20
Mepitel RCT,Randomized Phase III Trial With Mepitel Film for the Prophylaxis of Radiation Dermatitis in Breast Cancer Patients,4.841095890410959,"Active, not recruiting",Interventional,No,No,Principal Investigator,216
ShandongCHI-07,Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy,7.005479452054795,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,200
D8532C00005,"A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833",0.11232876712328767,Completed,Interventional,No,No,Sponsor,6
CADEX-0001,Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer,4.589041095890411,Suspended,Observational,No,No,Sponsor,750
ELIPSE (SOLTI-1905),"Elacestrant in Preoperative Setting, a Window of Opportunity Study",1.0438356164383562,Completed,Interventional,Yes,No,Sponsor,23
VI-ISRP-026,A Prospective Trial to Assess Breast Cancer Survivors and Vaginal Atrophy Treatment Outcomes,1.5835616438356164,Suspended,Interventional,No,Yes,Sponsor-Investigator,10
5652-18-SMC,Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients,1.1095890410958904,Completed,Interventional,No,No,Sponsor,136
Ä°boelif22,"The Relationships Between Physical Activity Level, Quality of Life and Cognitive Level in Breast Cancer Patients",0.6657534246575343,Recruiting,Observational,No,No,Principal Investigator,54
FEMAL,Comparison of the Efficacy and Tolerability of Femal Versus Placebo,2.8958904109589043,Completed,Interventional,No,No,Sponsor,34
20-30638,Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP),1.5808219178082192,Recruiting,Interventional,Yes,No,Sponsor,20
R.20.11.1099,Ultrasonographic Axillary Localization,1.2931506849315069,Unknown status,Interventional,No,No,Principal Investigator,75
IRB00074154,Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients,2.6931506849315068,Recruiting,Interventional,Yes,No,Sponsor,50
SMC 2021-05-045,SMC Radiation Oncology Breast Cancer Cohort Study,10.002739726027396,Recruiting,Observational,No,No,Principal Investigator,500
CI-01022,Online Psychological Care Program for Women Who Attend a Breast Clinic.,1.2547945205479452,Not yet recruiting,Interventional,No,No,Principal Investigator,50
SamsunU,Combination of Serratus Anterior and Pectoral Nerve Blocks (PECS II) as Main Anesthetic Method in Breast Cancer Surgery,1.0356164383561646,Recruiting,Observational,No,No,Principal Investigator,1
ShandongCHI-18,Patient Report Outcome and Oncological Safety -Oncoplastic and Conventional BCS Cohort,3.249315068493151,Not yet recruiting,Observational,No,No,Principal Investigator,5000
JWCI OBCS WITH IORT,Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation.,4.131506849315069,Recruiting,Interventional,No,Yes,Principal Investigator,30
AAAT8915,Vaginal Dilator Therapy Among Women With Gynecologic and Breast Cancers Experiencing Dyspareunia,1.5753424657534247,Recruiting,Interventional,No,Yes,Principal Investigator,59
20-513,Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer,3.9397260273972607,Recruiting,Interventional,No,No,Sponsor,72
IRB00313835,Evaluating the Use of Patient Navigation to Promote Timely Diagnostic Evaluation During the COVID-19 Pandemic,1.873972602739726,Recruiting,Interventional,No,No,Sponsor,196
HE-202012,Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer,7.115068493150685,Recruiting,Interventional,No,No,Principal Investigator,1072
NCC201804007,Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model,1.4986301369863013,Unknown status,Interventional,No,No,Principal Investigator,50
110.01-2016-GES-0001,Automated Breast Ultrasound Case Collection Registry,0.5397260273972603,Terminated,Observational,No,Yes,Sponsor,13
PREVENT,"Swiss Multi-centre, Randomized, Placebo Controlled Trial of Pregabalin for Prevention of Persistent Pain in High Risk Patients Undergoing Breast Cancer Surgery",5.980821917808219,Recruiting,Interventional,No,No,Sponsor-Investigator,300
QL-KPTB-150,Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients With Colorectal or Breast Cancer,0.12876712328767126,Completed,Interventional,No,No,Sponsor,48
REaCT-Hot Flashes Pilot,Utilizing MyChart to Assess the Effectiveness of Interventions for Vasomotor Symptoms: A Feasibility Study,0.5726027397260274,Completed,Interventional,No,No,Sponsor,56
IRB00081356,Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer,21.057534246575344,Recruiting,Observational,Yes,No,Sponsor,102
VIL-HEQ-17-014,Health and QoL in Oncological Patients: Management of Bone Pathology in Italian Citbl Population,3.254794520547945,Unknown status,Observational,No,No,Principal Investigator,700
COMPLEMENT,Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients,2.750684931506849,Not yet recruiting,Interventional,Yes,No,Principal Investigator,136
DHLI-BC/OC-BE-001,Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (LipodoxÂ®) in Chinese Patients,0.7561643835616438,Recruiting,Interventional,No,No,Sponsor,80
GS18/107321,ePainQ - Feasibility Study,1.6493150684931508,Unknown status,Interventional,No,No,Sponsor,25
2019-003825-56,"Study Comparing LymphoseekÂ® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer",1.4191780821917808,Unknown status,Interventional,No,No,Sponsor-Investigator,30
80252,Breast Reconstruction and Neoadjuvant Radiotherapy,1.8356164383561644,Not yet recruiting,Interventional,No,No,Principal Investigator,20
Exo-LCR,Feasibility of Exosome Analysis in Cerebrospinal Fluid During the Diagnostic Workup of Metastatic Meningitis (Exo-LCR),3.9095890410958907,Recruiting,Interventional,No,No,Sponsor,30
MCC-19117,Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer,8.786301369863013,"Active, not recruiting",Interventional,Yes,No,Sponsor,119
EA1181,CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy,18.898630136986302,Recruiting,Interventional,No,No,Sponsor,2156
PAL-ZJCC-02,Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients,2.1890410958904107,Recruiting,Interventional,No,No,Sponsor,150
GCO 18-1832,Leflunomide in Previously Treated Metastatic Triple Negative Cancers,6.465753424657534,Recruiting,Interventional,Yes,No,Sponsor-Investigator,54
DS_v01,A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations,3.345205479452055,Recruiting,Observational,No,No,Principal Investigator,285
T06/024/21,Exercise and Tumor Blood Flow in Lymphoma And Breast Cancer Patients (EXETUMOR 3),1.3917808219178083,Recruiting,Interventional,No,No,Principal Investigator,28
ES,Effect of Low-dose Esketamine on Postoperative Depression in Patients With Breast Cancer,1.2438356164383562,Completed,Interventional,No,No,Principal Investigator,90
Study00145121,Pilot Study of Effects of DuaveeÂ® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms,1.1643835616438356,Terminated,Interventional,Yes,No,Sponsor-Investigator,11
STU 042018-083,Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod,11.191780821917808,"Active, not recruiting",Interventional,No,Yes,Principal Investigator,74
AcuBreast 2020,Fatigue as a Late Effect in Breast Cancer Survivors - is Acupuncture a Treatment Option?,1.83013698630137,Recruiting,Interventional,No,No,Sponsor,250
4-2020-1093,Radiotherapy for Thoracic and Breast Cancer and the Related Cardiotoxicity Following Treatment (RACCOON),1.9424657534246577,Unknown status,Observational,No,No,Sponsor,200
A012103,Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab,10.065753424657535,Not yet recruiting,Interventional,No,No,Sponsor,1295
HREBA.CC-22-0128,Impact of Metabolic Health Patterns And Breast Cancer Over Time in Women,3.991780821917809,Not yet recruiting,Interventional,No,No,Sponsor,65
A191901,Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy,4.627397260273972,Suspended,Interventional,No,No,Sponsor,1180
VICCBRE2257,Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy,5.008219178082192,Not yet recruiting,Interventional,Yes,No,Principal Investigator,120
HCI69515,Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment,7.9232876712328775,Recruiting,Interventional,Yes,No,Sponsor,15
TX05-03E,Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03,2.5506849315068494,Completed,Interventional,Yes,No,Sponsor,338
2019/639,Effect of Nurse-led Supportive Care on Caregiver Burden and Well-being,0.7397260273972602,Completed,Interventional,No,No,Principal Investigator,60
GBG 107,Long-term Safety and Efficacy of GBG Study Participants,7.605479452054795,Recruiting,Observational,No,No,Sponsor,400
CE-MRI&CESM in breast lesions,CE-MRI&CESM in Solid Breast Lesions,2.082191780821918,Not yet recruiting,Observational,No,No,Principal Investigator,50
PBCST,Precision Breast Conserving Surgery With Guidance.,1.4191780821917808,Completed,Interventional,No,No,Sponsor,92
NEODOC- 2021668610-221,Comparison Trial of Open-tip Pulsed Needle Biopsy and Conventional Core Biopsy in Axillary Lymph Nodes,1.4684931506849315,Unknown status,Interventional,No,No,Sponsor,320
9785-CL-0018,A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer,0.9178082191780822,Completed,Interventional,Yes,No,Sponsor,24
2021-03165,Validation of Scales in Reconstructive Breast Surgery,6.504109589041096,Recruiting,Observational,No,No,Sponsor,500
IRB202202679,Exercise to ReGain Stamina and Energy (The EXERGISE Study),1.0027397260273974,Not yet recruiting,Interventional,No,No,Sponsor,24
Arise-FJ-B102,Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer,4.002739726027397,Not yet recruiting,Interventional,No,No,Sponsor,77
453190,Study of the Effects of Cyclodynon on Reducing the Cumulative Risk of Breast Cancer Development in a Female Aged 40-52,1.7753424657534247,Unknown status,Interventional,No,No,Sponsor-Investigator,150
RenJiH-2018-038,"CTC in Predicting Neoadjuvant Chemotherapy Among LABC Patients: a Single-center, Prospective, Exploratory Clinical Trial",0.8493150684931506,Completed,Interventional,No,No,Principal Investigator,29
202110124,Utilizing Social Contacts to Facilitate Mammogram Screening Among African American Women,0.28493150684931506,Completed,Interventional,No,No,Sponsor,156
MCC-21262,A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV),2.9287671232876713,Recruiting,Interventional,Yes,No,Sponsor,18
18-003544,Comparison of Three Methods for Early Detection of Breast Cancer,1.9753424657534249,Completed,Interventional,Yes,No,Principal Investigator,3
CKRC2021-CCV,Feasibility of Providing a Purpose Renewal Intervention for Cancer Survivors Via Virtual Groups,2.967123287671233,Enrolling by invitation,Interventional,No,No,Sponsor-Investigator,20
BEXMET,The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC,2.745205479452055,Recruiting,Interventional,No,No,Sponsor,12
PICC One Day 01 (ET15-123),Iterative PICC Placement Versus Long Term Device,0.0,Withdrawn,Interventional,No,No,Sponsor,0
IRB00049061,Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer,2.5561643835616437,Completed,Interventional,No,No,Sponsor,23
CP-13-001,MarginProbe 2.0 Data Collection Protocol,2.0438356164383564,Recruiting,Observational,No,Yes,Sponsor,1000
SOLTI-1710,Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy,2.263013698630137,Completed,Interventional,No,No,Sponsor,22
IJB-SYNERGY-012017,Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC,4.761643835616439,"Active, not recruiting",Interventional,No,No,Sponsor,129
IRB00046759,Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer,0.6027397260273972,Completed,Interventional,No,Yes,Sponsor,25
18947,Sentinel Lymph Node Mapping With Near Infrared Fluorescent Markers,3.849315068493151,Completed,Interventional,No,No,Principal Investigator,31
2021-A03027-34,Shared Decision Making on Care Pathways and CAMs: A Pilot Study,0.915068493150685,Not yet recruiting,Interventional,No,No,Sponsor,100
IRB-44367,Blossom Smart Expander Technology in Breast Reconstruction in Participants With Breast Cancer Undergoing Mastectomy,4.336986301369863,Recruiting,Interventional,No,Yes,Sponsor,10
NEPA-17-05,A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer,0.5123287671232877,Completed,Interventional,Yes,No,Sponsor,404
Pectoral nerve block in breast,Pectoral Nerve Block During Mastectomy,1.7506849315068493,Not yet recruiting,Interventional,No,No,Principal Investigator,40
SHR6390-III-303,"Phase III Study ï¼SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative",10.509589041095891,Enrolling by invitation,Interventional,No,No,Sponsor,4350
I3Y-MC-B009,A Prospective Post-Marketing Observational Safety Study of VerzeniosÂ® (Abemaciclib) Among Breast Cancer Patients in China VerzeniosÂ® (Abemaciclib) Among Breast,4.169863013698631,Not yet recruiting,Observational,Yes,No,Sponsor,1500
17/222,Under- and Overdiagnosis in BreastScreen Norway,1.9397260273972605,Completed,Observational,No,No,Sponsor,3915
JCL2020,A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast,6.219178082191781,Recruiting,Interventional,No,No,Sponsor,20
2022-761,Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality,1.4136986301369863,Not yet recruiting,Interventional,No,No,Principal Investigator,180
19-302,"Study of iBreast, a Handheld Device to Detect Breast Abnormalities During Screening Visits for Breast Cancer",2.9232876712328766,"Active, not recruiting",Interventional,No,Yes,Sponsor,310
BFH-BC,ESM Versus OM ï¼A Randomized Controlled Trial,2.082191780821918,Unknown status,Interventional,No,No,Principal Investigator,287
RT 1901,Hypofractionated Versus Conventional Fractionation Radiotherapy,1.4219178082191781,Unknown status,Interventional,No,No,Sponsor,80
MC1732,Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before Surgery,5.002739726027397,"Active, not recruiting",Interventional,No,Yes,Sponsor,25
ET19-084 - CICA-RT,Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients,2.3424657534246576,Unknown status,Interventional,No,No,Sponsor,248
A5481160,"Demographics, Characteristics, Treatment Patterns and Clinical Outcomes of Palbociclib Treated Patients in Israel",0.8328767123287671,Completed,Observational,,,Sponsor,559
21623,Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer,0.5671232876712329,Withdrawn,Interventional,No,No,Sponsor,0
CASE10116,Breast Reconstruction Following Breast Cancer in Very High Risk Patients,3.0876712328767124,Withdrawn,Interventional,No,No,Sponsor,0
2021/271,Effect of Laughter Therapy on Perceived Stress and Quality of Life,0.3150684931506849,Completed,Interventional,No,No,Principal Investigator,42
CASE5Y21,A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose,2.6986301369863015,Recruiting,Interventional,No,Yes,Sponsor,90
University in Zielona Gora,Inertial Rehabilitation in Women After Mastectomy,0.3095890410958904,Completed,Interventional,No,No,Principal Investigator,24
T148/2020,Exercise and Tumor Blood Flow in Breast Cancer Patients,4.317808219178082,Recruiting,Interventional,No,No,Sponsor,20
ICO-2019-16,Satisfaction and QUality of Life After Breast REconstruction,0.2273972602739726,Completed,Observational,No,No,Sponsor,300
ISI dV SP - NSM-01,Robotic vs. Open NSM for Early Stage Breast Cancer,3.671232876712329,Not yet recruiting,Interventional,No,Yes,Sponsor,200
ATOPE18,Attenuating Cancer Treatment-related Toxicity in Oncology Patients With a Tailored Physical Exercise Program,3.334246575342466,Recruiting,Interventional,No,No,Principal Investigator,110
ChungnamNU.J1,VR-based Intervention for Cognitive Restoration,5.063013698630137,Recruiting,Interventional,No,No,Principal Investigator,200
EC/2017/1261,Effect of Non-estrogenic Pollen Extract PCC-100 on Hot Flushes,5.213698630136986,Recruiting,Interventional,No,No,Sponsor,300
M21REO,"Association of Silicone Breast Implant Reconstruction and -Enlargement With Overall Wellbeing, Lymphoma and Auto-immune Disease",2.9205479452054797,Not yet recruiting,Observational,No,No,Principal Investigator,15000
EORTC-2129-BCG,TREAT ctDNA Elacestrant,7.005479452054795,Not yet recruiting,Interventional,No,No,Sponsor,220
22-001501,Characterization of TRPC6 to Predict and Prevent Chemotherapy Related Cardiac Toxicity and Heart Failure in Patients With Breast Cancer,5.041095890410959,Recruiting,Observational,No,No,Sponsor,300
NCI-2021-11793,Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer,2.0000000000000004,Recruiting,Interventional,Yes,No,Sponsor,42
ET19-283,Prospective Study of Immune Alterations in Operable Breast and Ovarian Carcinoma,10.005479452054795,Not yet recruiting,Observational,No,No,Sponsor,160
2019-4433,Angiomammography and Neoadjuvant Chemotherapy,6.493150684931507,Recruiting,Interventional,No,No,Sponsor,100
THERMOEDEME,Spa Therapy for Upper Limb Lymphoedema,3.452054794520548,Unknown status,Interventional,No,No,Sponsor,160
C3621001,Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC,2.835616438356164,Terminated,Interventional,Yes,No,Sponsor,36
LSB-12345,Intraoperative Use of ClearEdge Device in Breast Conserving Surgery,2.2273972602739724,Recruiting,Interventional,No,Yes,Sponsor,288
108511,Breathwork App for Cancer Survivors,1.5342465753424657,Recruiting,Interventional,No,No,Sponsor-Investigator,40
202101421A0,Pilot Study of Single-port Robot-assisted Nipple-sparing Mastectomy,1.0054794520547947,"Active, not recruiting",Interventional,No,Yes,Principal Investigator,30
960-CSP-USA_DenseBreasts_USS1,A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts,1.041095890410959,Terminated,Interventional,No,Yes,Sponsor,435
PROICM 2018-09 BSA,Clinical Database of Safe Personalized Adjuvant Breast Radiotherapy Based on Individual Radiosensitivity,5.03013698630137,Recruiting,Observational,No,No,Sponsor,500
211521,nCCR for Chemotherapy Related Cognitive Impairment Randomized Study,2.5835616438356164,Recruiting,Interventional,No,No,Principal Investigator,20
BC-P30(FZQ),Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy,4.397260273972603,Recruiting,Interventional,No,No,Principal Investigator,102
2017-0672,"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas",6.1808219178082195,Recruiting,Interventional,Yes,No,Sponsor,95
2019-4432,Screening Contrast-enhanced Mammography,5.975342465753425,Recruiting,Observational,No,No,Sponsor,300
22-508,Implantable Microdevice for TNBC - Pilot Study,5.342465753424658,Not yet recruiting,Interventional,Yes,Yes,Principal Investigator,24
NCC2021-0335,Local and Regional Radiotherapy for Nipple Sparing Mastectomy With Implant,7.131506849315069,Enrolling by invitation,Observational,No,No,Principal Investigator,128
TNBC,Epidemiology of TNBC in Asyut Clinical Oncology Department,1.082191780821918,Not yet recruiting,Observational,No,No,Principal Investigator,50
NU 18B05,Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast,4.3561643835616435,Recruiting,Interventional,Yes,No,Sponsor,156
20476,Immune Effects in Patients Treated With Whole Breast Irradiation,1.4164383561643836,Unknown status,Interventional,No,No,Principal Investigator,50
ICRCTSU/2019/10068,PreOperative Endocrine Therapy for Individualised Care With Abemaciclib,11.276712328767124,Recruiting,Interventional,Yes,No,Sponsor,2500
EU001,Magseed Pro(R)/ Sentimag(R) Gen3,1.8356164383561644,Not yet recruiting,Interventional,No,No,Sponsor,224
2018-63,Does Chemotherapy Train the Mutation of the Pig-A Gene? (PIGA),2.0027397260273974,Unknown status,Interventional,No,No,Sponsor,30
2020-06245,Effects of Expectations and Body Image in Breast Reconstruction,3.9150684931506854,Recruiting,Observational,No,No,Sponsor,500
18-168,"Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue",5.958904109589041,"Active, not recruiting",Interventional,No,No,Principal Investigator,60
2021-A01407-34,Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration,1.0000000000000002,Not yet recruiting,Interventional,No,No,Sponsor,100
soh-Med-21-02-05,Modified Pectoral Nerve Block Versus Serratus Plane Block,2.252054794520548,Not yet recruiting,Interventional,No,No,Principal Investigator,60
CIMPAX BREAST,Continuous Serrates Plane Block in Axillary Dissection,2.0027397260273974,Unknown status,Interventional,No,No,Principal Investigator,84
YOUNGBC-20,Detection and Analysis of MBC With Heterogeneous ER Expression,0.915068493150685,Completed,Observational,No,No,Principal Investigator,51
18D.003,"Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence",4.254794520547946,Recruiting,Interventional,No,No,Sponsor,285
20-002505,Mayo Designed Soft Tissue Ultrasound-Detectable Marker,1.4273972602739726,Completed,Interventional,No,Yes,Principal Investigator,8
XianganHXiamenU,NIR Fluorescent Molecular Probe for the Identification of Breast Tissue,0.947945205479452,Recruiting,Interventional,No,No,Sponsor-Investigator,20
YOUNGBC-21,Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab,0.5808219178082191,"Active, not recruiting",Observational,No,No,Principal Investigator,300
201900572,The SONImage Study,5.575342465753424,Recruiting,Interventional,No,No,Principal Investigator,100
MEDOPP459,Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67â¥10%,1.4219178082191781,Not yet recruiting,Interventional,No,No,Sponsor,92
MedOPP485,A PoC Study to Evaluate Treatments Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population,4.501369863013698,Not yet recruiting,Interventional,No,No,Sponsor,1260
09.2019.866,Ultrasonographic Evaluation of Changes After Complex Decongestive Therapy,0.4438356164383562,Unknown status,Interventional,No,No,Sponsor,30
A5481128,Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.,2.452054794520548,Completed,Observational,,,Sponsor,317
YOUNGBC-3,500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI,1.0027397260273974,Completed,Observational,No,No,Principal Investigator,130
020-008,Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC,3.128767123287671,Recruiting,Interventional,Yes,No,Sponsor,20
YOUNGBC-14,Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine,1.4164383561643836,Completed,Observational,No,No,Principal Investigator,224
LQiao,HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BC,3.0027397260273974,Recruiting,Interventional,No,No,Principal Investigator,92
2021157,Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer,2.0027397260273974,Not yet recruiting,Interventional,No,No,Sponsor,30
2020-KY-051,Type I Interferon Alfa-2a in Postmastectomy Breast Reconstruction,0.936986301369863,Completed,Interventional,No,No,Principal Investigator,21
YOUNGBC-25,Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor,0.4136986301369863,Recruiting,Observational,No,No,Principal Investigator,52
Shengjing-LCG011,"Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC",5.890410958904109,Recruiting,Interventional,No,No,Principal Investigator,12
BC-09374,LymphoVenous Anastomosis to Prevent Breast Cancer Related Lymphedema,4.495890410958904,Recruiting,Interventional,No,No,Sponsor,80
2021-02902,PACED-digitized Support During Adjuvant Endocrine Therapy,3.1041095890410957,Recruiting,Interventional,No,No,Sponsor,300
GCO 19-0477,"Vaccination With Flt3L, Radiation, and Poly-ICLC",5.909589041095891,Recruiting,Interventional,Yes,No,Principal Investigator,56
202100318,Testosterone & Tamoxifen Trial,1.1479452054794521,Recruiting,Interventional,No,No,Principal Investigator,6
19-458,A Study of the Use of Text Message Reminders to Take Palbociclib,4.002739726027397,"Active, not recruiting",Interventional,No,No,Sponsor,45
S1904,Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE),7.753424657534247,Recruiting,Interventional,No,No,Sponsor,415
Seno_Ex_MAC 003,Comparison of Conventional With Sonography Assisted Breast Surgery After Neoadjuvant Chemotherapy,4.501369863013698,Recruiting,Interventional,No,No,Sponsor,340
E2018210,Effect of Radiation and Its Timing on Breast Reconstruction in Chinese Patients,4.249315068493151,Unknown status,Observational,No,No,Sponsor,1344
CL(3204),Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms,1.8054794520547945,Recruiting,Interventional,No,No,Principal Investigator,146
211-2018,MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients With Triple Negative or HER2+ MBC,2.5643835616438357,Unknown status,Interventional,No,No,Principal Investigator,50
J17120,"Cancer, Obesity/Overweight and Insomnia Study",2.4712328767123286,Completed,Interventional,No,No,Sponsor,30
AAAO1760,CBPR - BRCA Genetic Testing Among Orthodox Jews,0.8821917808219178,Completed,Interventional,No,No,Principal Investigator,50
1712078374,"Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome",4.295890410958904,Completed,Interventional,No,Yes,Sponsor,29
D17168,The Prone to Supine Breast MRI Trial,2.0547945205479454,Completed,Interventional,No,No,Principal Investigator,72
ShandongCHI-14,Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC,1.4136986301369863,Unknown status,Observational,No,No,Principal Investigator,200
2020-KY-007,The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome,9.002739726027396,Not yet recruiting,Interventional,No,No,Principal Investigator,234
DELFINO trial,Density Lowering Effect of OFS Add on to TMX(DELFINO Trial),5.082191780821918,Recruiting,Interventional,No,No,Sponsor,224
PRISMA,Primary Hormone-sensitive Breast Cancer: Need-driven Health Care Improvement by Patient-centred Digital Application,2.5835616438356164,Not yet recruiting,Interventional,No,No,Sponsor,400
3125001,Safety and Pharmacokinetics of ODM-209,4.46027397260274,"Active, not recruiting",Interventional,No,No,Sponsor,38
ShandongCHI-16,"Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis",1.1616438356164382,Unknown status,Interventional,Yes,No,Principal Investigator,100
ERAS-ABR,ERAS in Autologous Breast Reconstruction: A Pilot RCT,0.6520547945205479,Completed,Interventional,No,No,Principal Investigator,20
ProFertil,Use of GnRHa During Chemotherapy for Fertility Protection,8.843835616438357,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,500
MEDOPP240,Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients,3.7726027397260276,"Active, not recruiting",Interventional,No,No,Sponsor,68
TQB3616-I-0001,A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics,2.5863013698630137,Unknown status,Interventional,No,No,Sponsor,30
7964,Clinical Validation of an Artificial Intelligence Algorithm to Help Interpret Mammograms,1.6986301369863013,Recruiting,Observational,No,No,Sponsor,1000
BreastIls-1605,Endogenous Mechanisms of Inactivation of the Endothelium Tumor,1.6657534246575343,Unknown status,Observational,No,No,Sponsor,70
18-00309,Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy,4.304109589041096,Recruiting,Interventional,Yes,No,Sponsor,60
2005P002282,Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions,0.7342465753424657,Completed,Observational,No,No,Principal Investigator,240
2023-9333,The MARVIN Chatbots to Provide Information for Different Health Conditions,11.676712328767124,Not yet recruiting,Interventional,No,No,Principal Investigator,400
STUDY00020501,"Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study",2.5397260273972604,Recruiting,Interventional,No,No,Principal Investigator,60
[2016]124,Serratus Plane Block in Preventing Postoperative Pain of Mastectomy,1.3342465753424657,Completed,Interventional,No,No,Sponsor-Investigator,50
IIT2018-04-MCARTHUR-NEOHP,Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab,6.435616438356164,Recruiting,Interventional,Yes,No,Principal Investigator,174
MCP Study,Prevention of Obesity-related Cancers: Setting up of a Multi-Cancer Education and Prevention Program in Hong Kong,5.405479452054794,Recruiting,Interventional,No,No,Principal Investigator,10000
STUDY00000194,"Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases",1.2547945205479452,Withdrawn,Interventional,Yes,No,Principal Investigator,0
mastectomy coverage formula 20,New Formula to Predict the Need for Reconstructive Coverage Following Mastectomy,0.25205479452054796,Completed,Observational,No,No,Principal Investigator,30
SIB2232,SMART-ER: Symptom Monitoring With Patient-reported Outcomes,0.6821917808219178,Recruiting,Interventional,No,No,Sponsor,40
KC19EEDT0031,Omitting vs. Doing Intraoperative Frozen Section Biopsy for Margin Status in Breast Conserving Surgery,5.6876712328767125,Recruiting,Interventional,No,No,Principal Investigator,1292
22-008,Onvansertib + Paclitaxel In TNBC,6.383561643835616,Recruiting,Interventional,Yes,No,Sponsor-Investigator,50
1807188-16,FUSCC Refractory TNBC Umbrella (FUTURE),4.123287671232877,Recruiting,Interventional,No,No,Principal Investigator,140
OSU-20429,Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel,3.2356164383561645,Recruiting,Interventional,Yes,No,Principal Investigator,100
2020/295,"The PreQ-20 TRIAL, a Prospective Cohort Study of Patients Undergoing Prepectoral Breast Reconstruction",6.446575342465754,Recruiting,Interventional,No,No,Principal Investigator,81
SunYatsenU2H-LQ4,"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC",12.427397260273972,Recruiting,Interventional,No,No,Principal Investigator,260
Phaon1,Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy,4.841095890410959,"Active, not recruiting",Interventional,No,No,Sponsor,416
SUGBG-2021002,Premarking of Axillary Nodes Before Start of Neoadjuvant Chemotherapy Using Magnetic Approach,1.747945205479452,Recruiting,Interventional,No,No,Principal Investigator,80
S2018-2450-0001,Distress Reduction by Activity Tracking and Activity Enhancement by Mobile Support Group in Oncology,1.8602739726027397,Completed,Interventional,No,No,Principal Investigator,202
IIT-0016,Exercise and Compression for Lymphedema,2.0136986301369864,Recruiting,Interventional,No,No,Sponsor,40
N.sativavsRID BreastCancerpt.,Evaluation of the Effect of Nigella Sativa for the Prophylaxis to Radiation Induced Dermatitis in Breast Cancer Patients,1.1863013698630136,Recruiting,Interventional,No,No,Principal Investigator,132
00130272,PhysioTouch for Treatment of Radiation Fibrosis,1.3342465753424657,Withdrawn,Interventional,No,No,Principal Investigator,0
URCC-18007,Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors,4.742465753424658,Recruiting,Interventional,Yes,No,Principal Investigator,422
jcl2020-2 breast cancer,3D Printed Bolus in Post-mastectomy Radiotherapy,1.1369863013698631,Unknown status,Interventional,No,No,Sponsor,70
OP-1250-003,Phase 1b Combo w/ Ribociclib and Alpelisib,2.0027397260273974,Recruiting,Interventional,Yes,No,Sponsor,60
17-001546,Evaluating Mepitel in Post-mastectomy Patients and the Role of the Skin Microbiome in Radiation Dermatitis,1.6246575342465754,Completed,Observational,,,Principal Investigator,40
38285020.8.0000.0072,"Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer",1.084931506849315,Completed,Interventional,No,No,Principal Investigator,50
TMP-0315-2018,Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel),3.1452054794520548,Recruiting,Interventional,No,No,Sponsor-Investigator,35
21-3117.cc,Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC,0.9068493150684932,Withdrawn,Interventional,Yes,No,Sponsor,0
IRB00103558,Resistance Training to Improve Fatigue and Physical Function in Postmenopausal Breast Cancer Survivors,1.2547945205479452,Completed,Interventional,No,No,Principal Investigator,28
ICOnnectat-BC,"Online Psychosocial Cancer Screening, Monitoring and Stepped Treatment in Cancer Survivors",1.4931506849315068,Unknown status,Interventional,No,No,Principal Investigator,193
C3441038,Korea Post Marketing Surveillance (PMS) Study of TalzennaÂ®,2.5835616438356164,Not yet recruiting,Observational,Yes,No,Sponsor,600
20-028,Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA),5.498630136986302,Recruiting,Interventional,Yes,No,Principal Investigator,40
ICO-2021-36,Pain and Functional Recovery After Mastectomy and IBR by Implant: Prepectoral Versus Subpectoral Technique,1.0000000000000002,Not yet recruiting,Observational,No,No,Sponsor,30
STU-2022-0091,Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy,1.9041095890410962,Recruiting,Interventional,No,Yes,Sponsor-Investigator,90
2021-0048-B,Erector Spinae Block vs. Placebo Block Study,1.252054794520548,Not yet recruiting,Interventional,No,No,Sponsor,60
Breastblock,Regional Anesthesia for Breast Surgery,3.010958904109589,Unknown status,Interventional,No,No,Principal Investigator,150
OMS-I141 (KEYNOTE-890),Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC,5.810958904109589,Recruiting,Interventional,Yes,Yes,Sponsor,65
L424,Cancer Surveillance and Support,2.4465753424657533,Recruiting,Observational,No,No,Principal Investigator,565
BHP0111,Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza),2.1397260273972605,Completed,Interventional,No,No,Principal Investigator,270
18-001926,Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors,4.654794520547945,Recruiting,Interventional,No,No,Sponsor,20
20CX6399,Histolog Comparison to Standard Histology,2.493150684931507,"Active, not recruiting",Observational,No,No,Sponsor,101
REDHEMOPACH,Hemopatch Versus Axillary Drainage After Axillary Lymphadenectomy,2.958904109589041,Completed,Interventional,No,No,Principal Investigator,228
PMC_TTAC-0001_06 / KEYNOTE-C14,Olinvacimab With Pembrolizumab in Patients With mTNBC,4.917808219178082,Recruiting,Interventional,No,No,Sponsor,36
INSPIRE-001,Intercostobrachial Nerve Sparing to Reduce Post-Surgical Pain,1.1315068493150684,Unknown status,Interventional,No,No,Sponsor,50
STUDY00149312,Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC,2.9917808219178084,Recruiting,Interventional,Yes,No,Sponsor,139
IIT2021-10-Giuliano-OmitRT,Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response,6.005479452054795,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,25
VICCBRE2256,Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort,14.01095890410959,Recruiting,Interventional,Yes,No,Sponsor-Investigator,64
Patient reported outcome,Patient Reported Outcomes After Oncoplastic Breast Conserving Surgery,1.5068493150684932,Not yet recruiting,Observational,No,No,Sponsor,100
EAZ171,Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer,4.183561643835617,"Active, not recruiting",Interventional,Yes,No,Sponsor,249
2017/62,Effects of Slow-Stroke Back Massage on CRF,0.8246575342465754,Completed,Interventional,No,No,Principal Investigator,62
17-001864,SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer,2.6684931506849314,Completed,Interventional,No,Yes,Sponsor,27
SCHBCC-N031,An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.,3.504109589041096,Recruiting,Interventional,No,No,Sponsor,138
20429001,Central Obesity and Cancer Prevention for Chinese American Women,1.1287671232876713,Unknown status,Interventional,No,No,Sponsor,30
2000020335,"Lifestyle, Exercise, and Nutrition Study Early After Diagnosis",5.997260273972603,"Active, not recruiting",Interventional,No,No,Sponsor,173
KN026-CHN-001,Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer,4.953424657534247,"Active, not recruiting",Interventional,No,No,Sponsor,63
Pro00103527,mHealth Behavioral Cancer Pain Intervention for Medically Undeserved Patients,3.2849315068493152,Recruiting,Interventional,No,No,Sponsor,180
21-374,A Study of Tumor Imaging With Multispectral Optoacoustic Tomography,1.0000000000000002,Recruiting,Observational,No,No,Sponsor,35
CBCRP 23AB-1400,Reducing Breast Cancer Risk in Korean American Women,0.7945205479452054,Completed,Interventional,No,No,Sponsor,48
MC02/04/19,"A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)",2.967123287671233,Recruiting,Interventional,No,No,Sponsor,74
EJERDIETLINF,Reduction of Lymphedema Secondary to Breast Cancer,3.0027397260273974,"Active, not recruiting",Interventional,No,No,Sponsor,100
22-5074,Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE),4.504109589041096,Not yet recruiting,Interventional,No,No,Sponsor,15
STUDY00018789,StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients,1.2493150684931507,Not yet recruiting,Interventional,No,Yes,Principal Investigator,92
SCHBCC-SOAPET,Sentinel Node Biopsy Vs Observation After Axillary PET,7.9972602739726035,Recruiting,Interventional,No,No,Principal Investigator,1528
3212,"A Survey to Assess Knowledge, Attitudes & Practices in Surgeons With Regards to Breast Conservation Surgery & Mastectomy",0.5808219178082191,Completed,Observational,No,No,Principal Investigator,72
ATADEK-2022/08/20,The Effect of Manual Lymph Drainage in the Treatment of Breast Edema,1.63013698630137,Recruiting,Interventional,No,No,Principal Investigator,36
2018-06,Early Detection of Imaging-derived Subclinical Cardiac Injuries,5.610958904109589,Recruiting,Observational,No,No,Principal Investigator,148
OBU-BC-â¡-077,"Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer",2.0027397260273974,Not yet recruiting,Interventional,No,No,Principal Investigator,52
RG1005296,"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer",5.197260273972603,Recruiting,Interventional,Yes,No,Sponsor,16
H-49731,Improving Comprehensive Care of Cancer Patients,3.16986301369863,Recruiting,Interventional,No,No,Principal Investigator,340
B7391012,A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer,2.213698630136986,Not yet recruiting,Observational,,,Sponsor,400
ONCO-FIRE,ONCOlogy-targeted NLP-powered Federated Hyper-archItecture and Data Sharing Framework for Health Data Reusability,2.504109589041096,Not yet recruiting,Observational,No,No,Sponsor,5000
2021-01534,Effect of Breast Implants om Mammography Screening,2.638356164383562,"Active, not recruiting",Observational,No,No,Sponsor,2500
RD19/123502,Plant Sterol INtervention for Cancer Prevention (PINC),1.8904109589041096,Recruiting,Interventional,No,No,Principal Investigator,50
091-19,Study on Physical Activitys Relationship With Cancer and Cognition,1.7917808219178082,Completed,Interventional,No,No,Principal Investigator,30
PR139/21,Axillary Reverse Mapping in Breast Cancer,2.5013698630136987,Recruiting,Interventional,No,No,Principal Investigator,30
2021.341,Project Breast47: Effect of an Educational Intervention,0.4438356164383562,Completed,Interventional,No,No,Principal Investigator,424
17-361,BEFORE Decision Aid Implementation Study,1.3315068493150686,Unknown status,Interventional,No,No,Principal Investigator,224
PPMP_INO,Persistant Post-mastectomy Pain in Breast Cancer : Incidence and Risk Factors,2.241095890410959,Completed,Observational,No,No,Principal Investigator,722
Overcome project,"Overcome, a Program of Therapeutic Exercise and Functional Recovery to Improve the Functional Capacity of Women With Breast Cancer and Bone Metastases",1.9835616438356167,Recruiting,Interventional,No,No,Principal Investigator,58
DS8201-A-A103,DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein,4.493150684931507,Completed,Interventional,No,No,Sponsor,12
Xiangan Hospital of XMU,Artificial Intelligence Analysis of Fluorescence Image to Intraoperatively Detect Metastatic Sentinel Lymph Node.,3.084931506849315,Recruiting,Observational,Yes,No,Sponsor,40
OBU-BJ-BB-BC-II-007,Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy,3.115068493150685,Recruiting,Interventional,No,No,Principal Investigator,30
NU 21B01,"Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study",1.5917808219178082,Recruiting,Interventional,No,Yes,Sponsor,120
COOL-CLIN-2022-01,Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss,1.5835616438356164,Not yet recruiting,Interventional,No,Yes,Sponsor,125
110.01-2018-GES-0001,Automated Breast Ultrasound as an Adjunct to Screening Digital Breast Tomosynthesis,3.0027397260273974,Withdrawn,Observational,No,Yes,Sponsor,0
NURS-IIR-IUSCCC-0748,Biobehavioral Correlates of Cancer-related Cognitive Dysfunction and Its Co-occurring Symptoms,0.6931506849315069,Completed,Observational,No,No,Principal Investigator,682
2020-1243,Music and Surgery Associated With Relationship and Satisfaction,1.2767123287671234,Unknown status,Interventional,No,No,Principal Investigator,304
OSU-19085,Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer,1.1643835616438356,Withdrawn,Interventional,Yes,No,Principal Investigator,0
SYSUCC-012,GM1 Prophylaxis for WBRT Related Cognitive Dysfunction,4.632876712328767,Recruiting,Interventional,No,No,Principal Investigator,204
IMPACTT,Impact of a Patient Decision Aid Intervention,1.5452054794520549,Recruiting,Interventional,No,No,Sponsor,274
UUBreast01,Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ,7.8356164383561655,Recruiting,Interventional,Yes,No,Principal Investigator,500
1/2020,Impact of Oncotype DXÂ® on Treatment Recommendation and Its Economic Evaluation Under the Brazilian Society Perspective,0.49315068493150693,Completed,Observational,No,No,Principal Investigator,155
CBBCT2018CIH,The Technical Operations And Standard Clinical Application Protocol of CBBCT in Diagnostic Process of Breast Cancer,3.0,Completed,Interventional,No,No,Sponsor,800
30-225 ex 17/18,Laser vs Hyaluronic Acid for GSM in Breast Cancer,4.936986301369863,Recruiting,Interventional,No,No,Sponsor,50
ITSligo SG,Using an Adjustable Compression Garment for Secondary Upper Limb Lymphoedema,1.2547945205479452,Unknown status,Interventional,No,No,Sponsor,30
STUDY00003067,Lung and Breast Cancer Prevention by an Integrated Intervention of Maternal Smoking Cessation and Breastfeeding,2.493150684931507,"Active, not recruiting",Interventional,No,No,Sponsor-Investigator,40
850366,"The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer Patients",1.9260273972602742,Recruiting,Interventional,No,No,Principal Investigator,70
PROICM 2019-02 PRA,Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic  Patient Reported Outcome ) on Breast-related Quality of Life,4.756164383561644,Recruiting,Interventional,No,No,Sponsor,105
060021-HMO-CTIL,"Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap",1.7616438356164383,Recruiting,Observational,No,No,Principal Investigator,1200
2018/13,Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer,4.136986301369864,Completed,Interventional,No,No,Sponsor,17
A095053,Breast Screening - Risk Adaptive Imaging for Density,7.432876712328767,Recruiting,Interventional,No,No,Principal Investigator,13200
202302077,Prehabilitation to Revolutionize Oncology: Telehealth Exercise for Cognitive Triumphs (The PROTECT Trial),1.5068493150684932,Not yet recruiting,Interventional,No,No,Sponsor,40
MC210301,"Long Term Followup of Patients Enrolled in MC1137, BEAUTY Study",10.934246575342465,Recruiting,Observational,No,No,Sponsor,140
Yunwei Wei 2019-09-12,Study on Skin Microbiome of HFS,1.0986301369863014,Unknown status,Observational,Yes,No,Sponsor,50
2.510.081,PILATES METHOD ON THE UPPER LIMBS FUNCTIONALITY,0.7506849315068493,Completed,Interventional,No,No,Principal Investigator,22
K170702J,Follow-up of Elderly Patients in Ambulatory Surgery,1.1616438356164382,Unknown status,Observational,No,No,Sponsor,320
GX-I7-CA-006,Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899),5.019178082191781,"Active, not recruiting",Interventional,No,No,Sponsor,83
R17137,Thermal Suit With Forced-air Warming in Breast Cancer Surgery,0.3726027397260274,Completed,Interventional,No,No,Sponsor,40
2021-395,Efficacy of Cilostazol in Prevention of Peripheral Neuropathy,0.7589041095890411,Completed,Interventional,No,No,Principal Investigator,71
CIMS-2019-01,4FMFES-PET Imaging of Endometrial and Ovarian Cancers,5.0,Recruiting,Interventional,No,No,Principal Investigator,72
IC 2018-09,Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR),2.495890410958904,Recruiting,Interventional,No,No,Sponsor,190
NeoCAT,A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs,2.7534246575342465,Recruiting,Interventional,No,No,Principal Investigator,58
AAAR9515,The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL,3.9369863013698634,"Active, not recruiting",Interventional,No,Yes,Principal Investigator,100
2019-01395CE3508,Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients,4.295890410958904,Recruiting,Observational,No,No,Sponsor,150
RG1007463,"Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer",1.0767123287671232,Terminated,Interventional,Yes,No,Sponsor,1
PA191001001,Pectoral Nerve Block II and Erector Spine Plane Block in Breast Cancer Surgery,1.1726027397260275,Completed,Interventional,No,No,Principal Investigator,90
18070604,A Study of Serum Folate Levels in Patients Treated With Olaparib,3.8657534246575347,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,75
1613494-3,Improving Cancer Screening and Prevention During the COVID-19 Pandemic in Underserved Populations of Rhode Island,2.0109589041095894,Unknown status,Observational,No,No,Sponsor,100
2021198-1,Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer,3.756164383561644,Recruiting,Interventional,No,No,Sponsor,75
PROTOCOL-M7-037,Micrima MARIA Data Collection for Machine Learning Study,1.1726027397260275,Recruiting,Interventional,No,No,Sponsor,400
201801105,RANKL Inhibition and Breast Tissue Biomarkers,0.5068493150684932,Completed,Interventional,Yes,No,Sponsor,10
202004120MINB,The Effect of Intraoperative Dexmedetomidine on Postoperative Morphine Requirements After Breast Cancer Surgery,4.2,Recruiting,Interventional,No,No,Sponsor,60
CHIR-05-IMTAD,Ideal Marker for Targeted Axillary Dissection,2.408219178082192,Recruiting,Observational,No,No,Sponsor,100
EAQ201,COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation,2.9123287671232876,"Active, not recruiting",Observational,No,No,Sponsor,14
STUDY00001356,IIT2020-20-SHIRAZIP-WALK: Nature Walks,2.4465753424657533,Recruiting,Interventional,No,No,Principal Investigator,40
PANTHERA,Evaluation of the Subjectively Perceived Pelvic Floor Function in Patients With Gynecological Tumors and Breast Cancer Under Systemic Tumor Therapy Using a Validated Questionnaire,5.7534246575342465,Recruiting,Observational,No,No,Sponsor,200
IC 2020-04,ER-One: A Double-blind Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery,2.093150684931507,Recruiting,Interventional,No,No,Sponsor,292
Remimazolam_recovery,Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil vs. Propofol,0.3863013698630137,Completed,Interventional,No,No,Principal Investigator,66
BIOC-046,A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide,2.3205479452054796,Recruiting,Observational,No,No,Sponsor,40
RECHMPL21_0525,Tridimensional Geometric Modeling of the Breast,1.6712328767123288,"Active, not recruiting",Interventional,No,No,Sponsor,200
2022037,Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage â¡-â¢ HR-positive/HER2-negative Breast Cancer,1.9178082191780825,Not yet recruiting,Interventional,No,No,Sponsor,30
Q122-2001,Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor,1.8794520547945206,Completed,Interventional,Yes,No,Sponsor,132
S64410,UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research,14.761643835616438,Recruiting,Interventional,No,No,Sponsor,100
MC1689,"Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer",5.098630136986301,Suspended,Interventional,Yes,No,Sponsor,39
2017C0165,Cancer Activity and Lifestyle Measurement Study,5.83013698630137,"Active, not recruiting",Observational,No,No,Principal Investigator,14
2017-0301,Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers,7.090410958904109,Withdrawn,Interventional,No,No,Sponsor,0
S59396,Cancer Related Cognitive Impairment After Chemotherapy: Evaluation of Potential Therapeutic Interventions,3.0,Unknown status,Interventional,No,No,Principal Investigator,120
1105/18,The Immersive Experience of Virtual Reality During Chemotherapy in Patients With Early Breast and Gynecological Cancers: the Patients Dream Study,2.0027397260273974,Completed,Interventional,No,No,Principal Investigator,44
RFID,Breast Localization: RFID Tags vs Wire Localization,2.504109589041096,Recruiting,Observational,No,No,Sponsor,90
SP11631,Trial to Compare the Efficacy and Safety of F-627 and GRANÂ®,1.1863013698630136,Completed,Interventional,No,No,Sponsor,242
EKNZ 2015-026,Cancer/Testis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus,1.5041095890410958,Withdrawn,Interventional,No,No,Sponsor,0
5505,PREDICTION OF GERMLINE BRCA 1/2 GENES FROM HEALTHY OVARIES,3.1205479452054794,Not yet recruiting,Observational,No,No,Sponsor,1300
H-37314,Translating Research Into Practice,4.821917808219178,"Active, not recruiting",Interventional,No,No,Sponsor,1224
852666,Improving Utilization of Supplemental Breast MRI Screening for Women With Extremely Dense Breasts,0.978082191780822,Enrolling by invitation,Interventional,No,No,Sponsor,2000
Three birds with one stone,Three Birds With One Stone,2.249315068493151,"Active, not recruiting",Interventional,No,No,Sponsor,27099
XZP-3287-1001,A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors,4.610958904109589,Unknown status,Interventional,No,No,Sponsor,300
I 56617,"Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer, Sarcoma, Skin Cancer, or Soft Tissue Malignancy and Healthy Volunteers",4.715068493150685,Terminated,Interventional,No,No,Sponsor,7
TAK-676-1003,A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers,2.4438356164383563,Recruiting,Interventional,Yes,No,Sponsor,65
STUDY00022229,ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer,2.0054794520547947,Not yet recruiting,Interventional,Yes,No,Principal Investigator,14
2018-03,SENTINEL LYMPH NODE BIOPSY AFTER NEOADJUVANT CHEMOTHERAPY,5.002739726027397,Unknown status,Observational,No,No,Sponsor,500
CR108557,"A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults",0.263013698630137,Completed,Interventional,No,No,Sponsor,18
FMP-2020-01-TIP,TIP in Patients Affected by Metastatic TNBC,3.0027397260273974,Recruiting,Observational,No,No,Sponsor,100
UPCC 25920,Pilot Study of an NTproBNP Guided Strategy of Cardioprotection,4.208219178082192,Recruiting,Interventional,No,No,Sponsor,105
MEDOPP243,"DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease",2.8602739726027395,Completed,Interventional,No,No,Sponsor,41
4901,An Enhanced Artificial Intelligence Breast MRI Interpretation System,1.252054794520548,Unknown status,Interventional,No,No,Sponsor-Investigator,1526
22-269,Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial),2.4767123287671233,Recruiting,Interventional,No,Yes,Principal Investigator,80
2016-051-000001- 1731,The Role of Circadian Rhythms in Cancer-Related Symptoms,2.0000000000000004,Unknown status,Observational,No,No,Principal Investigator,124
Yvonne Wengstrom,Sensorimotor Training Using Whole Body Vibration Exercise to Reduce Chemotherapy-induced Peripheral Neuropathy,1.5232876712328767,Recruiting,Interventional,No,No,Principal Investigator,44
4-2019-0795,Improvement of Patient Experience and Healthcare Providers Productivity Using Virtual Reality in the Field of Radiation Therapy,1.5534246575342465,Unknown status,Interventional,No,No,Sponsor,196
None yet,An Observational Prospective Cohort Study Using an Actigraphy Device.,0.2958904109589041,Completed,Observational,No,No,Sponsor,40
REaCT-Hold BMA,Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer,4.065753424657535,Recruiting,Interventional,No,No,Sponsor,240
20180569-01H,Evaluation of a Novel Axillary Lymph Node Ink Localization Technique: A Feasibility Study,3.580821917808219,Recruiting,Interventional,No,No,Principal Investigator,70
2020-0761,Evaluation of Mailers Promoting Mammogram Screening,1.0082191780821919,Completed,Interventional,No,No,Principal Investigator,1342
202005217,Implementing BREASTChoice Into Practice,2.484931506849315,"Active, not recruiting",Interventional,No,No,Sponsor,412
Abbreviated Breast MRI,Abbreviated Breast MRI in Cancer Detection,2.9178082191780823,Unknown status,Observational,No,No,Principal Investigator,100
SBI-CIP 20-002,Fluorescence Imaging of Carcinoma During Breast Conserving Surgery,2.5972602739726027,Recruiting,Interventional,Yes,No,Sponsor,370
DS8201-A-U106,DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer,4.057534246575343,Recruiting,Interventional,Yes,No,Sponsor,115
A2018-002,Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations,3.7643835616438355,Unknown status,Interventional,No,No,Principal Investigator,217
STUDY00016221,Nurse AMIE for Echo Show: Randomized Control Trial,1.0712328767123287,Completed,Interventional,No,No,Principal Investigator,42
2669,Prospective Observational Study for Breast Microcalcifications Classification With Artificial Intelligence Techniques,3.010958904109589,Recruiting,Observational,No,No,Principal Investigator,1426
PR275/20,Impact of Systematic Shaving on Margins,3.0246575342465754,Recruiting,Interventional,No,No,Principal Investigator,234
X-PACT 101,"X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma",3.1534246575342464,Recruiting,Interventional,Yes,Yes,Sponsor,12
SHF-WBI,Super Hypofractionated Irradiation For Whole Breast Treatment,5.882191780821918,Recruiting,Interventional,No,No,Principal Investigator,217
MCC-20257,Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk,2.9726027397260273,"Active, not recruiting",Observational,No,No,Sponsor,244
19-07020531,Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study,7.506849315068493,Recruiting,Interventional,No,Yes,Sponsor,60
DS8201-A-U105,Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer,4.032876712328767,"Active, not recruiting",Interventional,Yes,No,Sponsor,99
NAUTILUS study,No Axillary sUrgical Treatment In Clinically Lymph Node Negative Patients After UltraSonography,7.295890410958904,"Active, not recruiting",Interventional,No,No,Sponsor,1734
BrUOG 387,TAS-116 Plus Palbociclib in Breast and Rb-null Cancer,1.9205479452054797,Not yet recruiting,Interventional,Yes,No,Sponsor,27
Instituto Nacional do CÃ¢ncer,Effectiveness of Compressive Bandage Use in Seroma Prevention,1.389041095890411,Not yet recruiting,Interventional,No,Yes,Principal Investigator,270
HP-LY-CL-2063,Clinical Study With LymfactinÂ® in the Treatment of Patients With Secondary Lymphedema (AdeLE),6.49041095890411,"Active, not recruiting",Interventional,No,No,Sponsor,39
2008222-12,Accuracy of VABB Elite 10G Versus BARD 14G CNB,1.6602739726027398,"Active, not recruiting",Interventional,No,No,Sponsor,1470
2019-0837-002,Capsular Contracture After PMRT Using Prepectoral Versus Subpectoral Implant-based Breast Reconstruction: PREPER Trial,5.082191780821918,Not yet recruiting,Interventional,No,No,Principal Investigator,114
9785,Non-contrast DWI for Supplemental Screening,9.967123287671233,Enrolling by invitation,Observational,No,Yes,Sponsor,375
BCP24,To Accurately Assess Lymph Node Response to NACT by Wire Localization of Clip-marked Lymph Nodes,3.695890410958904,Recruiting,Interventional,No,No,Principal Investigator,230
IRB00083573,Cardiac Outcomes With Near-Complete Estrogen Deprivation,5.249315068493151,Recruiting,Interventional,Yes,No,Sponsor,90
CCR5199,ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab,4.0410958904109595,Recruiting,Interventional,No,No,Sponsor,48
HVST-HEMO-20,The Effectiveness of HemopatchÂ® in the Reduction of Post-surgical Serous Drainage,0.9808219178082193,Recruiting,Interventional,No,No,Sponsor,118
1708018471,Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome,3.5232876712328767,Completed,Observational,No,No,Sponsor,66
APBI Registry,Registry for Accelerated Partial Breast Irradiation With (SBRT) or (IMRT),3.504109589041096,Withdrawn,Observational,No,No,Sponsor,0
STUDY00019979,Women In Steady Exercise Research - Window of Opportunity for Exercise and Tumor Biology,2.345205479452055,Recruiting,Interventional,No,No,Principal Investigator,30
109489,Time Restricted Eating on Cancer Risk,1.9945205479452057,Recruiting,Interventional,No,No,Principal Investigator,44
IIT2019-14-SHIRAZIP-SWEAT,Streaming Web-based Exercise At Home: A Pilot Study,2.728767123287671,Completed,Interventional,No,No,Sponsor-Investigator,12
SGNTUC-019,Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations,4.3863013698630136,"Active, not recruiting",Interventional,Yes,No,Sponsor,217
EORTC-1984-BCG,Chemo-free BRCA-targeted Neoadjuvant Strategy,7.471232876712329,Not yet recruiting,Interventional,No,No,Sponsor,152
H-43277,Wrist Cooling for Hot Flashes Clinical Trial,0.8273972602739726,Recruiting,Interventional,No,Yes,Sponsor,30
Oncolact2020,Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact,1.9863013698630139,Recruiting,Interventional,No,No,Sponsor,73
OE20/2020,Effectiveness of Cohesive Bandage on Axillary Web Syndrome After,2.893150684931507,Unknown status,Interventional,No,No,Principal Investigator,90
GNC-035-101ï¼V1.1ï¼,"A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors",1.7095890410958905,Withdrawn,Interventional,No,No,Sponsor,0
2022-0880,Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation,5.580821917808219,Recruiting,Interventional,No,No,Sponsor,126
ABCB1 in Paclitaxel Neuropathy,ABCB1 SNPs as Predictors of PIPN,1.9205479452054797,Completed,Observational,No,No,Principal Investigator,92
ACT16432,Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors,3.7972602739726034,Recruiting,Interventional,Yes,No,Sponsor,94
AAAT8817,IMPACT Trial: Intervention to iMProve AdherenCe Equitably,5.16986301369863,Recruiting,Interventional,No,No,Principal Investigator,350
19-07020533,Prospective Randomized Study of Accelerated Radiation Therapy (PRART),6.115068493150685,Recruiting,Interventional,No,Yes,Sponsor,400
PSIBBR,Prepectoral and Subpectoral Implant-based Breast Reconstruction,1.9123287671232878,Unknown status,Interventional,No,No,Principal Investigator,300
THRIVORSBH-01,Physical Activity Platform to Improve Bone Health in Cancer Survivors,1.1095890410958904,Completed,Interventional,No,No,Principal Investigator,134
20190516,Prevention of Taxane-associated Acute Pain Syndrome With Etoricoxib,1.326027397260274,Completed,Interventional,No,No,Principal Investigator,144
RECHMPL20_0614,Assessment of Cryotherapys Analgesic Impact in Anti-aromatase-induced Arthralgia,1.8356164383561644,Not yet recruiting,Interventional,No,No,Sponsor,70
NNF19OC0057928,"PreoperatIve MRI to Obtain Adequate Resection Margins in Breast Conserving Surgery, (PRIMAR) Trial",5.580821917808219,Recruiting,Interventional,No,No,Principal Investigator,440
RD19/121361,Role of ABUS as an Alternative to Breast MRI in Assessing Response to Neoadjuvant Chemotherapy,2.8575342465753426,Unknown status,Interventional,No,No,Sponsor,100
BRAVEHeartV1,Breast Radiotherapy Audio Visual Enhancement for Sparing the Heart,4.879452054794521,"Active, not recruiting",Interventional,No,No,Sponsor,45
R/19.08.578,Reconstruction of Partial Mastectomy Defects With Pectoralis Myo-glandular Local Flap.,2.5178082191780824,Unknown status,Interventional,No,No,Principal Investigator,15
DHP107_Bioimaging,A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor,0.47671232876712333,Completed,Interventional,No,No,Principal Investigator,2
18-5029,Evaluating Positron Emission Mammography Imaging of Suspicious Breast Abnormalities,1.9589041095890414,Recruiting,Interventional,No,No,Sponsor,100
201902048MINC,Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ,6.676712328767123,Recruiting,Interventional,No,No,Sponsor,810
050811,Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer,2.0849315068493155,Unknown status,Interventional,Yes,No,Sponsor,24
0594,The Genomic Medicine at VA Study,5.208219178082191,Recruiting,Interventional,No,No,Principal Investigator,1076
APHP201173,BENEFIT OF MECHANICAL ISCHEMIC PRECONDITIONING ON TOLERANCE OF ADIPOSE TISSUE TO ISCHEMIA REPERFUSION OF TYPE DIEP (DEEP INFERIOR EPIGASTRIC PERFORATOR) FREE FLAPS.,2.0027397260273974,Not yet recruiting,Interventional,No,No,Sponsor,35
2019-001,Evolution of the Physical Condition in Treated Cancer Patients,1.7068493150684931,Unknown status,Interventional,No,No,Sponsor,300
19-315,Glucose Monitoring to Predict and Treat High Glucose Levels After Steroid Treatment,4.953424657534247,Recruiting,Observational,No,No,Sponsor,50
UMCC 2019.125,Altering Lipids for Tolerance of Aromatase Inhibitor Therapy,2.758904109589041,"Active, not recruiting",Interventional,Yes,No,Sponsor,77
2022P000354,Evaluating the Impact of an Equity Focused Dashboard and Clinical Support,1.2684931506849315,Recruiting,Interventional,No,No,Principal Investigator,3600
SB-2101,Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy,2.9342465753424656,Recruiting,Observational,No,No,Sponsor,350
00001137,Improving Genetic Counseling for BRCA+ Mothers,5.504109589041096,Recruiting,Interventional,No,No,Sponsor,200
2017/2805,Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery,5.994520547945205,"Active, not recruiting",Observational,No,No,Sponsor,220
C3661001,A Study of PF-06873600 in People With Cancer,6.734246575342466,"Active, not recruiting",Interventional,Yes,No,Sponsor,155
4-2020-0430,The Effects of Perioperative PECS Block During Robotic Breast Surgery and Breast Reconstruction,1.2575342465753425,Completed,Interventional,No,No,Sponsor,30
N16PRB,Preoperative Breast Irradiation,0.410958904109589,Terminated,Interventional,No,No,Sponsor,4
CASE10119,"Interventional Program Educates, Identifies + Overcomes Barriers to Complete Screening Mammography",2.3835616438356166,Recruiting,Interventional,No,No,Sponsor,100
21-012300,Tonation Breathing Technique Method to Ease Aromatase Inhibitor-induced Joint and/or Muscle Pain,2.06027397260274,Recruiting,Interventional,No,No,Sponsor,20
Breast MRI,Non-mass Enhancement in Breast MRI,1.5041095890410958,Unknown status,Observational,,,Principal Investigator,50
KY-Q-2021-182,Hyperbaric Oxygen in the Prevention of Radiation Pneumonitis,2.8383561643835615,Recruiting,Interventional,No,No,Sponsor,380
DOLPHIN,Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment,2.8657534246575342,Recruiting,Observational,No,No,Principal Investigator,50
METC20-099,External Vacuum Expansion: Evaluation in Breast Reconstructive Surgery Evaluation in Breast Reconstructive Surgery,5.2246575342465755,Recruiting,Interventional,No,No,Sponsor,90
2020-0501,Contrast-Enhanced Mammography for the Evaluation of Mammographic Microcalcifications,2.104109589041096,Recruiting,Observational,No,No,Sponsor,151
D8534C00001,Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6),6.410958904109589,Recruiting,Interventional,Yes,No,Sponsor,300
NUV-422-03,Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC,4.002739726027397,Withdrawn,Interventional,Yes,No,Sponsor,0
CLEE011ARU01,"A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With RisargÂ®, PiqrayÂ®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia",3.9287671232876717,Recruiting,Observational,,,Sponsor,3290
FIS-APBI-2019-02,Accelerated Partial Irradiation of the Breast: New Altered Fractionation,6.671232876712328,Recruiting,Observational,No,No,Sponsor,174
17/0774,Extended Follow up of the TARGIT-A Trial,4.463013698630137,Recruiting,Observational,No,No,Sponsor,714
OSU-18094,Evaluation of Perforator Phase Contrast Angiography in Developing Surgery Plans for Patients With Breast Cancer Undergoing Breast Reconstruction With Free-Flap Methods After Mastectomy,1.5808219178082192,Withdrawn,Interventional,No,Yes,Principal Investigator,0
21-3100.cc,Second Opinions in Oncology,3.052054794520548,"Active, not recruiting",Observational,No,No,Sponsor,236
10840098-604.01.01-E.184,"Effectiveness of PNF Training for Improving for Muscle Strength, Function, and Pain After Axillary Lymph Node Dissection",1.5534246575342465,Completed,Interventional,No,No,Sponsor,66
Breast Cancer Chemotherapy,Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses,2.252054794520548,Recruiting,Interventional,No,No,Sponsor,15
STUDY02001039,"21DIF039: Prone to Supine Breast MRI II, P2S2 Breast MRI Trial",0.25205479452054796,Not yet recruiting,Interventional,No,No,Principal Investigator,60
CSCS,Cognitive Stimulation and Chemobrain. An Innovative Intervention for Cancer Survivors,1.4958904109589042,Recruiting,Interventional,No,No,Principal Investigator,120
2020/6422,"Effects of Bromelain and Boswellia Serrata Casperome With Centella Asiatica and Vitamins on Edema, Paresthesia and Postoperative Pain After Quadrantectomy With or Without Sentinel Lymph Node Biopsy.",1.084931506849315,Unknown status,Interventional,No,No,Principal Investigator,120
2022-0150,A Feasibility and Acceptability Pilot Study Evaluating a Patient-Specific Targeted Intervention Using Patient Navigators or Routine Clinical Care,1.3506849315068492,Recruiting,Interventional,No,No,Sponsor,40
2007-0003,Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism,2.0027397260273974,Withdrawn,Interventional,Yes,No,Sponsor,0
2-028-22,Chemotherapy Induced Cognitive Impairment,1.5424657534246575,Recruiting,Observational,No,No,Sponsor,50
CASE2119,A Study of the Use of AirXpanders AeroForm in Patients Undergoing Post-Mastectomy Radiation Therapy,2.882191780821918,Withdrawn,Interventional,No,Yes,Sponsor,0
GEN-602-CT-101,Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer,4.756164383561644,"Active, not recruiting",Interventional,Yes,No,Sponsor,127
STUDY00000228,RCT Comparing ESPB Solutions in Breast Surgery,2.9917808219178084,Recruiting,Interventional,Yes,No,Sponsor,75
PRESIONA20,Preventing Chemotherapy-induced Peripheral Neuropathy Using PRESIONA Exercise Program,3.0,Recruiting,Interventional,No,No,Principal Investigator,25
IPAC,Optimizing the Management of Patients With Oral Therapy,3.1780821917808217,Unknown status,Interventional,No,No,Sponsor,406
CASE5122,Breast Margin Study: Routine Cavity Shave Margins Vs. Selective Margins Using Savi ScoutÂ®,3.506849315068493,Not yet recruiting,Interventional,No,No,Sponsor,204
CTMS# 18-0135,Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy,5.879452054794521,Suspended,Interventional,No,No,Sponsor,60
3734,Assessment of the Breast Cosmesis Using Deep Neural Networks: an Exploratory Study (ABCD),4.912328767123288,Recruiting,Observational,No,No,Principal Investigator,720
6077,Multicentric Study for External Validation of a Deep Learning Model for Mammographic Breast Density Categorization,0.8301369863013699,Not yet recruiting,Observational,No,No,Sponsor,277
2022LS100,Assessing the Time Demands of Cancer,7.673972602739727,Not yet recruiting,Observational,No,No,Sponsor,80
STX-478-101,First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor,3.16986301369863,Recruiting,Interventional,Yes,No,Sponsor,160
18-486,Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease,4.961643835616439,Recruiting,Interventional,No,Yes,Sponsor,145
2019-02661,Added Value of Preoperative Contrast Enhanced Mammography in Staging of Malignant Breast Lesions,3.1616438356164385,Recruiting,Interventional,No,No,Sponsor,440
110181,Probiotics and Breast Health,2.5013698630136987,Completed,Interventional,No,No,Principal Investigator,60
IRB-55153,"Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts",1.9643835616438359,Recruiting,Interventional,No,Yes,Principal Investigator,15
GS3,GlobalSurg 3: Quality and Outcomes in Global Cancer Surgery,0.6657534246575343,Unknown status,Observational,No,No,Sponsor,2000
20953,"Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer",4.252054794520548,Withdrawn,Interventional,Yes,No,Sponsor-Investigator,0
QT MG PRE Phase 1,Understanding Patient Experience and Preferences for the QT Scanner Compared to Mammography,3.4027397260273973,Suspended,Observational,No,Yes,Sponsor,20
MC1932,TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol,6.115068493150685,Recruiting,Interventional,Yes,No,Principal Investigator,450
2018-A011828-47,Assessment of Health Related Quality of Life in Women Who Underwent Breast Reconstruction After Radical Surgery,6.005479452054795,Recruiting,Observational,No,No,Sponsor,200
EXPLLN21-01,A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG,1.8356164383561644,Not yet recruiting,Interventional,No,No,Sponsor,9
22-457,Losartan in Prevention of Radiation-Induced Heart Failure,0.915068493150685,Not yet recruiting,Interventional,Yes,No,Principal Investigator,10
GW10029,Assessing the Sensitivity of SureTouchâ¢ in Women Undergoing Diagnostic and Screening Mammography,2.104109589041096,Terminated,Interventional,No,No,Sponsor,213
GCC1950,First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies,4.715068493150685,Recruiting,Interventional,Yes,No,Sponsor,77
Erector block after mastectomy,Dexmedetomedine and Ketamine in Erector Spinae Block for Postoperative Analgesia Following Mastectomy.,0.6602739726027397,Recruiting,Interventional,No,No,Principal Investigator,75
2021-0025,Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge,3.043835616438356,Recruiting,Interventional,No,Yes,Sponsor,66
HCI148669,Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System,5.0,Recruiting,Interventional,No,Yes,Sponsor,34
CBYL719CKR01,A Post Marketing Surveillance on Piqray in Korea,4.8712328767123285,Recruiting,Observational,,,Sponsor,900
21/59848,Lymphaticovenous Anastomosis as Treatment for Lymphedema,1.726027397260274,Recruiting,Interventional,No,No,Principal Investigator,10
221-005,Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin Â®,0.8301369863013699,Completed,Interventional,No,No,Sponsor,87
RECHMPL20_0005-UF7919,Hepatitis C Screening Paired With Mammography,3.0027397260273974,Recruiting,Observational,No,No,Sponsor,1500
P.T.REC/012/002615,Aquatic Versus Land Based Exercise on Lymphedema Post Mastectomy,1.4164383561643836,Completed,Interventional,No,No,Principal Investigator,50
INT31/19,Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases,2.4602739726027396,Unknown status,Interventional,No,No,Principal Investigator,110
Telerehab CH Usability,Telerehabilitation Cognitive Impairments Following Chemotherapy Usability Study,0.5671232876712329,Completed,Observational,No,No,Sponsor,4
ICO-N-2018-15,Delayed Breast Reconstruction by Prepectoral Implant After Lipo-preparation (RM2prepec),4.002739726027397,"Active, not recruiting",Observational,No,No,Sponsor,60
B00394,Automated Low Dose Risk Assessment Mammography (ALDRAM),3.986301369863014,Completed,Interventional,No,No,Sponsor,154
CKMW-1801,Compass Course: Efficacy Study,3.1671232876712327,Completed,Interventional,No,No,Principal Investigator,41
EGC101,A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers,0.6931506849315069,Completed,Interventional,Yes,No,Sponsor,135
69HCL20_1018,Remediation for Mild Cognitive Deficits After Cancer,3.5835616438356164,Recruiting,Interventional,No,No,Sponsor,24
300.08-2018-Samsungmedison-S,Breast Ultrasound Image Reviewed With Assistance of Deep Learning Algorithms,1.3643835616438356,Unknown status,Interventional,No,No,Sponsor,300
ICO-A-2020-10,Electrotherapy in the Management of Myofascial Syndrome,2.2383561643835614,Recruiting,Interventional,No,No,Sponsor,50
INT157/17,Impact of Dietary Intervention on Tumor Immunity: the DigesT Trial,2.504109589041096,Unknown status,Interventional,No,No,Principal Investigator,100
13155,ciNPT in Autologous Abdominal Tissue Breast Reconstruction,1.0000000000000002,Not yet recruiting,Interventional,No,Yes,Sponsor,24
BO40933,"A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.",2.56986301369863,Completed,Interventional,Yes,No,Sponsor,51
IRB20-0528,Low-dose Imaging Technique (LITE),0.0,Withdrawn,Interventional,No,No,Sponsor,0
2018-0345-1105,Feasibility of Preoperative Tattooing of Percutaneously Biopsied Axillary Lymph Node: A Quasi Experimental Pilot Study,1.7671232876712328,Unknown status,Observational,No,No,Principal Investigator,40
NL67696.068.18,Functional MRI Study Reconstructed Breasts,1.8876712328767122,Unknown status,Interventional,No,No,Sponsor,30
UW17032,Alterations in the Vaginal Microenvironment Using a Non-pharmacological Intervention,0.30684931506849317,Terminated,Interventional,No,Yes,Sponsor,2
MedOPP321,"ABemaciclib, ET Â± paclItaxel in aGgressive HR+/HER2- MBC trIaL",2.915068493150685,Recruiting,Interventional,No,No,Sponsor,160
RECHMPL21_0379,Cancer Predictive Score on Breast MRI,1.7452054794520548,Enrolling by invitation,Observational,No,No,Sponsor,428
2017-8737,Post-op Outcomes of Enhanced Energy Delivery Dissection for Mastectomy With Immediate Breast Reconstruction,1.167123287671233,Unknown status,Interventional,No,No,Sponsor,15
IRB-53132,LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy,8.728767123287671,Suspended,Interventional,No,No,Principal Investigator,80
AP2204-50104,Efficacy of Serratus Anterior Plane Block With Dexmedetomidine During Breast Surgery,1.041095890410959,Recruiting,Interventional,No,No,Principal Investigator,172
5160378,Effect of Resveratrol on Serum IGF2 Among African American Women,5.189041095890411,Suspended,Interventional,No,No,Sponsor,50
R.21.11.1523,Comparison of Different Volumes Spread of Erector Spinae Block in Post Mastectomy Pain Syndrome Management,0.7205479452054795,Recruiting,Interventional,No,No,Principal Investigator,50
CYP003,A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers,1.8712328767123287,Recruiting,Interventional,Yes,No,Sponsor,90
315581,Randomised Trial Comparing Biological Matrices With Synthetic Meshes,3.0,Not yet recruiting,Interventional,No,No,Sponsor,60
2022000438,Clinical Outcomes and Patient Satisfaction With Use of the Amma System,2.1123287671232878,Recruiting,Observational,No,Yes,Sponsor,15
CTB in Breast surgery,Ultrasound Guided Costotransverse Block for Breast Cancer Surgery,0.31232876712328766,Completed,Interventional,No,No,Principal Investigator,70
RS1307/20,Prognostic Relevance of Coagulation Activation in RIsk Assessment and Stratification,3.9452054794520555,Recruiting,Observational,No,No,Sponsor,108
H-18041465,Pain Phenotyping of Patients With Bone Cancer Pain,3.991780821917809,Unknown status,Observational,No,No,Principal Investigator,70
RIS42756,Remote Time-restricted EAting DeliverY,0.9972602739726029,Recruiting,Interventional,No,No,Principal Investigator,178
18-294,"Evaluation of an Online, Remote Cognitive Battery for Use in Cancer Survivorship",5.978082191780822,"Active, not recruiting",Observational,No,No,Sponsor,441
YH32367-101,Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor,4.115068493150686,Recruiting,Interventional,No,No,Sponsor,110
HP-00088085,GammaPod Registry and Quality of Life Nomogram,8.915068493150685,Recruiting,Observational,No,Yes,Principal Investigator,160
2020-0974,Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance Metrics,2.8767123287671232,Recruiting,Observational,No,No,Sponsor,1000
2021.127,Music Intervention for Preoperative Anxiety and Acute Pain Among Mastectomy Patients,0.8082191780821918,Completed,Interventional,No,No,Principal Investigator,36
ShantouCH,Lidocaine Mucilage-ICG as an Optical Agent for Tumor Delineation During Breast-conserving Surgery,3.367123287671233,Recruiting,Interventional,No,No,Principal Investigator,60
HYACOM,"Efficacy of Preparation in Self-Hypnosis by Anchoring Versus Conversational Hypnosis, Used Alone or Combined, in Patients Undergoing Breast Macrobiopsies",1.7232876712328766,Recruiting,Interventional,No,No,Sponsor,100
NL82061.096.22,Evaluating the Use of Magnetic Resonance Imaging and Contrast Enhanced Mammography After MagTraceÂ® Use,0.3506849315068493,Not yet recruiting,Observational,No,No,Principal Investigator,25
36264PR116/2/23,Vitamin C on Acute and Chronic Post Mastectomy Pain,1.6712328767123288,Recruiting,Interventional,No,No,Principal Investigator,204
MCC-20335,Evaluation of EnVisio SmartClip for Intraoperative Localization of Breast Masses,3.0136986301369864,Recruiting,Observational,No,Yes,Sponsor,50
00101494,Technology-Based Cancer Screening Intervention,3.4904109589041097,Enrolling by invitation,Interventional,No,No,Principal Investigator,22497
ETK00-2020-0103,Effects of Clinical Pilates and Yoga Training in Lymphedema,1.295890410958904,Completed,Interventional,No,No,Principal Investigator,28
DIVA-001,"Randomized, Controlled Trial With Hybrid Fractional Laser",2.8493150684931505,Completed,Interventional,No,Yes,Sponsor,25
PRO00030436,The Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure,3.052054794520548,Completed,Interventional,No,No,Principal Investigator,11
JS2021-6-1,Hypofractionated Post Mastectomy Radiation With Two-Stage Expander/Implant Reconstruction,4.0630136986301375,Recruiting,Interventional,No,No,Principal Investigator,57
20180335,An Investigator Initiated Study of Intra-Operative Radiation Therapy (IORT) Using the XoftÂ® AxxentÂ® eBx System,10.561643835616438,Recruiting,Interventional,No,Yes,Sponsor,50
DRBX201901/PRO,A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection,0.4712328767123288,Completed,Interventional,No,No,Sponsor,32
21-04,Performance Assessment of the Fluorescence Technique Alone in the Search for the Sentinel Node in Breast Surgery,1.610958904109589,Recruiting,Interventional,No,No,Sponsor,350
A221505,Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer,17.506849315068493,"Active, not recruiting",Interventional,No,No,Sponsor,897
UC-0107/1803,Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast,15.523287671232879,Recruiting,Interventional,No,No,Sponsor,300
SHS-An-1-2022,Nociception Level Monitor (NOL) During Guided Analgesic Delivery in Breast Surgeries,3.164383561643836,Enrolling by invitation,Interventional,No,No,Sponsor,60
R01CA249419,The Engaging Primary Care in Cancer Survivorship (EPICS) Study,3.6931506849315068,Enrolling by invitation,Interventional,No,No,Principal Investigator,2450
STU 072016-058,Using Hyperpolarized [1-13C]Pyruvate to Detect Cardiotoxicity,4.668493150684932,Enrolling by invitation,Interventional,Yes,No,Principal Investigator,110
22-0241,What is Optimal Post-operative Prophylactic Therapy in Irradiated Breasts Undergoing Repeat Surgery,2.5863013698630137,Not yet recruiting,Interventional,No,No,Principal Investigator,105
DS1103-074,A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors,3.2246575342465755,Not yet recruiting,Interventional,Yes,No,Sponsor,78
NEUROTOX,Relationship Between Serum Interleukin-20 Level and Paclitaxel-associated Neuropathy,1.2465753424657535,Recruiting,Observational,Yes,No,Principal Investigator,50
Biofeedback_based_music,Effects of Biofeedback-based Music Program Using a Smart Device Application on Perioperative Sleep Quality.,0.4054794520547945,Not yet recruiting,Interventional,No,No,Principal Investigator,68
IRB-21-28,Can Chronic Post-surgical Pain be Reduced by Preserving Intercostobrachial Nerve During Axillary Lymph Node Dissection? : A Randomized Controlled Trial,0.6684931506849315,Enrolling by invitation,Interventional,No,No,Principal Investigator,182
BREAST-Pyrotinib,Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC,4.504109589041096,Not yet recruiting,Interventional,No,No,Principal Investigator,250
ELEGANT - ET18-262,Satisfaction & Efficacy of Compression Using Surgical Gloves in Chemo-induced Peripheral Neuropathies,4.002739726027397,"Active, not recruiting",Observational,No,No,Sponsor,177
A5481065,Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCEÂ®,7.501369863013698,Recruiting,Observational,No,,Sponsor,1000
L19-065,Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction,4.002739726027397,Recruiting,Interventional,Yes,No,Sponsor,70
HP-00068503,Cardiac MRI Biomarker Testing (GCC 1618),4.605479452054794,Terminated,Observational,No,No,Principal Investigator,6
TQB211-III-01,A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.,2.8904109589041096,Unknown status,Interventional,No,No,Sponsor,338
AP2110-30111,Erector Spinae Plane Block Versus Serratus Anterior Block on Post Mastectomy Pain Syndrome,1.1616438356164382,Recruiting,Interventional,No,No,Principal Investigator,120
IRB202101449,UFPTI 2105-BR05: Improving Breast Radiotherapy Setup and Delivery Using Mixed-Reality Visualization,0.9095890410958904,Recruiting,Interventional,No,No,Sponsor,24
NL72808.068.20,AFT: Introduction of a Full Breast Reconstructive Method,5.813698630136987,Recruiting,Observational,No,No,Sponsor,350
IIT2021-01-Shiao-CSF1Ri,Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation,1.6767123287671233,Not yet recruiting,Interventional,Yes,No,Sponsor-Investigator,35
WHITE TEA,White Tea for Prevention of Chemotherapy Induced Mucositis,2.8273972602739725,"Active, not recruiting",Interventional,No,No,Sponsor,88
R17096,Intraoperative Tissue Identification by Analyzing Surgical Smoke,0.2136986301369863,Completed,Observational,No,No,Principal Investigator,20
2017/15,Study of the Impact of DPD Activity on the Efficacy of Capecitabine,4.701369863013698,Recruiting,Interventional,No,No,Sponsor,155
A222101,Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II),7.1726027397260275,Not yet recruiting,Interventional,No,No,Sponsor,98
AP2014-50103,Dexmedetomidine in Erector Spinae Block in Postoperative Analgesia,0.24931506849315072,Completed,Interventional,No,No,Sponsor-Investigator,58
DMT-2015.002,Delphinus SoftVueâ¢ ROC Reader Study,0.0,Completed,Observational,No,Yes,Sponsor,6
21-318,Use of an Interactive 3D Tool During Consultation for Breast Reconstruction Surgery,1.9397260273972605,"Active, not recruiting",Interventional,No,No,Sponsor,88
IRAS 283017,Comparison of Patient Reported Outcome Measures Using the BREAST-Q Questionnaire in Patients Undergoing Pre Versus Sub-pectoral Implant Based Immediate Breast Reconstruction.,3.252054794520548,Unknown status,Observational,No,No,Sponsor,60
BXU572940,Doxil/Caelyx BE Study,0.6684931506849315,Not yet recruiting,Interventional,Yes,No,Sponsor,36
62/19-06-18,Guided Imagery & Music in Cancer,2.504109589041096,Unknown status,Interventional,No,No,Principal Investigator,20
ZUH-MICB-UMPR,The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery.,2.0273972602739727,Completed,Interventional,No,No,Sponsor,36
20/WS/0110,Contrast-Free Magnetic Resonance Imaging for Breast Disease,2.989041095890411,Recruiting,Observational,No,No,Sponsor,1030
RG1007834,Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy,19.81917808219178,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,2
KCT001,"Clinical Evaluation of a Novel Wearable Compression Technology in the Treatment of Lymphedema, An Open-Label Controlled Study",0.810958904109589,Completed,Interventional,No,Yes,Sponsor,40
HE641269,Efficacy of Parecoxib Combined With Paracetamol in Mastectomy,0.1178082191780822,Recruiting,Interventional,No,No,Principal Investigator,60
AIUR trial,The AIUR Trial: Surgical Gloves to Prevent Peripheral Neuropathy,2.758904109589041,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,104
ATADEK 2021-14/18,Aromatherapy Methods in Reducing Anxiety Before Breast Biopsy,0.8328767123287671,Recruiting,Interventional,No,No,Principal Investigator,150
S-20200094,Lymphedema Screening,0.9890410958904111,Unknown status,Interventional,No,No,Principal Investigator,250
LBS-CA-PTL-033,HydroMARK Post-market Clinical Follow-up Study,2.789041095890411,Recruiting,Observational,No,Yes,Sponsor,832
19-665,CONFIRM: Magnetic Resonance Guided Radiation Therapy,3.1342465753424658,Recruiting,Interventional,No,Yes,Principal Investigator,70
RECHMPL18_0244,Pre Pectoral Implant for Immediate Breast Reconstruction Using Single Port Endoscopy in Prophylactic Indication,7.495890410958904,Recruiting,Interventional,No,No,Sponsor,20
TBio-4101-001,A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors,1.452054794520548,Recruiting,Interventional,Yes,No,Sponsor,30
UCCS19102,Memory and Attention Adaptation Training-Geriatrics (MAAT-G),2.717808219178082,Recruiting,Interventional,No,No,Principal Investigator,39
UCCS20127,Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II,3.419178082191781,Recruiting,Interventional,No,No,Principal Investigator,85
U21-08-4519,Assessment of Cancer Related Brain Fog Using the Test of Strategic Learning,1.0000000000000002,Recruiting,Observational,No,No,Sponsor,10
RCB: 2022-A01349-34,Algology in Oncology Osteopathic Support (ALGOS),1.9095890410958907,Recruiting,Interventional,No,No,Sponsor,120
211820931,Urtica Comp. Gel for Prevention and Therapy of Radiation Dermatitis,3.780821917808219,Completed,Interventional,No,No,Sponsor,31
CTC-SMMiL-E-1901,Feasibility of a New Technology for Isolating Circulating Tumour Cells,3.7260273972602738,Recruiting,Interventional,No,No,Sponsor,76
LCI-BRE-VITD-001,A Study of High-Dose Vit D Versus Standard of Care Vit D Supplementation,3.210958904109589,Recruiting,Interventional,No,No,Sponsor,128
CLEE011A2412B,Roll-over Study to Allow Continued Access to Ribociclib,5.616438356164384,Recruiting,Interventional,Yes,No,Sponsor,137
PB-2020-01,ARGONAUT: Stool and Blood Sample Bank for Cancer Patients,3.504109589041096,Recruiting,Observational,Yes,No,Sponsor,5000
OX2022-203-01,Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors,4.112328767123288,Recruiting,Interventional,Yes,No,Sponsor,115
2018-0561,"ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors",4.504109589041096,"Active, not recruiting",Interventional,Yes,No,Sponsor,35
IRB00180383,e-CHEC-uP: Scaling up an Efficacious Cancer Screening Intervention for Women With Limited English,1.095890410958904,Completed,Interventional,No,No,Sponsor,40
ID-RCB: 2018-A03356-49,Feasibility and Safety of CareMin650 in Patients at Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis,1.4575342465753425,Completed,Interventional,No,No,Sponsor,72
2021/058,Novel Skin Care Product for the Management of Acute Radiodermatitis,1.3287671232876712,Recruiting,Interventional,No,No,Sponsor,100
2011684,Radiofrequency Chip for Localization of Non-Palpable Breast Lesions,2.504109589041096,Completed,Interventional,No,Yes,Principal Investigator,38
CDK-002-101,"A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors",2.271232876712329,Completed,Interventional,Yes,No,Sponsor,27
SAPB for MRM 2.0,Serratus Anterior Plane Block for Modified Radical Mastectomy: Double-point VS Single-point,0.5780821917808219,Recruiting,Interventional,No,No,Principal Investigator,60
2020_16,"Metabolism, Circadian Rhythms and Ovarian Function",2.9397260273972603,Recruiting,Observational,No,No,Sponsor,50
TJ107001STM202,Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors,2.1123287671232878,Recruiting,Interventional,No,No,Sponsor,133
2015C0090,Tango for Neuropathy Among Breast Cancer Survivors,1.997260273972603,Recruiting,Interventional,No,No,Principal Investigator,52
Study-21-00112,Mammography and Breast Arterial Calcification: An Information-Sharing Trial,4.421917808219178,Recruiting,Interventional,No,No,Principal Investigator,14875
NeuroMod-PCCI,Cognitive Training and Brain Stimulation in Women With Post-chemotherapy Cognitive Impairment,1.7452054794520548,Recruiting,Interventional,No,No,Sponsor,52
2020-013-00US3,A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors,2.5616438356164384,Recruiting,Interventional,Yes,No,Sponsor,112
D8530C00004,"A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833",0.30684931506849317,Completed,Interventional,No,No,Sponsor,32
19-5250.0,Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy,3.0027397260273974,Suspended,Interventional,No,No,Sponsor,30
STU 2019-1099,Hyperpolarized Carbon 13-Based Metabolic Imaging to Detect Radiation-Induced Cardiotoxicity,3.9589041095890414,Suspended,Interventional,Yes,Yes,Principal Investigator,10
2020.253 NL72539.029.20,Supervised Exercise to Promote Infiltration of NK-cells Into the Tumor,1.547945205479452,Completed,Interventional,No,No,Principal Investigator,20
NU22-09-00539,Prostate Cancer Screening With Abbreviated MRI Protocol,3.671232876712329,Recruiting,Interventional,No,No,Sponsor,300
A5481173,Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies,3.786301369863014,Recruiting,Interventional,Yes,No,Sponsor,35
RCT Pristina 2/TR,Self-compression Mammography in Clinical Practice,2.9342465753424656,Completed,Interventional,No,No,Sponsor,502
2021-0568-001,A Study to Reduce Persistent Post-mastectomy Pain Using Opioid-free Anesthesia,3.8767123287671237,Recruiting,Interventional,No,No,Principal Investigator,230
STUDY00143316,Sexual Health Empowerment for Womens Health,4.389041095890411,"Active, not recruiting",Interventional,No,No,Principal Investigator,279
2019P001434-1,Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey,0.28493150684931506,Completed,Observational,No,No,Principal Investigator,539
19-238,Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction,3.991780821917809,Recruiting,Interventional,Yes,No,Sponsor,1500
FDRT-BC007,Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery,10.005479452054795,Recruiting,Interventional,No,No,Principal Investigator,4052
PMPS 1,Incidence and Factors Affecting the Development and Outcome of Post Mastectomy Pain Syndrome,1.084931506849315,Not yet recruiting,Observational,No,No,Sponsor,200
2004-219-1119,Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy,1.0904109589041096,Completed,Interventional,No,No,Principal Investigator,113
2000031319,The In4M Study: Integrating 4 Measures to Assess Physical Function in Cancer Patients,2.5123287671232877,Recruiting,Observational,No,No,Sponsor,200
DS1062-A-J101,First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01),6.923287671232877,Recruiting,Interventional,Yes,No,Sponsor,770
CMUH110-REC1-122,Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Radiation CareÂ® Gel,0.8328767123287671,Recruiting,Interventional,No,No,Principal Investigator,30
IIT-ePRO,A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys,1.5068493150684932,Recruiting,Interventional,No,No,Sponsor,128
ICO-2020-22,"Breast Reconstruction by Exclusive Lipomodulin : Feasibility, Evaluation of the Aesthetic Result and Quality of Life",0.19452054794520549,Completed,Observational,No,No,Sponsor,118
22-091,Culturally Aware AET Non-Initiation Intervention,0.5808219178082191,Not yet recruiting,Interventional,No,No,Principal Investigator,30
UTK-IRB-22-07195,Womens Interventions for Sexual Health: WISH,0.7753424657534247,Recruiting,Interventional,No,Yes,Principal Investigator,30
ERC#2020-3379-10190,Outcomes of Local Perforator Flaps in Oncoplastic Surgery,1.2,Completed,Observational,No,No,Principal Investigator,25
PROICM 2018-07 BPR,Memory Perception Assessment in Central/Non-central Nervous System Cancers,4.476712328767123,Recruiting,Interventional,No,No,Sponsor,420
5271,SEroma Reduction pOst MAstectomy SEROMA Study,2.734246575342466,Unknown status,Interventional,No,No,Sponsor,100
ZG01012019,Closed Incision Disposable Negative Pressure Wound Therapy in Immediate Postmastectomy Breast Reconstruction,2.4986301369863013,Unknown status,Interventional,No,No,Principal Investigator,60
PO18091,Per-operative Exploration of the Peri-pancreatic Lymphatic Pathways During Pancreatic Surgical Resection,2.0027397260273974,Unknown status,Interventional,No,No,Sponsor,20
22-197,The Effect of Acupuncture on Nerve Pain Caused by Taxane (Chemotherapy) Treatment,2.9753424657534246,Recruiting,Interventional,No,No,Sponsor,80
21-055,Study of the Safety of MRI Scans in People Who Have Breast Tissue Expanders After Mastectomy,3.0,Recruiting,Observational,No,No,Sponsor,60
1955K,Multicentric Risk Evaluation of Autologous Fat Grafting Procedure,1.0027397260273974,Unknown status,Observational,No,No,Principal Investigator,6510
20-5111,The Person-centered Evolution of Radiotherapy Services in Ontario Study,3.969863013698631,"Active, not recruiting",Interventional,No,No,Sponsor,109
PROICM 2020-06 BIO,Pain Monitoring After Breast Biopsy: Benefit of E-health,2.473972602739726,Recruiting,Interventional,No,No,Sponsor,192
IRB-46373,Phase 2 Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma,6.282191780821917,Recruiting,Interventional,No,No,Sponsor,21
UPCC 21220,CTNNA1 Familial Expansion Study,2.797260273972603,Recruiting,Observational,No,No,Principal Investigator,100
2019_NOV_CP_001,Evaluation Protocols for Isolation of Analytes From Urine for Future Oncology Applications,2.786301369863014,Recruiting,Interventional,No,No,Sponsor,200
DEGENCA,"Feasibility Study of a Molecular Karyotype Using a Very High-throughput Sequencing Approach, the Massive Parallel Sequencing on Circulating Tumor DNA",2.967123287671233,Unknown status,Interventional,No,No,Sponsor,20
IRB-2022- 1451,Axillary Versus Primary Breast Approach for Second-stage Breast Reconstruction,2.0027397260273974,Not yet recruiting,Interventional,No,No,Sponsor,136
ASO.RianGen.22.02,Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery,1.167123287671233,Enrolling by invitation,Interventional,No,No,Sponsor,160
19-00222,Pilot Usability and Feasibility Testing on Kinect-Enhanced Training System for Lymphatic Exercises,0.25205479452054796,Completed,Interventional,No,No,Sponsor,30
C4431001,A Study of PF-07260437 in Advanced or Metastatic Solid Tumors,3.969863013698631,Recruiting,Interventional,Yes,No,Sponsor,100
M336,Comparison of Erector Spinae Plane Block With Serratus Anterior Plane Block for Breast Surgery,1.1232876712328768,Completed,Interventional,No,No,Principal Investigator,62
MAGREES,Effectiveness and Safety of Preoperative Magnetic Detection of Non-palpable Breast Lesions,0.9616438356164385,Completed,Observational,No,No,Sponsor,34
KIA 2018/155,The Effect of Thoracal Paravertebral Block on Seroma Reduction in Breast Surgery,0.4876712328767124,Completed,Interventional,No,No,Principal Investigator,40
B-1206-158-005,Pilot Study of Skin Quality Improvement After Adipose-drived Stem Cell Transfer in Irradiated Breasts,1.0794520547945206,Withdrawn,Interventional,No,No,Sponsor,0
190311,Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction,2.4465753424657533,Recruiting,Interventional,No,Yes,Principal Investigator,120
20-021,Does Immediate Lymphatic Reconstruction Decrease the Risk of Lymphedema After Axillary Lymph Node Dissection,3.9452054794520555,Recruiting,Interventional,No,No,Sponsor,174
202200395A3,"Effect of Helmet Type, Home-use Low-level Light Therapy Device for Chemotherapy-induced Alopecia",3.3753424657534246,Recruiting,Interventional,No,No,Principal Investigator,88
PECS in Breast Cancer Surgery,PECS Block With Bupivacaine Vs Bupivacaine and Dexmedetomidine in Modified Radical Mastectomy,0.33424657534246577,Unknown status,Interventional,No,No,Principal Investigator,45
Analgesia in breast surgey,Combined PECS II and Transversus Plane Blocks Versus Erector Spinae Block in Modified Radical Mastectomy,1.810958904109589,Unknown status,Interventional,No,No,Principal Investigator,60
159-2019,Magnetic Occult Lesion Localization Instrument (MOLLI) Guidance System for Breast Lesion Localization,2.627397260273973,Recruiting,Interventional,No,No,Principal Investigator,207
9778,MRI Characterization of Mammographically Detected DCIS,13.95890410958904,Recruiting,Observational,No,Yes,Sponsor,150
LCCC1920,Fathers and Mothers Invested in Lives of Their Youth (FAMILY) Study: A Pilot Intervention,2.6027397260273974,Completed,Interventional,No,No,Sponsor,15
MCC-19650,Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1,3.252054794520548,Terminated,Interventional,Yes,No,Sponsor,16
2018-05-0009,Living Well After Breast Surgery,2.3123287671232875,Completed,Interventional,No,No,Principal Investigator,17
STU00214745,Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage,0.9698630136986303,Recruiting,Interventional,Yes,No,Principal Investigator,30
DCIS Cryo,Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ,5.002739726027397,Recruiting,Interventional,No,No,Principal Investigator,30
ENTheR,Exploratory Study on Therapy for Breath Hold in Radiotherapy,0.7123287671232876,Completed,Interventional,No,No,Sponsor,20
Michal Nissim 2,"Effectiveness of Aquatic Exercise on Fatigue, Neuropathy and Quality of Life Among Cancer Patients",4.416438356164384,Recruiting,Interventional,No,No,Principal Investigator,150
IUSCC-0533,Trial of Oral Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated Arthralgias,0.0,Withdrawn,Interventional,Yes,No,Sponsor-Investigator,0
Version 1.1.6,Magnetic Occult Lesion Localization and Imaging (MOLLI),1.5972602739726027,Completed,Interventional,No,No,Principal Investigator,20
GALENO 1,Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies,2.202739726027397,Unknown status,Interventional,No,No,Principal Investigator,60
MMSTD1Pecs2,Establishing Technique for PECS2 Catheter Insertion,1.0794520547945206,Completed,Interventional,No,No,Principal Investigator,80
875329,Training Data Collection & AI Development,0.6931506849315069,"Active, not recruiting",Interventional,No,No,Principal Investigator,20
ST-067-001,"Phase 1a and Phase 2 Study for PK, PD, Safety and Preliminary Efficacy of ST-067",3.4876712328767123,Recruiting,Interventional,Yes,No,Sponsor,198
H-40045,Scalable Communication Modalities for Returning Genetic Research Results,1.2410958904109588,Recruiting,Interventional,No,No,Sponsor,2275
SYSKY-2023-122-02,Clinical Value of Breast High-Resolution MR Ductography in Patients With Pathological Nipple Discharge,1.2465753424657535,Recruiting,Interventional,No,No,Principal Investigator,60
TRV-002,Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs,1.5013698630136987,Recruiting,Observational,No,No,Sponsor,130
KOU KAEK 2018/487,Comparison of Bi-level Erector Spine Plane Block and Combined Pectoral I-II Block in Breast Surgery,1.041095890410959,Completed,Interventional,No,No,Principal Investigator,70
TREM-1,Pilot Study of the Predictive Value of TREM1 Expression and Activation in Inflammation and Radio-induced Mammary Fibrosis,2.7534246575342465,Recruiting,Interventional,No,No,Sponsor,20
RC31/17/0335,Quality of Life in Patients With Standard External Compared to Custom-made Breast Prosthesis.,1.0109589041095892,Unknown status,Interventional,No,No,Sponsor,64
201912245RINB,Effects on Recovery of Postoperative Gastrointestinal Function With Multimodal Analgesia,5.778082191780822,Not yet recruiting,Interventional,No,No,Sponsor,30
KND-QX-CXXT,Clinical Study of Vascular Imaging Evaluation of Computed Tomography Photoacoustic Breast Imaging System,0.7534246575342466,Unknown status,Observational,No,No,Sponsor,152
ALTERTASTE,Improving Food Pleasure and Intake of Oncology Patients Receiving Chemotherapy,1.4191780821917808,Unknown status,Observational,No,No,Principal Investigator,100
CUT_DN_02,Prevention of Radiodermatitis in Breast and Head and Neck Cancer Patients in Cyprus,0.49863013698630143,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,100
Pro00052823,Tissue Expansion in Breast Reconstruction Without Drains,1.6027397260273972,Completed,Observational,No,Yes,Principal Investigator,5
PKUPH10B001,Comparison of pCR Rate After Neadjuvant Chemotherapy Guided by Result of in Vitro Cell Culture Drug Sensitivity or Physicians Choice,2.0027397260273974,Unknown status,Interventional,No,No,Sponsor,200
19.58/ONCO19.08,PBMT for the Management of CIA ( HAIRLASER ),2.5397260273972604,Recruiting,Interventional,No,No,Principal Investigator,30
CCS1477-01,Study to Evaluate CCS1477 in Advanced Tumours,5.610958904109589,Recruiting,Interventional,Yes,No,Sponsor,350
CIRCADIAN,Chemotherapy-induced Circadian Rhythm Disruption,3.136986301369863,Recruiting,Observational,No,No,Sponsor,27
CO-338-098,A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR),2.819178082191781,Terminated,Interventional,Yes,No,Sponsor,25
UBP-A103-HER2,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers",1.0767123287671232,Completed,Interventional,No,No,Sponsor,18
UMCC 2021.071,Developing a Psychosexual Educational Partners Program: PEPP A Feasibility Study,0.4575342465753425,Completed,Interventional,No,No,Sponsor,18
Pro00040035,Home-Based Physical Activity Intervention for Taxane-Induced CIPN,4.131506849315069,Recruiting,Interventional,No,No,Sponsor,312
18-6047,The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease,3.975342465753425,Recruiting,Interventional,No,No,Sponsor,100
Real-HER2,Real World Study on the Efficacy and Safety of Anti-HER2 Therapy,2.334246575342466,Recruiting,Observational,No,No,Sponsor,200
PI2018068,Peer Support Program in Cancer Patients Elkar Laguntza,3.5835616438356164,Recruiting,Interventional,No,No,Sponsor-Investigator,120
CBCSG-040,Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two-stage IBBR Augmented With TiLoopÂ® Bra(COSTA),5.517808219178082,Recruiting,Interventional,No,No,Sponsor-Investigator,450
Metimedi-202,OMT-111 for Terminal Stage Solid Tumors,2.0000000000000004,Unknown status,Interventional,No,No,Sponsor,78
NUV-422-02,Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors,1.7287671232876711,Terminated,Interventional,Yes,No,Sponsor,72
UBT 2022-01,A Clinical Investigation to Confirm the Ability of MammoWave in Breast Lesions Detection,1.3972602739726028,Recruiting,Interventional,No,No,Sponsor,600
2020-A01534-35,A Proximity-incentive Strategy for Cervical Cancer Screening,3.4575342465753423,Recruiting,Interventional,No,No,Sponsor,600
181367,Physical Activity Intervention for Young Cancer Survivors,1.082191780821918,Completed,Interventional,No,No,Principal Investigator,34
PRO00041443,Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction,4.336986301369863,Recruiting,Interventional,No,No,Principal Investigator,80
19SM5221,Development and Validation of a Tumour Oxygenation Monitoring Probe,0.8136986301369863,Unknown status,Observational,No,No,Sponsor,20
METCZ20190024,The Risk of Postoperative Wound Complications Following the Use of Negative Pressure Wound Therapy in Patients Undergoing Mastectomy,1.0054794520547947,Completed,Interventional,No,No,Principal Investigator,162
22-01024342,Trial to Compare MRI-guided Precision Prone Irradiation (PPI) Versus CT-guided Breast Irradiation,5.673972602739726,Not yet recruiting,Interventional,No,Yes,Sponsor,380
PUMA-NER-9501,HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib,1.8602739726027397,Terminated,Observational,No,Yes,Sponsor,1583
SY-5609-101,"A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors",4.441095890410959,"Active, not recruiting",Interventional,Yes,No,Sponsor,160
MCC-20487,Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease,3.8958904109589048,Recruiting,Interventional,Yes,No,Sponsor,39
DWI breast cancer,Diffusion Magnetic Resonance Imaging in Mamographically Detected Asymmetric Densities,0.8328767123287671,Unknown status,Observational,No,No,Principal Investigator,50
2022/73,The Effect of the Motivational Interviewing Technique on Breast and Cervical Cancer Screenings,0.5013698630136987,Not yet recruiting,Interventional,No,No,Principal Investigator,120
TBMZ-Radio-boron gel,Preventive Effect of Boron-based Gel on Radiation Dermatitis,0.8767123287671232,Completed,Interventional,No,No,Principal Investigator,257
0141-19-RMB,Characterization of Skin Microbiome Profile and its Correlation to Radiation Dermatitis,1.0000000000000002,"Active, not recruiting",Observational,No,No,Sponsor,100
BT5528-100,Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression,5.153424657534247,Recruiting,Interventional,Yes,No,Sponsor,288
2021P000209,Mapping and Quantifying Lymphatic Drainage of the Arms Alternate Pathway,3.336986301369863,Recruiting,Observational,No,No,Principal Investigator,142
REaCT-TEMPO,Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance,6.005479452054795,Not yet recruiting,Interventional,No,No,Sponsor,240
SYSKY-2022-117-01,Endoscopic Breast Conserving Surgery With Intra-operative Navigation System,2.9178082191780823,Recruiting,Interventional,No,No,Principal Investigator,41
IRB 22-211,Global Cardio Oncology Registry,5.002739726027397,Recruiting,Observational,No,No,Principal Investigator,5000
PROT-P2-024,M5 vs. M6 Comparison Study With a Sub Study Into the Dielectric Constant of Aspirated Cyst Fluid,0.9260273972602739,Completed,Interventional,No,No,Sponsor,22
2022-0454,Vapocoolant Analgesia for Breast Lymphoscintigraphy,0.5013698630136987,Recruiting,Interventional,No,No,Sponsor,30
Pro00101109,Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS),0.3041095890410959,Completed,Interventional,No,No,Sponsor,322
22-071,A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction,1.9424657534246577,Recruiting,Interventional,No,No,Sponsor,352
ZL-2306-006,A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment,2.0767123287671234,Terminated,Interventional,No,No,Sponsor,60
OTT-15-02,"Tumor Bed Dose Delivery Using A Breast Specific Radiosurgery Device, The Gammapod: (A Clinical Feasibility Study)",1.0000000000000002,Unknown status,Interventional,No,No,Sponsor,20
CONFIDENCE-01,CONFIDENCE Registry,4.054794520547945,Enrolling by invitation,Observational,No,Yes,Sponsor,600
K 2020-9716,[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors,3.106849315068493,Recruiting,Interventional,No,No,Principal Investigator,72
NCC20180327,Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion,1.6684931506849314,Unknown status,Interventional,No,No,Principal Investigator,248
3121_MATFIH22,"First-in-human, Study of MATTISSEÂ® Tissue Engineering Chamber in Adult Female Patients Undergoing Immediate Breast Reconstruction After Mastectomy for Cancer",3.336986301369863,Recruiting,Interventional,No,No,Sponsor,50
Modi-1-001,"Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer",4.232876712328768,Recruiting,Interventional,Yes,Yes,Sponsor,144
20-437,Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement,1.873972602739726,"Active, not recruiting",Interventional,No,No,Principal Investigator,125
16-01,Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging,2.978082191780822,Terminated,Interventional,No,Yes,Sponsor,21
IEO 1002/,Evaluation of the Effectiveness of Prepectoral Breast Reconstruction,4.328767123287672,Recruiting,Interventional,No,No,Sponsor,58
3271,PBI for Breast In Situ Carcinoma of Intermediate Low Risk as Local Adjuvant Treatment,6.898630136986301,Recruiting,Interventional,No,No,Sponsor,150
21-559,Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study,2.254794520547945,Recruiting,Interventional,No,No,Principal Investigator,135
LCCC2139,Comparison of CE-DBT and MRI in Patients With Known Breast Lesions,1.5561643835616439,Recruiting,Interventional,Yes,No,Sponsor,20
NK-101,FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors,2.9095890410958902,Completed,Interventional,Yes,No,Sponsor,44
1903399639,High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT),1.3342465753424657,Not yet recruiting,Interventional,Yes,Yes,Sponsor,100
18-00684,Abbreviated Breast MRI (AB-MRI) With Golden-angle Radial Compressed-sensing and Parallel Imaging (GRASP),5.232876712328767,"Active, not recruiting",Observational,No,No,Sponsor,264
MCC-19-15167,Improving Uptake of Genetic Cancer Risk Assessment in African American Women- Video,2.164383561643836,Recruiting,Interventional,No,No,Sponsor,70
CASE5117,Drain-Less Abdominally Based Breast Reconstruction Using Lysine-Derived Urethane Adhesive,0.8328767123287671,Withdrawn,Interventional,No,Yes,Sponsor,0
CASE10117,Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction,2.2575342465753425,Withdrawn,Interventional,Yes,No,Sponsor,0
Medipol Hospital 18,ESPB and RIB for Pain Management Following Mastectomy Surgery,0.8410958904109589,Completed,Interventional,No,No,Principal Investigator,60
18-431,Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung,4.961643835616439,"Active, not recruiting",Interventional,Yes,No,Sponsor,107
SPI-POZ-203,A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies,2.265753424657534,Terminated,Interventional,Yes,No,Sponsor,1
STUDY21070030,CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study,4.750684931506849,Recruiting,Interventional,Yes,Yes,Sponsor-Investigator,1855
E2018124,Application of Intra-operative Prophylactic Antibiotics/Antiseptics in Chinese Breast Reconstruction Patients,3.378082191780822,Unknown status,Interventional,No,No,Sponsor,291
2140-002,A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002),2.8547945205479452,"Active, not recruiting",Interventional,Yes,No,Sponsor,210
2019(S073),Application of Ultrasound Artificial Intelligence and Elastography in Differential Diagnosis of Breast Nodules,1.084931506849315,Unknown status,Observational,No,Yes,Sponsor-Investigator,2000
21-288,A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer,3.0027397260273974,Recruiting,Interventional,Yes,No,Sponsor,150
OSU-21198,Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery,0.536986301369863,Completed,Observational,No,No,Principal Investigator,31
RadOnc,Combined Optical and Infrared Imaging for Early Prediction of Erythema During Breast and Chestwall Radiotherapy,2.419178082191781,Unknown status,Interventional,No,No,Principal Investigator,150
INX-315-01,"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer",3.180821917808219,Recruiting,Interventional,Yes,No,Sponsor,81
228012,Impact of Topical Tranexamic Acid in Breast Reconstruction,1.5068493150684932,Recruiting,Interventional,Yes,No,Sponsor,150
JSKN003-101,First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors,2.328767123287671,Recruiting,Interventional,No,No,Sponsor,45
20-275,Testing a New Imaging Agent to Identify Cancer,4.002739726027397,Recruiting,Interventional,Yes,No,Sponsor,20
018-781,DWIBS-MRI: An Adjunct to the Traditional Diagnostic Breast Imaging Evaluation,5.005479452054795,Recruiting,Observational,No,No,Principal Investigator,200
IGAR-TO-007,IGAR-Breast TeleOp Trial,0.9972602739726029,Unknown status,Interventional,No,No,Sponsor,10
Laser LabCorp #001,Real-time Diagnosis and Visualization of Tumor Margins in Excised Breast Specimens Using Zenith FLIM Diagnostics,0.8821917808219178,Suspended,Interventional,No,No,Sponsor,100
2020-04936,Mammography Screening With Artificial Intelligence (MASAI),4.002739726027397,"Active, not recruiting",Interventional,No,No,Sponsor,100000
NCC2962,Multi-center Study of Deep Learning AI in Breast Mass,2.052054794520548,Recruiting,Observational,No,No,Sponsor,1122
IRB-50877,Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution,0.915068493150685,Not yet recruiting,Interventional,Yes,Yes,Sponsor,20
PER-19-04,Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.,1.7506849315068493,Recruiting,Interventional,No,Yes,Sponsor,333
KL166-I-01-CTP,A Study of A166 in Patients With Advanced Solid Malignant Tumors,5.397260273972603,Recruiting,Interventional,No,No,Sponsor,120
PROTOCOL-P2-054,The ABC Study: Assessment of Breast Density Classification,0.7041095890410959,Recruiting,Interventional,No,No,Sponsor,800
254-18,Reconstructions With Back Donor Site Flaps and Validation of Quality of Life Scales,5.419178082191781,Recruiting,Interventional,No,No,Sponsor,550
MIP-2019-001,BIOpsychosocial Approach of the CAncer-RElated FAtigue (BIOCARE FActory),3.4164383561643836,Not yet recruiting,Interventional,No,No,Sponsor,200
B076201420067,Zhongnan Hospital of Wuhan University,1.7972602739726027,Unknown status,Interventional,No,No,Sponsor,124
21051,Incorporating ePrognosis for the Encouragement of Smarter Screening for Breast and Colorectal Cancer in Older Adults,0.8493150684931506,Completed,Interventional,No,No,Sponsor,75
DE-17-17,Clinical Investigation to Evaluate the Ability of MammoWave in Breast Lesions Detection,0.9260273972602739,Completed,Interventional,No,No,Sponsor,353
CLINP-001013,Retrospective Data Collection on the Use of Motiva Flora TE in Breast Reconstruction,0.24657534246575347,Not yet recruiting,Observational,No,No,Sponsor,120
201701045,Optimizing Decision Making About Breast Reconstruction After Mastectomy: A Patient-Centered Approach,0.7890410958904109,Completed,Interventional,No,No,Sponsor,120
ICO-2021-05,"Retrospective and Prospective Evaluation of Scapulohumeral Comfort, Aesthetic Result and Quality of Life",3.0027397260273974,Recruiting,Observational,No,No,Sponsor,200
E20210210,Breast Mesh Used in Two-staged Breast Reconstruction,5.002739726027397,Recruiting,Interventional,No,No,Sponsor,300
735CLD Rev.04,The ClearCoastâ¢ Magnetic Resonance Outcome PMS Study,3.526027397260274,Recruiting,Observational,No,No,Sponsor,93
CLP-0004,A Retrospective Breast Reconstruction Study,2.5315068493150683,Completed,Observational,No,No,Sponsor,223
EMC-0124-18,Evaluation of the SmartBx System for Breast Biopsy,0.2273972602739726,Completed,Interventional,No,No,Sponsor,30
LYL797-101,A Study to Investigate LYL797 in Adults With Solid Tumors,4.4301369863013695,Recruiting,Interventional,Yes,No,Sponsor,54
2834,TIVA Admnistration and Autologous Fat Transfer in Breast Reconstruction,0.5780821917808219,Completed,Interventional,No,No,Principal Investigator,46
IC 2021 07,Opioid Free Versus Opioid Based Anaesthesia for Secondary Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.,3.271232876712329,Recruiting,Interventional,No,No,Sponsor,158
APHP220816,Cognitive Processing Slowness as a Marker of Cognitive Impairment in Non-central Nervous System Cancer Patients,3.0027397260273974,Not yet recruiting,Observational,No,No,Sponsor,200
GEN1B-01,Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications,2.0328767123287674,Suspended,Interventional,No,Yes,Sponsor,4
2020-00493,Red Bull Energy Drink Intake After Autologous Microsurgical Breast Reconstruction,2.643835616438356,Completed,Interventional,No,No,Principal Investigator,100
20210817-01H,TAP vs QL for Postoperative Analgesia After DIEP Free Flap Breast Reconstruction,0.915068493150685,Not yet recruiting,Interventional,No,No,Principal Investigator,46
CIRB Ref. No: 2019/2090,Accessible Cancer Care to Enable Support for Survivors Programme,2.0027397260273974,Unknown status,Interventional,No,No,Principal Investigator,226
20295,Dermacell ADM Without Basement Membrane,2.665753424657534,Unknown status,Interventional,No,No,Sponsor,120
TO-TAS0728-101,A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities,4.178082191780822,Terminated,Interventional,Yes,No,Sponsor,19
124.03-2017-GES-0005,Patient-Assisted Compression in 3D - Impact on Image Quality and Workflow,0.0136986301369863,Completed,Interventional,No,Yes,Sponsor,36
IIT2018-21-AMERSI-BREADS,BREADS: Breast Adjuvant Diet Study,3.1506849315068495,Terminated,Interventional,No,No,Sponsor-Investigator,6
PSG SOMAVAC,Evaluation of SOMAVAC 100 Sustained Vacuum System,1.4986301369863013,Completed,Observational,No,Yes,Sponsor,25
FMSU2017-003,Fujifilm Feature Comparison Reader Study to Compare Old vs New Processing,0.38904109589041097,Completed,Observational,No,Yes,Sponsor,600
3-2021-0468,Pectoralis Nerve Block and Quality of Recovery in Mastectomy Patients,3.0821917808219177,Recruiting,Interventional,No,No,Principal Investigator,156
IB 2019-01,Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors,3.92054794520548,Recruiting,Interventional,No,No,Sponsor,247
2022-010,F-Tryptophan PET/CT in Human Cancers,2.2575342465753425,Recruiting,Interventional,Yes,No,Principal Investigator,24
Reader-02 Study,Optoacoustic Images Versus ImagioÂ® Ultrasound,0.263013698630137,Completed,Interventional,No,Yes,Sponsor,480
20-03,"A Prospective, Multi-site Clinical Study to Collect User Feedback Using AffirmÂ® Contrast Biopsy",1.4547945205479451,Completed,Interventional,No,Yes,Sponsor,60
YWBC-002,Prevention and Treatment of Pyrrolitinib-associated Diarrhea,2.956164383561644,Recruiting,Interventional,No,No,Sponsor,470
PER-19-03,Wide-field Optical Coherence Tomography Imaging of Excised Breast Tissue.,0.9808219178082193,Completed,Observational,No,Yes,Sponsor,173
2018-4107,Does a Preoperative Prophylactic Antibiotic Reduce Surgical Site Infection Following Wire-localized Lumpectomy,1.6767123287671233,Completed,Interventional,No,No,Sponsor,326
2019-1176,Patient-Specific Decision Aid System for Shared Decision Making About Breast Reconstruction,2.2164383561643834,Recruiting,Interventional,No,No,Sponsor,40
2021-0290,Effect of Neurotization on QoL and Sensory Restoration,0.7534246575342466,Not yet recruiting,Interventional,No,No,Sponsor,50
0180910/16,The Combination of PECS II Block and Parasternal Block for Radical Mastectomy,0.36164383561643837,Completed,Interventional,No,No,Principal Investigator,65
ETNA-CRCI,Development and Validation of a Novel Functional Eye-Tracking Software Application for Cancer-related Cognitive Impairment (CRCI),2.813698630136986,Recruiting,Observational,No,No,Sponsor,230
INTRUSION,INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701,2.2465753424657535,Not yet recruiting,Interventional,No,No,Principal Investigator,60
2019-A00121-56,Analgesia Nociception Index (ANI) After Unilateral Radical Mastectomy as an Evaluation of Paravertebral Block Failure,4.0849315068493155,"Active, not recruiting",Observational,No,No,Sponsor,100
2018-9409,Intra-Operative Radiation Registry,6.005479452054795,Recruiting,Observational,No,No,Principal Investigator,250
R.22.09.1830,Comparison of Analgesic Efficacy of Ultrasound Guided Rhomboid Intercostal Block Versus Serratus Anterior Plane Block for Mastectomy Surgery,0.3287671232876712,Recruiting,Interventional,No,No,Principal Investigator,60
SCOUT2021,Streamlined Localization Using SCOUTÂ® at Biopsy (STREAMLoc ),1.9178082191780825,Recruiting,Interventional,No,No,Sponsor,500
PROICM 2019-07 PRE,Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction,6.473972602739726,Recruiting,Interventional,No,No,Sponsor,250
2022-A01940-43,Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL,1.5041095890410958,Not yet recruiting,Interventional,No,No,Sponsor,60
Reader-01,"Imagio Feasibility Multi-Reader, Multi-Case Study",0.07123287671232877,Completed,Interventional,No,Yes,Sponsor,155
2020-0980,What Women Want: Real Time Results During Screening Mammography in the Era of Patient-Experience Driven Care,2.7753424657534245,Recruiting,Observational,No,No,Sponsor,1000
STUDY00025461,Use of Virtual Reality Goggles During Chemotherapy Infusion to Reduce Anxiety-Related Symptoms,0.18356164383561643,Not yet recruiting,Interventional,No,No,Principal Investigator,44
19D.203,Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings,2.5972602739726027,Completed,Interventional,No,No,Sponsor,107
BCD-178-1,"A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or PerjetaÂ® in Healthy Volunteers",1.4821917808219178,"Active, not recruiting",Interventional,No,No,Sponsor,100
2019P003607-11,Data Analysis for Drug Repurposing for Effective Alzheimers Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole,0.25205479452054796,"Active, not recruiting",Observational,Yes,No,Principal Investigator,16989
SHR6390-I-114,Study of SHR6390 in Renal Insufficiency and Healthy Subjects,0.7780821917808219,Recruiting,Interventional,No,No,Sponsor,30
19-005445,Determining Molecular Drivers of Radiation Dermatitis,3.0246575342465754,Enrolling by invitation,Observational,No,No,Principal Investigator,20
2204MDJ,Testing Video Information About Mammography Screening,0.12054794520547947,Unknown status,Interventional,No,No,Principal Investigator,400
mastectomy regional anesthesia,Regional Anesthesia for Modified Radical Mastectomy With Axillary Lymph Node Dissection,2.835616438356164,Completed,Interventional,No,No,Principal Investigator,13
PECS 2019,The Analgesic Efficacy of the Pectoral Nerves Block Versus Local Anesthetic Infiltration After Mastectomy,1.663013698630137,Unknown status,Interventional,No,No,Sponsor,50
R-2017/UEM11,Acute Effect of Chromatic Environment During Chemotherapy,2.671232876712329,Unknown status,Interventional,No,No,Principal Investigator,20
IBIO-302,Food Effect Study of D-0502 Tablet in Healthy Volunteers,0.4821917808219179,Completed,Interventional,Yes,No,Sponsor,14
LAE203CN2101,PhI to Solid Tumors and PhII to Locally Advanced or mTNBC,3.1342465753424658,Recruiting,Interventional,No,No,Sponsor,101
SN132D CSP final version 6.0,A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer,3.2739726027397262,Completed,Interventional,No,No,Sponsor,14
2022-1151,Implementation of Population Breast Cancer Genetic Services in Federally Qualified Health Centers (FQHC),4.336986301369863,Not yet recruiting,Interventional,No,No,Principal Investigator,130
CIRB Ref. No: 2017/3139,Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS),4.208219178082192,Recruiting,Observational,No,No,Principal Investigator,236
LCCC1754,UNC Pleural Fluid Registry,32.02191780821918,Recruiting,Observational,No,No,Sponsor,9999
Tomosymthesis,Tomosymthesis for Breast Mass Lesion Characterization,2.082191780821918,Not yet recruiting,Observational,,,Sponsor-Investigator,30
NINTAU,ConquerFear-Group: A Psychological Intervention for Fear of Cancer Recurrence,2.671232876712329,Completed,Interventional,No,No,Principal Investigator,85
BCA-AI,Development of Artificial Intelligence System for Detection and Diagnosis of Breast Lesion Using Mammography,2.082191780821918,Completed,Observational,No,No,Principal Investigator,5809
21-002713,3D Ultrasound Microvessel Imaging for Breast Masses,2.671232876712329,Recruiting,Interventional,No,Yes,Sponsor,50
LIVFOU-930411,Pectoral Nerves Block vs Wound Infiltration for Partial Mastectomy - a Prospective Randomized Trial.,1.1945205479452055,Completed,Interventional,No,No,Principal Investigator,60
21-BI-1607-01,BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors,4.347945205479452,Recruiting,Interventional,No,No,Sponsor,116
20-378,Researching the Effect of Exercise on Cancer,4.002739726027397,Recruiting,Interventional,No,No,Sponsor,70
2019-A0872-55,Study on Skin Toxicities Induced by Cancer Treatments,3.665753424657534,Recruiting,Interventional,No,No,Sponsor,300
CAAA504A12101,Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress Î±vÎ²3 and Î±vÎ²5 Integrins.,2.073972602739726,Recruiting,Interventional,Yes,No,Sponsor,80
20190701041GH,Antler Plate on Preventing Mammary High-risk Lesions From Malignant Development,5.002739726027397,Recruiting,Observational,No,No,Principal Investigator,6000
D6900C00001,First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies,3.7013698630136984,Recruiting,Interventional,Yes,No,Sponsor,198
HNCH-BC004,A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity,1.6465753424657534,Completed,Interventional,No,No,Principal Investigator,159
CMUH106-REC2-117,Evaluation of the Efficacy of Acupuncture in Chemotherapy Induced Peripheral Neuropathy,2.2904109589041095,Unknown status,Observational,No,No,Principal Investigator,50
20200491,Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences,3.504109589041096,Recruiting,Interventional,No,No,Principal Investigator,40
2019-06214,Psychological Effects of Implant Loss,5.838356164383562,Recruiting,Observational,No,No,Sponsor,150
LS2023012,Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy,1.0000000000000002,Recruiting,Interventional,No,No,Principal Investigator,10
PRO2021-1428,Efficacy and Safety of TILs in Treatment of Patients With Advanced or Metastatic Refractory Gynecological Cancer,5.0,Not yet recruiting,Interventional,No,No,Sponsor,91
ZN-A-1041-101,Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors,3.7095890410958905,Recruiting,Interventional,No,No,Sponsor,84
HCC 21-265,"Dignity, Legacy, Advocacy, and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community",3.221917808219178,Recruiting,Interventional,No,No,Principal Investigator,5
HNCH-BC007,GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel,1.9506849315068495,Withdrawn,Interventional,No,No,Principal Investigator,0
2020-0498,Myofascial Release or Trigger Point Injections for the Reduction of Post-Mastectomy Pain Syndrome,0.0,Withdrawn,Interventional,No,Yes,Sponsor,0
NBE-002-01,NBE-002 in Patients With Advanced Solid Tumors,5.454794520547945,"Active, not recruiting",Interventional,Yes,No,Sponsor,100
PROT002 - Test Plan 01 Rev A,Blue Note Therapeutics Product BNT 103 Usability and User Engagement,0.3315068493150685,Completed,Interventional,No,Yes,Sponsor,15
1B-22-2,"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors",3.0027397260273974,Recruiting,Interventional,Yes,No,Sponsor,18
Gen 2 - 01,Clinical Evaluation of Opto-Acoustic Image Quality With the Gen 2 Imagio System,0.49863013698630143,Completed,Interventional,No,Yes,Sponsor,38
PROT001,Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment,1.2986301369863014,Terminated,Interventional,No,No,Sponsor,31
MW05-2020-CP301,Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF,2.1232876712328768,Completed,Interventional,No,No,Sponsor,586
BYON5667.002,Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985,2.9753424657534246,"Active, not recruiting",Interventional,No,No,Sponsor,48
UZBRU_VHH2_1,Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT,3.4054794520547946,Recruiting,Interventional,No,No,Sponsor,37
v24-9-2017,Psyhosomatic Medicine in Oncologic and Cardiac Disease Study,4.684931506849315,Unknown status,Observational,No,No,Principal Investigator,220
19-007547,"Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial",4.3342465753424655,"Active, not recruiting",Interventional,Yes,No,Sponsor,40
Pro00092817,VR Ultrasound Guided Breast Localization,0.9835616438356165,Completed,Interventional,No,No,Sponsor,60
Pro00112215,The Use of Virtual Reality During Breast Ultrasound-Guided Biopsy Procedures,1.0438356164383562,Enrolling by invitation,Interventional,No,No,Sponsor,60
Ageing-NIO,"Examining and Comparing the Temporal Changes and Results of Cosmetic, Quality of Life and Patient Satisfaction Achieved With Immediate and Delayed-immediate Implant-based Breast Reconstruction Procedures and Contralateral Symmetrization Techniques",6.956164383561644,Recruiting,Observational,No,No,Principal Investigator,528
M16-573,A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors,4.8,"Active, not recruiting",Interventional,Yes,No,Sponsor,169
5R44CA203608,LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge),3.3068493150684932,Recruiting,Interventional,No,Yes,Sponsor,60
ACROPOLI (SOLTI-1904),Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors,3.6684931506849314,"Active, not recruiting",Interventional,No,No,Sponsor,73
NL52329.075.15,Intra-individual Comparison of Conventional and Digital PET/CT Scanners,1.6794520547945206,Completed,Interventional,No,No,Principal Investigator,225
DPCVC,Diagnostic Power Comparison Between VOCs and CTCs,1.547945205479452,Unknown status,Observational,No,No,Principal Investigator,200
AAAT2490,AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc,4.583561643835616,Recruiting,Interventional,No,No,Principal Investigator,240
0S-20-6,Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy,3.5013698630136987,Recruiting,Observational,No,No,Sponsor,100
SRNSM,"Examining the Cosmetic Results, Quality of Life and Patient Satisfaction Achieved With Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction, and Comparing it to Classic Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgeries",6.967123287671233,Recruiting,Observational,No,No,Principal Investigator,110
CMP-001-009,A Trial to Find Out if Vidutolimod Together With Cemiplimab is Safe and if it Works in Adult Participants With Advanced Cancer or Metastatic Cancer,5.2684931506849315,Recruiting,Interventional,Yes,No,Sponsor,200
5890-001,Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001),6.6876712328767125,"Active, not recruiting",Interventional,Yes,No,Sponsor,202
SS-SP01-201904,Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents,2.4547945205479453,Recruiting,Interventional,No,No,Principal Investigator,60
H19-03343,Carbon-Fibre Accessory (CARA) for Supine Breast Positioning to Reduce Toxicity in Whole Breast Radiotherapy,4.558904109589041,Recruiting,Interventional,No,No,Principal Investigator,220
BPI-2358-106 phase 3,Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia,5.928767123287671,"Active, not recruiting",Interventional,Yes,No,Sponsor,221
EK 1623/2020,Dose-staged Gamma Knife Radiosurgery Versus Microsurgical Resection,3.419178082191781,Recruiting,Interventional,No,No,Principal Investigator,100
TRX518-004,A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors,1.1534246575342466,Terminated,Interventional,Yes,No,Sponsor,10
20200110,Study of the Effects of Transcutaneous Vagus Nerve Stimulation on Cancer Patients,1.7424657534246575,Recruiting,Interventional,No,No,Principal Investigator,130
ASPB vs ESBP for mastectomy,Comparison Between Serratus Anterior Plane Block and Erector Spinae Plane Block for Mastectomy,0.8301369863013699,Completed,Interventional,No,No,Principal Investigator,25
2018-01,Quantitative Evaluation of the Breasts Morphological Variations During Radiotherapy: MorphoBreast3D,2.2054794520547945,Completed,Interventional,No,No,Sponsor,60
TYKM1602101,A Study of TY-302 in Patients With Advanced Solid Tumors,2.9835616438356163,Recruiting,Interventional,No,No,Sponsor,60
BrUOG 351,BrUOG 351: PRE-OPERATIVE APBI USING NIBB,0.8931506849315068,Withdrawn,Interventional,No,No,Sponsor-Investigator,0
PI-3958,Opioid Free Anaesthesia in Oncologic Gynaecological Surgery: Is There Any Benefit?,1.9945205479452057,Completed,Observational,Yes,No,Sponsor,132
KL264-01,"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies",5.761643835616439,Recruiting,Interventional,Yes,No,Sponsor,430
Medipol Hospital 26,Different Volumes of Erector Spinae Plane Block for Breast Surgery,1.16986301369863,Recruiting,Interventional,No,No,Principal Investigator,60
NeoVAB,Evaluation of the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB),2.232876712328767,Unknown status,Interventional,No,No,Sponsor,67
16-136,Ipilimumab and Nivolumab in Leptomeningeal Metastases,3.4328767123287673,Completed,Interventional,Yes,No,Principal Investigator,18
SGN228-001,A Study of SGN-CD228A in Advanced Solid Tumors,3.515068493150685,Terminated,Interventional,Yes,No,Sponsor,88
1612017795,Web-based Family History Tool,3.3123287671232875,Completed,Interventional,No,No,Sponsor,250
7902-005,Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005),4.86027397260274,"Active, not recruiting",Interventional,Yes,No,Sponsor,590
UUBreast02,PREMs on PROMs in Breast Disease (PREMs_PROMs),1.663013698630137,Completed,Interventional,No,No,Principal Investigator,230
2021-0842,Single Step Lesion Annotation and Localization of Suspicious Breast Lesions,1.558904109589041,Recruiting,Interventional,No,Yes,Sponsor,100
GN19HS442,Augmented Reality (AR): The Future of Patient Information Leaflets,1.3287671232876712,Recruiting,Interventional,No,No,Sponsor,20
06-2020/1,Validation of the Russian and Kazakh Versions of the Beck Depression Inventory and Beck Anxiety Inventory,2.2986301369863016,Completed,Observational,No,No,Sponsor,226
MCC-21622,Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies,2.9726027397260273,Recruiting,Interventional,Yes,No,Sponsor,88
SIBP-03-01,A Phase â a Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.,3.0,Recruiting,Interventional,No,No,Sponsor,68
IRB00047335,Speeding Recovery From Pain and Opioid Use,1.5835616438356164,Withdrawn,Interventional,Yes,No,Sponsor,0
217510,Microbiome and Association With Implant Infections,4.260273972602739,Recruiting,Interventional,Yes,No,Sponsor,200
RIN20230039,Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure,0.7561643835616438,Not yet recruiting,Interventional,No,No,Sponsor,30000
4-2019-0834,Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction,2.558904109589041,"Active, not recruiting",Observational,No,No,Principal Investigator,300
UI/EC/20/0275,The Effect of Octreotide on Wound Drainage After Mastectomy,0.9561643835616439,Completed,Interventional,No,No,Sponsor-Investigator,41
AB-201-01,A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors,4.087671232876713,Not yet recruiting,Interventional,Yes,No,Sponsor,133
IOM-040369,Patient Preference for Pegfilgrastim (NeulastaÂ®) Application Forms,1.210958904109589,Completed,Interventional,No,No,Sponsor,404
233,Effect of tDCS of the Motor Cortex on Chemotherapy Induced Nausia and Vomiting,1.6657534246575343,Unknown status,Interventional,No,No,Sponsor-Investigator,30
TQB3616-I-02,Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects,0.1506849315068493,Completed,Interventional,No,No,Sponsor,16
MAR-BAS-18-005,The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy,3.8191780821917813,Recruiting,Interventional,No,No,Sponsor,384
107709,Acupuncture Treatment of Chemotherapy-Induced Peripheral Neuropathy in Women,0.7698630136986301,Terminated,Interventional,No,Yes,Principal Investigator,3
20-1456,Improving Cancer Screening and Follow-up in Community Health Centers,0.49863013698630143,Not yet recruiting,Interventional,No,No,Principal Investigator,15
UTN: U1111-1278-1680,CPAP for Motion Management in Breast Radiotherapy; and Lung & Liver SABR,1.0000000000000002,Not yet recruiting,Interventional,No,No,Principal Investigator,70
19-104,The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting,2.1671232876712327,Recruiting,Interventional,No,No,Principal Investigator,144
MASCT-I-1003,A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor,2.202739726027397,Unknown status,Interventional,No,No,Sponsor,28
REC/RCR&AHS/22/0511,Effects Of Lymphatic Drainage on Axillary Web Syndrome,0.726027397260274,Recruiting,Interventional,No,No,Sponsor,20
18-264,Enhancing Cancer Prevention and Control Pathways-Native Health Initiative,2.5013698630136987,Recruiting,Interventional,No,No,Sponsor,200
KY20202093-F-1,Clinical Study of 68Ga Labeled HER2 Affibody Analogues,1.5013698630136987,Not yet recruiting,Interventional,No,No,Sponsor,56
P050001 TiLOOPÂ® Bra Pocket,Post Market Clinical Follow Up to Patient Reported Outcome Using a Titanised Polypropylene Mesh (TiLOOPÂ® Bra Pocket),3.66027397260274,"Active, not recruiting",Observational,No,No,Sponsor,313
2021-0262,Home Based Exercise for Patients With Breast or Prostate Cancer (The BENEFIT-CA Study),1.7315068493150685,Recruiting,Interventional,No,No,Sponsor,80
H18-02014,CARA Treatment Pilot Study for Breast Positioning,1.1123287671232878,Completed,Interventional,No,No,Principal Investigator,20
262180,Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane,3.7150684931506848,Recruiting,Interventional,Yes,No,Sponsor,25
IRB19-2074,Abbreviated MRI Protocol: Initial Experience With DotaremÂ® (Gadoterate Meglumine),2.717808219178082,Recruiting,Interventional,Yes,No,Sponsor,50
TG1819ONC,A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors,3.6986301369863015,Recruiting,Interventional,No,No,Sponsor,233
STUDY00018917,The PAI Trial for Breast and Colon Cancer Survivors,0.0,Withdrawn,Interventional,No,No,Principal Investigator,0
STUDY00002789,CONTIGO - Informing Latinas About HBOC Risk,4.586301369863014,Enrolling by invitation,Interventional,No,No,Sponsor,332
S66520,Use of Fractional CO2 Laser Versus Erbium:YAG Laser for the Treatment of GSM in Patients Using Aromatase Inhibitors,2.9315068493150687,Recruiting,Interventional,No,No,Sponsor,162
P.T.REC/012/002677,Effectiveness of Low Level Laser Therapy on Insulin Resistance and Inflammatory Biomarkers,3.16986301369863,Recruiting,Interventional,No,No,Principal Investigator,60
ISPY-P1.01,ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer,0.30684931506849317,Withdrawn,Interventional,Yes,No,Sponsor,0
NCI-2017-01921,Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery,4.315068493150685,"Active, not recruiting",Interventional,Yes,No,Sponsor,33
"2016-051-000001, 1835",Investigating Public Enthusiasm for Mammography Screening in Denmark,0.16164383561643836,Completed,Interventional,No,No,Sponsor,768
CF21163B,Clinical Outcome of Extracorporeal Shock Wave Therapy in Patient With Axillary Web Syndrome,2.884931506849315,Recruiting,Interventional,No,No,Sponsor,30
D-FR-01072-002,"Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)",0.40821917808219177,Terminated,Interventional,Yes,No,Sponsor,9
Breast-Nektaria,The Impact of Pecs Blocks on Postmastectomy Pain Syndrome,1.663013698630137,Completed,Interventional,No,No,Principal Investigator,64
1413727,An Intimacy Intervention for Couples Completing Breast or Prostate Cancer,1.063013698630137,Completed,Interventional,No,No,Principal Investigator,14
1049/2018,Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy,2.786301369863014,Completed,Observational,No,Yes,Sponsor,128
20200426,Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants,0.08493150684931507,Completed,Interventional,Yes,No,Sponsor,13
VALO-001,START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer,0.9123287671232877,Recruiting,Interventional,No,No,Sponsor,15
IMU R204/2017,Perioperative Oral Nutrition Supplementation in Malnourished Surgical Cancer Patients,2.5123287671232877,Completed,Interventional,No,No,Principal Investigator,91
LCCC1915,3-D Super Resolution Ultrasound Microvascular Imaging,2.3534246575342466,Recruiting,Interventional,Yes,Yes,Sponsor,45
RiphahIU Shafaq,Effects of Active Release Technique (ART) on Pectoralis Minor Tightness in Post Mastectomy Women.,0.4328767123287671,Completed,Interventional,No,No,Sponsor,60
CRX100-001,Study of CRX100 in Patients With Advanced Solid Tumors,4.145205479452056,Recruiting,Interventional,Yes,No,Sponsor,24
HREBA.CC-20-0077,Time-restricted Eating in Survivors Trial,0.978082191780822,Completed,Interventional,No,No,Sponsor,22
TST-9-H,Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors,1.167123287671233,Withdrawn,Interventional,No,No,Sponsor,0
OCOG-2022-RAPID2,A Randomized Trial of Five Fraction Partial Breast Irradiation,8.753424657534246,Not yet recruiting,Interventional,No,No,Sponsor,910
20181004,Mindful After Cancer: A Mindfulness-based Therapy Intervention for Sexual Health After Cancer,1.2657534246575342,Completed,Interventional,No,No,Sponsor,28
18-571,EHR-embedded OCDT in Breast or GI Cancer,2.7013698630136984,Completed,Interventional,No,No,Principal Investigator,100
R19-159,Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction,2.210958904109589,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,20
HR-BLTN-DDI-07,Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects,0.40273972602739727,Completed,Interventional,No,No,Sponsor,36
201612723,NR in Chemo-induced Peripheral Neuropathy,2.2986301369863016,Terminated,Interventional,Yes,No,Sponsor-Investigator,5
2012285106,Dedicated Breast CT for Quantitative Breast Density Measurements in Mexican-origin Women in Southern Arizona,1.2547945205479452,Recruiting,Observational,No,No,Sponsor,100
AWS,Effects of a Manual Therapy Program to Reduce the Evolution Time of Axillary Web Syndrome,2.008219178082192,Recruiting,Interventional,No,No,Principal Investigator,46
2022-0328,"Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics",0.5205479452054795,Recruiting,Interventional,No,No,Sponsor,1000
20/007-E_TFM,Study of the Effectiveness of Supervised vs. Non-Supervised Therapeutic Exercise in Cancer Patients,1.4191780821917808,Unknown status,Interventional,No,No,Sponsor,58
Internal Code 012-23,Efficacy and Safety of Supervised Therapeutic Exercise in Cancer Patients With and Without Concurrent Treatment.,2.254794520547945,Not yet recruiting,Interventional,No,No,Sponsor,78
0352-2189,"A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis",1.1287671232876713,Not yet recruiting,Interventional,No,No,Sponsor,30
HCI128055,[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma,3.5534246575342467,Recruiting,Interventional,Yes,No,Sponsor,79
180097,Olaparib in People With Malignant Mesothelioma,2.282191780821918,Completed,Interventional,Yes,Yes,Principal Investigator,23
190134,Vaccine Response With NT-I7,2.052054794520548,Recruiting,Interventional,Yes,No,Sponsor,68
TH1902-CTR-0001,TH1902 in Patients With Advanced Solid Tumors,1.9917808219178084,"Active, not recruiting",Interventional,Yes,No,Sponsor,70
18112,64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy,2.0767123287671234,Recruiting,Interventional,Yes,No,Sponsor,6
KY20172047-1,Safety Study of 3D Printing Personalized Biodegradable Implant for Breast Reconstruction,7.424657534246576,Recruiting,Interventional,No,No,Sponsor,30
BREAST HEMATOMA,Vacuum-Assisted Evacuation (VAE) Of Symptomatic and/or Voluminous Breast Haematomas Following Surgeries And Percutaneous Procedures: a Retrospective Analysis,0.2054794520547945,Completed,Observational,No,Yes,Principal Investigator,15
mRNA-2752-P101,Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies,6.347945205479452,Recruiting,Interventional,Yes,No,Sponsor,264
1380800-R,Unified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments,1.6849315068493151,Recruiting,Interventional,No,No,Principal Investigator,123
7621,Opening the Conversation Study,3.334246575342466,Recruiting,Interventional,No,No,Principal Investigator,200
TomBakerCC,Mobile App Postoperative Home Monitoring After Enhanced Recovery Oncologic Surgery,1.8520547945205479,Completed,Interventional,No,No,Principal Investigator,72
SVIFT Nodal Trial,Breast Fractionation Study - Standard Versus Investigational Fractionation Trial - Nodal Radiation,6.586301369863014,Recruiting,Interventional,No,No,Principal Investigator,132
CASE1Z21,Patient Recall of Cancer Screening and Diagnosis,1.0027397260273974,Recruiting,Interventional,No,No,Sponsor,100
IRB00075787,Mastectomy Flap Temperature Study,1.0054794520547947,Recruiting,Interventional,No,No,Sponsor,30
HB-AT-001,Radiation Therapy (HB-001) by Alpha-particle Sources for Recurrent Malignant Solid Tumors in Japan,3.0082191780821916,Completed,Interventional,No,No,Sponsor,14
D161100000816006,Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion,1.3123287671232877,Completed,Observational,No,No,Principal Investigator,1981
ART4215C001,A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors,3.8849315068493153,Recruiting,Interventional,Yes,No,Sponsor,330
Duke-NUS,Marital Satisfaction and Sexual Health of Female Cancer Patients in Singapore,3.665753424657534,Recruiting,Interventional,No,No,Principal Investigator,60
226947,SS-INQ Information Needs Questionnaire in SjÃ¶grens Syndrome,2.7753424657534245,Completed,Observational,No,No,Sponsor,243
SKNA pilot,Measurement of the Skin Sympathetic Nerve Activity,0.16986301369863013,Completed,Interventional,No,No,Principal Investigator,20
IIT2018-05-ASHER-IMPROV2,LOL: Its All Improv After Cancer!â¢,5.917808219178082,"Active, not recruiting",Interventional,No,No,Sponsor-Investigator,13
OU-SCC Virtual Reality,Virtual Reality Software to Reduce Stress in Cancer Patients,2.0027397260273974,Not yet recruiting,Interventional,No,No,Sponsor,20
2020-A03205-34,"Meditation and Cancer, Pilot Feasibility Study (MAEva Pilot Study)",1.2493150684931507,Recruiting,Interventional,No,No,Sponsor,40
OPERA2,OperaÂ® for Aromatase Inhibitor-related Arthralgia Management (AIA),1.0000000000000002,Completed,Interventional,No,No,Principal Investigator,53
TaiHao BR-USCAD VT 20-249,Evaluation of TaiHao Breast Ultrasound Diagnosis Software,0.2136986301369863,Completed,Interventional,No,Yes,Sponsor,16
201907039,RANKL Inhibition and Mammographic Breast Density,7.016438356164383,Recruiting,Interventional,Yes,No,Sponsor,210
UMCC 2021.004,Sleep Coach: A Mobile App to Address Insomnia Symptoms Among Cancer Survivors,1.2410958904109588,Completed,Interventional,No,No,Sponsor,30
UPMREB 2021-140-01,Bacterial Cellulose-monolaurin Hydrogel for Acute Radiation Dermatitis,1.2493150684931507,Recruiting,Interventional,No,No,Sponsor,54
15/LO/1038 BRACELET,Breast: Recovery After Axillary Node Clearance - Evaluating Limbs With E-Technology (the BRACELET Study),3.6904109589041094,Unknown status,Observational,No,No,Sponsor,75
KS01,Serratus Plane Block vs Erector Spinae Plane Block on Postoperative Analgesia in Patients Undergoing Unilateral Breast Surgery,0.4191780821917808,Completed,Interventional,No,No,Principal Investigator,70
MS-268-2019,Effectiveness of Ultrasound Guided Erector Spinae Plane Block Against Ultrasound Guided Serratus Anterior Block in Modified Radical Mastectomy,0.3589041095890411,Completed,Interventional,No,No,Principal Investigator,60
BoCCE,Biopsy of Calcifications Under Contrast Enhancement Guide (BoCCE),1.356164383561644,Unknown status,Interventional,No,No,Sponsor,200
875329B,Real-Life Pilot Feasibility Study (LC_RLP_PUC1),0.7479452054794521,Recruiting,Interventional,No,No,Sponsor,120
BrUOG 390,BrUOG 390: Neoadjuvant Treatment With Talazoparib,5.764383561643836,"Active, not recruiting",Interventional,Yes,No,Sponsor,1
MS-536-2021,Dexmedetomidine Versus Dexamethasone as Adjuncts in Erector Spinae Plane Block in Modified Radical Mastectomy,1.2465753424657535,Completed,Interventional,No,No,Principal Investigator,90
Gyn F-Chem,Effects of Music or Hypnotherapy on Cancer Patients During Chemotherapy,3.750684931506849,Terminated,Interventional,No,No,Principal Investigator,81
PROICM 2019-06 COH,Management of Perioperative Anxiety by the Cardiac Coherence Technique Coupled With a Hypnosis Session,1.9178082191780825,Completed,Interventional,No,No,Sponsor,53
NCCH1905,Asian Multicenter Prospective Study of ctDNA Sequencing,3.1671232876712327,Recruiting,Observational,No,No,Sponsor,506
D3614C00004,A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body,0.14246575342465753,Completed,Interventional,Yes,No,Sponsor,11
1449,Pre-pectoral Versus Sub-pectoral Implant Placement in Immediate Breast Reconstruction,4.358904109589041,Recruiting,Interventional,No,No,Sponsor,56
RocuMAST,Effect of Rocuronium on BIS Values,0.23835616438356166,Recruiting,Observational,No,No,Principal Investigator,8
CHD22_0002,Interest of Virtual Reality on Anxiety Before the Planning CT Scan in Radiotherapy,1.8246575342465754,Recruiting,Interventional,No,No,Sponsor,256
CLINP-001001,Motiva Flora Tissue Expander PMCF,2.5013698630136987,Recruiting,Interventional,No,No,Sponsor,136
1920306,Purpose in Life Survey,2.0849315068493155,Enrolling by invitation,Observational,No,No,Sponsor-Investigator,300
17-VIN-0855,A Bioequivalence Study of Capecitabine Tablets 500 mg in Adult Cancer Patients Under Fed Condition,0.5041095890410959,Unknown status,Interventional,Yes,No,Sponsor,45
2022-01423-01,Optimizing Postoperative Recovery After Breast Reconstruction With Autologous Tissue (BestDIEP),4.668493150684932,Recruiting,Observational,No,No,Sponsor,380
2019-0557,Novel Application of Indocyanine Green as a Biomarker to Identify Tissue Necrosis in Mastectomy Patients,0.2328767123287671,Completed,Interventional,Yes,Yes,Sponsor,10
Breast 2019,PCR Based CEUS in BI RADS 4A Nodules,2.750684931506849,Unknown status,Observational,No,No,Sponsor,260
D0817C00098,Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib,4.432876712328767,Enrolling by invitation,Interventional,Yes,No,Sponsor,292
2017-377,The Effect of Double Injection Erector Spinae Plane Block on Postoperative Pain Following Breast Surgery,0.08767123287671233,Completed,Interventional,No,No,Principal Investigator,50
IZKSZ3_188408 / 1,The DIALOGUE Study: Swiss-Korean Billateral Collaboration,2.7150684931506848,Recruiting,Interventional,No,No,Principal Investigator,228
2018-94,Comparison of Erector Spinae Plane Block With Thoracic Paravertebral Block for Breast Surgery,0.3972602739726027,Completed,Interventional,No,No,Principal Investigator,75
ORIN1001-C1,Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.,2.9972602739726026,"Active, not recruiting",Interventional,Yes,No,Sponsor,350
UMCC 2020.041,Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias,1.7972602739726027,Recruiting,Interventional,Yes,No,Sponsor,44
H-42207 GAIL-N,C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N),19.621917808219177,Recruiting,Interventional,Yes,No,Principal Investigator,94
Esogu Anesthesia,Comparison of Erector Spina Plane Block and Thoracic Epidural Block,0.21643835616438356,Completed,Interventional,No,No,Principal Investigator,20
TED16925,Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors,4.21095890410959,Recruiting,Interventional,Yes,No,Sponsor,200
Telerehab CH Feasibility,Telerehabilitation Cognitive Impairments Following Chemotherapy Feasibility Study,0.6383561643835617,Recruiting,Interventional,No,No,Sponsor,40
RPC006,A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.,2.5178082191780824,"Active, not recruiting",Interventional,Yes,No,Sponsor,90
BEX15859,"Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women",0.1780821917808219,Completed,Interventional,No,No,Sponsor,6
waitingroom,Anxiety on the First Day of Chemotherapy,1.3342465753424657,Unknown status,Interventional,No,No,Principal Investigator,106
CP-10-001,In Vivo Smart Biopsy Device Protocol In Radiology,1.0493150684931507,Unknown status,Interventional,No,No,Sponsor,41
REB16-1463,Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors,2.252054794520548,Unknown status,Interventional,No,No,Principal Investigator,128
UF-STO-ETG-003,Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types,3.0794520547945203,Recruiting,Interventional,Yes,No,Sponsor,29
UMCC 2020.157,Lighting Intervention for Cancer-related Fatigue,1.6493150684931508,Completed,Interventional,No,No,Sponsor,139
OnkoFit II,Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy,5.002739726027397,Recruiting,Interventional,No,No,Principal Investigator,201
R7075-ONC-2009,REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors,5.279452054794521,Recruiting,Interventional,Yes,No,Sponsor,434
CART-TnMUC1-01,A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers,3.147945205479452,Terminated,Interventional,Yes,No,Sponsor,16
PT06-01,A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors,1.3287671232876712,Unknown status,Interventional,Yes,No,Sponsor,60
2019/2944,Cryotherapy in Breast B3 Lesions,1.082191780821918,Recruiting,Interventional,No,No,Sponsor,12
SPI-POZ-501,A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib,7.504109589041096,"Active, not recruiting",Interventional,Yes,No,Sponsor,20
LCB-1801-001,A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers,3.4246575342465753,Recruiting,Interventional,No,No,Sponsor,40
PECS vs SAP,Comparing the Quality of Analgesia With Pectoral Nerve Block and Serratus Plane Block in Modified Radical Mastectomy,0.3287671232876712,Completed,Interventional,No,No,Principal Investigator,50
2020-000495-37,"Assessment of 99mTc-NTP 15-5 Uptake on Cartilage, a New Proteoglycan Tracer",1.8520547945205479,Completed,Interventional,No,No,Sponsor,6
2018-0175,Post-Mastectomy Analgesia Using Exparel (Liposomal) Versus Standard Bupivacaine or Placebo,2.421917808219178,Unknown status,Interventional,Yes,No,Sponsor,100
2021-082,DIEP Flap Surgery and Intraabdominal Pressure,0.7698630136986301,Completed,Observational,No,No,Principal Investigator,13
012018CONTROL,Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines,4.161643835616439,"Active, not recruiting",Interventional,No,No,Sponsor-Investigator,80
18232,Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY),4.747945205479452,Recruiting,Observational,No,No,Sponsor,200
R19258,The LYSA (Linking You to Support and Advice) Trial,2.4712328767123286,"Active, not recruiting",Interventional,No,No,Principal Investigator,200
2020/03FEV/065,Mechanically-Assisted and Non-Invasive Ventilation for Breathing-related Tumor Motion Mitigation.,2.243835616438356,Unknown status,Interventional,No,No,Sponsor,241
2012-001-108,Ramosetron on Late PONV (Postoperative Nausea and Vomiting),0.8712328767123287,Completed,Interventional,No,No,Principal Investigator,144
HREC/74777/Alfred-2021,Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial,5.52054794520548,Recruiting,Interventional,No,No,Principal Investigator,4300
7905,Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief,2.0767123287671234,Recruiting,Interventional,No,No,Sponsor,40
ARX788-1711,"A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)",5.704109589041096,"Active, not recruiting",Interventional,Yes,No,Sponsor,106
69HCL18_0492,Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture),1.7972602739726027,Recruiting,Interventional,No,No,Sponsor,132
BB-1701-101,A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors,3.345205479452055,Recruiting,Interventional,Yes,No,Sponsor,208
D9720C00001,Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies,5.178082191780822,Recruiting,Interventional,Yes,No,Sponsor,559
XuanWuH-NK,Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killerï¼NKï¼Cells,3.931506849315069,Unknown status,Interventional,No,No,Principal Investigator,200
FPX-01-01,A Phase 1/2 Study of [225Ac]-FPI-1434 Injection,7.375342465753425,Recruiting,Interventional,Yes,No,Sponsor,253
RAPA-201-STP-01,RAPA-201 Therapy of Solid Tumors,3.419178082191781,Recruiting,Interventional,Yes,No,Sponsor,22
HC-404-FCP-2011,A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD),2.750684931506849,Recruiting,Interventional,Yes,No,Sponsor,36
assuitu faculty of medicine,Outcomes of Breast Conservative Surgery for Post Chemotherapy Tumour Size After Response to Neoadjuvant Chemotherapy,3.504109589041096,Recruiting,Interventional,No,No,Principal Investigator,1
STUDY00015358,Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact,3.9150684931506854,"Active, not recruiting",Interventional,No,No,Principal Investigator,30
ONCX-NAV-G201,A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors,2.3643835616438356,Recruiting,Interventional,Yes,No,Sponsor,180
CRUKD/22/002,HMBD-001 in Advanced HER3 Positive Solid Tumours,4.810958904109589,Recruiting,Interventional,No,No,Sponsor,135
042201,Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted,4.449315068493151,Recruiting,Interventional,Yes,No,Principal Investigator,60
DCC-2036-01-004,A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors,3.8328767123287677,"Active, not recruiting",Interventional,Yes,No,Sponsor,117
NM1F-T1-01,"A First-in-human, Phase I, Open-label, Multicenter Study of NM1F Administered as Monotherapy and in Combination With Pembrolizumab to Patients With Advanced Solid Tumors.",3.506849315068493,Not yet recruiting,Interventional,Yes,No,Sponsor,38
213409,A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study,4.580821917808219,"Active, not recruiting",Interventional,Yes,No,Sponsor,26
ICO-2020-06,Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ,12.498630136986302,Recruiting,Interventional,No,No,Sponsor,262
OMO-103-01,"Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours",3.5972602739726027,"Active, not recruiting",Interventional,No,No,Sponsor,22
849679,RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR),1.8027397260273972,Recruiting,Interventional,No,No,Sponsor,150
UC-0101/1709,Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours,6.534246575342466,"Active, not recruiting",Interventional,No,No,Sponsor,150
4-2020-0165,Prospective Study of MAstectomy With Reconstruction Including Robot Endoscopic Surgery,10.002739726027396,Recruiting,Observational,No,No,Principal Investigator,2000
ZN-A-1041-101-US,A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors,3.126027397260274,Recruiting,Interventional,Yes,No,Sponsor,210
UW21084,Self-administered Acupressure to Improve Cancer-related Fatigue Among Cancer Patients Undergoing Chemotherapy,2.9178082191780823,Recruiting,Interventional,No,No,Principal Investigator,138
IRB#56402,Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study,2.2684931506849315,Enrolling by invitation,Observational,No,No,Sponsor,500
TAEK-VAC-HerBy-001,TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer,5.810958904109589,Recruiting,Interventional,Yes,No,Sponsor,55
C4161001,PF-07104091 as a Single Agent and in Combination Therapy,5.3123287671232875,Recruiting,Interventional,Yes,No,Sponsor,320
MORAb-202-G000-201,"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRÎ±)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types",4.652054794520548,Recruiting,Interventional,Yes,No,Sponsor,55
18-27025,SCOPE-Chinese Women Study,1.4465753424657535,Completed,Interventional,No,No,Sponsor,40
APHP210583,Personalized Estimation of Doses Delivered During Image Guided Radiation Therapy Tests,2.0000000000000004,Not yet recruiting,Observational,No,No,Sponsor,320
19-652,"Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers",4.0849315068493155,"Active, not recruiting",Interventional,No,No,Principal Investigator,220
BESTa,"Development, Implementation and Evaluation of an Individual Decision Aid in Swedish Cancer Screening Programs",1.8383561643835618,Recruiting,Interventional,No,No,Principal Investigator,220
EC/2018/0315,Hormone Replacement Trial Against ALzheimers Disease,5.7095890410958905,Recruiting,Interventional,No,No,Sponsor,300
SOLTI-1804,HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a),5.010958904109589,Recruiting,Interventional,No,No,Sponsor,180
M19-037,"A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors",4.482191780821918,"Active, not recruiting",Interventional,Yes,No,Sponsor,150
2020-00256; ch18Weber4,Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy OPBC-02PREPEC,12.6,Recruiting,Interventional,No,No,Sponsor,372
OSU-21313,A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer,2.73972602739726,Recruiting,Interventional,No,No,Principal Investigator,225
AN0025S0103,AN0025 and Pembrolizumab Combination in Advanced Solid Tumors,5.276712328767124,Recruiting,Interventional,Yes,No,Sponsor,84
202202104,Implementation of a Health System Intervention to Improve Quality of Cancer Care for Rural Patients,3.8657534246575347,Recruiting,Interventional,No,No,Sponsor-Investigator,100
Medipol Hospital 9,Pectoral Nerve Block Type-II and Rhomboid Intercostal Block for Pain Management Following Mastectomy Surgery,0.915068493150685,Completed,Interventional,No,No,Principal Investigator,90
69HCL18_0369,Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients,9.09041095890411,Recruiting,Interventional,No,No,Sponsor,410
2019/629,Breast Density Measurements in Digital Mammography and Breast Tomosynthesis Systems of Different Pixel Size,0.8356164383561644,Unknown status,Observational,No,Yes,Principal Investigator,300
200023,Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors,3.1780821917808217,Recruiting,Interventional,Yes,No,Sponsor,64
RB-vs-RG-BCS,"Comparison of the Cosmetic Results, Quality of Life and Patient Satisfaction Achieved With Round-block and Retroglandular Oncoplastic Breast Conserving Surgeries",6.967123287671233,Recruiting,Observational,No,No,Principal Investigator,242
CHANCES-IPC 2021-008,A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors,3.032876712328767,Recruiting,Interventional,No,No,Sponsor,27
17-694,Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia,1.1342465753424658,Terminated,Interventional,No,Yes,Principal Investigator,5
SLS17-201/MK3475-770,Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers,3.8410958904109593,"Active, not recruiting",Interventional,Yes,No,Sponsor,90
AP2207-30110,Dexmedetomidine vs Dexamethasone as Adjuvant to Bupivacaine in Bilevel Erector Spinae Plane Block in Breast Surgeries,1.0383561643835617,Recruiting,Interventional,No,No,Principal Investigator,60
FZPL-â¢-301-OC,A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients,3.673972602739726,"Active, not recruiting",Interventional,No,No,Sponsor,252
2015-KAEK-64-22-09,High Intensity vs Low Intensity Resistive Exercise In Patient With Upper Extremity Lymphedema,0.23013698630136986,Completed,Interventional,No,No,Principal Investigator,36
2022-0329,Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.,0.5315068493150685,Recruiting,Interventional,No,No,Sponsor,1000
CLODIS,Local Compression Seroma DIminution Objective (CLODIS),1.8712328767123287,Unknown status,Interventional,No,No,Sponsor,60
KE-0254/92/2018,ESP in Breast Surgery Due to Cancer,0.5397260273972603,Completed,Interventional,No,No,Principal Investigator,75
G423 Multi TP,Improving Cancer Outcomes Through Personalized Care Planning and Symptom Management.,0.7068493150684931,Completed,Interventional,No,No,Sponsor,51
2019-001982-34,Measuring Oncological Value of Exercise and Statin,4.7095890410958905,Not yet recruiting,Interventional,No,No,Principal Investigator,240
201803061RIND,Ventilation Efficacy of Size 3 or Size 4 I-gel in Female Patient Weighing 50 to 60 Kilograms,0.9260273972602739,Unknown status,Interventional,No,No,Sponsor,98
192004,"KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer",6.2684931506849315,Recruiting,Interventional,Yes,No,Sponsor-Investigator,42
RIPH3-RNI18/NEUROTAX,Involvement of SK3 Calcium Channel in Taxane Neuropathy,1.347945205479452,Completed,Observational,No,No,Sponsor,97
22339,Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors,1.4054794520547946,Not yet recruiting,Interventional,Yes,No,Sponsor,120
TAS2940-101,A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer,3.7095890410958905,Recruiting,Interventional,Yes,No,Sponsor,42
Bio2738,Shoulder Rehabilitation Using a Mobile App Following Breast Reconstruction,1.0082191780821919,Recruiting,Interventional,No,No,Principal Investigator,48
20252,Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety,1.3013698630136987,Completed,Interventional,No,No,Sponsor,1
2021-PrMa-RWiberg,"Prophylactic Mastectomy: Prospective Evaluation of the Correlation Between Skin Flap Thickness, Residual Glandular Tissue and Skin Necrosis by Imaging and Clinical Examination",5.353424657534247,Recruiting,Observational,No,No,Principal Investigator,45
STM-IRB-22B-001,Development and Testing of a TTDSS for Cancer Patients,1.7013698630136986,Recruiting,Interventional,No,No,Sponsor,136
69HCL20_0346,Impact of the COVID-19 Pandemic in Gynecological Oncology,0.5698630136986301,Completed,Observational,No,No,Sponsor,205
21-5539,Rehabilitation for People With Advanced Cancer,1.4109589041095891,Recruiting,Interventional,No,No,Sponsor,117
2018-1361,Physical Activity Promotion for Breast and Endometrial Cancer Survivors,4.1506849315068495,"Active, not recruiting",Interventional,No,No,Sponsor,323
MC1713,A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ,4.169863013698631,Recruiting,Interventional,Yes,No,Sponsor,43
HREBA.CC-18-0028,The ONE-MIND Study: Evaluating the Efficacy of Online Mindfulness-Based Cancer Recovery During Chemotherapy Treatment,5.589041095890411,Recruiting,Interventional,No,No,Principal Investigator,178
E-SN@P PROJECT-IPC 2017-029,Assessment of Outpatient Digital Follow-up of Patients Over 70 Years of Age Undergoing Chemotherapy Treatment,3.0,Not yet recruiting,Interventional,No,No,Sponsor,119
PASCA,A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.,7.336986301369863,Recruiting,Interventional,No,No,Sponsor,858
XL102-101,Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101),3.6410958904109587,Recruiting,Interventional,Yes,No,Sponsor,298
Dnr 2019-04151,Exercise as Medicine for People With Cancer Sweden,2.808219178082192,Recruiting,Interventional,No,No,Principal Investigator,200
2021-001624-17,Micronized Progesterone Versus Norethisterone Acetate in Combination With Estrogen as Menopausal Hormone Therapy,5.767123287671233,Recruiting,Interventional,No,No,Sponsor-Investigator,390
GCO 21-0012,Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials,2.271232876712329,Recruiting,Interventional,No,No,Principal Investigator,1705
2018-0004,Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery,5.0,Recruiting,Interventional,No,No,Sponsor,80
TJ-IRB20211129,68Ga-HER2 Affibody PET/CT Imaging for HER2-Positive Cancer Patients,4.035616438356165,Recruiting,Observational,No,No,Principal Investigator,100
823981A,Oncology Episode Payment Model in Hawaii,6.506849315068493,"Active, not recruiting",Interventional,No,No,Principal Investigator,7
NIT-110 (KEYNOTE PNA60),NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors,3.9452054794520555,Recruiting,Interventional,Yes,No,Sponsor,238
69HCL19_0731,"Identify the Obstacles to Early Diagnosis of Cancer in Patients Over 75 Years Old, on an Outpatient Basis",0.40273972602739727,Completed,Observational,No,No,Sponsor,16
BT-001.01,A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors,4.178082191780822,Recruiting,Interventional,No,No,Sponsor,48
EAQ161CD,Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting,4.898630136986301,"Active, not recruiting",Observational,,,Sponsor,201
Pro00106186,Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study),1.3041095890410959,Completed,Interventional,No,No,Sponsor,3
G-5097-2019,Evaluation of Postoperative Nausea and Vomiting Incidence in Patients With Mastectomy Surgery According to Apfel Risk Scoring System,0.24931506849315072,Completed,Observational,No,No,Principal Investigator,57
Laser treatment,Laser Treatment of Genito-urinary Syndrome in Women,4.252054794520548,Not yet recruiting,Interventional,No,No,Principal Investigator,160
NIMAO/2016/PC-01,Kinetics of Perioperative Circulating DNA in Cancer Surgery,0.8027397260273973,Completed,Observational,No,No,Sponsor,30
IIT-2021-CANINE,To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment,4.093150684931508,"Active, not recruiting",Observational,No,No,Sponsor,500
PROICM 2017-05 BAL,Analysis of Circulating Tumor Markers in Blood,5.002739726027397,Recruiting,Interventional,No,No,Sponsor,620
Breast Biopsy,The Effect of Education Given at Different Times Before a Breast Biopsy,0.24657534246575347,Completed,Interventional,No,No,Principal Investigator,60
2018P000084,Evaluation of ADM Soft Tissue Reinforcement,2.0000000000000004,Unknown status,Observational,No,Yes,Principal Investigator,152
IRB00167074,Sensory Restoration After DIEP Flap Neurotization,5.0849315068493155,Recruiting,Interventional,No,No,Sponsor,156
GOP,Goserelin for Ovarian Protection in Premenopausal Patients Receiving Cyclophosphamide,2.0027397260273974,Unknown status,Interventional,No,No,Principal Investigator,100
NIP IT!,Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!),3.868493150684932,Recruiting,Observational,No,No,Sponsor,500
CDKY709A12101C,Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.,6.03013698630137,"Active, not recruiting",Interventional,Yes,No,Sponsor,99
IRB#21-001169,Postoperative Opt-In Narcotics Treatment in Breast,1.0000000000000002,Not yet recruiting,Interventional,No,No,Principal Investigator,240
PRO 1676,A Digimed Oncology PharmacoTherapy Registry,2.484931506849315,Unknown status,Observational,No,No,Sponsor,500
Pro00102260,Hypertension Management in Cancer Patients,0.4821917808219179,Terminated,Interventional,No,No,Sponsor,4
19829,"A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein",3.8301369863013703,"Active, not recruiting",Interventional,Yes,No,Sponsor,14
00011271,HeartPhone Cancer Survivors Trial 2019,1.6931506849315068,Terminated,Interventional,Yes,No,Principal Investigator,3
CE3220.,Efficacy of the MepitelÂ® Film on the Prevention of Radiodermatitis in the Inguinal Fold.,4.002739726027397,Not yet recruiting,Interventional,No,No,Sponsor,35
METCZ20220056,EvaLuating negAtive pressUre Wound theRapy in brEast coNserving Surgery,0.8301369863013699,Not yet recruiting,Interventional,No,No,Sponsor,300
RC31/17/0350,Use of Compression Bandages in the Prevention of Post-mastectomy Lymphoceles,1.210958904109589,Recruiting,Interventional,No,No,Sponsor,84
19-179,Acupuncture Pilot Study for Cancer-related Cognitive Function,4.002739726027397,"Active, not recruiting",Interventional,No,No,Sponsor,48
180276,Promotora Navigator - Culturally Appropriate Patient Navigator,0.3561643835616438,Completed,Interventional,No,No,Principal Investigator,101
213353,Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer,2.2794520547945205,Terminated,Interventional,Yes,No,Sponsor,41
ebeddows,Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy,4.484931506849315,Recruiting,Interventional,Yes,No,Principal Investigator,40
IFCT-1703,Her2-positive Lung Cancer Treated With Dedicated Drug,4.126027397260274,"Active, not recruiting",Interventional,No,No,Sponsor,46
69HCL17_0642,Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study,2.8438356164383563,Recruiting,Observational,No,No,Sponsor,220
CS001-SA,Safety Assessment of P2Et Extract in Healthy Voluntary Subjects in Colombia,1.0054794520547947,Unknown status,Interventional,No,No,Sponsor,24
MSK8/22,The Effect of Rhomboid Intercostal Block and Serratus Anterior Plane Block on Postoperative Respiratory Functions,0.5616438356164384,Completed,Interventional,No,No,Principal Investigator,64
JAB-2485-1001,JAB-2485 Activity in Adult Patients With Advanced Solid Tumors,3.6164383561643834,Recruiting,Interventional,Yes,No,Sponsor,102
PVMEDCT202201,Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk,0.7479452054794521,Recruiting,Observational,No,No,Principal Investigator,500
BA3021-001,CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2),5.010958904109589,Recruiting,Interventional,Yes,No,Sponsor,420
2020-05-001B,Regional Anesthesia in Breast Surgery,0.9972602739726029,Unknown status,Interventional,No,No,Sponsor,120
13104,Tranexamic Acid for Alloplastic Breast Reconstruction,2.0027397260273974,Not yet recruiting,Interventional,No,No,Sponsor,106
PRT2527-01,A Study of PRT2527 in Participants With Advanced Solid Tumors,1.7945205479452055,Recruiting,Interventional,Yes,No,Sponsor,30
RECHMPL22_0024,Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC),2.213698630136986,Recruiting,Interventional,No,No,Sponsor,63
120134,NPWT for Abdominal Incisions in DIEP Reconstructions: A RCT,2.0849315068493155,Withdrawn,Interventional,No,Yes,Principal Investigator,0
21-369,A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer,2.0000000000000004,Recruiting,Interventional,No,No,Sponsor,200
Pro00078230,Erector Spinae Plane Block Versus Paravertebral Block,2.915068493150685,Completed,Interventional,No,No,Sponsor,48
18-000948,Investigating Magnesium Glycinate in Structure/Function Role of Hot Flashes.,2.7150684931506848,Completed,Interventional,No,No,Principal Investigator,40
20-08,Prospective Case Collection Study for New Mammography Technologies,3.9780821917808225,Recruiting,Interventional,No,Yes,Sponsor,5400
AP2001-50504,Erector Spinae Block Versus PECS Block Type II for Breast Surgeries,0.9753424657534248,Completed,Interventional,No,No,Principal Investigator,60
FMBSURECS/30042019/Ali,Efficacy of Serratus Anterior Plane Block Mastectomy,0.5698630136986301,Completed,Interventional,No,No,Sponsor-Investigator,40
21-192,TIPOPS (Telemedicine vs In Person Oncology Patient Surveillance),1.252054794520548,Completed,Interventional,No,No,Principal Investigator,30
SBT6290-101,A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors,0.0821917808219178,Withdrawn,Interventional,Yes,No,Sponsor,0
SAHZhejiangU 123,Added Value of Contrast-enhanced Ultrasound for BI RADS 4A Nodules,3.0,Unknown status,Observational,No,No,Sponsor,500
CRYO for Mastectomy (DoD),Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Postoperative Pain After Mastectomy,3.663013698630137,Enrolling by invitation,Interventional,No,Yes,Principal Investigator,216
FMASUMD45/2021,Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity,2.0000000000000004,Recruiting,Interventional,No,No,Principal Investigator,100
PT3465,Effect of Thera Band Exercises on Adhesive Capsulitis Post Mastectomy,0.9863013698630139,Completed,Interventional,No,No,Sponsor-Investigator,70
Lishui Peoples Hospital,Interventional Therapy Sequential With the Fourth-generation CAR-T Targeting Nectin4/FAP for Malignant Solid Tumors,2.882191780821918,Unknown status,Interventional,No,No,Sponsor,30
HAN2014005-CT02,"Evaluation of the Efficacy and Safety of A High Molecular Weight, Natural Hyaluronic Acid Vaginal Gel in Women With Genitourinary Syndrome of Menopause",2.452054794520548,Completed,Interventional,No,No,Sponsor,80
SHEBA-19-6136-RS-CTIL,Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors,2.8493150684931505,Unknown status,Interventional,No,No,Sponsor-Investigator,30
2021/01159,Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI,4.843835616438356,Not yet recruiting,Interventional,No,No,Sponsor,10
GS-US-417-5937,Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants,0.1917808219178082,Completed,Interventional,Yes,No,Sponsor,27
SOGUG-2016-A-IEC(PRO)-12,Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL),4.263013698630137,Completed,Interventional,No,No,Sponsor,16
CCR5653,Accelerated Body Diffusion-Weighted MRI Using Artificial Intelligence,2.9068493150684933,Enrolling by invitation,Observational,No,No,Sponsor,450
PPP005-Ph2/3-01,Cannabis Oil and Radiation Therapy for the Management of Pain,0.7150684931506849,Terminated,Interventional,No,No,Sponsor,100
AAAS9968,Hair Care Product Use Among Women Of Color,2.252054794520548,Recruiting,Interventional,No,No,Sponsor,100
METCZ2019016,Seroma Reduction and Drain Free Mastectomy,3.4328767123287673,Recruiting,Interventional,No,No,Principal Investigator,250
1190532,Chilean Maternal & Infant Cohort Study II (CHiMINCs-II),3.9150684931506854,"Active, not recruiting",Observational,No,No,Principal Investigator,1927
HSL 2016-83,Determination of Autonomic Responses to the Exposure of Low Energy Electromagnetic Fields With Frequency Modulation in Patients With Advanced Hepatocellular Carcinoma and Healthy Individuals.,2.0027397260273974,Unknown status,Interventional,No,No,Principal Investigator,60
IMM2902-101,"IMM2902, a HER2/SIRPÎ± Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors",2.452054794520548,Recruiting,Interventional,Yes,No,Sponsor,135
NOX66-005,A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors,2.345205479452055,Recruiting,Interventional,Yes,No,Sponsor,70
CCR5063,Evaluation of an Educational Intervention for Women With Breast Pain,0.33424657534246577,Unknown status,Interventional,No,No,Sponsor,15
BGB-3111-108,A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects,0.0684931506849315,Completed,Interventional,Yes,No,Sponsor,18
2020/14MAI/273,Serum Neurofilament Light (NFL) in Surgery Under General Anaesthesia (GA) Compared to Surgery With Hypno-analgesia (Hyp),2.493150684931507,Recruiting,Interventional,No,No,Sponsor,100
B4T2-PRC-IIT-001,A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors,4.298630136986302,Recruiting,Interventional,No,No,Sponsor,36
PROACTIVE,"Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness",4.046575342465754,Recruiting,Interventional,No,No,Sponsor,160
2017-02028,Efficacy of the Consilium Smartphone App for Detecting Symptoms and Treatment Side Effects in Cancer Patients,2.6027397260273974,Terminated,Observational,No,No,Sponsor,224
JS001-PMS-CO1,Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .,3.3863013698630136,Not yet recruiting,Observational,No,No,Sponsor,800
875351,Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project,2.9123287671232876,Recruiting,Interventional,No,No,Sponsor,500
CX-839-011,Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors,1.1945205479452055,Terminated,Interventional,Yes,No,Sponsor,33
Pro00037562,Apple Womens Health Study,9.972602739726028,Recruiting,Observational,No,No,Sponsor,500000
16-010491,Preventing Lymphedema in Axillary Lymph Node Dissection,5.816438356164384,"Active, not recruiting",Interventional,No,No,Principal Investigator,264
INT17676,A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects,1.2547945205479452,Completed,Interventional,Yes,No,Sponsor,52
829785,Effect of PARP Inhibitors on Glomerular Filtration Rate,1.4082191780821918,Terminated,Observational,No,No,Sponsor,2
ESG401-101,Study of ESG401 in Adults With Solid Tumors,3.547945205479452,Recruiting,Interventional,No,No,Sponsor,177
GS-US-382-1587,Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels,1.2027397260273973,Recruiting,Interventional,Yes,No,Sponsor,45
20221202,Primary Lesion Treatment for Bone Metastases,3.0027397260273974,Not yet recruiting,Interventional,No,No,Principal Investigator,400
KSCM-CRD-001,KeraStat(R) Cream for Radiation Dermatitis,0.5726027397260274,Completed,Interventional,No,Yes,Sponsor,25
201707042,Diagnostic US for Reduction of Benign Breast Biopsies Using US-guided Optical Tomography,5.96986301369863,Recruiting,Interventional,No,Yes,Sponsor,335
201810102MINC,Does Letrozole Improve Pregnancy Outcome in Fresh Embryo Transfer IVF/ICSI Cycle?,1.956164383561644,Unknown status,Interventional,No,No,Sponsor,300
IRB 20-488,CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer,3.0493150684931507,"Active, not recruiting",Observational,No,No,Sponsor,39
GO-1,SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients Own Stem Cells,4.884931506849315,Recruiting,Interventional,Yes,Yes,Sponsor,10
1237087,A Mind-Body Intervention for Hot Flash Management,4.712328767123288,Recruiting,Interventional,No,No,Principal Investigator,232
P.T.REC/012/003747,Aerobic Training and Diet on the Immune System in Postmastectomy Patients Receiving Chemotherapy,0.8547945205479452,Recruiting,Interventional,No,No,Principal Investigator,60
GIHSYSU-26,"RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer",3.03013698630137,Not yet recruiting,Interventional,No,No,Principal Investigator,29
BRCA-ACP.2022,Acupuncture With/Without Self-acupressure for Post-oophorectomy Hot Flashes in BRCA Carriers,1.167123287671233,Not yet recruiting,Interventional,No,No,Principal Investigator,200
20,Early Detection of Heart Problems in Cancer Patients Receiving Chemotherapy,0.24109589041095894,Withdrawn,Observational,No,No,Sponsor,0
JK08.1.01,"A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer",3.347945205479452,Recruiting,Interventional,No,No,Sponsor,149
NC762-01,A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors,3.2575342465753425,Recruiting,Interventional,Yes,No,Sponsor,170
PARPA-293-001,Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors,4.098630136986301,Recruiting,Interventional,Yes,No,Sponsor,150
17237,HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases,5.002739726027397,Recruiting,Interventional,Yes,No,Sponsor,39
209514,Pilot Study of Pancreatic Cancer Screening,10.035616438356165,Recruiting,Observational,No,No,Sponsor,250
INT 36/18,Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients,4.997260273972603,Recruiting,Interventional,No,No,Sponsor,28
MER-XMT-2056-1,A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2,2.7726027397260276,Suspended,Interventional,Yes,No,Sponsor,171
Klotho _ LRP-6 _ GC,Klotho _ LRP-6 _ Gastric Adenocarcinoma,1.0027397260273974,Not yet recruiting,Observational,No,No,Principal Investigator,45
ZL-2306-912 ALTER-OC-02,Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors,1.9123287671232878,Unknown status,Interventional,No,No,Principal Investigator,52
CEP1:4/2016,BRCA Main Home Nutritional Intervention-random Study,2.0000000000000004,Unknown status,Interventional,No,No,Principal Investigator,300
Chemobrain Study,Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies,2.504109589041096,Not yet recruiting,Interventional,No,No,Principal Investigator,60
XB002-101,Study of XB002 in Subjects With Solid Tumors (JEWEL-101),3.336986301369863,Recruiting,Interventional,Yes,No,Sponsor,524
KlusPharma,Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene,4.380821917808219,"Active, not recruiting",Interventional,Yes,No,Sponsor,49
AJIRB-MED-THE-18-236,Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG,2.3808219178082193,Completed,Interventional,No,No,Principal Investigator,24
20/PR/0222,Precision Medicine for Liver Tumours With Quantitative Magnetic Resonance Imaging and Whole Genome Sequencing,2.4493150684931506,"Active, not recruiting",Observational,No,No,Sponsor,200
JTU-6H-20210227001,Comparison Between IORT and Postoperative Radiotherapy in Breast Conserving Surgery,4.000000000000001,"Active, not recruiting",Interventional,No,No,Sponsor-Investigator,80
69HCL22_0275,Control Cohort CTRL COH,5.002739726027397,Not yet recruiting,Interventional,No,No,Sponsor,350
REPLAMOD,Histological Modifications of Postmenopausal Vaginal Mucosa After Repeated Carbon Dioxide (CO2) Laser Treatment,1.997260273972603,Completed,Interventional,No,No,Principal Investigator,15
BTC-HER2,Trastuzumab in HER2-positive Biliary Tract Cancer,1.5972602739726027,Completed,Interventional,No,No,Sponsor-Investigator,4
CASE2117,Sensation After Nipple Sparing Mastectomy and Breast Reconstruction With or Without Neurotized Free Tissue Transfer,2.0027397260273974,Withdrawn,Interventional,No,No,Sponsor,0
GOUDET 2018,Study and Monitoring of Multiple Endocrine Neoplasia Type 1,10.583561643835617,Recruiting,Observational,No,No,Sponsor,1600
H-38855,Ruxolitinib for Premalignant Breast Disease,6.6438356164383565,Recruiting,Interventional,Yes,No,Sponsor-Investigator,100
FF-2018-084,Does Pecs II Block Reduce the Incidence of Post Mastectomy Pain Syndrome (PMPS)? A Cross Sectional Study,0.9616438356164385,Completed,Observational,No,No,Sponsor,288
4-2019-0648,Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy,2.6876712328767125,Unknown status,Interventional,No,No,Sponsor,34
TG-iConquerFear,Reducing Fear of Cancer Recurrence in Danish Colorectal Cancer Survivors,2.421917808219178,Not yet recruiting,Interventional,No,No,Sponsor,540
P2101,The AUS-PREDICT Registry for DCIS Patients With DCISionRT Testing,12.838356164383562,Recruiting,Observational,No,Yes,Sponsor,1500
TCM-padia001,Clinical Study on Prevention and Treatment of Pyrotinib Associated Diarrhea With Traditional Chinese Medicine,1.0000000000000002,Recruiting,Interventional,No,No,Sponsor,30
GO43860,"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",3.032876712328767,Recruiting,Interventional,Yes,No,Sponsor,365
C/35/2017,MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour,3.728767123287671,"Active, not recruiting",Interventional,No,No,Sponsor,120
2018-003115-21,Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors,4.263013698630137,Withdrawn,Interventional,No,No,Sponsor,0
EC29,Auto-Adjustable MOBIDERMÂ® Autofit NIGHT-time Compression Armsleeve in the Upper Limb LYMphedema in Maintenance Phase,3.419178082191781,Recruiting,Interventional,No,No,Sponsor,88
2021/117,Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Alopecia,7.846575342465754,Recruiting,Interventional,No,No,Sponsor,72
HS-10502-101,A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors,3.504109589041096,Not yet recruiting,Interventional,No,No,Sponsor,318
Health consortium maresme,Use of Glubran 2 Â® in Axillary Lymphadenectomy Without Drain,4.169863013698631,Recruiting,Interventional,No,No,Principal Investigator,134
STUDY00023183,Humidified Forest Oils for Immune System Recovery in Stage I-III Breast or Prostate Cancer,1.452054794520548,Enrolling by invitation,Interventional,No,No,Principal Investigator,25
201903142,Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors,6.597260273972603,Recruiting,Observational,No,No,Sponsor,3362
DCC-2036-01-003,A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors,4.035616438356165,"Active, not recruiting",Interventional,Yes,No,Sponsor,201
E-19-3943,Erector Spina Plane Block Versus Deep Serratus Anterior Plane Block for Post Mastectomy Analgesia,0.6410958904109589,Completed,Interventional,No,No,Principal Investigator,80
CASE6118,Free Flap Breast Reconstruction Using Virtual Surgical Planning and 3-D Modeling,3.0,"Active, not recruiting",Interventional,No,No,Sponsor,30
MCART-006,Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases,2.1726027397260275,Recruiting,Interventional,No,No,Principal Investigator,58
ONC-392-001,"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",4.293150684931507,Recruiting,Interventional,Yes,No,Sponsor,914
PRO1184-001,PRO1184 for Advanced Solid Tumors,2.736986301369863,Recruiting,Interventional,Yes,No,Sponsor,134
2021-04840,Lymphedema After Urologic Surgery,7.808219178082193,Recruiting,Observational,No,No,Sponsor,400
BPI-2358-105 phase 3,Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3,2.7013698630136984,Completed,Interventional,Yes,No,Sponsor,105
HCC 20-064,Telehealth and Memory Study,4.205479452054795,Recruiting,Interventional,No,No,Principal Investigator,200
E-19-773,"A Randomized Controlled Trial to Evaluate the Efficacy of Acupuncture Versus Aromatherapy as Treatments to Lessen Nausea, Vomiting and Anxiety Associated With Adriamycin and Cytoxan",4.109589041095891,Recruiting,Interventional,No,No,Sponsor,60
STUDY00003387,Exercise and Nutrition Interventions During Chemotherapy K07,5.134246575342465,Recruiting,Interventional,No,No,Principal Investigator,80
SBT6050-201,A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers,0.40821917808219177,Terminated,Interventional,Yes,No,Sponsor,2
MCART-002,Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis,2.808219178082192,Recruiting,Interventional,No,No,Principal Investigator,18
ARRAY-818-103,Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors,5.326027397260274,"Active, not recruiting",Interventional,Yes,No,Sponsor,56
Niraparib-5001,A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea,4.715068493150685,Recruiting,Observational,No,No,Sponsor,600
LINDA,Study To Evaluate The Sensitivity Of The Linda Thermal Device,1.4191780821917808,Recruiting,Observational,No,No,Sponsor,500
MC210302,Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer,1.6849315068493151,Completed,Interventional,Yes,No,Sponsor,6
QSPainRelief-patientCNS,"QSPainRelief-patientCNS : Clinical Biomarkers of Nociception, Sedation and Cognition",3.547945205479452,Not yet recruiting,Interventional,No,No,Sponsor,180
CARTIER,Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial),6.3342465753424655,Recruiting,Interventional,No,No,Sponsor,514
The Swedish DIRECT study,Direct Information to At-risk Relatives,5.904109589041096,Enrolling by invitation,Interventional,No,No,Principal Investigator,490
CKAF156A2104,"Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir",0.6082191780821918,Completed,Interventional,No,No,Sponsor,48
B3271007,Safety and Efficacy of Trastuzumab BS,2.024657534246576,Not yet recruiting,Observational,Yes,No,Sponsor,150
Elasto Trial,Comparison of Real-time and Shear Wave Elastography,4.838356164383562,"Active, not recruiting",Interventional,No,No,Sponsor,98
Soh-Med-22-09-01,Ultrasonography Screening for Breast Lesions During Pregnancy and Lactation,1.5835616438356164,Not yet recruiting,Observational,No,No,Principal Investigator,50
N201810002,Spirulina (FEM-102) Supplement to Chronic Hepatitis B Patients,1.0904109589041096,Completed,Interventional,No,No,Sponsor,75
MastoVit150,Possibilities of Phytomedicine in Monotherapy of Benign Breast Diseases,2.4136986301369863,Completed,Interventional,No,No,Sponsor-Investigator,150
OCOG-2021-ELISA,Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS),12.526027397260274,Recruiting,Observational,No,No,Sponsor,526
CASE1219,Incomplete Follow Up After Positive FIT or Stool DNA Testing: A Multimethod Approach,5.254794520547946,Recruiting,Interventional,No,No,Sponsor,30
CHIRCOLREC-IPC 2018-017,Prospective Database for Colonic or Rectal Resection Surgery Patients,50.78630136986301,Not yet recruiting,Observational,No,No,Sponsor,1000
RELI/19/Der-Rdt/001,Efficacy and Tolerability Evaluation of a Topical MD Based on SHBF in Management of Radiodermatitis.,2.2904109589041095,Completed,Interventional,No,No,Sponsor,70
GS-US-467-5643,"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies",6.63013698630137,Recruiting,Interventional,Yes,No,Sponsor,205
PRO00031416,Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors,4.082191780821918,Recruiting,Interventional,No,No,Principal Investigator,200
7635,Cannabinoids for Taxane Induced Peripheral Neuropathy,1.997260273972603,Terminated,Interventional,Yes,No,Principal Investigator,12
VAC for HPV,Video-Assisted Counseling for HPV Vaccination,0.8328767123287671,Unknown status,Interventional,No,No,Principal Investigator,70
ONCB-006-19F,Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer,3.747945205479452,Not yet recruiting,Interventional,Yes,No,Sponsor,30
70781,Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover,4.449315068493151,Recruiting,Interventional,Yes,No,Sponsor-Investigator,60
1407426,Family History Study on Cancer Risk,5.16986301369863,Recruiting,Interventional,No,No,Sponsor,18000
PRS-343-PCS_08_18,PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors,2.863013698630137,Unknown status,Interventional,Yes,No,Sponsor,45
NL72939.078.20,Bilateral Prophylactic Mastectomy; Should we Preserve the Pectoral Fascia?,1.9150684931506852,Recruiting,Interventional,No,No,Principal Investigator,21
HCI105691,Fatigue Interventions in Cancer (Exercise Intervention),4.934246575342466,"Active, not recruiting",Interventional,No,No,Sponsor,126
49/20 b,Breast Reconstruction in Previously Irradiated Breast,0.6383561643835617,Completed,Observational,No,No,Principal Investigator,2150
AP2007-50104,Comparison of Duloxetine Versus Pregabalin,0.27945205479452057,Unknown status,Interventional,No,No,Principal Investigator,70
PRO00032593,Virtual Reality Education Program to Reduce Anxiety During Radiation Therapy,0.673972602739726,Terminated,Interventional,No,No,Principal Investigator,28
H00020209,Dotarem vs Gadobutrol Contrast for Breast MRI,2.9972602739726026,Recruiting,Interventional,Yes,No,Principal Investigator,258
ROR2103,"Evaluating Patient Reported Outcomes in Radiation Therapy, The PRO-RT Study",1.83013698630137,Recruiting,Observational,No,No,Sponsor,150
BG01-2002,Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors,2.936986301369863,Recruiting,Interventional,No,No,Sponsor,120
Rhomboid,Analgesic Effects of Rhomboid Block,2.221917808219178,Recruiting,Interventional,No,No,Principal Investigator,72
KY-2021-012,A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2,2.506849315068493,Not yet recruiting,Observational,No,No,Principal Investigator,15
49/20,Adjuvant Radiotherapys Effect on One and Two Stages Prosthetic Breast Reconstruction and on Autologous Reconstruction,0.6383561643835617,Completed,Observational,No,No,Principal Investigator,3200
GC101 TIL-ST-01,A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid Tumors,2.7534246575342465,Recruiting,Interventional,No,No,Sponsor,60
IM014-032,Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants,0.2328767123287671,Completed,Interventional,Yes,No,Sponsor,22
CEEGOG EX-02,Tracers for Endometrial Cancer Sentinel Node Labeling,3.0,Recruiting,Interventional,No,No,Principal Investigator,83
93 /1801/2021,Lifting Effect on Recovery After Mastectomy,2.252054794520548,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,50
2020-3627-1407,"SSI Rates in Patients Undergoing Mastectomy Without Reconstruction- A Multicenter, Double-blinded RCT.",2.164383561643836,Unknown status,Interventional,No,No,Principal Investigator,384
OTH267,Iraqi Trial for Lung Cancer Screening,3.835616438356165,Unknown status,Interventional,No,No,Sponsor,500
Pro00054854,The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors,6.816438356164384,Recruiting,Observational,No,No,Sponsor,800
MF 22-02,Idiopathic Granulomatous Mastitis Combination Therapy,1.378082191780822,Recruiting,Interventional,No,No,Principal Investigator,150
2019-0989,Trastuzumab Biosimilar (SamfenetÂ®) Plus Treatment of Physicians Choice (TPC) in Patients With HER2-positive Solid Tumor,0.0,Unknown status,Interventional,No,No,Sponsor-Investigator,42
UCSD IIT 150729,Histology-Independent Study of Palbociclib in Patients With Advanced Cancer,5.5917808219178085,Withdrawn,Interventional,Yes,No,Sponsor-Investigator,0
P.T.REC/012/003464,Impact of Scapular Mobilization And Strengthening Exercises on Shoulder Function Post Mastectomy,0.547945205479452,Completed,Interventional,No,No,Principal Investigator,40
GCT1047-01,GEN1047 for Solid Tumors - First in Human (FIH) Trial,3.665753424657534,Recruiting,Interventional,Yes,No,Sponsor,500
BPX603-201A,Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors,6.073972602739726,Suspended,Interventional,Yes,No,Sponsor,220
KEEP-G 07,Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer,2.9178082191780823,Recruiting,Interventional,No,No,Sponsor,29
2021-0611,"Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases",3.276712328767123,Recruiting,Interventional,Yes,No,Sponsor,104
13022260-300-180785,Effect of Exercise in the Management of Peripheral Neuropathy,2.66027397260274,"Active, not recruiting",Interventional,No,No,Principal Investigator,60
INCB 123667-101,Study of INCB123667 in Subjects With Advanced Solid Tumors,4.07123287671233,Recruiting,Interventional,Yes,No,Sponsor,155
ICO-2020-19,Clinico-biological Data Collection Study of Metastatic Lung Cancer,8.476712328767125,"Active, not recruiting",Interventional,No,No,Sponsor,200
CRUKD/21/004- Treatment Arm 4,"DETERMINE Trial Treatment Arm 4: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations",6.575342465753424,Recruiting,Interventional,No,No,Sponsor,30
2019-A03336-51,Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy,3.175342465753425,Recruiting,Interventional,No,No,Sponsor,60
09.2020.125,Efect of Erector Spina Plane Block on Mastectomy,0.3178082191780822,Completed,Interventional,No,No,Principal Investigator,42
ANAE-341-19,Improving Tissue Oxygenation in Breast Reconstruction Surgery,4.391780821917808,Recruiting,Interventional,No,No,Principal Investigator,40
01-2/141 27,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,0.08493150684931507,Completed,Interventional,No,No,Principal Investigator,195
KF2019#1,KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug,0.6410958904109589,Recruiting,Interventional,No,No,Principal Investigator,10
Vein-project,Training of Arms to Reduce Pain With Peripheral Venous Catheter,2.841095890410959,Recruiting,Interventional,No,No,Sponsor,84
thoracic sympathectomy,Radiofrequency Thoracic Sympathectomy for Chronic Postmastectomy Pain; Randomized Placebo Controlled Study,1.7534246575342465,Completed,Interventional,No,No,Principal Investigator,70
20-240,Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases,4.383561643835616,Recruiting,Interventional,Yes,No,Principal Investigator,134
Debio 1143-106,Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143,2.9972602739726026,Completed,Interventional,Yes,No,Sponsor,46
457,Diagnostic Value of Bronchoscopic and Thoracoscopic Frozen Section Biopsies in Patients With Pleuropulmonary Tumors,1.5424657534246575,Not yet recruiting,Interventional,No,No,Principal Investigator,96
D8410C00001,Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies,3.4027397260273973,Recruiting,Interventional,Yes,No,Sponsor,195
229510,Combination Therapy in Cancers With Mutations in DNA Repair Genes,4.7534246575342465,Not yet recruiting,Interventional,Yes,No,Principal Investigator,24
034-2020,Radiomic Analysis for Predicting Treatment Response and Clinical Outcomes in Malignancies,5.0,"Active, not recruiting",Observational,No,No,Principal Investigator,1200
38RC17.291,EssaiClinique_CBSM,1.4191780821917808,Terminated,Observational,No,No,Sponsor,25
Estim Breast,Electrical Stimulation for Improving Postoperative Breast Sensation,2.16986301369863,Not yet recruiting,Interventional,No,No,Sponsor,30
YS-RVON-001,Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors,1.8794520547945206,Recruiting,Interventional,No,No,Sponsor,41
228-17-EP,Chemotherapy-Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study,2.8438356164383563,Completed,Observational,No,No,Principal Investigator,40
RG1006143,Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization,1.6136986301369862,Completed,Interventional,No,No,Sponsor,35
ZL-2306-914,Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma,2.4904109589041097,Recruiting,Interventional,No,No,Principal Investigator,83
2019-8890,Clinical Evaluation of CEM-guided Biopsy,1.997260273972603,Completed,Observational,No,Yes,Sponsor,66
2021-KY-073,The Efficacy of Hyperthermic Intraperitoneal Chemotherapy to Ovarian Cancer Patients With Homologous Recombination Repair Defect and Residual: a Prospective Cohort Study,2.9972602739726026,Recruiting,Observational,No,No,Sponsor,310
SNK01-102,Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers,1.923287671232877,Withdrawn,Interventional,Yes,No,Sponsor,0
C4551001,Study of PF-07248144 in Advanced or Metastatic Solid Tumors,5.980821917808219,Recruiting,Interventional,Yes,No,Sponsor,186
ONT-380-011,Effects of Tucatinib on Cardiac Repolarization in Healthy Participants,0.26027397260273977,Completed,Interventional,Yes,No,Sponsor,55
KCSG-ST18-20,AZD8186 and Paclitaxel in Advanced Gastric Cancer,3.6356164383561644,Unknown status,Interventional,No,No,Principal Investigator,49
HCC 20-117,GIST and Memory and Attention Adaptation Training,3.3863013698630136,Recruiting,Interventional,No,No,Principal Investigator,30
EXGEFATU,"Diagnostic Value of Exome/ Genome Sequencing, Conventional Methods in Rare Diseases and Familial Tumor Syndromes",2.6164383561643834,Recruiting,Observational,No,No,Sponsor,12000
HEM-ONCO-013,CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer,3.0027397260273974,Recruiting,Interventional,No,No,Principal Investigator,10
FESPET,FESPET Study: Female EStrogen recePtor in Endometrial Cancer Treatment,1.9178082191780825,Unknown status,Observational,No,No,Sponsor,40
22-501,Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC),3.0931506849315067,Enrolling by invitation,Interventional,No,No,Principal Investigator,800
STUDY00002021,Study of Sulphoraphane in Chronic Kidney Disease,1.5835616438356164,Recruiting,Interventional,Yes,No,Principal Investigator,24
OLATRA,Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma,4.101369863013699,Completed,Interventional,No,No,Sponsor,9
ELVN-002-001,ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer,3.2849315068493152,Recruiting,Interventional,Yes,No,Sponsor,178
FN-1501-UP1,A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML,3.558904109589041,Terminated,Interventional,Yes,No,Sponsor,67
ILYAD1_2019,Initiative in LYon for Lung cAncer Screening Development - Prevalence Study,0.2054794520547945,Completed,Observational,No,No,Sponsor,4595
RBN-2397-19-001,"Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors",4.000000000000001,Recruiting,Interventional,Yes,No,Sponsor,130
STUDY00000334,Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers,1.3287671232876712,Completed,Interventional,No,Yes,Principal Investigator,15
OPT-IN Research Protocol,"Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring",1.167123287671233,Recruiting,Interventional,No,No,Sponsor,100
2017-A02018-45,OncoSNIPE - Study of Molecular Profiles Associated With the Development of Resistance in Solid Cancer Patients,5.232876712328767,Unknown status,Interventional,No,No,Sponsor,600
CX-5461-04,"Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation",2.7315068493150685,Recruiting,Interventional,Yes,No,Sponsor,52
919/2020/Oss/IOR,"Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma",3.8136986301369866,Recruiting,Observational,No,No,Principal Investigator,810
MC16C2,Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors,1.9835616438356167,Completed,Interventional,Yes,No,Sponsor,2
NL75863.068.21,Magtrial: MagtraceÂ® as Tracer for Sentinel Lymph Node Detection in Early Stage Epithelial Ovarian Cancer,2.336986301369863,Not yet recruiting,Interventional,No,No,Sponsor,10
20-009,Pre-consultation Compassion Among Patients Referred to a Cancer Center,1.167123287671233,Recruiting,Interventional,No,No,Principal Investigator,470
PUMCH-NM-11/041,68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis,1.082191780821918,Recruiting,Interventional,No,No,Sponsor,30
ISU104-001,"Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors",3.682191780821918,"Active, not recruiting",Interventional,No,No,Sponsor,33
SLNB,Sentinel Lymph Node Biopsy in Rectal Cancer,2.589041095890411,Not yet recruiting,Interventional,No,No,Principal Investigator,87
BR/2019/487,Binaural Music Study,0.21095890410958903,Completed,Interventional,No,No,Sponsor,57
ATADEK/2022.11,Genital Laser Treatment in Postmenopausal Patients,1.0000000000000002,Not yet recruiting,Interventional,No,No,Principal Investigator,1
60116787-020/34123,Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients,0.4191780821917808,Completed,Interventional,No,No,Principal Investigator,64
BARBEN 2020,Impact of Age and Geriatric Co-morbidities on Lymphocyte Phenotype in Patients 70 Years of Age and Older,0.0,Withdrawn,Observational,No,No,Sponsor,0
CHUB-Hystocor,Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer,1.6465753424657534,Withdrawn,Interventional,No,No,Principal Investigator,0
BLU-222-1101,(VELA) Study of BLU-222 in Advanced Solid Tumors,4.484931506849315,Recruiting,Interventional,Yes,No,Sponsor,366
Soh-Med-22-09-16,Role of IMP3 Expression in Colorectal Carcinoma: An Immunohistochemical Study,0.6657534246575343,Recruiting,Observational,,,Principal Investigator,60
Shengjing-LJY05,The Effect of Gravity on the Occurrence of Lactational Mastitis,2.082191780821918,Recruiting,Observational,No,No,Principal Investigator,2000
CHUBX 2015/17,Dynamic Contrast Enhanced Ultrasound for Predict and Assess Rectal Cancer Response After Neo-adjuvant Chemoradiation - RECT,0.5589041095890411,Completed,Interventional,No,No,Sponsor,2
1766419-7,Storytelling Intervention for African Americans Living With Hypertension,0.5863013698630137,Recruiting,Interventional,No,No,Sponsor,60
NUV-868-01,NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors,3.849315068493151,Recruiting,Interventional,Yes,No,Sponsor,246
436,Effects of Clinical Pilates Exercises in Patients With Rheumatoid Arthritis,0.7698630136986301,Unknown status,Interventional,No,No,Principal Investigator,30
200155,"Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta Trap/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)",3.5178082191780824,"Active, not recruiting",Interventional,Yes,No,Sponsor,12
2021-BRV-004,Scaffold-guided Breast Surgery,4.016438356164384,Recruiting,Interventional,No,No,Sponsor,20
PREDICT,The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor,3.180821917808219,"Active, not recruiting",Observational,No,No,Sponsor,757
EJC001,Compassion Meditation for Cancer Survivor-Caregiver Dyads,1.83013698630137,Completed,Interventional,No,No,Sponsor-Investigator,82
CHU-426,Evaluation by Oncologists of Strategies for the Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathies,0.1863013698630137,Completed,Observational,No,No,Sponsor,216
PHOX-CLI_001,"First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours",4.038356164383562,Recruiting,Interventional,No,No,Sponsor,146
NICSO,NICSO National Study: Physician - Nurse Monitoring Project About Oncological Adverse Events,3.923287671232877,Completed,Interventional,No,No,Sponsor,645
BJK-Z-F18HN-202010-YZGK,Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTcâMDP-BSÂ±SPECT,1.178082191780822,Completed,Interventional,No,No,Sponsor,280
A-ER-109-415,Effect of Reconditioning Exercise on Older Adults With Urinary Tract Cancer Following Curative Surgery,0.7726027397260274,Recruiting,Interventional,No,No,Principal Investigator,150
2-107-05-162,Investigation of the Strategy of Preventing Post-operative Opioid-induced Hyperalgesia,0.9698630136986303,Unknown status,Interventional,No,No,Principal Investigator,100
IRAS307166,How Does Skin Tone Affect Quantitative Photoacoustic Imaging,1.0383561643835617,Not yet recruiting,Observational,No,No,Principal Investigator,42
20.60-onco20.07,An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 Pandemic,0.6328767123287671,Completed,Interventional,No,No,Sponsor,43
YBCSG-21-04,Granisetron Transdermal Patch for Prophylaxis of Delayed CINV,2.5561643835616437,Not yet recruiting,Interventional,No,No,Sponsor,140
SamanRostambeigi,Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity,1.0547945205479454,Completed,Interventional,No,No,Principal Investigator,80
20190131,Study of AMG 650 in Adult Participants With Advanced Solid Tumors,2.9342465753424656,Completed,Interventional,Yes,No,Sponsor,66
999916161,The Role of Emotions and Regulatory Focus in Decision Making That Involves Risk Tradeoffs,0.03287671232876713,Withdrawn,Observational,,,Sponsor,0
IRB00038262,"The Effect of Nitroglycerin Ointment, Fluorescent Angiography, and Incisional Negative Pressure Wound Therapy on Mastectomy Skin Flap Perfusion-Related Problems",1.1123287671232878,Terminated,Interventional,Yes,No,Sponsor,17
IRB00095260,Efficacy of Massage for the Treatment of Cancer-Related Fatigue (CRF) in Prostate Cancer Survivors,1.1863013698630136,Completed,Interventional,No,No,Principal Investigator,8
TapeK_Gesso_ABM_PSO,Taping to Control Edema in Patients With Forearm Plaster for Wrist Fracture.,1.7424657534246575,Completed,Interventional,No,No,Principal Investigator,23
29BRC18-0005 (VinMetAtezo),Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer,3.084931506849315,Completed,Interventional,No,No,Sponsor,80
1000-1,Womens Assessed Cardiovascular Evaluation With MCG,1.7643835616438357,Completed,Observational,No,Yes,Sponsor,32
OPTIMUM,Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy,2.5835616438356164,Recruiting,Interventional,No,No,Principal Investigator,62
R-17-360,Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy,2.136986301369863,Unknown status,Observational,No,No,Sponsor,20
2017-003582-10,Immunotherapy In Locally Advanced Rectal Cancer,4.671232876712328,"Active, not recruiting",Interventional,No,No,Sponsor,101
BIC4VMR,Breakthrough Improvement Collaborative for Ventral Mesh Rectopexy,2.0027397260273974,Not yet recruiting,Observational,No,No,Principal Investigator,320
2017_43,Impact of Supportive Care on the Experience of Hospitalization of Patients Staying in the Protected Area of the Department of Blood Diseases,4.967123287671233,Recruiting,Interventional,No,No,Sponsor,70
4397,Social Risk Factors and Discrimination in Cancer Survivorship,4.4082191780821915,Recruiting,Interventional,No,No,Sponsor,1116
00000001,Effects of Selected Exercise Program on Microcirculation and Lymphedema in Postmastectomy Patients,0.16712328767123288,Not yet recruiting,Interventional,No,No,Principal Investigator,30
IRB-2019-118,Aesthetic Effect of Steri-Strip Orientation on Healing and Scar Appearance in Breast Surgery,2.452054794520548,Recruiting,Interventional,No,Yes,Principal Investigator,126
RGC-1501-001,Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy,2.0000000000000004,Not yet recruiting,Interventional,Yes,No,Sponsor,32
19CX5601,PROState Pathway Embedded Comparative Trial,1.9780821917808222,Completed,Observational,No,No,Sponsor,139
20-03021615,FaCT Trial (Facilitated Cascade Testing Trial),2.282191780821918,Recruiting,Interventional,No,No,Sponsor,600
210026,Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma,6.676712328767123,Recruiting,Interventional,Yes,No,Sponsor,43
702576,Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo,2.082191780821918,Recruiting,Interventional,Yes,No,Sponsor,100
MT-5111_001,Study of MT-5111 in HER2-positive Solid Tumors,5.471232876712329,Recruiting,Interventional,Yes,No,Sponsor,178
APHP180576,18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma,5.002739726027397,Not yet recruiting,Observational,No,No,Sponsor,222
2020-1255,High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies,2.7753424657534245,Recruiting,Interventional,No,No,Sponsor,60
RC2022_prg.15,Evaluation of the Effects of Orange Consumption on Carbohydrate and Lipid Metabolism in Subjects With MAFLD (Metabolic Associated Fatty Liver Disease),0.8356164383561644,Recruiting,Interventional,No,No,Principal Investigator,60
IEO 1740,68Ga-DOTATOC Radio-Guided Surgery With Î²-Probe in GEP-NET,1.0000000000000002,Recruiting,Observational,No,No,Principal Investigator,20
UW 19-436,A Resilience Promotion Program for Parents of Children With Cancer,0.9397260273972603,Completed,Interventional,No,No,Sponsor,103
EDGE 000339,"SHIFTPLAN: an RCT Investigating the Effect of a Shift Work Intervention on Fatigue, Sleep and Health.",0.8328767123287671,Not yet recruiting,Interventional,No,No,Sponsor,176
METCZ20210156,Exploring an Alternative Pre-operative SLN Mapping Method Using a Magnetic Tracer and MRI for Melanoma Patients,2.0027397260273974,Recruiting,Interventional,No,No,Principal Investigator,40
2000031462,Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases,1.2767123287671234,Recruiting,Interventional,Yes,No,Principal Investigator,24
METCZ20210103,Sentinel Lymph Node Mapping Using Magtrace and MRI in Healthy Subjects for Potential Use in Melanoma Patients,0.052054794520547946,Completed,Interventional,No,No,Principal Investigator,6
2017/184 HP,VASCular Impact of Angiogenic Treatment in Patients With Advanced Colorectal Cancer,3.506849315068493,Unknown status,Interventional,No,No,Sponsor,40
20-002000,Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer,3.734246575342466,"Active, not recruiting",Interventional,No,No,Sponsor,4
18.068,PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer,6.005479452054795,Recruiting,Interventional,No,No,Sponsor,1000
Soh-Med-22-03-01,IMP3 and PCNA Expression in Laryngeal Squamous Cell Carcinoma in Sohag Governorate,1.0000000000000002,Recruiting,Observational,No,No,Principal Investigator,70
2020-3547,Impact of Aerobic Exercise on Immune Response and Side Effects of Cancer Treatments,1.9150684931506852,Completed,Interventional,No,No,Sponsor,19
CTM-N2D,Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Î³Î´ T Cells for Relapsed or Refractory Solid Tumour,1.2493150684931507,Unknown status,Interventional,No,No,Sponsor,10
IMT-009-101,Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas,2.3424657534246576,Recruiting,Interventional,Yes,No,Sponsor,119
B.30.2.ATA.0.01.00/1/6,Ultrasound-guided Paravertebral Block Versus Mid-point Transverse Process Pleura Block in Mastectomy Surgery,1.0684931506849316,Completed,Interventional,No,No,Principal Investigator,64
SYSKY-2022-019-02,Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCC,4.002739726027397,Recruiting,Interventional,No,No,Sponsor,70
2019-02Obs-CHRMT,Psychological Determinants of the Therapeutic Observance of Osteoporotic Patients,2.627397260273973,Completed,Observational,No,No,Sponsor,152
CHGH-IRB:(864)110-10,The Effect of Nursing Education Intervention on Womens Health Literacy of Plasticizers,0.8301369863013699,Recruiting,Interventional,No,No,Principal Investigator,100
PROT-CI2021,US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism,4.816438356164384,Not yet recruiting,Interventional,No,Yes,Sponsor,854
CP-MGC018-01,MGC018 With or Without MGA012 in Advanced Solid Tumors,4.323287671232877,Terminated,Interventional,Yes,No,Sponsor,143
RTX-224-01,RTX-224 Monotherapy in Patients With Solid Tumors,0.8821917808219178,Terminated,Interventional,Yes,No,Sponsor,7
2021-A01625-36,Clinical and Cyto-histological Evaluation of Fractional CO2 Laser Treatment on Genito-Urinary Syndromes of Menopause Related to Vaginal Atrophy,3.1041095890410957,Recruiting,Interventional,No,No,Sponsor,75
SGNB7H4V-001,A Study of SGN-B7H4V in Advanced Solid Tumors,5.054794520547945,Recruiting,Interventional,Yes,No,Sponsor,375
ShuangHoH,Smart Home Care of Cloud Base ECG on the Cardiotoxicity Prevention on the Cancer Patients.,1.997260273972603,Not yet recruiting,Observational,No,No,Sponsor-Investigator,400
P130935,"Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy",0.9643835616438358,Recruiting,Interventional,No,No,Sponsor,12
794/2020/Farm/IOR,Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse,6.336986301369863,Recruiting,Interventional,No,No,Principal Investigator,67
2000029793,Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma,5.432876712328767,Recruiting,Interventional,Yes,No,Sponsor-Investigator,43
CMUH109-REC2-101,Evaluation of the Efficacy of Chinese Herbal Medicine in Patients With Obesity,1.0000000000000002,Unknown status,Observational,No,No,Principal Investigator,500
RNI 2021 LEBRETON 3 (EVIGE),Evaluation of the Inter-center Variability of the Measurement of Thrombin Generation by the ST Genesia System,1.3150684931506849,Recruiting,Observational,No,No,Sponsor,65
SBNK-YJ-2020-016-02,Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas,4.994520547945205,Recruiting,Interventional,No,No,Principal Investigator,60
ThirdMMUb,Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors,4.169863013698631,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,57
2693-CL-0307,A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause,1.8712328767123287,Completed,Interventional,No,No,Sponsor,150
2020NZKY-062-01,The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease,1.4958904109589042,Completed,Interventional,No,No,Principal Investigator,120
2021-13614,Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color,1.1945205479452055,Recruiting,Interventional,No,Yes,Principal Investigator,30
MER-XMT-1660-1,A Study of XMT-1660 in Participants With Solid Tumors,3.3835616438356166,Recruiting,Interventional,Yes,No,Sponsor,166
no: P.T.REC/012/002774,"Aerobic Exercise With Diet Induces Hormonal, Metabolic, and Psychological Changes",2.3808219178082193,Recruiting,Interventional,No,No,Principal Investigator,60
SBNK-YJ-2019-006-02,Study of Recombinant Human Endostatin Combined With Temozolomide and Irinotecan in Recurrent Gliomas,4.8,Recruiting,Interventional,No,No,Principal Investigator,109
1648/2019,"Glucocorticoids, Immunotherapy and Radiosurgery for Brain Metastases",3.9178082191780828,Recruiting,Observational,No,No,Principal Investigator,200
2020/900/88,Assessment of the Efficacy of Injectable Hyaluronic Acid for Genitourinary Syndrome of Menopause,0.5863013698630137,Completed,Interventional,No,No,Sponsor,42
DF1001-001,Study of DF1001 in Patients With Advanced Solid Tumors,6.06027397260274,Recruiting,Interventional,Yes,No,Sponsor,490
STUDY00000224,Connecting Families to Overcome Ovarian Cancer,2.6904109589041094,Recruiting,Interventional,No,No,Principal Investigator,1240
2693-CL-0304,A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause,2.4904109589041097,Completed,Interventional,Yes,No,Sponsor,1831
ZUH-ITP-MBCS,ITP Block: Single or Multiple Injection?,0.019178082191780823,Recruiting,Interventional,No,No,Sponsor,12
21-007867,Physical Activity Intervention for Hematopoietic Cell Transplant Recipients and Caregivers,1.821917808219178,"Active, not recruiting",Interventional,No,No,Principal Investigator,30
1 TP2AH000076-01-00,Evaluation of Momentary Affect Regulation - Safer Sex Intervention,3.032876712328767,Recruiting,Interventional,No,No,Sponsor,600
Masters thesis,The Effect of Art-Based Mandala on Mental Health in Bone Marrow Transplant Patients,0.3287671232876712,Completed,Interventional,No,No,Sponsor-Investigator,46
22072,A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting,0.47945205479452063,"Active, not recruiting",Observational,No,No,Sponsor,2400
CPI-006-001,CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers,7.608219178082193,"Active, not recruiting",Interventional,Yes,No,Sponsor,378
HKG-KZ-PRAD-103,"Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC",3.504109589041096,Withdrawn,Observational,No,No,Sponsor,0
RG1001812,Effects of Alternative Healthy Eating Index-Based Diet on Inflammatory Markers and Breast Density in Healthy Participants,1.063013698630137,Completed,Interventional,No,No,Sponsor,21
25922,Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition,1.2931506849315069,Not yet recruiting,Interventional,No,No,Sponsor,450
2693-CL-0305,A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause,2.093150684931507,Completed,Interventional,No,No,Sponsor,302
PET/CT in malignancy,Validity of Mediastinal Blood Pool SUV Ratio,1.5808219178082192,Not yet recruiting,Observational,No,Yes,Principal Investigator,55
2021-A01570-41,Interventional Study on DEterminants and Factors of Physical ACtivity After Treatments in Oncology,1.5095890410958903,Recruiting,Interventional,No,No,Principal Investigator,150
2693-CL-0302,A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2,1.789041095890411,Completed,Interventional,Yes,No,Sponsor,501
2693-CL-0301,A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause,2.0876712328767124,Completed,Interventional,Yes,No,Sponsor,527
AssiutNT,Risk Assessment of Endometrial Hyperplasia and Endometrial Cancer,2.8328767123287673,Recruiting,Observational,No,No,Principal Investigator,328
PUMCH-NM-RR,68Ga-RM26-RGD PET/CT Imaging in the GRPR and Î±vÎ²3 Positive Tumor Patients,1.3753424657534246,Recruiting,Interventional,No,No,Sponsor,90
HKG-Bng-HCC-100,HCC Screening Using DNA Methylation Changes in ctDNA,2.202739726027397,Completed,Observational,No,No,Sponsor,403
IX-2021-DS-LEARN,LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology,3.0027397260273974,Not yet recruiting,Observational,No,No,Sponsor,300
1-1-7-05-114,Decision Support for the Renal Replacement Therapy With End-stage Renal Disease,0.7808219178082192,Completed,Interventional,No,No,Principal Investigator,76
Pro00101102,Cancer Treatment Decision-making in the HIV Population: an Observational Study of Physician-patient Interactions,0.8082191780821918,Terminated,Observational,No,No,Sponsor,14
ALXN2040-HV-102,Potential Drug Interaction Between ALXN2040 and Rosuvastatin,0.1726027397260274,Completed,Interventional,Yes,No,Sponsor,20
NL66650.041.18,The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study,5.002739726027397,Recruiting,Observational,No,Yes,Principal Investigator,6000
NCI-2020-01206,Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer,3.4657534246575343,Recruiting,Interventional,Yes,No,Sponsor,55
21083,Narrative Exposure Therapy to Reduce Symptoms of Traumatic Stress in Cancer Survivors,1.4958904109589042,"Active, not recruiting",Interventional,No,No,Sponsor,6
STUDY00144314,KanSurvive: Testing a Model for Improving Cancer Survivorship Care in Rural Practice,3.6191780821917807,Recruiting,Interventional,No,No,Principal Investigator,20
19-068,OPTimizing Treatment Focused Genetic Testing IN Cancer,9.04109589041096,"Active, not recruiting",Interventional,No,No,Principal Investigator,1200
69HCL21_0409,"CAncer, NUtrition and Taste 2",1.2465753424657535,Recruiting,Interventional,No,No,Sponsor,211
HALO Dx 001,Phase I Human Analytics (HALO) Study,14.96986301369863,Recruiting,Observational,No,Yes,Sponsor,2000
D8532C00003,A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole,0.2328767123287671,Completed,Interventional,No,No,Sponsor,14
UC-0107/1603,Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 3 Bone-only Metastases,9.501369863013698,Recruiting,Interventional,No,No,Sponsor,196
AK_2021_HP,Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients,1.5397260273972602,Enrolling by invitation,Interventional,No,No,Principal Investigator,15
C4391001,Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors,5.394520547945206,Recruiting,Interventional,Yes,No,Sponsor,198
ICO-2020-14,"Evaluation of Different Smoking Cessation Protocols: Nicotine Replacement, Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy in Cancer Patients Scheduled for Surgery",1.923287671232877,Recruiting,Interventional,No,No,Sponsor,100
20-2458.cc,Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.,3.652054794520548,Recruiting,Interventional,No,No,Sponsor,300
844554,TumorGlow Intraoperative Molecular Imaging (IMI),2.063013698630137,Not yet recruiting,Interventional,Yes,No,Sponsor,500
659/2017BO1,Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac,9.005479452054795,Recruiting,Interventional,No,No,Principal Investigator,472
SYSU_AI01,Diagnosis Predictive Modle for Dense Density Breast Tissue Based on Radiomics,0.0,Unknown status,Observational,No,No,Principal Investigator,1000
XL092-001,A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors,5.624657534246575,Recruiting,Interventional,Yes,No,Sponsor,1195
HSC-SPH-20-1117,Accelerating the Implementation of a Breast and Cervical Cancer Screening and HPV Vaccination Intervention,1.8712328767123287,Not yet recruiting,Interventional,No,No,Principal Investigator,2000
B2017-113R,Tumor Landscape Pathological Diagnosis by Large Tissue Sections,3.495890410958904,Unknown status,Observational,No,No,Sponsor,2000
PH-FAPGA-01/22,A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors,0.7534246575342466,Not yet recruiting,Interventional,No,No,Sponsor,20
FPA150-001,FPA150 in Patients With Advanced Solid Tumors,3.1232876712328768,Completed,Interventional,Yes,No,Sponsor,95
GCT1029-01,GEN1029 (HexaBodyÂ®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors,3.4547945205479453,Terminated,Interventional,Yes,No,Sponsor,48
STU-2019-0522,Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM),1.6465753424657534,Completed,Observational,,,Principal Investigator,10
HEALED_CPS3,Health and Energy Through Active Living Every Day (HEALED) After Cancer Pilot Intervention for Cancer Survivors,0.38082191780821917,Unknown status,Interventional,No,No,Principal Investigator,98
PJ-KS-KY-2019-134,The Clinical Study of Modern Therapies on Flora in Body Fluids and Blood of Malignant Tumor Patients,2.8958904109589043,Unknown status,Observational,No,No,Sponsor,500
PY314-1-01,A Study of PY314 in Subjects With Advanced Solid Tumors,2.9972602739726026,Recruiting,Interventional,Yes,No,Sponsor,288
LAUMCRH.YJ1.16/Jul/2019,Effect of Dexmedetomidine on the Duration of Pain Control in ESP Block for Breast Surgery,2.506849315068493,Unknown status,Interventional,Yes,No,Principal Investigator,44
DMT-2019.002,Delphinus SoftVueâ¢ ROC Reader Study (DMT SV RRS3),0.06575342465753425,Completed,Observational,No,Yes,Sponsor,32
DMT-2019.001,Delphinus SoftVueâ¢ ROC Reader Study,0.06575342465753425,Completed,Observational,No,Yes,Sponsor,32
AD10,KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method),0.915068493150685,Not yet recruiting,Observational,No,No,Sponsor,1000
CASE7Y16,A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors,1.6164383561643836,Completed,Observational,No,Yes,Sponsor,8
1474/19,Trigger Point Injections for Post-Mastectomy Pain Syndrome,3.9178082191780828,Recruiting,Interventional,No,No,Sponsor,120
CNZV930X2101,A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.,4.252054794520548,Terminated,Interventional,Yes,No,Sponsor,127
TirolGESUND,"TirolGESUND: Baseline-controlled Comparison of the Effects of Fasting Dietary Intervention or Smoking Cessation Combined With Exercise in Healthy Female Tyrolean Volunteers Aged 30-60 on Epigenetic and Multi-omic Biomarkers of Health, Ageing, and Disease",2.2794520547945205,"Active, not recruiting",Interventional,No,No,Principal Investigator,156
R20-3896L,PECS Block in Partial Mastectomy for Postoperative Pain Control,1.16986301369863,Unknown status,Interventional,No,No,Principal Investigator,130
69HCL19_0992,Interest of Virtual Reality to Prevent Cancer Patient Anxiety Before Chemotherapy or an Invasive Act,2.1671232876712327,Recruiting,Interventional,No,No,Sponsor,66
201805930,Comparison of Pre-op and Post-op Pectoralis Nerve Block,2.6410958904109587,Completed,Interventional,No,No,Sponsor-Investigator,35
2018-0075,Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery,5.4,Recruiting,Interventional,Yes,No,Sponsor,24
LOCAL/2020/DR-01,18F-DOPA-PET in Non-tumoral and Tumoral Brain Lesions,0.16164383561643836,Completed,Observational,No,No,Sponsor,74
IRB-300003680,Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy,1.389041095890411,Completed,Interventional,Yes,No,Principal Investigator,21
HSC-MS-16-0467,Serratus Anterior Muscle Plane Block vsThoracic Paravertebral Block For Unilateral Mastectomies,1.0000000000000002,Withdrawn,Interventional,Yes,No,Principal Investigator,0
PJ-KS-KY-2019-135,"Clinical Study on Raman Spectra of Blood, Saliva and Urine in Patients With Cancer Treated by Modern Therapy",2.0027397260273974,Unknown status,Observational,No,No,Sponsor,1000
2021/03-12,Effects of US-guided SAPB During Breast Surgery,0.5835616438356165,Completed,Interventional,No,No,Principal Investigator,20
D0817R00010,OLAP (OLAparib Regulatory Post-marketing Surveillance),3.9150684931506854,Recruiting,Observational,,,Sponsor,650
201610,Predicting Chronic Pain Following Breast Surgery,2.452054794520548,Recruiting,Observational,No,No,Principal Investigator,500
VAR-2021-12,Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy,0.8657534246575342,Recruiting,Interventional,No,Yes,Sponsor,30
WVU010518,Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy,3.5561643835616437,Terminated,Interventional,No,No,Sponsor,8
NUSMart NM,Evaluating the Relative Effectiveness of Two Front-of-pack Nutrition Labels,0.3424657534246575,Completed,Interventional,No,No,Principal Investigator,154
XmAb22841-01,A Study of XmAbÂ®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors,3.723287671232877,Completed,Interventional,Yes,No,Sponsor,78
PREDAPT,A Multicenter Cancer Biospecimen Collection Study,6.994520547945205,Recruiting,Observational,No,No,Sponsor,1650
SC103,Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors,4.471232876712329,Recruiting,Interventional,Yes,No,Sponsor,200
ACE1702-001,ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors,4.038356164383562,Recruiting,Interventional,Yes,No,Sponsor,36
RP12146-2101,"Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, a PARP Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors",1.821917808219178,Recruiting,Interventional,No,No,Sponsor,60
RG1005815,"Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study",3.5315068493150683,Enrolling by invitation,Interventional,No,No,Sponsor,200
HH-PRT-0001,Development and Validation of Harbinger Health Test for Early Cancer Detection,3.0356164383561643,Recruiting,Observational,No,No,Sponsor,10000
MP01,Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours,3.0027397260273974,Not yet recruiting,Interventional,No,No,Sponsor,50
AD07,GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescence PCR Method),0.915068493150685,Not yet recruiting,Observational,No,No,Sponsor,1000
5688,Psychosocial Transitional Group Pragmatic Trial,1.6712328767123288,Not yet recruiting,Interventional,No,No,Principal Investigator,100
RG1005140,"Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer",4.449315068493151,Recruiting,Interventional,Yes,No,Sponsor,18
BT8009-100,Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumor Malignancies,5.3780821917808215,Recruiting,Interventional,Yes,No,Sponsor,329
HN20190929,PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma,3.0027397260273974,Recruiting,Interventional,No,No,Sponsor,25
STUDY00018000,EXERCISING TOGETHER for Couples Coping With Cancer,4.704109589041096,"Active, not recruiting",Interventional,No,No,Principal Investigator,534
00003543,Comorbidities And Reducing inEquitieS,2.1534246575342464,"Active, not recruiting",Interventional,No,No,Principal Investigator,63
OSU-19199,Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM),3.1205479452054794,Recruiting,Interventional,No,Yes,Sponsor-Investigator,20
KB-0742-1001,A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma,4.813698630136987,Recruiting,Interventional,Yes,No,Sponsor,170
GQ1001X2101,Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors,3.8191780821917813,Recruiting,Interventional,Yes,No,Sponsor,96
21820,"A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors",4.564383561643836,Recruiting,Interventional,Yes,No,Sponsor,270
NL 70691.091.19,TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention,19.97808219178082,Recruiting,Interventional,No,No,Principal Investigator,3000
ORM-5029-01-001,Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors,2.9972602739726026,Recruiting,Interventional,Yes,No,Sponsor,87
NCI-2017-01232,PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery,6.035616438356165,"Active, not recruiting",Interventional,Yes,No,Sponsor,21
PRT3645-01,A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors,1.9315068493150687,Recruiting,Interventional,Yes,No,Sponsor,51
123glioma,Correlation Between SPECT/CT and IDH Mutation in Brain Glioma,1.082191780821918,Not yet recruiting,Observational,No,No,Principal Investigator,40
HMBD-002-V4C26-01,"A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab",3.0027397260273974,Recruiting,Interventional,Yes,No,Sponsor,240
NCH04-2020,"Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery",3.5013698630136987,Recruiting,Observational,No,No,Principal Investigator,100
BakircayU/D208,Chemotherapy-induced Peripheral Neuropathy (CIPN) on Motor and Sensory Function,1.1917808219178083,Completed,Observational,No,No,Principal Investigator,72
RG1121550,Clinical Outcomes for Offering Genetic Testing in a Tiered Approach,1.4109589041095891,Completed,Interventional,No,No,Sponsor,6
KYL[2020091],Surgical Intervention for Refractory Granulomatous Lobular Mastitis,6.663013698630137,Recruiting,Interventional,No,No,Principal Investigator,300
TJ004309STM103,A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQÂ®) in Patients With Ovarian Cancer and Selected Solid Tumors,1.5780821917808219,"Active, not recruiting",Interventional,Yes,No,Sponsor,25
AP1904-50102,Magnesium and Ketamine in Postoperative Analgesia,1.084931506849315,Completed,Interventional,No,No,Sponsor,90
GCT1044-01,A Study on the Safety of GEN1044 (DuoBodyÂ®-CD3x5T4) in Patients With Malignant Solid Tumors,1.2904109589041095,Terminated,Interventional,Yes,No,Sponsor,48
EOC317X1101,Study of EOC317 in Chinese Patients With Advanced Solid Tumors,2.506849315068493,Unknown status,Interventional,No,No,Sponsor,140
SZMC-0216-22,A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC,5.950684931506849,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,50
7465-CL-202,A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202),4.397260273972603,"Active, not recruiting",Interventional,Yes,No,Sponsor,288
ELU-FRÎ±-1,A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRÎ±),3.504109589041096,Recruiting,Interventional,Yes,No,Sponsor,166
IMP7068 - 101,The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors,2.5095890410958903,Recruiting,Interventional,Yes,No,Sponsor,350
D0818R00008,A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer,0.20273972602739726,Not yet recruiting,Observational,No,No,Sponsor,150
2000028592,Congenital Uterine Anomalies: Identifying Cancer Associations and Genetic and Environmental Factors to Improve Clinical Care,3.632876712328767,Recruiting,Observational,No,No,Sponsor,300
D17062,Biomarkers in Chemotherapy-Induced Peripheral Neurotoxicity,3.9616438356164387,Completed,Interventional,No,Yes,Principal Investigator,7
SGNPDL1V-001,A Study of SGN-PDL1V in Advanced Solid Tumors,4.186301369863014,Recruiting,Interventional,Yes,No,Sponsor,315
22/006-P,Palliative Care Costs for Outpatient Setting Management in Catalunya,1.0000000000000002,Not yet recruiting,Observational,No,No,Sponsor,100
SAIL-002,Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity,0.4821917808219179,Completed,Interventional,No,No,Sponsor,30
101,CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors,3.8301369863013703,Recruiting,Interventional,Yes,No,Sponsor,48
PREFER,PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine,1.9506849315068495,Recruiting,Observational,,,Sponsor,2500
C3881001,PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors,3.4876712328767123,Terminated,Interventional,Yes,No,Sponsor,49
TT420X1103,Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors,1.3835616438356164,Recruiting,Interventional,Yes,No,Sponsor,225
RP2-001-18,Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors,3.706849315068493,Recruiting,Interventional,No,No,Sponsor,36
M18HAR,Health After eaRly Menopause Due to Oophorectomy,2.8904109589041096,Unknown status,Observational,No,No,Sponsor,750
8259,PostmenopausAL heaLth And DIseAse (PALLADIA) Study,4.252054794520548,Recruiting,Observational,,No,Principal Investigator,4000
20-458,Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients,3.7095890410958905,Recruiting,Observational,No,No,Sponsor,625
STUDY00020679,SMMART Adaptive Clinical Treatment (ACT) Trial,3.3315068493150686,Not yet recruiting,Interventional,Yes,No,Principal Investigator,131
M20COM,The Prospective Observational COMPRAYA Cohort Study,13.961643835616439,Recruiting,Observational,No,No,Sponsor,4000
21-508,Video Education With Result Dependent dIsclosure,4.079452054794521,Recruiting,Interventional,No,No,Principal Investigator,1020
CPG-01-001,COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.,5.238356164383561,"Active, not recruiting",Interventional,Yes,No,Sponsor,140
TJCC-LC-20190108,Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC,1.7561643835616438,Unknown status,Interventional,No,No,Sponsor,45
S1714,Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer,7.002739726027397,"Active, not recruiting",Observational,,,Sponsor,1336
2000026840,Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC,2.254794520547945,Not yet recruiting,Interventional,Yes,No,Sponsor,24
2020/2706,Impact of Measures Taken to Contain COVID-19 on Hospital Surgical Care Services and Clinical Outcomes,0.663013698630137,Completed,Observational,No,No,Sponsor,11000
INCB 106385-102,INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors,2.9013698630136986,Recruiting,Interventional,Yes,No,Sponsor,230
GCT1046-01,GEN1046 Safety Trial in Patients With Malignant Solid Tumors,5.556164383561644,Recruiting,Interventional,Yes,No,Sponsor,752
127-CL-01,Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors,3.89041095890411,"Active, not recruiting",Interventional,No,No,Sponsor,60
Pro00077309,Prevent Cancer- Greenville,11.008219178082191,Recruiting,Observational,No,No,Sponsor,1000
KY1044-CT01,Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer,5.764383561643836,Recruiting,Interventional,Yes,No,Sponsor,280
UAB30,A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer,3.835616438356165,Recruiting,Interventional,Yes,No,Principal Investigator,84
MCC-20086,Developing and Testing a Spanish-Language Intervention to Reduce Cancer-Related Sleep Disturbance,1.652054794520548,Completed,Interventional,No,No,Sponsor,60
Oncoplastic breast surgeries,The Role of Lipofilling After Oncoplastic Breast Surgeries : Evaluation of Outcomes and Patient Satisfaction,1.704109589041096,Recruiting,Interventional,No,No,Principal Investigator,20
105909,Influence of Chemotherapy on Postural Control in Women With Cancer,2.232876712328767,Recruiting,Observational,No,No,Sponsor-Investigator,31
XmAb20717-01,A Study of XmAbÂ®20717 in Subjects With Selected Advanced Solid Tumors,4.161643835616439,Completed,Interventional,Yes,No,Sponsor,150
PBC017,Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer,4.194520547945206,Recruiting,Interventional,No,No,Sponsor,40
19ON033,Vibrational Spectroscopy for Endometrial Cancer Diagnosis,4.789041095890411,Recruiting,Observational,No,No,Sponsor,150
Parameters of resistence,Parameters Declaring PCO Infertile Patients Either Sensitive or Resistant to Different Doses of Clomiphene Citrate.,1.1616438356164382,Recruiting,Observational,No,No,Principal Investigator,100
NCI-2017-01979,"Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery",0.0,Withdrawn,Interventional,Yes,No,Sponsor,0
NCI-2018-01375,"Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study",4.0630136986301375,"Active, not recruiting",Observational,No,No,Sponsor,150
Pro20170001392,"Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability",5.572602739726028,Recruiting,Interventional,Yes,No,Principal Investigator,40
A005D-E01-201,[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR),1.0054794520547947,Terminated,Interventional,Yes,No,Sponsor,19
A212102,Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection,2.506849315068493,Recruiting,Observational,No,No,Sponsor,2000
TAP_Sett17,Kinesio Tex Tape in Reducing Edema and Seroma After Complex Reconstructive Breast Surgery,2.2465753424657535,Unknown status,Interventional,No,No,Principal Investigator,60
CPO-100-US-101,Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors,3.9397260273972607,Recruiting,Interventional,Yes,No,Sponsor,126
IRB00058758,Paclitaxel Therapeutic Drug Monitoring in Cancer Patients,4.057534246575343,Recruiting,Observational,No,No,Sponsor,20
20-117,Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors,3.9780821917808225,"Active, not recruiting",Interventional,No,Yes,Sponsor,102
19-002006,Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer,3.6301369863013697,"Active, not recruiting",Interventional,No,No,Sponsor,250
Plasticity Longitudinal cANcer,Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET),3.8328767123287677,Recruiting,Interventional,No,No,Sponsor,500
2021-025,Ask Questions (ASQ):Implementation of a Communication Intervention,1.934246575342466,Recruiting,Interventional,No,No,Principal Investigator,225
ATRC-101-A01,A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies,5.054794520547945,Recruiting,Interventional,Yes,No,Sponsor,240
ST101-101,A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors,3.504109589041096,Recruiting,Interventional,Yes,No,Sponsor,162
190143,Non-Viral TCR Gene Therapy,6.673972602739726,Recruiting,Interventional,Yes,No,Sponsor,210
CYT-0851-01,A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors,4.147945205479452,Recruiting,Interventional,Yes,No,Sponsor,320
MC210102,"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study",2.9068493150684933,Recruiting,Interventional,Yes,No,Sponsor,36
17573,A Study of Lasmiditan in Healthy Volunteers,0.3863013698630137,Completed,Interventional,Yes,No,Sponsor,96
NCI-2020-13883,"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial",5.073972602739726,Recruiting,Interventional,Yes,No,Sponsor,15
TT00420CN04,To Evaluate Efficacy and Safety of TT-00420 as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors,2.304109589041096,Recruiting,Interventional,No,No,Sponsor,114
ONCR-177-101,"Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors",8.12054794520548,"Active, not recruiting",Interventional,Yes,No,Sponsor,132
SGNSTNV-001,A Study of SGN-STNV in Advanced Solid Tumors,5.2,Recruiting,Interventional,Yes,No,Sponsor,315
2021-0299,Tumor Treating Fields Therapy in Combination With Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax,4.345205479452055,Recruiting,Interventional,Yes,Yes,Sponsor,36
SKL27969C001,"Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients",1.9726027397260277,Recruiting,Interventional,Yes,No,Sponsor,96
ACE-Pan tumor-02,ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02),0.4547945205479452,Withdrawn,Interventional,Yes,No,Sponsor,0
HCC 20-266,Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC),8.098630136986303,Recruiting,Interventional,Yes,No,Sponsor-Investigator,61
2019-0239,Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives,3.3643835616438356,Recruiting,Observational,No,No,Sponsor,320
D9090C00003,A Study to Assess the Effect of Multiple Doses of AZD5462 on the Pharmacokinetics (PK) of Drugs in Healthy Participants,0.20273972602739726,Completed,Interventional,Yes,No,Sponsor,32
FT500-101,FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors,3.750684931506849,Completed,Interventional,Yes,No,Sponsor,37
17364,A Study of LY3435151 in Participants With Solid Tumors,0.35342465753424657,Terminated,Interventional,Yes,No,Sponsor,2
180043,Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy,1.6657534246575343,Terminated,Observational,No,No,Sponsor,98
NCI-2020-06906,Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations,2.9232876712328766,Recruiting,Interventional,Yes,No,Sponsor,36
INT 48/21,Quantifying Systemic Immunosuppression to Personalize Cancer Therapy,2.1890410958904107,Recruiting,Observational,No,No,Sponsor,1000
IDE161-001,A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors,2.506849315068493,Not yet recruiting,Interventional,Yes,No,Sponsor,68
AK2018_1,18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer,0.873972602739726,Completed,Interventional,No,No,Principal Investigator,10
FT536-101,FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors,4.838356164383562,Recruiting,Interventional,Yes,No,Sponsor,322
STUDY00000719,Adaptive Symptom Self-Management Immunotherapy Study,4.254794520547946,Not yet recruiting,Interventional,No,No,Sponsor,400
DV001,The Effect of Androgen Receptor Polymorphism on Endometrial Cancer,2.0027397260273974,Not yet recruiting,Observational,No,No,Principal Investigator,150
JZP712-201,Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors,2.3095890410958906,Recruiting,Interventional,Yes,No,Sponsor,60
CancerDyads,Improving Survivorship Among Minority Cancer Dyads,3.504109589041096,Withdrawn,Interventional,No,No,Sponsor,0
TMPS-101,Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors,3.2986301369863016,Recruiting,Interventional,Yes,No,Sponsor,110
IIBSP-ECV-2019-103,Study of Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2 Mutation Carriers (BRCA-HRT),3.5561643835616437,Recruiting,Observational,,,Sponsor,45
00000441,Same-Day Discharge After Nipple-sparing Mastectomy or Skin-sparing Mastectomy With Breast Reconstruction,2.0027397260273974,Unknown status,Interventional,No,No,Sponsor,60
CCI-2003,Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC),3.6904109589041094,Recruiting,Interventional,Yes,No,Sponsor,18
SGNB6A-001,A Study of SGN-B6A in Advanced Solid Tumors,4.4,Recruiting,Interventional,Yes,No,Sponsor,572
MLB-PK-001,A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer,2.0027397260273974,Not yet recruiting,Interventional,Yes,No,Sponsor,6
XmAb23104-01,A Study of XmAbÂ®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3),6.342465753424658,Recruiting,Interventional,Yes,No,Sponsor,300
2020-0439,Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors,4.0410958904109595,Recruiting,Interventional,Yes,No,Sponsor,50
CYH33-G102,Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.,3.334246575342466,Recruiting,Interventional,Yes,No,Sponsor,350
20-410,Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer,2.8547945205479452,"Active, not recruiting",Interventional,No,No,Principal Investigator,210
202101,Comprehensive Outcomes for After Cancer Health,1.441095890410959,Recruiting,Interventional,No,No,Sponsor,500
NB-ND021 (NM21-1480)-101,A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors,4.372602739726028,Recruiting,Interventional,Yes,No,Sponsor,406
SBT6050-101,A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors,2.347945205479452,"Active, not recruiting",Interventional,Yes,No,Sponsor,58
17-262-01,REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies,4.153424657534247,Terminated,Interventional,Yes,No,Sponsor,64
UC-IMM-2101,Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO,3.0,Recruiting,Interventional,No,No,Sponsor,646
ADCT-301-103,Study of ADCT-301 in Patients With Selected Advanced Solid Tumors,4.082191780821918,Terminated,Interventional,Yes,No,Sponsor,78
170177,Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer,1.4328767123287671,Terminated,Interventional,Yes,No,Principal Investigator,1
TPST-1120-001,TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers,5.265753424657534,"Active, not recruiting",Interventional,Yes,No,Sponsor,138
180032,Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer,2.5643835616438357,Completed,Interventional,Yes,No,Principal Investigator,11
VICC SUPP 2112,Improving Care After Inherited Cancer Testing,6.328767123287672,Recruiting,Interventional,No,No,Principal Investigator,720
IB2022-03,Streamlined Geriatric and Oncological Evaluation Based On IC Technology,2.756164383561644,Not yet recruiting,Interventional,No,No,Sponsor,720
PR148/21,Axillary Lymph Node Dissection vs Axillary Radiotherapy in Positive Sentinel Node After Neoadjuvant Therapy,5.002739726027397,Recruiting,Interventional,No,No,Principal Investigator,1666
2020-117,DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer,4.556164383561644,Recruiting,Interventional,No,No,Sponsor-Investigator,260
A9001502,Treatment Resistance Following Anti-cancer Therapies,1.8356164383561644,Terminated,Interventional,No,No,Sponsor,38
NCI-2020-05428,"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer",2.9123287671232876,Recruiting,Interventional,Yes,No,Sponsor,74
2021-0175,Phase I Study of ZN-c3 and Bevacizumab Â± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors,0.0,Withdrawn,Interventional,Yes,No,Sponsor,0
CCT303-406-mST01,A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors,4.723287671232876,Recruiting,Interventional,No,No,Sponsor,15
6B-20-1,18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases,4.002739726027397,"Active, not recruiting",Interventional,Yes,No,Sponsor,10
NRG-BN009,Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery,9.134246575342466,Recruiting,Interventional,No,No,Sponsor,350
TCR2-21-01,A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer,5.449315068493151,Recruiting,Interventional,Yes,No,Sponsor,115
NCI-2020-05956,Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV,4.997260273972603,Recruiting,Interventional,Yes,No,Sponsor,18
Pro9646,Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy,2.936986301369863,Recruiting,Observational,No,No,Principal Investigator,106
CA052-002,A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors,5.306849315068493,Recruiting,Interventional,Yes,No,Sponsor,665
IMX-110-001,IMX-110 in Patients With Advanced Solid Tumors,5.413698630136986,Recruiting,Interventional,Yes,No,Sponsor,70
IIR 17-127,Measuring and Improving the Safety of Test Result Follow-Up,4.920547945205479,"Active, not recruiting",Interventional,No,No,Sponsor,11
WPH 2201,A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler Heads,1.126027397260274,Not yet recruiting,Interventional,No,Yes,Sponsor,12
IRB20-0462,The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care,6.147945205479452,Recruiting,Interventional,No,No,Sponsor,860
XmAb808-01,"Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAbÂ®808 in Combination With Pembrolizumab in Advanced Solid Tumors",4.967123287671233,Recruiting,Interventional,Yes,No,Sponsor,220
2019-1091,Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases,4.293150684931507,"Active, not recruiting",Interventional,Yes,No,Sponsor,10
INT156-19,Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment,2.6794520547945204,Completed,Observational,No,No,Sponsor,247
02-MX-003,ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation,6.405479452054794,Recruiting,Observational,No,No,Sponsor,1000
VAR-2022-04,Evaluation of a Cone-beam CT Scanner for Image Guided Radiotherapy,0.8712328767123287,Recruiting,Interventional,No,Yes,Sponsor,40
Phase 1 SV-101,Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors,0.9123287671232877,Recruiting,Interventional,No,No,Principal Investigator,20
NYPC ERC# 2019-002,Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors,4.93972602739726,Recruiting,Interventional,No,Yes,Sponsor,1800
TTX-080-001,TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers,3.8849315068493153,Recruiting,Interventional,Yes,No,Sponsor,240
P.T.REC/012/003744,Endermologie Versus Negative Pressure Therapy on Postmastectomy Lymphedema,0.9232876712328767,Recruiting,Interventional,No,No,Principal Investigator,68
P.T.REC/012/004199,Effect of Wii-console Based Exercise on Shoulder Range of Motion for Post-mastectomy Lymphedema Patients,0.5808219178082191,Recruiting,Interventional,No,No,Principal Investigator,40
Doaa Atef,Virtual Reality Versus Proprioceptive Neuromuscular Facilitation on Postmastectomy Lymphedema,1.16986301369863,Completed,Interventional,No,No,Sponsor-Investigator,30
09.2018.466,Reliability of Subcutaneous Echogenicity (SEG) Grade and Subcutaneous Echo-free Space (SEFS) Grade,0.1178082191780822,Completed,Observational,No,No,Sponsor,50
0752-20-HMO,Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers,5.750684931506849,Recruiting,Interventional,No,No,Sponsor,3
OCEL-01,A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers,2.071232876712329,Recruiting,Interventional,No,No,Sponsor,80
ILBS-VASMPCa-103,Effectiveness of Video Assisted Self Management Program on Chemotherapy Related Side Effects .,0.09315068493150686,Completed,Interventional,No,No,Sponsor,60
NuTide:303,NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours,1.9178082191780825,Not yet recruiting,Interventional,Yes,No,Sponsor,91
IC 2020-11_ALCINA4,Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4,5.515068493150685,Recruiting,Interventional,No,No,Sponsor,820
AMT-151-01,AMT-151 in Patients With Selected Advanced Solid Tumours,1.7643835616438357,Recruiting,Interventional,No,No,Sponsor,30
MDNA11-01,A Beta-only IL-2 ImmunoTherapY (ABILITY) Study,3.345205479452055,Recruiting,Interventional,Yes,No,Sponsor,100
SGNTGT-001,A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer,4.923287671232877,Recruiting,Interventional,Yes,No,Sponsor,429
PT199X1101,Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor,1.526027397260274,Recruiting,Interventional,Yes,No,Sponsor,41
GB1275-1101 (KEYNOTE-A36),GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma,2.663013698630137,Terminated,Interventional,Yes,No,Sponsor,61
IB2022-02,Cancer Risk Assessment in Patients With a Constitutional Alteration of the PTEN Gene,24.915068493150685,Recruiting,Observational,No,No,Sponsor,430
INCAGN 2385-101,A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies,2.3068493150684932,Completed,Interventional,Yes,No,Sponsor,22
IB 2017-01,A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors,7.665753424657535,Recruiting,Interventional,No,No,Sponsor,747
INCAGN 2390-101,A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies,2.9013698630136986,Completed,Interventional,Yes,No,Sponsor,40
NU04,.Exercise and Follow-up After a Mastectomy,0.5753424657534246,Completed,Interventional,No,No,Sponsor,60
STUDY00001436,Enhance the Use of Genetic Counseling and Testing in Latinas,1.9369863013698632,Completed,Interventional,No,No,Sponsor,61
20430,HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics,3.0054794520547947,Recruiting,Interventional,No,No,Sponsor,435
STUDY00015588,Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial,5.912328767123288,Recruiting,Interventional,Yes,No,Principal Investigator,40
IRB00092505,Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy,4.838356164383562,Not yet recruiting,Interventional,No,No,Sponsor,244
NX-1607-101,A Study of NX-1607 in Adults With Advanced Malignancies,3.419178082191781,Recruiting,Interventional,Yes,No,Sponsor,268
GLP-CDK-1009,Evaluation of GLR2007 for Advanced Solid Tumors,2.0383561643835617,Completed,Interventional,Yes,No,Sponsor,19
0S-17-4,"Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer",2.071232876712329,Withdrawn,Observational,No,No,Sponsor,0
Teleclub_cam,Telerehabilitation in Oncology Patients,0.4191780821917808,Unknown status,Interventional,No,No,Principal Investigator,30
AS-IRB-BM-17056,Taiwan Cancer Moonshot Project,13.865753424657534,Recruiting,Observational,No,No,Sponsor,4190
HZDH20-002,Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.,1.9917808219178084,Recruiting,Interventional,No,No,Sponsor,98
Pro00100029,Calming Alternatives Learned During MRI-Guided Breast Biopsy,0.6767123287671233,Completed,Interventional,No,No,Sponsor,58
2022-0712,Feasibility Study: IGNITE-TX (Identifying Texans at Risk for Hereditary Cancer) Intervention,4.550684931506849,Recruiting,Interventional,No,No,Sponsor,80
2018-0439,Genetic Education in BRCA Families,4.167123287671234,Enrolling by invitation,Interventional,No,No,Principal Investigator,426
CR109080,A Study of Lazertinib (JNJ-73841937) in Healthy Participants,0.4,Completed,Interventional,Yes,No,Sponsor,20
GIMI-IRB-20004,4SCAR-CD44v6 T Cell Therapy Targeting Cancer,3.5835616438356164,Recruiting,Interventional,No,No,Principal Investigator,100
2020-0079-E,Evaluation of the Effectiveness and Implementation of the BETTER Women Peer Health Coaching Program,2.8,Recruiting,Interventional,No,No,Principal Investigator,408
2020-3,Experiment on the Use of Innovative Computer Vision Technologies for Analysis of Medical Images in the Moscow Healthcare System,3.8630136986301373,Recruiting,Observational,No,No,Sponsor,133000
IRB00056774,Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors,3.4328767123287673,"Active, not recruiting",Interventional,No,No,Sponsor,645
EAQ202,Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials,3.2465753424657535,Recruiting,Interventional,No,No,Sponsor,400
SYNERGY-AI,SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry,7.419178082191781,Recruiting,Observational,No,No,Sponsor,50000
V937-013,A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013),2.756164383561644,"Active, not recruiting",Interventional,Yes,No,Sponsor,185
10000045,"T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers",4.079452054794521,Recruiting,Interventional,Yes,No,Sponsor,100
19-006717,Cancer Genetic Testing in Ethnic Populations,3.8410958904109593,Recruiting,Interventional,No,No,Sponsor,800
ATLAS-101,A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies,2.389041095890411,Recruiting,Interventional,Yes,No,Sponsor,80
19-151,Personalized Disease Prevention,2.904109589041096,Recruiting,Interventional,No,No,Sponsor-Investigator,660
21-00715,Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain,3.7424657534246575,Recruiting,Interventional,Yes,No,Sponsor,750
TAC01-HER2-03,TAC T-cells for the Treatment of HER2-positive Solid Tumors,3.791780821917808,Recruiting,Interventional,Yes,No,Sponsor,70
UW17009,Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer,4.627397260273972,Completed,Interventional,Yes,No,Sponsor,30
UMCC 2021.076,Methods for Increasing Genetic Testing Uptake in Michigan,4.863013698630137,Recruiting,Interventional,No,No,Sponsor,759
H19-04010,Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity,4.293150684931507,Recruiting,Interventional,No,No,Sponsor,200
F/N-R19-3893L,Effect of Hemp-CBD on Patients With CIPN,2.8465753424657536,"Active, not recruiting",Interventional,Yes,No,Principal Investigator,56
CRUKD/21/005,TT-702 in Patients With Advanced Solid Tumours.,3.6191780821917807,Recruiting,Interventional,No,No,Sponsor,114
Adela-EDMRD-001,cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease,4.583561643835616,Recruiting,Observational,No,No,Sponsor,7000
YXLL-KY-2022(057),Effect of Precise Grip Strength Training on PICC Catheter-Related Thrombosis in Cancer Patients,0.5041095890410959,Completed,Interventional,No,No,Sponsor-Investigator,270
ISI dV Xi-NSM,Robotic-Assisted da Vinci Xi Prophylactic Nipple-Sparing Mastectomy,7.769863013698631,Recruiting,Interventional,No,Yes,Sponsor,145
16712,A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer,2.484931506849315,Completed,Interventional,Yes,No,Sponsor,172
HREBA.CC-20-0098,EXCEL: Exercise for Cancer to Enhance Living Well,7.331506849315068,Recruiting,Interventional,No,No,Sponsor,1500
IPO/PI134,Impact of Group Psychological Interventions on Extracellular Vesicles in People Who Had Cancer,0.0,Unknown status,Interventional,No,No,Sponsor,108
IMM2520-001,"IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors",2.5972602739726027,Not yet recruiting,Interventional,Yes,No,Sponsor,48
Cancer Genetic Counseling.PSI,Assessment Psychological Distress for Cancer Heredity Test,3.252054794520548,Unknown status,Observational,No,No,Principal Investigator,800
OM-GRPR-02,Safety and Tolerability of Â²Â¹Â²Pb-DOTAM-GRPR1 Â²Â¹Â²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors,2.03013698630137,Recruiting,Interventional,Yes,No,Sponsor,50
17493,A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors,5.2027397260273975,Recruiting,Interventional,Yes,No,Sponsor,100
LOXO-IDH-20002,Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations,2.5397260273972604,"Active, not recruiting",Interventional,Yes,No,Sponsor,200
1623168,Healthy Moms: Prenatal Counseling for Postpartum Health,2.367123287671233,"Active, not recruiting",Interventional,No,No,Sponsor,451
11190071,Multimodal Assesment of Acute Cardiac Toxicity Induced by Thoracic Radiotherapy in Cancer Patients,3.8109589041095897,"Active, not recruiting",Observational,No,No,Sponsor,60
PACT-0101,A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors,3.1123287671232878,Suspended,Interventional,Yes,No,Sponsor,21
PROICM 2021-05 SER,Quantifying Systemic Immunosuppression to Personalize Cancer Therapy,1.652054794520548,Withdrawn,Interventional,No,No,Sponsor,0
IRB-300002068,Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health,4.495890410958904,Recruiting,Interventional,No,No,Principal Investigator,652
0000-0001-5580-7256,Education Intervention in Patients With Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment.,2.3315068493150686,Unknown status,Interventional,No,No,Principal Investigator,40
2017-0319,Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF,6.041095890410959,Recruiting,Interventional,Yes,No,Sponsor,120
TRV-003,Mass Response of Malignant Fluid Cells as a Biomarker for Rapid Therapy Guidance,3.964383561643836,Recruiting,Observational,No,No,Sponsor,200
ATOS-016R,Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density,4.03013698630137,Recruiting,Interventional,No,No,Sponsor,240
HSP70CTC,Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells,1.2,Recruiting,Observational,No,No,Principal Investigator,120
Pro00104093,Assessing the Immunogenicity of pING-hHER3FL,4.389041095890411,Recruiting,Interventional,Yes,No,Sponsor-Investigator,24
VNC-236-101,Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer,1.8547945205479452,Recruiting,Interventional,Yes,No,Sponsor,24
DB-1303-O-1001,A Study of DB-1303 in Advanced/Metastatic Solid Tumors,3.6684931506849314,Recruiting,Interventional,Yes,No,Sponsor,363
Metabolic Cancer 001,"Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer",5.33972602739726,Withdrawn,Interventional,No,No,Sponsor,0
POWER,Potential of Moderate Whole Body Hyperthermia to Enhance Response,4.832876712328767,Recruiting,Interventional,No,No,Principal Investigator,80
19-000756,Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues,11.956164383561644,Recruiting,Interventional,Yes,Yes,Sponsor,30
7339-002,"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)",6.975342465753425,Recruiting,Interventional,Yes,No,Sponsor,390
2018-001744-62,Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors,5.975342465753425,Suspended,Interventional,No,No,Sponsor,1000
20-533,Pembrolizumab And Lenvatinib In Leptomeningeal Metastases,1.7342465753424658,Recruiting,Interventional,Yes,No,Principal Investigator,19
D9950C00001,First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours,2.7041095890410958,"Active, not recruiting",Interventional,Yes,No,Sponsor,61
19-011472,"Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study",4.043835616438357,"Active, not recruiting",Interventional,No,No,Sponsor,230
7684A-005,MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005),5.438356164383562,Recruiting,Interventional,Yes,No,Sponsor,610
2017-0719,Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT,6.232876712328767,Recruiting,Interventional,Yes,No,Sponsor,18
CBX-12-101,Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors,2.915068493150685,Recruiting,Interventional,Yes,No,Sponsor,130
1801,9-ING-41 in Patients With Advanced Cancers,6.83013698630137,Recruiting,Interventional,Yes,No,Sponsor,350
MOHCCN-O,Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O),4.304109589041096,Recruiting,Observational,No,No,Sponsor,500
STU00209558,Plan to Thrive: Extending Cancer Survivorship Care Beyond the Clinic,0.36712328767123287,Completed,Observational,No,No,Principal Investigator,33
IJB-IRAES-2020,Immunological Variables Associated to ICI Toxicity in Cancer Patients,2.252054794520548,Recruiting,Interventional,No,No,Principal Investigator,441
IRB00229163,Behavioral Weight Loss Program for Cancer Survivors in Maryland,2.76986301369863,"Active, not recruiting",Interventional,No,No,Sponsor,300
ON-1002,"A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer",2.2794520547945205,Completed,Interventional,Yes,No,Sponsor,30
SGN47M-001,A Safety Study of SGN-CD47M in Patients With Solid Tumors,1.1643835616438356,Terminated,Interventional,Yes,No,Sponsor,16
TP-CA-001,Tempus Priority Study: A Pan-tumor Observational Study,10.005479452054795,Recruiting,Observational,No,No,Sponsor,1000
P-MUC1C-ALLO1-001,P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors,17.134246575342466,Recruiting,Interventional,Yes,No,Sponsor,100
NTI1GSA,"Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid",1.9150684931506852,Recruiting,Interventional,No,No,Sponsor,12
FT538-102,FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors,3.8082191780821923,Recruiting,Interventional,Yes,No,Sponsor,189
OHSN-REB#20170381-01H,Randomized Trial of eOncoNote,3.0356164383561643,Completed,Interventional,No,No,Principal Investigator,181
H-43405 VISTA,"Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors",18.054794520547944,Recruiting,Interventional,Yes,No,Principal Investigator,45
QUILT-2.025,QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.,2.3917808219178083,Unknown status,Interventional,Yes,No,Sponsor,16
ZZTIL-012,Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors,14.008219178082191,Recruiting,Interventional,No,No,Sponsor,40
202211038RINA,Microscopy Imaging of Whole-mount Stained Human Tissues,1.9753424657534249,Not yet recruiting,Observational,No,No,Sponsor,250
20201421,"With Love, Grandma (Con CariÃ±o, Abuelita) Pilot Study",1.2712328767123289,Recruiting,Interventional,No,No,Principal Investigator,80
YSCH-01-0000,Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study,2.0849315068493155,Recruiting,Interventional,No,No,Sponsor,28
SNB-101-101,"Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors",3.1945205479452055,Recruiting,Interventional,No,No,Sponsor,36
1224/2018,Cryotherapy vs. Cryocompression for Preventing Chemotherapy-induced-peripheral-neuropathy in Women Undergoing Chemotherapy,4.002739726027397,Recruiting,Interventional,No,No,Sponsor,196
438-IO-101,Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors,2.06027397260274,Recruiting,Interventional,Yes,No,Sponsor,71
831-IO-101,Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors,2.673972602739726,Recruiting,Interventional,Yes,No,Sponsor,79
BHP0120,A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation,3.838356164383562,Recruiting,Interventional,No,No,Principal Investigator,1500
CDX527-01,A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies,2.6575342465753424,"Active, not recruiting",Interventional,Yes,No,Sponsor,27
HREBA.CC-22-0196,LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study,1.515068493150685,Recruiting,Observational,No,No,Sponsor,75
Meet-URO 12,Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy,2.0164383561643837,Completed,Interventional,Yes,No,Principal Investigator,58
NC318-01,A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors,4.50958904109589,"Active, not recruiting",Interventional,Yes,No,Sponsor,109
STR-004-001,Strata PATHâ¢ (Precision Indications for Approved Therapies),8.005479452054795,Recruiting,Interventional,Yes,No,Sponsor,700
Pro00103249,Symptom Management for YA Cancer Survivors,5.695890410958904,Recruiting,Interventional,No,No,Sponsor,120
21850,Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors,5.610958904109589,Recruiting,Interventional,Yes,Yes,Sponsor-Investigator,32
180049,Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer,9.550684931506849,Recruiting,Interventional,Yes,No,Sponsor,270
ARC-5 (AB928CSP0005),A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies,3.115068493150685,Completed,Interventional,Yes,No,Sponsor,48
201809177,PROactive Evaluation of Function to Avoid CardioToxicity,3.9726027397260277,Terminated,Interventional,No,Yes,Sponsor,49
2020-2110,Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel,0.5561643835616439,Completed,Interventional,Yes,No,Principal Investigator,27
AVS4TL - 0921,Avera/Sema4 Oncology and Analytics Protocol,5.167123287671233,Recruiting,Observational,No,No,Sponsor,25000
IIT2020-24-SHIRAZIP-BURN,The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors,2.1616438356164385,Recruiting,Interventional,No,No,Principal Investigator,20
PY159-2-01,A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors,2.4054794520547946,Recruiting,Interventional,Yes,No,Sponsor,343
C3651010,Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia,1.2465753424657535,Completed,Interventional,Yes,No,Sponsor,18
Palliach,Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care,1.4109589041095891,Unknown status,Interventional,No,No,Sponsor,80
DPM401,Study to Evaluate the Safety of Nanoxel M Inj.,4.873972602739726,Recruiting,Observational,No,No,Sponsor,1498
BR-DTX-OS-401,Docetaxel Ethanol-induced Symptoms; The Incidence and Risk Forecating Factor,1.0383561643835617,Completed,Observational,No,No,Sponsor,458
TAK-500-1001,A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors,2.9013698630136986,Recruiting,Interventional,Yes,No,Sponsor,118
PRT1419-02,A Study of PRT1419 in Patients With Advanced Solid Tumors,1.4904109589041097,Completed,Interventional,Yes,No,Sponsor,26
IIT2020-13-GRESHAM-ELLY,Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients,1.5972602739726027,Recruiting,Interventional,No,No,Sponsor-Investigator,100
2018-0663,Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients,2.493150684931507,Recruiting,Interventional,Yes,No,Sponsor,40
APHP190973,Integrated Care Pathway in Oncology (PASSION),2.8602739726027395,"Active, not recruiting",Observational,No,No,Sponsor,1800
C3441037,A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors,1.5835616438356164,Completed,Interventional,Yes,No,Sponsor,73
CE 07-14-2020,Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer,3.838356164383562,Recruiting,Interventional,No,No,Principal Investigator,200
ELVCAP-001-01,Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors,2.671232876712329,"Active, not recruiting",Interventional,Yes,No,Sponsor,75
202100484,Early Ageing During Therapy in AYA Cancer Patients,1.6383561643835616,Recruiting,Observational,No,No,Principal Investigator,120
143631,"Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.",1.3643835616438356,Withdrawn,Interventional,Yes,No,Sponsor,0
ZZITICI-004,Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors,15.01095890410959,Recruiting,Interventional,Yes,No,Sponsor,200
QBS-72S-1001,"Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S",2.4246575342465753,Completed,Interventional,No,No,Sponsor,15
2440LM-002,DNX-2440 for Resectable Colorectal Liver Metastasis,2.873972602739726,Recruiting,Interventional,Yes,No,Sponsor,30
MX-011-219,Project CADENCE (CAncer Detected Early caN be CurEd),2.819178082191781,Recruiting,Observational,No,No,Sponsor,15000
VISTA-101,A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101),1.832876712328767,Recruiting,Interventional,Yes,No,Sponsor,314
ZZICI3-015,Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors,3.997260273972603,Recruiting,Interventional,Yes,No,Sponsor,100
ALS-6000-101,"A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours",1.956164383561644,Recruiting,Interventional,Yes,No,Sponsor,80
AA1809,Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors,3.0931506849315067,Completed,Interventional,No,No,Principal Investigator,13
PMV-586-101,The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE),5.7095890410958905,Recruiting,Interventional,Yes,No,Sponsor,181
R231-A14057,Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.,2.082191780821918,Completed,Observational,No,No,Principal Investigator,722
AMXT1501-102,Oral AMXT 1501 Dicaprate in Combination With IV DFMO,1.336986301369863,Recruiting,Interventional,Yes,No,Sponsor,56
201909133,Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers,2.706849315068493,Recruiting,Interventional,No,No,Sponsor,25
ROOT,The Registry of Oncology Outcomes Associated With Testing and Treatment,10.413698630136986,Recruiting,Observational,No,No,Sponsor,100000
BBI-355-101,"Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy, in Subjects With Tumors With Oncogene Amplifications",2.7753424657534245,Recruiting,Interventional,Yes,No,Sponsor,47
FPI-1966-101,A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours,4.619178082191781,Recruiting,Interventional,Yes,No,Sponsor,155
MYCT001,The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology),4.980821917808219,Recruiting,Observational,No,No,Sponsor,1000
JAB-3312-1002,A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China,3.4767123287671233,Recruiting,Interventional,No,No,Sponsor,24
707-IO-101,Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies,4.0630136986301375,Recruiting,Interventional,Yes,No,Sponsor,179
UW18101,Immunonutrition and Carbohydrate Loading Strategies in Breast Reconstruction,2.750684931506849,Completed,Interventional,No,No,Sponsor,125
JAB-3312-1001,"A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors",4.432876712328767,Recruiting,Interventional,Yes,No,Sponsor,24
PAL-E602-001,Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01),3.304109589041096,Recruiting,Interventional,Yes,No,Sponsor,273
340-74,CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC),2.4657534246575343,Withdrawn,Interventional,Yes,No,Sponsor,0
PRO17070414,Self-Advocacy Serious Game in Advanced Cancer,2.263013698630137,Completed,Interventional,No,No,Principal Investigator,78
MAPreminder1,UCLA Health Patient Health Maintenance Text Reminder,1.273972602739726,Not yet recruiting,Interventional,No,No,Principal Investigator,24000
MFLeong,RCT of Acceptance and Commitment Therapy Versus Mindfulness-based Stress Reduction in Head and Neck Cancer,3.0,Not yet recruiting,Interventional,No,No,Principal Investigator,90
1100,NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy,9.375342465753425,Recruiting,Interventional,Yes,No,Sponsor,145
MAPinitial,UCLA Health Patient Health Maintenance Outreach Text Message,1.3123287671232877,Enrolling by invitation,Interventional,No,No,Principal Investigator,48000
MAPreminder2,UCLA Health Patient Health Maintenance With Interactive Text Reminder,1.106849315068493,Not yet recruiting,Interventional,No,No,Principal Investigator,24000
G190165,Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites,3.7095890410958905,"Active, not recruiting",Interventional,No,Yes,Sponsor-Investigator,20
JSKN003-102,To Evaluate the Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors,2.8383561643835615,Not yet recruiting,Interventional,No,No,Sponsor,365
RAIN-3202,Milademetan in Advanced/Metastatic Solid Tumors,2.750684931506849,Recruiting,Interventional,Yes,No,Sponsor,65
IN10018-010,IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients,2.813698630136986,"Active, not recruiting",Interventional,No,No,Sponsor,240
05-2019,Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection,4.66027397260274,"Active, not recruiting",Observational,No,No,Sponsor,1200
56160922.7.3001.5274,Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds,1.0027397260273974,Not yet recruiting,Interventional,No,No,Principal Investigator,106
PN #1082409C,Post Market Clinical Follow-up Study on da VinciÂ® Robotic-assisted Prophylactic Nipple Sparing Mastectomy With Breast Reconstruction,1.9534246575342469,"Active, not recruiting",Observational,No,No,Sponsor,7
CH1701,CH1701 for Prevention and Treatment of Radiation Burns,1.4109589041095891,Unknown status,Interventional,No,No,Sponsor,92
A222001,Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer,2.756164383561644,Recruiting,Interventional,Yes,No,Sponsor,87
D0816C00020,Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients,4.109589041095891,Completed,Interventional,No,No,Sponsor,279
K01CA190659,Culturally Appropriate Nutrition Communication for Mexican American Women,3.756164383561644,"Active, not recruiting",Interventional,No,No,Principal Investigator,800
TOS-358-001,A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors,2.7945205479452055,Recruiting,Interventional,Yes,No,Sponsor,241
UW19-183,"The Effect of Metacognition-based, Manualized Intervention on Fear of Cancer Recurrence",2.4465753424657533,Recruiting,Interventional,No,No,Principal Investigator,174
2011P002580-207,Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints,1.1835616438356165,Completed,Observational,Yes,No,Principal Investigator,105711
SI-B003-101,"A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors",2.4712328767123286,Recruiting,Interventional,No,No,Sponsor,159
PROT004,Virtual Trial to Compare Two Digital Therapeutics as Interventions for Physical and Mental Health in People With Cancer,0.7671232876712328,"Active, not recruiting",Interventional,No,Yes,Sponsor,352
EK 1612/2018,Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing,3.663013698630137,Completed,Interventional,No,No,Sponsor-Investigator,406
202006168,Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome,2.5616438356164384,Recruiting,Interventional,No,No,Sponsor,150
FT-003,"Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy",18.487671232876714,Recruiting,Observational,Yes,,Sponsor,76
BO41929,A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors,0.978082191780822,Terminated,Interventional,Yes,No,Sponsor,1
IRB202201399 -N-R,A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials,4.6657534246575345,Not yet recruiting,Interventional,No,No,Sponsor,350
FLX475-02,Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab,5.186301369863013,Recruiting,Interventional,Yes,No,Sponsor,375
2019-A02135-52,Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine,9.063013698630137,Recruiting,Interventional,No,No,Sponsor,1644
18-504,Smartphone Technology to Alleviate Malignant Pain (STAMP),3.4986301369863013,Completed,Interventional,No,No,Principal Investigator,20
DB-1305-O-1001,First-in-human Study of DB-1305 for Advanced/Metastatic Solid Tumors,2.9506849315068493,Recruiting,Interventional,Yes,No,Sponsor,235
TAS0612-101,A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer,3.6301369863013697,Recruiting,Interventional,Yes,No,Sponsor,242
IIT2021-07-Atkins-CARMA,Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial,1.9013698630136988,"Active, not recruiting",Interventional,No,No,Principal Investigator,20
1948-CL-0101,"A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors",4.997260273972603,"Active, not recruiting",Interventional,Yes,No,Sponsor,190
CO-338-100,A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes,2.649315068493151,Terminated,Interventional,Yes,No,Sponsor,83
STUDY00020629,Identifying and Caring for Individuals With Inherited Cancer Syndrome,10.26027397260274,Recruiting,Interventional,No,No,Principal Investigator,27500
E7766-G000-101,Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101,2.419178082191781,Completed,Interventional,Yes,No,Sponsor,24
NRG-GU006,BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER,10.520547945205479,"Active, not recruiting",Interventional,Yes,No,Sponsor,311
BBI-20201001,A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors,6.6876712328767125,Recruiting,Interventional,Yes,No,Sponsor,390
ZWI-ZW49-101,A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers,6.301369863013699,Recruiting,Interventional,Yes,No,Sponsor,174
SAHoWMU-CR2021-02-404,Gastric Cancer Marker Detection and Its Kit Development,10.0,Recruiting,Observational,No,No,Sponsor,530
BVAC-B-P1,Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care,1.2082191780821918,Completed,Interventional,No,No,Sponsor,8
IDE397-001,Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion,3.213698630136986,Recruiting,Interventional,Yes,No,Sponsor,382
MDK-703-102,A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors,2.5643835616438357,Recruiting,Interventional,Yes,No,Sponsor,150
19-011444,Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ,5.435616438356164,Recruiting,Interventional,Yes,No,Sponsor-Investigator,104
ATTCK-34-01,Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers,1.0000000000000002,Terminated,Interventional,Yes,No,Sponsor,6
BDTX-189-01,"A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.",2.745205479452055,Terminated,Interventional,Yes,No,Sponsor,91
DB-1310-O-1001,A Study of DB-1310 in Advanced/Metastatic Solid Tumors,3.4027397260273973,Not yet recruiting,Interventional,Yes,No,Sponsor,287
NRG-GU009,"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial",13.052054794520547,Recruiting,Interventional,Yes,No,Sponsor,2478
7101,Womens Knowledges About Gynaecological Aftercare,1.0000000000000002,Unknown status,Observational,No,No,Sponsor,100
17504,A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer,2.4273972602739726,Completed,Interventional,Yes,No,Sponsor,52
DGD-44-065,Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years,7.778082191780823,Recruiting,Interventional,Yes,No,Sponsor,2076
22-OBU-SH-CA-II-019,Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy,1.8356164383561644,Not yet recruiting,Interventional,No,No,Principal Investigator,80
20220586-01H,Reexamining Her Cardiovascular Risk - Ottawa WomeNs Longitudinal Cohort Study,1.104109589041096,Not yet recruiting,Interventional,No,No,Sponsor,210
D8532C00004,"Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers",0.5013698630136987,Completed,Interventional,Yes,No,Sponsor,59
CLIN-17-008,Study of the Safety and Effectiveness of Motiva ImplantsÂ®,14.90958904109589,"Active, not recruiting",Interventional,No,Yes,Sponsor,800
200-04,A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.,3.8246575342465756,Recruiting,Observational,No,No,Sponsor,200
Ad-p53-002,Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.,4.252054794520548,Unknown status,Interventional,Yes,No,Sponsor,40
TUMAGNOSTIC(CP506-001),Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI,3.084931506849315,Not yet recruiting,Interventional,No,No,Sponsor,126
20210104,A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression,3.846575342465754,Recruiting,Interventional,Yes,No,Sponsor,303
01GS,Early Detection of Five Common Cancers Using the ctDNA Analysing Test,1.643835616438356,Recruiting,Observational,No,No,Sponsor,3000
217228,First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors,3.7753424657534245,Recruiting,Interventional,Yes,No,Sponsor,162
CBP-1019-101,A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors,2.5506849315068494,"Active, not recruiting",Interventional,Yes,No,Sponsor,260
FT516-102,FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors,2.389041095890411,Completed,Interventional,Yes,No,Sponsor,12
19-110,Minnesota Care Coordination Effectiveness Study,2.547945205479452,"Active, not recruiting",Observational,No,No,Sponsor,75000
IMC-F106C-101,Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors,5.93972602739726,Recruiting,Interventional,Yes,No,Sponsor,170
TK-Onko,Evaluation of a Oncology Day Care Unit Programme With Two Different Focuses,1.7972602739726027,Completed,Interventional,No,No,Principal Investigator,100
Pro00103812,Neoadjuvant Immunotherapy in Brain Metastases,0.6164383561643836,Terminated,Interventional,Yes,No,Sponsor-Investigator,1
17894,Taking Time to Connect: A Study of Programs for Hispanic Mothers Diagnosed With Cancer and Their Children,3.4602739726027396,Completed,Interventional,No,No,Principal Investigator,43
M19-345,"Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors",5.13972602739726,Recruiting,Interventional,Yes,No,Sponsor,260
21-00072,Effect of Postoperative Single Dose of Ketamine on Pain After Mastectomy,0.9232876712328767,Completed,Interventional,Yes,No,Sponsor,31
20246,"Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants",0.7671232876712328,Completed,Interventional,Yes,No,Sponsor,14
UW21090,The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer,1.2246575342465753,Completed,Interventional,No,No,Sponsor,118
18-222,GENetic Education Risk Assessment and TEsting Study,8.654794520547945,"Active, not recruiting",Interventional,No,No,Principal Investigator,1000
4830-001,Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001),7.323287671232877,Recruiting,Interventional,Yes,No,Sponsor,442
2020-002766-14,Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab,5.901369863013699,Recruiting,Interventional,No,No,Sponsor,112
17-01135,Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome,6.087671232876712,Recruiting,Observational,No,No,Sponsor,300
2019-00134,Vitamin D3 - Omega3 - Home Exercise - HeALTHy Aging and Longevity Cohort,4.098630136986301,Enrolling by invitation,Observational,No,No,Sponsor-Investigator,534
AG0315OG/CTC0140,RegoNivo vs Standard of Care Chemotherapy in AGOC,5.002739726027397,Recruiting,Interventional,Yes,No,Sponsor,450
63646,Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer,4.3123287671232875,Recruiting,Interventional,No,No,Principal Investigator,2996
19-007,DECIDE: Developing Tools for Lung Cancer Screening Discussion Improvement,3.9452054794520555,Withdrawn,Observational,No,No,Sponsor,0
2018-01B,Stool Collection Sub-Study of Exact Sciences Protocol 2018-01,1.8438356164383563,Completed,Observational,No,No,Sponsor,291
201617079.3,Accelerated Hypofractionated Whole Breast Irradiation Plus Sequential Boost Versus Concomitant Boost Following BCS,3.0821917808219177,Unknown status,Interventional,No,No,Principal Investigator,185
IOSI-COVID19-001,A Study on the Immune-response to COVID-19 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study,2.0657534246575344,Completed,Observational,No,No,Sponsor-Investigator,177
C4221015,A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer,5.904109589041096,Recruiting,Interventional,Yes,No,Sponsor,815
ARRAY-818-202,An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer,5.076712328767123,"Active, not recruiting",Interventional,Yes,No,Sponsor,98
0482-001,A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001),5.676712328767123,Recruiting,Interventional,Yes,No,Sponsor,230
03.CP.0.3,Study to Evaluate VORTX Rx (Theresa),1.3232876712328767,Completed,Interventional,No,Yes,Sponsor,8
GO42144,"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation",4.342465753424658,Recruiting,Interventional,Yes,No,Sponsor,498
Ordu55,Nutrition Education and Quality of Life in Cancer Cachexia,0.8383561643835616,Not yet recruiting,Interventional,No,No,Principal Investigator,80
ORDU551,"Slimming Myokines, Cancers,Nutritional and Psychology Support",2.0027397260273974,Not yet recruiting,Interventional,No,No,Principal Investigator,240
ONO-4059-09,Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study),4.506849315068493,Recruiting,Interventional,Yes,No,Sponsor,112
19741,"Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug",3.5315068493150683,"Active, not recruiting",Interventional,Yes,No,Sponsor,56
GOG-8030,Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199,,Not yet recruiting,Observational,,,Sponsor,2605
JTX-8064-101,"Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors",2.96986301369863,"Active, not recruiting",Interventional,Yes,No,Sponsor,281
IBC0966-I/IIa,Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors,4.254794520547946,Recruiting,Interventional,No,No,Sponsor,228
"019/026/ICI, CEI/1330/18",Effect of Two Cognitive-Behavioral Interventions on Cervical Cancer Patients,1.9589041095890414,Unknown status,Interventional,No,No,Principal Investigator,92
LCH-112020,Subzero and Scorpion Trial,2.791780821917808,Recruiting,Interventional,No,No,Principal Investigator,20
HP-00070946,Exercise Effect on Chemotherapy-Induced Neuropathic Pain,5.254794520547946,"Active, not recruiting",Interventional,No,No,Principal Investigator,60
18HLGENE03,Evaluation of the Adhesion to the GENEPY Network,1.4191780821917808,Unknown status,Observational,No,No,Sponsor,450
FGCL-4592-898,A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies,1.1561643835616437,Recruiting,Interventional,No,No,Sponsor,146
2000034075,Buprenorphine Integration Research and Community Health,3.350684931506849,Recruiting,Interventional,No,No,Sponsor,20
CR108454,A Study of Participants With Advanced Prostate Cancer in Canada,8.246575342465754,"Active, not recruiting",Observational,No,No,Sponsor,374
APHP180586,Evaluating Effectiveness of a Communication Facilitator : A Randomized Trial,1.4164383561643836,Unknown status,Interventional,No,No,Sponsor,400
NCI-2020-07841,Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer,3.4876712328767123,Recruiting,Interventional,Yes,No,Sponsor,55
S60857,FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study,6.808219178082192,Recruiting,Interventional,No,No,Sponsor-Investigator,200
MO19/127559,Tolerance of Anti-Cancer Therapy in the Elderly,2.580821917808219,Recruiting,Observational,No,No,Sponsor,500
RPCR-breast 01,Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT),4.7972602739726025,Recruiting,Observational,No,No,Sponsor,200
T30-0002,Evaluation of Viatarâ¢ Oncopheresis System in Removing CTC From Whole Blood,0.663013698630137,Unknown status,Interventional,No,Yes,Sponsor,100
WP-2021-03,Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy,2.16986301369863,Not yet recruiting,Observational,No,No,Sponsor,150
CAMH2_1001,"A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer",3.345205479452055,Recruiting,Interventional,Yes,No,Sponsor,70
CIRB Ref. No: 2019/2135,Health-related Quality of Life-intervention in Survivors of Breast and Other Cancers Experiencing Cancer-related Fatigue Using Traditional Chinese Medicine: The HERBAL Trial,2.627397260273973,Unknown status,Interventional,No,No,Principal Investigator,80
Nigeria World Cancer Walk 2022,"Step up to Health, Nigeria! Impact of 2022 World Cancer Day Walk on Health Behaviors Among Nigerians",0.0,Not yet recruiting,Interventional,No,No,Sponsor,527
NRG-HN010,"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer",5.838356164383562,Recruiting,Interventional,Yes,No,Sponsor,116
D081SC00001Sub,Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort),4.76986301369863,"Active, not recruiting",Interventional,Yes,No,Sponsor,108
FatebenefratelliH,Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging,9.756164383561643,Recruiting,Observational,No,No,Sponsor,10000
D081SC00001,Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer,4.000000000000001,"Active, not recruiting",Interventional,Yes,No,Sponsor,796
2019P001434-2,Examining Validity and Reliability of the Shared Decision Making Process Survey in Adults With Depression,0.6712328767123288,Completed,Observational,No,No,Principal Investigator,494
H18-02052,BREAST ADM Trial for Alloplastic Breast Reconstruction,1.0986301369863014,Unknown status,Interventional,No,No,Principal Investigator,328
REG-114-2019,Histopathologic Effect of Calcium Electroporation on Cancer in the Skin,3.786301369863014,Recruiting,Interventional,No,No,Sponsor,24
20-0270-E,Family History App in Personalized Medicine,2.197260273972603,"Active, not recruiting",Interventional,No,No,Principal Investigator,627
PRO00104179,Onco-primary Care Networking to Support TEAM-based Care,2.797260273972603,Recruiting,Interventional,No,No,Sponsor,800
SJHH_PSPM,Post SBRT Pulmonary Metastasectomy (PSPM) Trial,3.4657534246575343,Recruiting,Interventional,No,No,Sponsor,39
823871-iGame,Digital Intervention for the Modification of Lifestyles (iGame),2.073972602739726,Not yet recruiting,Interventional,No,No,Principal Investigator,48
2018-0419,Pediatric Reporting of Adult-Onset Genomic Results,3.5972602739726027,Recruiting,Interventional,No,No,Principal Investigator,705
2019-00965,The SERENITY Study: Online Mindfulness-Based Cancer Recovery for Patients With Gynecological Cancer,2.7835616438356166,Completed,Interventional,No,No,Principal Investigator,62
COALESE/2021/103,Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy,1.4986301369863013,Recruiting,Interventional,No,No,Principal Investigator,50
BC 09915,Lymphedema After Gyneco-oncologic Treatment,3.0821917808219177,Recruiting,Observational,No,No,Sponsor,400
7013,MRI in Ductal Carcinoma in Situ (DCIS),0.9315068493150684,Unknown status,Observational,No,No,Sponsor,74
2017_71,PAGETEXÂ® Photodynamic Therapy Device for the Treatment of Extra Mammary Pagets Disease of the Vulva (EMPV).,4.934246575342466,Recruiting,Interventional,No,No,Sponsor,24
22-200,"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer",8.991780821917809,Not yet recruiting,Observational,No,No,Principal Investigator,5000
PYC001,The Use of PycnogenolÂ® to Alleviate Menopausal Symptoms Induced or Increased by Breast and Gynecological Cancer Treatments,1.9589041095890414,Unknown status,Interventional,No,No,Principal Investigator,40
22-01516,NYC Cancer Outreach Network in Neighborhoods for Equity and Community Translation,3.504109589041096,Not yet recruiting,Interventional,No,No,Sponsor,2160
2U01HG007292-05,Cancer Health Assessments Reaching Many,5.380821917808219,"Active, not recruiting",Interventional,No,No,Sponsor,967
20201224,Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate,3.589041095890411,Not yet recruiting,Interventional,No,No,Principal Investigator,50
CTMS# 19-0069,Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0,3.8821917808219184,"Active, not recruiting",Interventional,Yes,No,Sponsor,26
E2019453,Bovine Pericardial Patch and TiLOOPÂ® Bra Mesh in Immediate Implant Breast Reconstruction.,3.0,Unknown status,Interventional,No,No,Sponsor,176
21-103,A Study to Develop a Strategy to Increase Lung Cancer Screening in Women Who May Be at Risk for Lung Cancer,3.0027397260273974,"Active, not recruiting",Interventional,No,No,Sponsor,30
ABCSG C08,ABCSG C08-Exercise II: Trial of Endurance Exercise Following Adjuvant Chemotherapy for Colorectal Cancer,7.800000000000001,Recruiting,Interventional,No,No,Sponsor,788
PCA001,Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer,4.169863013698631,Recruiting,Interventional,Yes,No,Sponsor,137
CASE1121,Prepectoral vs Partial Subpectoral Two-Stage Implant-Based Breast Reconstruction,0.24931506849315072,Not yet recruiting,Interventional,No,No,Sponsor,62
Nigeria Cancer Walk,"Step up to Health, Nigeria! Impact of World Cancer Day Walk on Health Behaviors Among Nigerians",0.0,Completed,Interventional,No,No,Sponsor,527
20172841,The PREDICT Registry for DCIS Patients With DCISionRT Testing,17.687671232876713,Suspended,Observational,No,Yes,Sponsor,2500
RC31/18/0440,Abatacept and the Risk of Cancer: a Case Non-case Analysis in VigiBase,0.6027397260273972,Unknown status,Observational,No,No,Sponsor,594226
SDLNOC,Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy,0.5835616438356165,Recruiting,Observational,No,No,Principal Investigator,121
20-565,Comparing Two Different Surgical Techniques for Breast Reconstruction,0.9123287671232877,Withdrawn,Interventional,No,No,Sponsor,0
Arabic BREAST-Q,Validity and Reliability of Arabic Version of Breast Questionnaire,0.24931506849315072,Not yet recruiting,Interventional,No,No,Principal Investigator,87
UPCC 11919,Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients,3.3753424657534246,Recruiting,Interventional,No,No,Sponsor,560
2021-1211,Development of an Application-Based Digital Navigator for Perioperative Breast Surgery Patients,1.8383561643835618,Recruiting,Observational,No,No,Sponsor,40
segmental thoracic TEA-spinal,US-guided Thoracic Spinal Epidural Anesthesia VS GA for Abdominal and Breast Surgeries,0.6219178082191781,Completed,Interventional,No,No,Principal Investigator,63
IRB-22-34,Comparison of Patient Satisfaction in Post-operative Breast Surgery Patients Having Physical Clinic and Tele Clinic Follow up: A Randomized Controlled Trial,0.6657534246575343,Enrolling by invitation,Interventional,No,No,Principal Investigator,202
PSCI-19-112,Diminish Chemotherapy Related Side Effects Through Patient Education,2.7726027397260276,Recruiting,Interventional,No,No,Principal Investigator,50
LSHBSWMBC,Screening of Cancer Through Novel Female Specific Biomarkers,0.6301369863013698,Unknown status,Observational,No,Yes,Sponsor,60
2016-0463,REVOLVE or PureGraft Technique in Processing Fat Grafts for Patients Undergoing Breast Reconstruction,3.4794520547945207,Completed,Interventional,No,No,Sponsor,20
IIT-0013,MR Imaging Study Using the Northern Alberta Linac-MR (Northern LIGHTs - 1),1.9397260273972605,Recruiting,Interventional,No,No,Sponsor,100
BND and RND,Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection,0.9972602739726029,Unknown status,Interventional,No,No,Principal Investigator,10
TheNethersole,Effects of Music Intervention Combined With Progressive Muscle Relaxation in Cancer Patients,0.4246575342465753,Completed,Interventional,No,No,Principal Investigator,84
1655,Cell-free DNA in Hereditary And High-Risk Malignancies,5.254794520547946,Recruiting,Observational,No,No,Sponsor,1500
N-111012422,Diet Effect on Cancer Treatment Outcome,1.1726027397260275,"Active, not recruiting",Interventional,No,No,Sponsor,160
302,"177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)",2.336986301369863,Withdrawn,Interventional,Yes,No,Sponsor,0
MC01/01/19,Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE),2.926027397260274,Unknown status,Interventional,No,No,Sponsor,35
Colorectal Cancer,Colorectal Cancer Awareness in Turkey,0.29041095890410956,Unknown status,Observational,No,No,Principal Investigator,500
LCCC1748,Academic-Industrial Partnership for Translation of Acoustic Angiography,2.16986301369863,Completed,Interventional,No,Yes,Sponsor,20
1992110-1,Engaging Diverse and Underserved Communities in Cancer Awareness Training and Education,1.9863013698630139,Recruiting,Observational,No,No,Sponsor,1500
CSC-20200324,Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis,0.7561643835616438,Unknown status,Observational,No,No,Sponsor,1000
69HCL22_0466,Lung Cancer Screening Implementation Among Employees at Lyon Hospital,2.0000000000000004,Not yet recruiting,Interventional,No,No,Sponsor,600
IMPACNEO,IMPACt of an Enhanced Screening Program on the Detection of Non-AIDS NEOplasms in HIV Patients,3.6356164383561644,Recruiting,Interventional,No,No,Sponsor-Investigator,4638
0029-20-ZIV,Smurf2 Gene Expression in Urinary Tract Tumors,2.0000000000000004,Not yet recruiting,Observational,No,No,Sponsor,50
HKG-KZ-LNG-102,Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA,1.0493150684931507,Terminated,Observational,No,No,Sponsor,81
GCO 19-2707,To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer,3.0,Withdrawn,Interventional,Yes,No,Principal Investigator,0
LIFT project,Longitudinal Investigation of Cancer-related Fatigue and Its Treatment (LIFT Project),2.526027397260274,Recruiting,Observational,No,No,Sponsor,1400
RECO_CT29A,Investigation of Urinary Biomarkers for the Detection of Prostate Cancer,0.7534246575342466,Suspended,Interventional,No,No,Sponsor,200
S1614,Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors,8.024657534246577,"Active, not recruiting",Interventional,Yes,No,Sponsor,444
INT 292/20,Lung Cancer Prevention Screening Programme in Italy,3.9589041095890414,Recruiting,Interventional,No,No,Sponsor-Investigator,7324
STUDY21020095,Efficacy of a Self-advocacy Serious Game Intervention,4.027397260273973,Recruiting,Interventional,No,No,Principal Investigator,336
D967MC00001,A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations,7.052054794520548,"Active, not recruiting",Interventional,Yes,No,Sponsor,102
UHHeidelberg,Decision Aid to Support Advanced Cancer Patients,3.5013698630136987,Recruiting,Interventional,No,No,Principal Investigator,70
R01CA205025,Understanding the Post-Surgical Non-Small Cell Lung Cancer Patients Symptom Experience,4.83013698630137,Recruiting,Interventional,No,No,Principal Investigator,279
2019-PVSEP,Drugs for the Treatment of Multiple Sclerosis and Risk of Cancer: a Pharmacovigilance Analysis in Vigibase,0.1643835616438356,Unknown status,Observational,No,No,Sponsor,200000
HCB/2021/0130,Mapping Sentinel Lymph Node in Initial Stages of Ovarian Cancer,2.328767123287671,Recruiting,Interventional,No,No,Principal Investigator,62
TMHPO1763,A Pilot Study on HPV and Cervical Cancer Screening in Mumbai,0.0821917808219178,Unknown status,Interventional,No,No,Principal Investigator,227
002.1,Telegenetics or In-Person Genetic Counselling,3.0,Recruiting,Observational,No,No,Sponsor,150
LIFT,Longitudinal Investigation of Cancer-related Fatigue,6.257534246575342,Withdrawn,Observational,No,No,Sponsor,0
2767,The Role of Vitamin D in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer,2.9972602739726026,Recruiting,Observational,No,No,Principal Investigator,60
APHP210359,Evaluation of a Multimodal Strategy for Early Diagnosis of Men at High Genetic Risk of Prostate Cancer (HRPCa-II),5.087671232876712,Not yet recruiting,Interventional,No,No,Sponsor,880
M16VIB,Vinorelbine in Advanced BRAF-like Colon Cancer,2.0027397260273974,Unknown status,Interventional,No,No,Sponsor,82
EPOC1903,Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer,3.5013698630136987,"Active, not recruiting",Interventional,No,No,Principal Investigator,30
CASE2118,Integrated Imaging System for In Vivo Visualization of Free Flap Perfusion Using Indocyanine Dye,3.6931506849315068,Suspended,Interventional,No,Yes,Sponsor,25
PARALUC,Pneumonitis After Radiotherapy for Lung Cancer,3.750684931506849,Recruiting,Interventional,No,No,Principal Investigator,98
CTC20200417,Influence of Opioids on Circulating Tumor Cells in Radical Cystectomy,0.6383561643835617,Completed,Interventional,No,No,Principal Investigator,44
09.2019.1026,Prognostic Value of Body Composition in Lung Cancer,0.4958904109589042,Completed,Observational,No,No,Sponsor,83
CASE4119,The Impact of Functional Medicine On Wound Healing From Delayed Autologous Breast Reconstruction,2.1671232876712327,Recruiting,Interventional,No,No,Sponsor,20
EC/GOVT/24/IRB23,Comprehensive Digital Archive of Cancer Imaging-Radiation Oncology( CHAVI-RO ),2.4986301369863013,Completed,Observational,No,No,Sponsor,500
CFTSp195,A Survey Exploring Health and Screening Tests in People Treated for Hodgkin Lymphoma,0.32602739726027397,Completed,Observational,No,No,Sponsor,165
04/20,Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer,4.002739726027397,Recruiting,Observational,Yes,No,Principal Investigator,220
29BRC20.0021,Screening for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism,8.005479452054795,Recruiting,Interventional,No,No,Sponsor,1276
MRI in urinary bladder tumors,Role of MRI in Assessment of the Urinary Bladder Wall Post Transurethral Tumor Resection,1.6712328767123288,Not yet recruiting,Observational,No,No,Principal Investigator,58
CRUKD/21/004 - Treatment Arm 2,"DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition",6.506849315068493,Not yet recruiting,Interventional,No,No,Sponsor,30
20201491,Culturally Tailored Nurse Coaching Study for Cancer Symptom Management,1.6849315068493151,Recruiting,Interventional,No,No,Principal Investigator,98
32900654326,"TPVB, PECSB, ESPB for Postmastectmy Pain",2.336986301369863,Completed,Interventional,No,No,Principal Investigator,80
ReDA 13176,A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.,6.005479452054795,Not yet recruiting,Interventional,No,No,Sponsor-Investigator,180
64121317.4.1001.5330,Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial),3.750684931506849,"Active, not recruiting",Interventional,Yes,No,Sponsor,38
3-2020-0038,Intraoperative Radiation Therapy for Resectable Pancreatic Cancer,6.0,Recruiting,Interventional,No,No,Sponsor-Investigator,80
2018PS02,Pharmacist and Data Driven Quality Improvement in Primary Care,0.7863013698630137,Completed,Observational,No,No,Principal Investigator,19
